{"dad33cec20f30562d4f75601c5d37c990d983b1b": [["To the Editor,The COVID-19 outbreak is currently spreading throughout northern Italy and is forcing a rapid change of clinical priorities and organizational logistics.", [["The COVID", "TEST", 14, 23], ["organizational logistics", "TREATMENT", 142, 166], ["rapid", "OBSERVATION_MODIFIER", 102, 107]]], ["In this dramatic scenario, angio-suites and operatory rooms only admit urgent procedures and the interventional radiology (IR) service is mostly dedicated to assisting the emergency department in dealing with SARS-CoV-2-positive patients.", [["SARS", "DISEASE", 209, 213], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 209, 219], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["SARS", "TEST", 209, 213], ["CoV", "TEST", 214, 217]]], ["We share a case of pleural drainage in one COVID-19 patient and provide the IR community with some practical recommendations regarding the management of this particular category of patients.To the Editor,A 63-year-old woman with metastatic ovarian cancer and recurrent malignant pleural effusion came to our institutional ER with fever (39\u00b0C) and dyspnea at rest.", [["pleural", "ANATOMY", 19, 26], ["metastatic ovarian cancer", "ANATOMY", 229, 254], ["malignant pleural effusion", "ANATOMY", 269, 295], ["ER", "ANATOMY", 322, 324], ["pleural drainage", "DISEASE", 19, 35], ["ovarian cancer", "DISEASE", 240, 254], ["malignant pleural effusion", "DISEASE", 269, 295], ["fever", "DISEASE", 330, 335], ["39\u00b0C", "DISEASE", 337, 341], ["dyspnea", "DISEASE", 347, 354], ["pleural", "ORGAN", 19, 26], ["patient", "ORGANISM", 52, 59], ["patients", "ORGANISM", 181, 189], ["woman", "ORGANISM", 218, 223], ["ovarian cancer", "CANCER", 240, 254], ["malignant pleural", "CANCER", 269, 286], ["ER", "GENE_OR_GENE_PRODUCT", 322, 324], ["patient", "SPECIES", 52, 59], ["patients", "SPECIES", 181, 189], ["woman", "SPECIES", 218, 223], ["pleural drainage", "TREATMENT", 19, 35], ["the management", "TREATMENT", 135, 149], ["metastatic ovarian cancer", "PROBLEM", 229, 254], ["recurrent malignant pleural effusion", "PROBLEM", 259, 295], ["fever", "PROBLEM", 330, 335], ["dyspnea at rest", "PROBLEM", 347, 362], ["pleural", "ANATOMY", 19, 26], ["drainage", "OBSERVATION", 27, 35], ["metastatic", "OBSERVATION_MODIFIER", 229, 239], ["ovarian", "ANATOMY", 240, 247], ["cancer", "OBSERVATION", 248, 254], ["recurrent", "OBSERVATION_MODIFIER", 259, 268], ["malignant", "OBSERVATION_MODIFIER", 269, 278], ["pleural", "ANATOMY", 279, 286], ["effusion", "OBSERVATION", 287, 295], ["fever", "OBSERVATION", 330, 335]]], ["Being our institute located in a severely involved area of the COVID-19 outbreak, clinical symptoms were compatible with COVID-19 infection.", [["infection", "DISEASE", 130, 139], ["COVID-19", "SPECIES", 121, 129], ["the COVID", "TEST", 59, 68], ["clinical symptoms", "PROBLEM", 82, 99], ["COVID-19 infection", "PROBLEM", 121, 139], ["severely", "OBSERVATION_MODIFIER", 33, 41], ["infection", "OBSERVATION", 130, 139]]], ["Laboratory parameters included hemoglobin 10.7, white blood cells 3.98, C-reactive protein 43.5, arterial pH 7.5, pO 2 53 mmHg, pCO 2 31 mmHg and blood lactate concentration 1 mmol/L. Although the patient underwent a right pleurodesis 6 months ago, chest X-ray showed bilateral pleural effusion (loculated on the right side) as well as interstitial thickening (Fig. 1A) , a common imaging feature in COVID-19.", [["white blood cells", "ANATOMY", 48, 65], ["arterial", "ANATOMY", 97, 105], ["blood", "ANATOMY", 146, 151], ["pleural", "ANATOMY", 278, 285], ["right side", "ANATOMY", 313, 323], ["interstitial", "ANATOMY", 336, 348], ["lactate", "CHEMICAL", 152, 159], ["pleural effusion", "DISEASE", 278, 294], ["lactate", "CHEMICAL", 152, 159], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 31, 41], ["white blood cells", "CELL", 48, 65], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 72, 90], ["arterial", "MULTI-TISSUE_STRUCTURE", 97, 105], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["lactate", "SIMPLE_CHEMICAL", 152, 159], ["patient", "ORGANISM", 197, 204], ["pleural effusion", "PATHOLOGICAL_FORMATION", 278, 294], ["interstitial", "TISSUE", 336, 348], ["hemoglobin", "PROTEIN", 31, 41], ["white blood cells", "CELL_TYPE", 48, 65], ["C-reactive protein", "PROTEIN", 72, 90], ["patient", "SPECIES", 197, 204], ["Laboratory parameters", "TEST", 0, 21], ["hemoglobin", "TEST", 31, 41], ["white blood cells", "TEST", 48, 65], ["C-reactive protein", "TEST", 72, 90], ["arterial pH", "TEST", 97, 108], ["pO", "TEST", 114, 116], ["mmHg", "TEST", 122, 126], ["pCO", "TEST", 128, 131], ["mmHg", "TEST", 137, 141], ["blood lactate concentration", "TEST", 146, 173], ["a right pleurodesis", "TREATMENT", 215, 234], ["chest X-ray", "TEST", 249, 260], ["bilateral pleural effusion", "PROBLEM", 268, 294], ["loculated on the right side", "PROBLEM", 296, 323], ["interstitial thickening", "PROBLEM", 336, 359], ["a common imaging feature", "TEST", 372, 396], ["COVID", "TEST", 400, 405], ["right", "ANATOMY_MODIFIER", 217, 222], ["pleurodesis", "OBSERVATION", 223, 234], ["chest", "ANATOMY", 249, 254], ["bilateral", "ANATOMY_MODIFIER", 268, 277], ["pleural", "ANATOMY", 278, 285], ["effusion", "OBSERVATION", 286, 294], ["loculated", "OBSERVATION_MODIFIER", 296, 305], ["right", "ANATOMY_MODIFIER", 313, 318], ["interstitial", "ANATOMY_MODIFIER", 336, 348], ["thickening", "OBSERVATION", 349, 359]]], ["She underwent a naso-/ oropharyngeal swab which turned positive for SARS-CoV-2 nucleic acid after being processed through a real-time reverse transcriptase polymerase chain reaction (Novel Coronavirus PCR Fluorescence Diagnostic Kit, BioGerm Medical Biotechnology).", [["oropharyngeal swab", "ANATOMY", 23, 41], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 68, 91], ["reverse transcriptase", "PROTEIN", 134, 155], ["SARS-CoV", "SPECIES", 68, 76], ["a naso-/ oropharyngeal swab", "TEST", 14, 41], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76], ["nucleic acid", "TREATMENT", 79, 91], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 134, 181], ["Novel Coronavirus PCR", "TEST", 183, 204], ["oropharyngeal", "ANATOMY", 23, 36]]], ["She started as an inpatient with 1 week of non-invasive assisted ventilation that reduced fever, clinical symptoms and normalized inflammatory laboratory values such as C-reactive protein.", [["fever", "DISEASE", 90, 95], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 169, 187], ["C-reactive protein", "PROTEIN", 169, 187], ["non-invasive assisted ventilation", "TREATMENT", 43, 76], ["reduced fever", "PROBLEM", 82, 95], ["clinical symptoms", "PROBLEM", 97, 114], ["normalized inflammatory laboratory values", "PROBLEM", 119, 160], ["C-reactive protein", "PROBLEM", 169, 187], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142], ["reactive protein", "OBSERVATION", 171, 187]]], ["Still, respiratory function and blood oxygen levels remained poor despite an increase in FiO 2 from 60 to 70%.", [["respiratory", "ANATOMY", 7, 18], ["blood", "ANATOMY", 32, 37], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 38, 44], ["FiO 2", "CHEMICAL", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["respiratory function", "TEST", 7, 27], ["blood oxygen levels", "TEST", 32, 51], ["an increase in FiO", "TREATMENT", 74, 92], ["respiratory function", "OBSERVATION", 7, 27], ["increase", "OBSERVATION_MODIFIER", 77, 85]]], ["Consequently, percutaneous drainage was requested with the aim of improving ventilation and blood oxygen saturation.", [["percutaneous", "ANATOMY", 14, 26], ["blood", "ANATOMY", 92, 97], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 98, 104], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["percutaneous drainage", "TREATMENT", 14, 35], ["improving ventilation", "TREATMENT", 66, 87], ["blood oxygen saturation", "TEST", 92, 115], ["percutaneous", "OBSERVATION_MODIFIER", 14, 26], ["drainage", "OBSERVATION", 27, 35], ["oxygen saturation", "OBSERVATION", 98, 115]]], ["The procedure was performed at the bedside in an isolated ward dedicated to COVID-19 patients.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["The procedure", "TREATMENT", 0, 13]]], ["The operator wore an FFp2 mask, double gloves, protective glasses and a surgical gown (Fig. 2 ).", [["an FFp2 mask", "TREATMENT", 18, 30], ["double gloves", "TREATMENT", 32, 45], ["protective glasses", "TREATMENT", 47, 65], ["a surgical gown", "TREATMENT", 70, 85]]], ["After local anesthesia, two 8F multi-hole drainages were inserted bilaterally using dedicated US equipment in the isolated ward as image guidance.", [["local anesthesia", "TREATMENT", 6, 22], ["two 8F multi-hole drainages", "TREATMENT", 24, 51], ["dedicated US equipment", "TREATMENT", 84, 106]]], ["The procedure lasted approximately 1 h and was well tolerated.", [["The procedure", "TREATMENT", 0, 13]]], ["Around 1800 mL was drained in the next 5 h from both sides.", [["drained", "OBSERVATION", 19, 26]]], ["All disposable equipment and devices were then immediately discarded in specific containers.", [["All disposable equipment and devices", "TREATMENT", 0, 36]]], ["Post-procedural chest X-rays showed a marked increase in the ventilated parenchyma.", [["parenchyma", "ANATOMY", 72, 82], ["parenchyma", "TISSUE", 72, 82], ["Post-procedural chest X-rays", "TEST", 0, 28], ["a marked increase in the ventilated parenchyma", "PROBLEM", 36, 82], ["chest", "ANATOMY", 16, 21], ["marked", "OBSERVATION_MODIFIER", 38, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["ventilated parenchyma", "OBSERVATION", 61, 82]]], ["Along with clinical symptoms, also laboratory markers rapidly improved and blood saturation levels reached the normal range (SpO 2 98%).", [["blood", "ANATOMY", 75, 80], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["clinical symptoms", "PROBLEM", 11, 28], ["laboratory markers", "TEST", 35, 53], ["blood saturation levels", "TEST", 75, 98], ["SpO", "TEST", 125, 128]]], ["The patient switched from assisted ventilation to a simple face mask (2 L/min O 2 ) and maintained normal peripheral capillary oxygen saturation.", [["face", "ANATOMY", 59, 63], ["peripheral capillary", "ANATOMY", 106, 126], ["oxygen", "CHEMICAL", 127, 133], ["O 2", "CHEMICAL", 78, 81], ["oxygen", "CHEMICAL", 127, 133], ["patient", "ORGANISM", 4, 11], ["peripheral capillary", "TISSUE", 106, 126], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["patient", "SPECIES", 4, 11], ["assisted ventilation", "TREATMENT", 26, 46], ["a simple face mask", "TREATMENT", 50, 68], ["normal", "OBSERVATION", 99, 105], ["peripheral", "ANATOMY_MODIFIER", 106, 116], ["capillary", "ANATOMY_MODIFIER", 117, 126], ["oxygen saturation", "OBSERVATION", 127, 144]]], ["At the time of writing, she is alive and close to hospital discharge.To the Editor,The current COVID-19 outbreak is causing a massive overcrowding of admitted patients for symptomatic pneumonia.", [["pneumonia", "DISEASE", 184, 193], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["symptomatic pneumonia", "PROBLEM", 172, 193], ["massive", "OBSERVATION_MODIFIER", 126, 133], ["symptomatic", "OBSERVATION_MODIFIER", 172, 183], ["pneumonia", "OBSERVATION", 184, 193]]], ["Patient presentation ranges from mild symptoms to severe respiratory syndrome due to extended parenchymal involvement, especially in the advanced-phase disease (8-14 days after the onset of first symptoms) [1] .To the Editor,Pleural effusion is not typical of COVID-19 infection, but is a common finding in metastatic oncologic patients and may severely impact respiratory function.", [["respiratory", "ANATOMY", 57, 68], ["parenchymal", "ANATOMY", 94, 105], ["Pleural effusion", "ANATOMY", 225, 241], ["metastatic oncologic", "ANATOMY", 307, 327], ["respiratory", "ANATOMY", 361, 372], ["respiratory syndrome", "DISEASE", 57, 77], ["Pleural effusion", "DISEASE", 225, 241], ["infection", "DISEASE", 269, 278], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 94, 105], ["patients", "ORGANISM", 328, 336], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 328, 336], ["COVID-19", "SPECIES", 260, 268], ["mild symptoms", "PROBLEM", 33, 46], ["severe respiratory syndrome", "PROBLEM", 50, 77], ["extended parenchymal involvement", "PROBLEM", 85, 117], ["the advanced-phase disease", "PROBLEM", 133, 159], ["first symptoms", "PROBLEM", 190, 204], ["Pleural effusion", "PROBLEM", 225, 241], ["COVID-19 infection", "PROBLEM", 260, 278], ["severely impact respiratory function", "PROBLEM", 345, 381], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["respiratory syndrome", "OBSERVATION", 57, 77], ["parenchymal", "ANATOMY_MODIFIER", 94, 105], ["involvement", "OBSERVATION", 106, 117], ["Pleural", "ANATOMY", 225, 232], ["effusion", "OBSERVATION", 233, 241], ["not typical of", "UNCERTAINTY", 245, 259], ["infection", "OBSERVATION", 269, 278], ["metastatic", "OBSERVATION_MODIFIER", 307, 317], ["respiratory function", "OBSERVATION", 361, 381]]], ["Whether the infection concurred to the recurrence of the pleural effusion is not known, but pleural effusion in COVID-19 patients has been described as a poor prognosticator of clinical evolution [2] .", [["pleural effusion", "ANATOMY", 57, 73], ["pleural effusion", "ANATOMY", 92, 108], ["infection", "DISEASE", 12, 21], ["pleural effusion", "DISEASE", 57, 73], ["pleural effusion", "DISEASE", 92, 108], ["pleural", "ORGAN", 57, 64], ["pleural effusion", "PATHOLOGICAL_FORMATION", 92, 108], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["the infection", "PROBLEM", 8, 21], ["the pleural effusion", "PROBLEM", 53, 73], ["pleural effusion", "PROBLEM", 92, 108], ["infection", "OBSERVATION", 12, 21], ["recurrence", "OBSERVATION_MODIFIER", 39, 49], ["pleural", "ANATOMY", 57, 64], ["effusion", "OBSERVATION", 65, 73], ["not known", "UNCERTAINTY", 77, 86], ["pleural", "ANATOMY", 92, 99], ["effusion", "OBSERVATION", 100, 108]]], ["Being ventilation the first line treatment for COVID-19 patients, pleural drainage is recommended to improve oxygenation.To the Editor,US-guided thoracic interventions like pleural drainage is a safe and practical procedure that can be performed at the bedside with due arrangements for operator's safety in case of infectious patients [3] .", [["pleural", "ANATOMY", 66, 73], ["thoracic", "ANATOMY", 145, 153], ["pleural", "ANATOMY", 173, 180], ["patients", "ORGANISM", 56, 64], ["pleural", "MULTI-TISSUE_STRUCTURE", 66, 73], ["thoracic", "MULTI-TISSUE_STRUCTURE", 145, 153], ["pleural", "MULTI-TISSUE_STRUCTURE", 173, 180], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 327, 335], ["ventilation", "TREATMENT", 6, 17], ["the first line treatment", "TREATMENT", 18, 42], ["COVID", "TEST", 47, 52], ["pleural drainage", "TREATMENT", 66, 82], ["US", "TEST", 135, 137], ["guided thoracic interventions", "TREATMENT", 138, 167], ["pleural drainage", "TREATMENT", 173, 189], ["practical procedure", "TREATMENT", 204, 223], ["pleural", "ANATOMY", 66, 73], ["drainage", "OBSERVATION", 74, 82], ["thoracic", "ANATOMY", 145, 153], ["pleural", "ANATOMY", 173, 180], ["drainage", "OBSERVATION", 181, 189]]], ["The versatility of US-guided procedures fits well with the need to entail procedures on isolated patients in separate places and times [4] .", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["US", "TEST", 19, 21], ["guided procedures", "TREATMENT", 22, 39], ["entail procedures", "TREATMENT", 67, 84]]], ["In fact, the possibility to perform the procedure at the bedside avoids the spread of disease outside the dedicated COVID-19 ward and does not require discontinuation of assisted ventilation.", [["the procedure", "TREATMENT", 36, 49], ["disease", "PROBLEM", 86, 93], ["assisted ventilation", "TREATMENT", 170, 190]]], ["This is not the first time that interventional radiologists have been called to actively contribute to an infectious outbreak.", [["an infectious outbreak", "PROBLEM", 103, 125], ["infectious", "OBSERVATION", 106, 116]]], ["In 2003, the SARS outbreak raised awareness among the IR community about the role of our specialty in such a delicate scenario.", [["SARS", "DISEASE", 13, 17]]], ["Lau et al. [5] proposed decentralization of the service, predilection of US-guided procedures, rigorous triage and strict respect of safety measures as key elements for delivering high-quality IR care.To the Editor,We acknowledge that in this historic moment the overcrowding of the emergency units may hinder multidisciplinary collaboration.", [["guided procedures", "TREATMENT", 76, 93], ["rigorous triage", "TEST", 95, 110], ["safety measures", "TREATMENT", 133, 148], ["high-quality IR care", "TREATMENT", 180, 200]]], ["However, considering that Fig. 1 A Chest X-ray shows bilateral pleural effusion and diffuse interstitial thickening.", [["pleural", "ANATOMY", 63, 70], ["interstitial", "ANATOMY", 92, 104], ["pleural effusion", "DISEASE", 63, 79], ["pleural effusion", "PATHOLOGICAL_FORMATION", 63, 79], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 104], ["A Chest X-ray", "TEST", 33, 46], ["bilateral pleural effusion", "PROBLEM", 53, 79], ["diffuse interstitial thickening", "PROBLEM", 84, 115], ["Chest", "ANATOMY", 35, 40], ["bilateral", "ANATOMY_MODIFIER", 53, 62], ["pleural", "ANATOMY", 63, 70], ["effusion", "OBSERVATION", 71, 79], ["diffuse", "OBSERVATION_MODIFIER", 84, 91], ["interstitial", "ANATOMY_MODIFIER", 92, 104], ["thickening", "OBSERVATION", 105, 115]]], ["B Chest X-ray performed 24 h after bilateral pleural drainages shows nearly complete resolution of the pleural effusions on both sides Fig. 2 Operator wearing protective equipment before the procedure COVID-19 is a rapidly changing respiratory syndrome with unpredictable clinical evolution, a smooth collaboration between IR and all the health workers involved in the management of COVID-19 patients will be critical in the upcoming months to effectively distribute the workload and timely ensure the best care possible.To the Editor,In conclusion, IR units should be responsive and equipped to deal with COVID-19 outbreak, as they may play a key role in the optimization of patient ventilation through minimally invasive procedures.To the Editor,Authors Contributions All the authors mentioned in the manuscript have made a significant contribution to this manuscript, agreed for authorship, read and approved the manuscript and agreed to its submission to CVIR.To the Editor,Funding The authors state that this work has not received any funding.Compliance with Ethical StandardsConflict of interest The authors declare that they have neither financial nor non-financial conflicts of interest.Compliance with Ethical StandardsEthical Approval and Informed Consent Both Institutional Review Board and Informed consent were obtained.Compliance with Ethical StandardsConsent for Publication Consent for publication was obtained for every individual person's data included in the study.Statistics and BiometryNo complex statistical methods were necessary for this paper.Statistics and BiometryStudy Subjects or Cohorts Overlap Study subjects or cohorts have not been previously reported.", [["pleural", "ANATOMY", 45, 52], ["pleural effusions", "ANATOMY", 103, 120], ["pleural effusions", "DISEASE", 103, 120], ["respiratory syndrome", "DISEASE", 232, 252], ["COVID", "DISEASE", 383, 388], ["pleural", "PATHOLOGICAL_FORMATION", 45, 52], ["pleural effusions", "PATHOLOGICAL_FORMATION", 103, 120], ["patients", "ORGANISM", 392, 400], ["patient", "ORGANISM", 676, 683], ["patients", "SPECIES", 392, 400], ["patient", "SPECIES", 676, 683], ["person", "SPECIES", 1448, 1454], ["B Chest X-ray", "TEST", 0, 13], ["bilateral pleural drainages", "TREATMENT", 35, 62], ["the pleural effusions", "PROBLEM", 99, 120], ["Operator wearing protective equipment", "TREATMENT", 142, 179], ["the procedure COVID", "TREATMENT", 187, 206], ["a rapidly changing respiratory syndrome", "PROBLEM", 213, 252], ["IR units", "TREATMENT", 550, 558], ["COVID", "TEST", 606, 611], ["patient ventilation", "TREATMENT", 676, 695], ["minimally invasive procedures", "TREATMENT", 704, 733], ["the study", "TEST", 1474, 1483], ["complex statistical methods", "PROBLEM", 1510, 1537], ["Chest", "ANATOMY", 2, 7], ["bilateral", "ANATOMY_MODIFIER", 35, 44], ["pleural", "ANATOMY", 45, 52], ["drainages", "OBSERVATION", 53, 62], ["nearly", "OBSERVATION_MODIFIER", 69, 75], ["complete", "OBSERVATION_MODIFIER", 76, 84], ["resolution", "OBSERVATION_MODIFIER", 85, 95], ["pleural", "ANATOMY", 103, 110], ["effusions", "OBSERVATION", 111, 120], ["Fig", "OBSERVATION_MODIFIER", 135, 138], ["respiratory syndrome", "OBSERVATION", 232, 252], ["complex", "OBSERVATION_MODIFIER", 1510, 1517], ["statistical", "OBSERVATION", 1518, 1529]]]], "PMC6631851": [], "PMC7144609": [["IntroductionCOVID-19 is spreading rapidly around the world, forcing previously unknown changes in our health care systems.", [["IntroductionCOVID", "TEST", 0, 17]]], ["This pandemic poses a great burden on medical resources such as hospital beds and protective equipment, in addition to medical personnel.", [["protective equipment", "TREATMENT", 82, 102], ["great", "OBSERVATION_MODIFIER", 22, 27], ["burden", "OBSERVATION_MODIFIER", 28, 34]]], ["Decisions regarding which type of care is to be continued and which can be postponed must be made and will require revision as the situation improves or worsens.", [["revision", "TREATMENT", 115, 123]]], ["It is yet unpredictable when to expect improvement in the COVID-19 situation, but this will also require a scenario for progressive resumption of medical care.", [["the COVID", "TEST", 54, 63], ["medical care", "TREATMENT", 146, 158]]], ["Several medical and surgical societies across the globe have developed lists to guide the decision-making process with regards to reduction of care, mainly focusing on adult patients or paediatric surgery in general.IntroductionWe present a statement with recommendations for pediatric urological cases based on published studies as well as expert opinion of the paediatric urology guidelines panel of the EAU.", [["EAU", "DISEASE", 406, 409], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["paediatric surgery", "TREATMENT", 186, 204], ["pediatric urological cases", "TREATMENT", 276, 302], ["published studies", "TEST", 312, 329], ["globe", "ANATOMY", 50, 55]]], ["However, sound clinical judgement and the local situation or regulations will influence individual decisions.Children and COVID-19COVID-19 appears similar to Severe Acute Respiratory Syndrome Corona virus (SARSCoV) and Middle East Respiratory Syndrome Corona virus (MERSCoV).", [["Acute Respiratory Syndrome Corona virus", "DISEASE", 165, 204], ["Children", "ORGANISM", 109, 117], ["Severe Acute Respiratory Syndrome Corona virus", "ORGANISM", 158, 204], ["Middle East Respiratory Syndrome Corona virus", "ORGANISM", 219, 264], ["MERSCoV", "CANCER", 266, 273], ["Children", "SPECIES", 109, 117], ["COVID-19COVID-19", "SPECIES", 122, 138], ["Severe Acute Respiratory Syndrome Corona virus", "SPECIES", 158, 204], ["SARSCoV", "SPECIES", 206, 213], ["Middle East Respiratory Syndrome Corona virus", "SPECIES", 219, 264], ["MERSCoV", "SPECIES", 266, 273], ["sound clinical judgement", "PROBLEM", 9, 33], ["COVID", "TEST", 122, 127], ["Severe Acute Respiratory Syndrome", "PROBLEM", 158, 191], ["Corona virus (SARSCoV)", "PROBLEM", 192, 214], ["Middle East Respiratory Syndrome", "PROBLEM", 219, 251], ["Corona virus", "PROBLEM", 252, 264], ["Severe", "OBSERVATION_MODIFIER", 158, 164], ["Acute", "OBSERVATION_MODIFIER", 165, 170], ["Respiratory Syndrome", "OBSERVATION", 171, 191], ["Corona virus", "OBSERVATION", 192, 204], ["Middle", "ANATOMY_MODIFIER", 219, 225], ["Respiratory Syndrome", "OBSERVATION", 231, 251], ["Corona virus", "OBSERVATION", 252, 264]]], ["With these epidemics severe symptoms of infection were relatively uncommon in children.", [["infection", "DISEASE", 40, 49], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["these epidemics severe symptoms", "PROBLEM", 5, 36], ["infection", "PROBLEM", 40, 49], ["epidemics", "OBSERVATION_MODIFIER", 11, 20], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["infection", "OBSERVATION", 40, 49]]], ["To date most reports on COVID-19 in children describe mild to moderate symptoms such as fever, cough and nasal discharge [1].", [["nasal", "ANATOMY", 105, 110], ["fever", "DISEASE", 88, 93], ["cough", "DISEASE", 95, 100], ["children", "ORGANISM", 36, 44], ["nasal", "ORGANISM_SUBDIVISION", 105, 110], ["COVID-19", "DNA", 24, 32], ["children", "SPECIES", 36, 44], ["mild to moderate symptoms", "PROBLEM", 54, 79], ["fever", "PROBLEM", 88, 93], ["cough", "PROBLEM", 95, 100], ["nasal discharge", "PROBLEM", 105, 120], ["moderate", "OBSERVATION_MODIFIER", 62, 70]]], ["The prevalence of severe symptoms is higher among children <5 years old, particularly <1-year-old [1].Children and COVID-19While most children themselves may not be severely ill with COVID-19, this pandemic will impact on pediatric urological care.", [["children", "ORGANISM", 50, 58], ["Children", "ORGANISM", 102, 110], ["COVID-19While", "CELL", 115, 128], ["children", "ORGANISM", 134, 142], ["children", "SPECIES", 50, 58], ["Children", "SPECIES", 102, 110], ["children", "SPECIES", 134, 142], ["severe symptoms", "PROBLEM", 18, 33], ["severely ill", "PROBLEM", 165, 177], ["pediatric urological care", "TREATMENT", 222, 247], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["symptoms", "OBSERVATION", 25, 33]]], ["Careful decisions must be made on what care requires postponement and what care is essential to be continued.Suggested reduction in surgical procedures during various stages of severity of the COVID-19 pandemicBelow are recommendations for paediatric urological surgical procedures.", [["surgical procedures", "TREATMENT", 132, 151], ["the COVID", "TREATMENT", 189, 198], ["paediatric urological surgical procedures", "TREATMENT", 240, 281], ["reduction", "OBSERVATION_MODIFIER", 119, 128], ["surgical procedures", "OBSERVATION", 132, 151]]], ["Conversely, for stage 3 & 4 suggestions encompass essential care that should continue, circumstances permitting.Suggested reduction in surgical procedures during various stages of severity of the COVID-19 pandemic", [["COVID", "DISEASE", 196, 201], ["essential care", "TREATMENT", 50, 64], ["surgical procedures", "TREATMENT", 135, 154], ["the COVID", "TEST", 192, 201], ["reduction", "OBSERVATION_MODIFIER", 122, 131], ["surgical", "OBSERVATION", 135, 143]]]], "PMC7162742": [["Manpower considerationsAs the tertiary hospital linked to NCID, TTSH supplies manpower and resources to staff NCID in times of Pandemic outbreaks.", [["TTSH", "CHEMICAL", 64, 68], ["NCID", "DISEASE", 110, 114], ["Pandemic", "DISEASE", 127, 135], ["Pandemic outbreaks", "PROBLEM", 127, 145]]], ["This is especially pertinent as NCID caters to 70% of Singapore\u2019s COVID-19 screening workload.", [["COVID", "TEST", 66, 71]]], ["Till today, it has screened more than 14,000 people and admitted more than 2,000 suspect and confirmed cases.The Department of General Surgery, which the Vascular Surgery Service is part of, has been deploying up to 25% of our staff in 10 days cycles to the NCID Screening Centre which also functions as a full-fledged Emergency Department as some patients may have symptoms of both COVID-19 and a concurrent medical or surgical presentation and diagnosis.", [["Vascular", "ANATOMY", 154, 162], ["people", "ORGANISM", 45, 51], ["patients", "ORGANISM", 348, 356], ["people", "SPECIES", 45, 51], ["patients", "SPECIES", 348, 356], ["General Surgery", "TREATMENT", 127, 142], ["symptoms", "PROBLEM", 366, 374], ["Vascular", "ANATOMY", 154, 162]]], ["Deployed surgeons are required to also manage conditions outwith their speciality.Manpower considerationsTo ensure continuity of an elective and emergency Vascular Surgery Service, we maintain at all times at least 2 to 3 Vascular Surgery Consultants within TTSH while the rest of manpower can be deployed out to NCID.", [["Vascular", "ANATOMY", 155, 163], ["Vascular", "MULTI-TISSUE_STRUCTURE", 155, 163], ["Vascular", "ANATOMY", 155, 163], ["Vascular", "ANATOMY", 222, 230]]], ["As we anticipate that there is already community transmission of SARS-CoV-2, it is vital to have another Vascular Surgery Consultant on standby in case the On call Vascular Surgery Consultant develops symptoms of COVID-19 and requires isolation.Manpower considerationsMeasures to ensure continuity and viability of our service include suspending all annual leave, overseas travel and conference leave.", [["Vascular", "ANATOMY", 105, 113], ["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["SARS", "PROBLEM", 65, 69], ["symptoms", "PROBLEM", 201, 209], ["COVID", "TEST", 213, 218], ["isolation", "TREATMENT", 235, 244], ["Vascular", "ANATOMY", 105, 113], ["Surgery", "OBSERVATION", 114, 121]]], ["This was implemented early in February 2020, once it was clear that a pandemic was imminent.", [["a pandemic", "PROBLEM", 68, 78]]], ["Healthcare workers returning from China and subsequently other affected hot spot countries were also put on a mandatory leave of absence of 14 days following overseas return to reduce the risk of imported infection.", [["infection", "DISEASE", 205, 214], ["imported infection", "PROBLEM", 196, 214], ["infection", "OBSERVATION", 205, 214]]], ["As the pandemic dragged on, staff were allowed to take 3 day breaks of annual leave but must remain contactable and recallable in the event of a surge in COVID-19 patients or Vascular Surgery Emergencies.Social distancing measuresAt the start of the outbreak, mask up policy with a surgical face mask was implemented in clinical areas and then further extended to the entire hospital premises.", [["Vascular", "ANATOMY", 175, 183], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["Vascular Surgery", "TREATMENT", 175, 191], ["a surgical face mask", "TREATMENT", 280, 300], ["Vascular", "ANATOMY", 175, 183], ["Surgery", "OBSERVATION", 184, 191]]], ["We have also been exploring electronic platforms such as Zoom for large group meetings where face to face contact is less important such as residency teaching, undergraduate teaching and some administrative department meetings.Social distancing measuresMeetings essential for clinical decision making such as the weekly Vascular-Radiology Multi-disciplinary meeting has continued with a mask up policy and attendees sitting 1 metre apart with less than 10 staff attending this meeting.Social distancing measuresDaily ward rounds are now conducted in 3 separate smaller teamlets, each led by a Consultant comprising 2 to 3 junior staff (Residents and Interns) so as to introduce some segregation amongst healthcare workers of the same specialty.", [["Vascular", "ANATOMY", 320, 328]]], ["SARS-CoV-2 positive or suspect patients are usually seen by the Consultant alone to reduce exposure to other members of the team.Vascular Surgery ClinicsClinic resources have been reduced by 50%, but a rapid access Diabetic Foot Clinic remains open as we felt Diabetic Foot patients usually require earlier and more urgent attention.", [["Vascular", "ANATOMY", 129, 137], ["Diabetic", "DISEASE", 215, 223], ["Diabetic", "DISEASE", 260, 268], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["patients", "ORGANISM", 31, 39], ["Vascular", "MULTI-TISSUE_STRUCTURE", 129, 137], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 274, 282], ["SARS-CoV", "TEST", 0, 8], ["a rapid access Diabetic Foot", "TREATMENT", 200, 228], ["Diabetic Foot", "PROBLEM", 260, 273], ["Foot", "ANATOMY", 224, 228], ["Foot", "ANATOMY", 269, 273]]], ["Patients with time-sensitive results, needing emergent surgery, or are symptomatic are booked into clinic slots while those on follow-up for chronic conditions or with non-urgent results have their appointments postponed.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["emergent surgery", "TREATMENT", 46, 62], ["symptomatic", "PROBLEM", 71, 82], ["chronic conditions", "PROBLEM", 141, 159]]], ["Phone consults are not infrequently carried out for non-urgent results to allay the anxiety of patients who are going to have their clinic visits postponed.", [["anxiety", "DISEASE", 84, 91], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103]]], ["Provisions are made for patients to obtain top-up of chronic medications without clinic consultation, with an option for a home delivery service.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["chronic medications", "TREATMENT", 53, 72], ["a home delivery service", "TREATMENT", 121, 144]]], ["New referrals are screened by consultants and appointments deferred depending on the acuity of the presenting complaints.Elective Vascular SurgeryAs the pandemic deepens, we not only have new COVID-19 patients but also a duty of care towards our Vascular Surgery patients, many of whom have life or limb-threatening conditions.", [["Vascular", "ANATOMY", 130, 138], ["Vascular", "ANATOMY", 246, 254], ["limb", "ANATOMY", 299, 303], ["Vascular", "MULTI-TISSUE_STRUCTURE", 130, 138], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 263, 271], ["limb", "ORGANISM_SUBDIVISION", 299, 303], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 263, 271], ["the presenting complaints", "PROBLEM", 95, 120], ["Elective Vascular Surgery", "TREATMENT", 121, 146], ["limb-threatening conditions", "PROBLEM", 299, 326], ["Vascular", "ANATOMY", 130, 138], ["Surgery", "OBSERVATION", 139, 146], ["Vascular", "ANATOMY", 246, 254], ["limb", "ANATOMY", 299, 303]]], ["We continue to perform selected Elective Vascular Operations and all listed elective operations are reviewed and triaged by a Consultant.", [["Vascular", "ANATOMY", 41, 49], ["Vascular", "MULTI-TISSUE_STRUCTURE", 41, 49], ["Elective Vascular Operations", "TREATMENT", 32, 60], ["Vascular", "ANATOMY", 41, 49]]], ["For each elective operation performed, we ask ourselves these questions1)Is this an essential surgery without which the patient will have a catastrophic morbidity or mortality if denied this?2)If surgery is denied, will this patient be admitted with a life or limb threatening condition which will utilize more resources if performed in an emergency setting?3)Do we have the expertise and resources to perform this surgery taking into consideration that some surgeons may be deployed to manage COVID-19 pandemic patients?", [["limb", "ANATOMY", 260, 264], ["pandemic", "DISEASE", 503, 511], ["patient", "ORGANISM", 120, 127], ["patient", "ORGANISM", 225, 232], ["limb", "ORGANISM_SUBDIVISION", 260, 264], ["patients", "ORGANISM", 512, 520], ["patient", "SPECIES", 120, 127], ["patient", "SPECIES", 225, 232], ["patients", "SPECIES", 512, 520], ["each elective operation", "TREATMENT", 4, 27], ["an essential surgery", "TREATMENT", 81, 101], ["a catastrophic morbidity", "PROBLEM", 138, 162], ["surgery", "TREATMENT", 196, 203], ["limb threatening condition", "PROBLEM", 260, 286], ["this surgery", "TREATMENT", 410, 422], ["essential", "OBSERVATION_MODIFIER", 84, 93], ["surgery", "OBSERVATION", 94, 101], ["catastrophic", "OBSERVATION_MODIFIER", 140, 152], ["morbidity", "OBSERVATION", 153, 162]]]], "b6ae4d88a03ac0b1142577db37678d6d59080bf3": [["Developmental and inherited disorders affecting the liver typically present in childhood but may affect individuals of any age.", [["liver", "ANATOMY", 52, 57], ["Developmental and inherited disorders affecting the liver", "DISEASE", 0, 57], ["liver", "ORGAN", 52, 57], ["Developmental and inherited disorders", "PROBLEM", 0, 37], ["inherited", "OBSERVATION_MODIFIER", 18, 27], ["disorders", "OBSERVATION", 28, 37], ["liver", "ANATOMY", 52, 57]]], ["The effect of inherited metabolic disorders on the liver may be considered primary, caused by the accumulation of a metabolite resulting from an enzyme defect (e.g. sphingomyelin in Niemann-Pick disease), or secondary, when the major changes in the liver are the result of a primarily extrahepatic defect (e.g. steatosis of the liver secondary to pancreatic insufficiency in Shwachman syndrome).", [["liver", "ANATOMY", 51, 56], ["liver", "ANATOMY", 249, 254], ["extrahepatic", "ANATOMY", 285, 297], ["liver", "ANATOMY", 328, 333], ["pancreatic", "ANATOMY", 347, 357], ["metabolic disorders", "DISEASE", 24, 43], ["sphingomyelin", "CHEMICAL", 165, 178], ["Niemann-Pick disease", "DISEASE", 182, 202], ["extrahepatic defect", "DISEASE", 285, 304], ["steatosis of the liver secondary to pancreatic insufficiency", "DISEASE", 311, 371], ["Shwachman syndrome", "DISEASE", 375, 393], ["sphingomyelin", "CHEMICAL", 165, 178], ["liver", "ORGAN", 51, 56], ["sphingomyelin", "SIMPLE_CHEMICAL", 165, 178], ["liver", "ORGAN", 249, 254], ["extrahepatic", "ORGAN", 285, 297], ["liver", "ORGAN", 328, 333], ["pancreatic", "ORGAN", 347, 357], ["inherited metabolic disorders on the liver", "PROBLEM", 14, 56], ["a metabolite", "PROBLEM", 114, 126], ["an enzyme defect", "PROBLEM", 142, 158], ["sphingomyelin", "PROBLEM", 165, 178], ["Pick disease", "PROBLEM", 190, 202], ["the major changes in the liver", "PROBLEM", 224, 254], ["a primarily extrahepatic defect", "PROBLEM", 273, 304], ["steatosis of the liver", "PROBLEM", 311, 333], ["pancreatic insufficiency", "PROBLEM", 347, 371], ["Shwachman syndrome", "PROBLEM", 375, 393], ["inherited", "OBSERVATION_MODIFIER", 14, 23], ["metabolic disorders", "OBSERVATION", 24, 43], ["liver", "ANATOMY", 51, 56], ["may be considered", "UNCERTAINTY", 57, 74], ["metabolite", "OBSERVATION_MODIFIER", 116, 126], ["enzyme defect", "OBSERVATION", 145, 158], ["Pick disease", "OBSERVATION", 190, 202], ["liver", "ANATOMY", 249, 254], ["primarily", "OBSERVATION_MODIFIER", 275, 284], ["extrahepatic", "ANATOMY", 285, 297], ["defect", "OBSERVATION", 298, 304], ["steatosis", "OBSERVATION", 311, 320], ["liver", "ANATOMY", 328, 333], ["pancreatic", "ANATOMY", 347, 357], ["insufficiency", "OBSERVATION", 358, 371], ["Shwachman syndrome", "OBSERVATION", 375, 393]]], ["Likewise, as the list of identified inherited metabolic disorders continues to expand, many have significant but indirect relevance to the liver.", [["liver", "ANATOMY", 139, 144], ["metabolic disorders", "DISEASE", 46, 65], ["liver", "ORGAN", 139, 144], ["inherited metabolic disorders", "PROBLEM", 36, 65], ["metabolic disorders", "OBSERVATION", 46, 65], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["liver", "ANATOMY", 139, 144]]], ["For example, liver histology is usually normal in primary hyperoxaluria while the kidneys and other organs may be irreparably damaged; however, despite medical management, dialysis and repetitive kidney transplants, cure is only obtained with a liver transplant.", [["liver", "ANATOMY", 13, 18], ["kidneys", "ANATOMY", 82, 89], ["organs", "ANATOMY", 100, 106], ["kidney", "ANATOMY", 196, 202], ["liver", "ANATOMY", 245, 250], ["primary hyperoxaluria", "DISEASE", 50, 71], ["liver", "ORGAN", 13, 18], ["kidneys", "ORGAN", 82, 89], ["organs", "ORGAN", 100, 106], ["kidney", "ORGAN", 196, 202], ["liver", "ORGAN", 245, 250], ["liver histology", "TEST", 13, 28], ["primary hyperoxaluria", "PROBLEM", 50, 71], ["medical management", "TREATMENT", 152, 170], ["dialysis", "TREATMENT", 172, 180], ["repetitive kidney transplants", "TREATMENT", 185, 214], ["a liver transplant", "TREATMENT", 243, 261], ["liver", "ANATOMY", 13, 18], ["histology", "OBSERVATION", 19, 28], ["normal", "OBSERVATION", 40, 46], ["primary", "OBSERVATION_MODIFIER", 50, 57], ["hyperoxaluria", "OBSERVATION", 58, 71], ["kidneys", "ANATOMY", 82, 89], ["organs", "ANATOMY", 100, 106], ["may be", "UNCERTAINTY", 107, 113], ["irreparably", "OBSERVATION_MODIFIER", 114, 125], ["damaged", "OBSERVATION", 126, 133], ["kidney", "ANATOMY", 196, 202], ["transplants", "OBSERVATION", 203, 214], ["liver", "ANATOMY", 245, 250], ["transplant", "OBSERVATION", 251, 261]]], ["1 In other inherited disorders, the liver disease may remain asymptomatic until precipitous acute liver failure develops; the classic example is Wilson disease.", [["liver", "ANATOMY", 36, 41], ["liver", "ANATOMY", 98, 103], ["inherited disorders", "DISEASE", 11, 30], ["liver disease", "DISEASE", 36, 49], ["acute liver failure", "DISEASE", 92, 111], ["Wilson disease", "DISEASE", 145, 159], ["liver", "ORGAN", 36, 41], ["liver", "ORGAN", 98, 103], ["other inherited disorders", "PROBLEM", 5, 30], ["the liver disease", "PROBLEM", 32, 49], ["asymptomatic", "PROBLEM", 61, 73], ["precipitous acute liver failure", "PROBLEM", 80, 111], ["Wilson disease", "PROBLEM", 145, 159], ["inherited", "OBSERVATION_MODIFIER", 11, 20], ["disorders", "OBSERVATION", 21, 30], ["liver", "ANATOMY", 36, 41], ["disease", "OBSERVATION", 42, 49], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["liver", "ANATOMY", 98, 103], ["failure", "OBSERVATION", 104, 111], ["Wilson disease", "OBSERVATION", 145, 159]]], ["2 This similarly occurs with developmental disorders; choledochal cyst may be diagnosed by prenatal sonography, or it may not become evident until late in childhood.", [["choledochal cyst", "ANATOMY", 54, 70], ["choledochal cyst", "DISEASE", 54, 70], ["choledochal cyst", "PATHOLOGICAL_FORMATION", 54, 70], ["developmental disorders", "PROBLEM", 29, 52], ["choledochal cyst", "PROBLEM", 54, 70], ["prenatal sonography", "TEST", 91, 110], ["choledochal", "ANATOMY", 54, 65], ["cyst", "OBSERVATION", 66, 70]]], ["In many cases the clinical diagnosis of an inherited disorder is not clinically evident, and consequently, diagnosis becomes the responsibility of the histopathologist, who may save not only the life of the patient, but that of other family members as well.", [["inherited disorder", "DISEASE", 43, 61], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["an inherited disorder", "PROBLEM", 40, 61], ["inherited", "OBSERVATION_MODIFIER", 43, 52], ["disorder", "OBSERVATION", 53, 61], ["not clinically", "UNCERTAINTY", 65, 79]]], ["Advances in molecular genetics constantly improve our understanding of the biological basis of many metabolic diseases.", [["metabolic diseases", "DISEASE", 100, 118], ["many metabolic diseases", "PROBLEM", 95, 118], ["metabolic diseases", "OBSERVATION", 100, 118]]]], "e39dc9d815205392a42ab86807cc84843996b7cc": [["J o u r n a l P r e -p r o o f 4To the Editor,Clinical severity of COVID-19 infections ranges widely, from asymptomatic or mild disease of the upper airways to pneumonia and acute respiratory distress syndrome (ARDS) [1] [2] [3] .", [["upper airways", "ANATOMY", 143, 156], ["respiratory", "ANATOMY", 180, 191], ["infections", "DISEASE", 76, 86], ["pneumonia", "DISEASE", 160, 169], ["acute respiratory distress syndrome", "DISEASE", 174, 209], ["ARDS", "DISEASE", 211, 215], ["upper airways", "ORGANISM_SUBDIVISION", 143, 156], ["COVID", "TEST", 67, 72], ["19 infections", "PROBLEM", 73, 86], ["asymptomatic", "PROBLEM", 107, 119], ["mild disease of the upper airways", "PROBLEM", 123, 156], ["pneumonia", "PROBLEM", 160, 169], ["acute respiratory distress syndrome", "PROBLEM", 174, 209], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["disease", "OBSERVATION", 128, 135], ["upper", "ANATOMY_MODIFIER", 143, 148], ["airways", "ANATOMY", 149, 156], ["pneumonia", "OBSERVATION", 160, 169], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["respiratory distress", "OBSERVATION", 180, 200]]], ["We aim to describe biological features and outcomes of 240 patients admitted for SARS-CoV-2 pneumonia, as well as identify predictors of intensive care unit (ICU) admission (either direct admission or transfer to ICU within 96 hours of admission from emergency department), need for invasive mechanical ventilation (IMV) and inhospital mortality.To the Editor,For this retrospective, observational study, all consecutive patients with laboratoryconfirmed SARS-CoV-2 infection and pneumonia (positive result by real-time polymerase chain reaction testing of a oropharyngeal plus nasopharyngeal sample 4 ), who visited the emergency department and were subsequently admitted to the hospital between February 28 th and April 21 st , 2020, were included.", [["oropharyngeal", "ANATOMY", 559, 572], ["nasopharyngeal sample", "ANATOMY", 578, 599], ["SARS", "DISEASE", 81, 85], ["pneumonia", "DISEASE", 92, 101], ["SARS-CoV-2 infection", "DISEASE", 455, 475], ["pneumonia", "DISEASE", 480, 489], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 421, 429], ["CoV-2", "SPECIES", 460, 465], ["SARS-CoV-2", "SPECIES", 455, 465], ["SARS", "PROBLEM", 81, 85], ["CoV", "PROBLEM", 86, 89], ["pneumonia", "PROBLEM", 92, 101], ["invasive mechanical ventilation", "TREATMENT", 283, 314], ["inhospital mortality", "PROBLEM", 325, 345], ["observational study", "TEST", 384, 403], ["laboratoryconfirmed SARS", "PROBLEM", 435, 459], ["CoV", "TEST", 460, 463], ["2 infection", "PROBLEM", 464, 475], ["pneumonia", "PROBLEM", 480, 489], ["a oropharyngeal plus nasopharyngeal sample", "TREATMENT", 557, 599], ["pneumonia", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 466, 475], ["pneumonia", "OBSERVATION", 480, 489], ["oropharyngeal", "ANATOMY", 559, 572]]], ["Patients without pneumonia were excluded.", [["pneumonia", "DISEASE", 17, 26], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["pneumonia", "PROBLEM", 17, 26], ["without", "UNCERTAINTY", 9, 16], ["pneumonia", "OBSERVATION", 17, 26]]], ["The Institutional Ethics Board approved this study and due to its nature, waived the need for informed consent.", [["this study", "TEST", 40, 50]]], ["Patients were divided into two groups: non-ICU and ICU-admitted (either direct admission or transfer to ICU within 96 hours of admission from emergency department).To the Editor,Descriptive statistics were used for basic features of study data; appropriate statistical tests were performed to compare both groups.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["study data", "TEST", 233, 243], ["appropriate statistical tests", "TEST", 245, 274]]], ["Univariate and multivariable binary logistic regression 5 , multinomial logistic regression 5 and Cox regression 6 analyses were performed to identify variables associated with ICU admission, mechanical ventilation and in-hospital mortality, respectively.", [["Univariate", "TREATMENT", 0, 10], ["multivariable binary logistic regression", "TREATMENT", 15, 55], ["multinomial logistic regression", "TREATMENT", 60, 91], ["Cox regression 6 analyses", "TEST", 98, 123], ["mechanical ventilation", "TREATMENT", 192, 214], ["mechanical ventilation", "OBSERVATION", 192, 214]]], ["When compared to non-ICU patients, ICU-admitted patients were more likely to be men and have higher body mass index (BMI).", [["body", "ANATOMY", 100, 104], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 48, 56], ["men", "ORGANISM", 80, 83], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 48, 56], ["men", "SPECIES", 80, 83], ["higher body mass index", "PROBLEM", 93, 115], ["mass", "OBSERVATION", 105, 109]]], ["ICU-admitted patients also showed higher levels of creatinine, C-reactive protein, neutrophils, lactate dehydrogenase (LDH), white blood cell count, troponin, D-dimer, ferritin, and troponin.", [["neutrophils", "ANATOMY", 83, 94], ["white blood cell", "ANATOMY", 125, 141], ["creatinine", "CHEMICAL", 51, 61], ["lactate", "CHEMICAL", 96, 103], ["creatinine", "CHEMICAL", 51, 61], ["lactate", "CHEMICAL", 96, 103], ["patients", "ORGANISM", 13, 21], ["creatinine", "SIMPLE_CHEMICAL", 51, 61], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 63, 81], ["neutrophils", "CELL", 83, 94], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 96, 117], ["LDH", "GENE_OR_GENE_PRODUCT", 119, 122], ["white blood cell", "CELL", 125, 141], ["troponin", "GENE_OR_GENE_PRODUCT", 149, 157], ["D-dimer", "GENE_OR_GENE_PRODUCT", 159, 166], ["ferritin", "GENE_OR_GENE_PRODUCT", 168, 176], ["troponin", "GENE_OR_GENE_PRODUCT", 182, 190], ["C-reactive protein", "PROTEIN", 63, 81], ["neutrophils", "CELL_TYPE", 83, 94], ["lactate dehydrogenase", "PROTEIN", 96, 117], ["LDH", "PROTEIN", 119, 122], ["troponin", "PROTEIN", 149, 157], ["D-dimer", "PROTEIN", 159, 166], ["ferritin", "PROTEIN", 168, 176], ["troponin", "PROTEIN", 182, 190], ["patients", "SPECIES", 13, 21], ["creatinine", "TEST", 51, 61], ["C", "TEST", 63, 64], ["reactive protein", "TEST", 65, 81], ["neutrophils", "TEST", 83, 94], ["lactate dehydrogenase", "TEST", 96, 117], ["LDH", "TEST", 119, 122], ["white blood cell count", "TEST", 125, 147], ["troponin", "TEST", 149, 157], ["D-dimer", "TEST", 159, 166], ["ferritin", "TEST", 168, 176], ["troponin", "TEST", 182, 190]]], ["Similarly, we observed elevated Creactive protein-to-lymphocyte, neutrophil-to-lymphocyte ratio and lower lymphocyte count and oxygen saturation upon admission (first 24h) in ICU-admitted patients.", [["lymphocyte", "ANATOMY", 53, 63], ["neutrophil", "ANATOMY", 65, 75], ["lymphocyte", "ANATOMY", 79, 89], ["lymphocyte", "ANATOMY", 106, 116], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 127, 133], ["lymphocyte", "CELL", 53, 63], ["neutrophil", "CELL", 65, 75], ["lymphocyte", "CELL", 79, 89], ["lymphocyte", "CELL", 106, 116], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["patients", "ORGANISM", 188, 196], ["Creactive protein", "PROTEIN", 32, 49], ["neutrophil", "CELL_TYPE", 65, 75], ["patients", "SPECIES", 188, 196], ["elevated Creactive protein", "PROBLEM", 23, 49], ["lymphocyte", "TEST", 53, 63], ["neutrophil", "TEST", 65, 75], ["lymphocyte ratio", "TEST", 79, 95], ["lower lymphocyte count", "PROBLEM", 100, 122], ["oxygen saturation", "TEST", 127, 144], ["elevated", "OBSERVATION_MODIFIER", 23, 31], ["lower lymphocyte count", "OBSERVATION", 100, 122], ["oxygen saturation", "OBSERVATION", 127, 144]]], ["During hospitalization (days 3-5), those admitted to the ICU developed severe lymphopenia more frequently (0.6 vs. 1.1; P<0.001) than non-ICU patients.", [["lymphopenia", "DISEASE", 78, 89], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["severe lymphopenia", "PROBLEM", 71, 89], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["lymphopenia", "OBSERVATION", 78, 89]]], ["Levels of C-reactive protein, neutrophils, white blood cell count, alanine aminotransferase (ALT) and LDH, Ddimer and ferritin were higher in ICU-admitted patients over time (day 3-5) ( This cohort study provides the first description of COVID-19 pneumonia in Barcelona, Spain.", [["neutrophils", "ANATOMY", 30, 41], ["white blood cell", "ANATOMY", 43, 59], ["alanine", "CHEMICAL", 67, 74], ["pneumonia", "DISEASE", 247, 256], ["alanine", "CHEMICAL", 67, 74], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 10, 28], ["neutrophils", "CELL", 30, 41], ["white blood cell", "CELL", 43, 59], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 67, 91], ["ALT", "GENE_OR_GENE_PRODUCT", 93, 96], ["LDH", "GENE_OR_GENE_PRODUCT", 102, 105], ["Ddimer", "GENE_OR_GENE_PRODUCT", 107, 113], ["ferritin", "GENE_OR_GENE_PRODUCT", 118, 126], ["patients", "ORGANISM", 155, 163], ["C-reactive protein", "PROTEIN", 10, 28], ["neutrophils", "CELL_TYPE", 30, 41], ["alanine aminotransferase", "PROTEIN", 67, 91], ["ALT", "PROTEIN", 93, 96], ["LDH", "PROTEIN", 102, 105], ["Ddimer", "PROTEIN", 107, 113], ["ferritin", "PROTEIN", 118, 126], ["patients", "SPECIES", 155, 163], ["Levels", "TEST", 0, 6], ["C-reactive protein", "TEST", 10, 28], ["neutrophils", "TEST", 30, 41], ["white blood cell count", "TEST", 43, 65], ["alanine aminotransferase", "TEST", 67, 91], ["ALT", "TEST", 93, 96], ["LDH", "TEST", 102, 105], ["Ddimer", "TEST", 107, 113], ["ferritin", "TEST", 118, 126], ["This cohort study", "TEST", 186, 203], ["COVID", "TEST", 238, 243], ["pneumonia", "PROBLEM", 247, 256], ["LDH", "ANATOMY", 102, 105], ["pneumonia", "OBSERVATION", 247, 256]]], ["Patients with higher BMI and elevated levels of C-reactive protein-to-lymphocyte ratio and ferritin upon admission presented with an increased risk of ICU admission.", [["lymphocyte", "ANATOMY", 70, 80], ["Patients", "ORGANISM", 0, 8], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 48, 66], ["ferritin", "GENE_OR_GENE_PRODUCT", 91, 99], ["C-reactive protein", "PROTEIN", 48, 66], ["ferritin", "PROTEIN", 91, 99], ["Patients", "SPECIES", 0, 8], ["higher BMI", "PROBLEM", 14, 24], ["elevated levels", "PROBLEM", 29, 44], ["C-reactive protein", "PROBLEM", 48, 66], ["lymphocyte ratio", "TEST", 70, 86], ["ferritin", "TEST", 91, 99], ["increased", "OBSERVATION_MODIFIER", 133, 142]]], ["This immunological dysregulation in severe COVID-19 8 .", [["COVID-19", "CHEMICAL", 43, 51], ["This immunological dysregulation", "TEST", 0, 32], ["severe COVID", "TEST", 36, 48], ["severe", "OBSERVATION_MODIFIER", 36, 42]]], ["Similarly, it is well known that obesity is a risk factor for severe infection, related to low-grade chronic inflammation and has a potential effect on immune responses 9 .To the Editor,Interestingly, we observed that platelet levels were an additional variable independently associated with ICU admission in both patients who went directly to the ICU and those who transferred to the ICU within 96 hours of admission to the emergency department.To the Editor,These results support the fact that a decrease in platelet count usually indicates multiple organ dysfunction, and provides prognostic information 10 .To the Editor,Twenty-four percent of our patients underwent IMV.", [["platelet", "ANATOMY", 218, 226], ["platelet", "ANATOMY", 510, 518], ["organ", "ANATOMY", 552, 557], ["obesity", "DISEASE", 33, 40], ["infection", "DISEASE", 69, 78], ["inflammation", "DISEASE", 109, 121], ["organ dysfunction", "DISEASE", 552, 569], ["platelet", "CELL", 218, 226], ["patients", "ORGANISM", 314, 322], ["platelet", "CELL", 510, 518], ["organ", "ORGAN", 552, 557], ["patients", "ORGANISM", 652, 660], ["patients", "SPECIES", 314, 322], ["patients", "SPECIES", 652, 660], ["obesity", "PROBLEM", 33, 40], ["a risk factor", "PROBLEM", 44, 57], ["severe infection", "PROBLEM", 62, 78], ["low-grade chronic inflammation", "PROBLEM", 91, 121], ["platelet levels", "TEST", 218, 233], ["a decrease in platelet count", "PROBLEM", 496, 524], ["multiple organ dysfunction", "PROBLEM", 543, 569], ["IMV", "TREATMENT", 671, 674], ["obesity", "OBSERVATION", 33, 40], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["infection", "OBSERVATION", 69, 78], ["low-grade", "OBSERVATION_MODIFIER", 91, 100], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["inflammation", "OBSERVATION", 109, 121], ["decrease", "OBSERVATION_MODIFIER", 498, 506], ["platelet count", "OBSERVATION", 510, 524], ["multiple", "OBSERVATION_MODIFIER", 543, 551], ["organ", "ANATOMY", 552, 557], ["dysfunction", "OBSERVATION", 558, 569]]], ["Notably, we found that C-reactive protein-to-lymphocyte ratio and ferritin levels upon admission were independently associated with the need for IMV.", [["lymphocyte", "ANATOMY", 45, 55], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 23, 41], ["ferritin", "GENE_OR_GENE_PRODUCT", 66, 74], ["C-reactive protein", "PROTEIN", 23, 41], ["ferritin", "PROTEIN", 66, 74], ["C-reactive protein", "TEST", 23, 41], ["lymphocyte ratio", "TEST", 45, 61], ["ferritin levels", "TEST", 66, 81], ["IMV", "TREATMENT", 145, 148]]], ["Previous studies reported that higher ferritin levels were associated with a clinical deterioration in patients with COVID-19.", [["COVID-19", "CHEMICAL", 117, 125], ["ferritin", "GENE_OR_GENE_PRODUCT", 38, 46], ["patients", "ORGANISM", 103, 111], ["ferritin", "PROTEIN", 38, 46], ["patients", "SPECIES", 103, 111], ["Previous studies", "TEST", 0, 16], ["higher ferritin levels", "PROBLEM", 31, 53], ["a clinical deterioration", "PROBLEM", 75, 99], ["COVID", "TEST", 117, 122]]], ["A meta-analysis also reported that both the neutrophil-to-lymphocyte ratio and C-reactive protein-tolymphocyte ratio significantly increased in severe COVID-19 cases 7 .", [["neutrophil", "ANATOMY", 44, 54], ["lymphocyte", "ANATOMY", 58, 68], ["COVID", "DISEASE", 151, 156], ["neutrophil", "CELL", 44, 54], ["lymphocyte", "CELL", 58, 68], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 79, 97], ["neutrophil", "CELL_TYPE", 44, 54], ["C-reactive protein", "PROTEIN", 79, 97], ["A meta-analysis", "TEST", 0, 15], ["the neutrophil", "TEST", 40, 54], ["lymphocyte ratio", "TEST", 58, 74], ["C", "TEST", 79, 80], ["reactive protein", "TEST", 81, 97], ["tolymphocyte ratio", "TEST", 98, 116], ["severe COVID", "TEST", 144, 156], ["severe", "OBSERVATION_MODIFIER", 144, 150]]], ["However, this cohort study is the first of its nature to explore the value of the C-reactive protein-tolymphocyte ratio in patients with COVID-19 pneumonia.", [["pneumonia", "DISEASE", 146, 155], ["C-reactive protein-tolymphocyte", "GENE_OR_GENE_PRODUCT", 82, 113], ["patients", "ORGANISM", 123, 131], ["C-reactive protein", "PROTEIN", 82, 100], ["patients", "SPECIES", 123, 131], ["this cohort study", "TEST", 9, 26], ["the C-reactive protein", "TEST", 78, 100], ["COVID", "TEST", 137, 142], ["pneumonia", "PROBLEM", 146, 155], ["pneumonia", "OBSERVATION", 146, 155]]], ["The level of C-reactive proteinto-lymphocyte ratio reflects the balance between the systemic inflammatory and immune responses.", [["lymphocyte", "ANATOMY", 34, 44], ["lymphocyte", "CELL", 34, 44], ["C-reactive proteinto", "TEST", 13, 33], ["lymphocyte ratio", "TEST", 34, 50], ["systemic", "ANATOMY", 84, 92], ["inflammatory", "OBSERVATION", 93, 105]]], ["An elevated C-reactive protein-to-lymphocyte ratio indicates an increase in the systemic inflammatory response and a decrease in the immune response.To the Editor,As we observed in our study, elevated C-reactive protein-to-lymphocyte ratio is an important predictor factor for both ICU admission (both direct admission and transfer to ICU) and need for IMV.", [["lymphocyte", "ANATOMY", 34, 44], ["lymphocyte", "ANATOMY", 223, 233], ["lymphocyte", "CELL", 223, 233], ["C-reactive protein", "PROTEIN", 12, 30], ["C-reactive protein", "PROTEIN", 201, 219], ["An elevated C-reactive protein", "PROBLEM", 0, 30], ["lymphocyte ratio", "TEST", 34, 50], ["an increase", "PROBLEM", 61, 72], ["the systemic inflammatory response", "PROBLEM", 76, 110], ["a decrease in the immune response", "PROBLEM", 115, 148], ["our study", "TEST", 181, 190], ["elevated C-reactive protein", "PROBLEM", 192, 219], ["lymphocyte ratio", "TEST", 223, 239], ["IMV", "TREATMENT", 353, 356], ["elevated", "OBSERVATION_MODIFIER", 3, 11], ["-reactive protein", "OBSERVATION", 13, 30], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["systemic", "OBSERVATION_MODIFIER", 80, 88], ["inflammatory response", "OBSERVATION", 89, 110], ["decrease", "OBSERVATION_MODIFIER", 117, 125], ["immune response", "OBSERVATION", 133, 148]]], ["The results of our study have important clinical implications and strengths.", [["our study", "TEST", 15, 24]]], ["As C-reactive protein-to-lymphocyte ratio could be quickly calculated based on a routine blood test performed upon admission, clinicians may be able to identify high-risk patients with COVID-19 during the early stages of the infection.", [["lymphocyte", "ANATOMY", 25, 35], ["blood", "ANATOMY", 89, 94], ["COVID-19", "CHEMICAL", 185, 193], ["infection", "DISEASE", 225, 234], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["patients", "ORGANISM", 171, 179], ["C-reactive protein", "PROTEIN", 3, 21], ["patients", "SPECIES", 171, 179], ["C-reactive protein", "TEST", 3, 21], ["lymphocyte ratio", "TEST", 25, 41], ["a routine blood test", "TEST", 79, 99], ["COVID", "TEST", 185, 190], ["the infection", "PROBLEM", 221, 234], ["infection", "OBSERVATION", 225, 234]]], ["The main limitation of the study is that it includes patients from a single center.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["the study", "TEST", 23, 32], ["main", "OBSERVATION_MODIFIER", 4, 8], ["limitation", "OBSERVATION_MODIFIER", 9, 19]]], ["Notwithstanding, important preliminary results concerning risk factors for ICU admission and need for IMV in patients with COVID-19 pneumonia are provided.To the Editor,Early recognition of easily obtainable markers upon hospital admission such as serum ferritin, D-dimer, platelet count and the C-reactive protein-to-lymphocyte ratio could help identify and prioritize patients with a higher probability for ICU admission (both direct admission and transfer to ICU) and need of IMV during the course of hospitalization.", [["serum", "ANATOMY", 248, 253], ["platelet", "ANATOMY", 273, 281], ["lymphocyte", "ANATOMY", 318, 328], ["pneumonia", "DISEASE", 132, 141], ["patients", "ORGANISM", 109, 117], ["serum", "ORGANISM_SUBSTANCE", 248, 253], ["ferritin", "GENE_OR_GENE_PRODUCT", 254, 262], ["D-dimer", "GENE_OR_GENE_PRODUCT", 264, 271], ["platelet", "CELL", 273, 281], ["patients", "ORGANISM", 370, 378], ["serum ferritin", "PROTEIN", 248, 262], ["D-dimer", "PROTEIN", 264, 271], ["C-reactive protein", "PROTEIN", 296, 314], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 370, 378], ["IMV", "TREATMENT", 102, 105], ["COVID", "TEST", 123, 128], ["pneumonia", "PROBLEM", 132, 141], ["serum ferritin", "TEST", 248, 262], ["D-dimer", "TEST", 264, 271], ["platelet count", "TEST", 273, 287], ["the C-reactive protein", "TEST", 292, 314], ["lymphocyte ratio", "TEST", 318, 334], ["IMV", "TREATMENT", 479, 482], ["pneumonia", "OBSERVATION", 132, 141]]]], "1dd754bc45872dbb88f147da1601ce6f343f6c9b": [["DESCRIPTION OF PROBLEMFeeding spray-dried plasma (SDP) to animals (pigs, poultry, calves, and pets) improves growth performance and health [1, 2, 3, 4, 5] .", [["plasma", "ANATOMY", 42, 48], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["pigs", "ORGANISM", 67, 71], ["calves", "ORGANISM", 82, 88], ["pigs", "SPECIES", 67, 71], ["calves", "SPECIES", 82, 88], ["pigs", "SPECIES", 67, 71], ["poultry", "SPECIES", 73, 80], ["PROBLEMFeeding spray", "TREATMENT", 15, 35], ["dried plasma (SDP)", "TREATMENT", 36, 54]]], ["Spray-dried plasma is available in multiple forms, including powder, granules, or in a water-soluble form.", [["plasma", "ANATOMY", 12, 18], ["granules", "ANATOMY", 69, 77], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["granules", "ORGANISM_SUBSTANCE", 69, 77], ["Spray", "TREATMENT", 0, 5], ["dried plasma", "TREATMENT", 6, 18], ["powder", "TREATMENT", 61, 67]]], ["Previous research [6] demonstrated that, in pigs, granulated SDP (Appetein) [7] improved growth performance to a greater extent than did powdered SDP (AP 920) [7] .", [["Appetein", "CHEMICAL", 66, 74], ["AP 920", "CHEMICAL", 151, 157], ["pigs", "ORGANISM", 44, 48], ["SDP", "SIMPLE_CHEMICAL", 61, 64], ["Appetein", "SIMPLE_CHEMICAL", 66, 74], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 44, 48], ["granulated SDP", "OBSERVATION", 50, 64], ["greater extent", "OBSERVATION_MODIFIER", 113, 127]]], ["However, no research 1 Corresponding author: joy.campbell@amerprotcorp.com has been reported comparing the efficacy of granulated SDP to powdered SDP in broilers.DESCRIPTION OF PROBLEMWhen fed to pigs, SDP is generally fed during the first 1 to 2 wk postweaning [2] and is not typically fed thereafter.", [["SDP", "CHEMICAL", 146, 149], ["SDP", "SIMPLE_CHEMICAL", 130, 133], ["SDP", "SIMPLE_CHEMICAL", 146, 149], ["broilers", "ORGANISM_SUBDIVISION", 153, 161], ["pigs", "ORGANISM", 196, 200], ["broilers", "SPECIES", 153, 161], ["pigs", "SPECIES", 196, 200], ["broilers", "SPECIES", 153, 161], ["pigs", "SPECIES", 196, 200], ["granulated SDP", "PROBLEM", 119, 133], ["no", "UNCERTAINTY", 9, 11], ["granulated", "OBSERVATION_MODIFIER", 119, 129], ["SDP", "OBSERVATION", 130, 133], ["powdered SDP", "OBSERVATION_MODIFIER", 137, 149]]], ["However, recent reports have suggested that SDP will improve growth performance of broilers [8] and pigs [9] in later phases of production.", [["SDP", "CHEMICAL", 44, 47], ["SDP", "SIMPLE_CHEMICAL", 44, 47], ["pigs", "ORGANISM", 100, 104], ["pigs", "SPECIES", 100, 104], ["SDP", "PROBLEM", 44, 47]]], ["Thus, the objective of the study was to evaluate the effect of duration of feeding and form (granular vs. powder) of SDP on performance and mortality of broilers under simulated production conditions.", [["SDP", "CHEMICAL", 117, 120], ["SDP", "SIMPLE_CHEMICAL", 117, 120], ["broilers", "ORGANISM_SUBDIVISION", 153, 161], ["the study", "TEST", 23, 32], ["duration of feeding", "TREATMENT", 63, 82], ["SDP", "PROBLEM", 117, 120]]], ["Powder = spray-dried powder plasma (AP 920) [7] .", [["AP 920", "CHEMICAL", 36, 42], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["Powder = spray", "TREATMENT", 0, 14]]], ["2 Granular = spray-dried granular plasma (Appetein) [7] .MATERIALS AND METHODSBroilers used in the experiment were handled in accordance with published guidelines [10].", [["granular plasma", "ANATOMY", 25, 40], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["Appetein", "SIMPLE_CHEMICAL", 42, 50], ["METHODSBroilers", "TREATMENT", 71, 86]]], ["Two hundred forty 1-d-old Ross \u00d7 Ross 308 male broilers (BW = 33.6 g) [11] were randomly assigned to 1 of 5 experimental treatments blocked by initial BW.", [["broilers", "ORGANISM", 47, 55], ["broilers", "SPECIES", 47, 55]]], ["Treatments included a control (no plasma) and 2 forms of SDP (powder, AP 920; granular, Appetein) fed continuously throughout the experiment or discontinued after d 14 (Table 1) .", [["plasma", "ANATOMY", 34, 40], ["SDP", "CHEMICAL", 57, 60], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["SDP", "SIMPLE_CHEMICAL", 57, 60], ["SDP (powder", "TREATMENT", 57, 68], ["granular, Appetein)", "TREATMENT", 78, 97]]], ["Diets were formulated to meet or exceed nutrient requirements for broilers [12] .MATERIALS AND METHODSThe feeding program consisted of 3 phases, with starter from d 0 to 14, grower from d 15 to 28, and finisher from d 29 to 35 of the experiment.", [["METHODSThe feeding program", "TREATMENT", 95, 121]]], ["Spray-dried plasma [7] was produced according to standard manufacturing procedures and added at the rate of 1.0, 0.5, and 0.25% in the starter, grower, and finisher diets, respectively.", [["plasma", "ANATOMY", 12, 18], ["plasma", "ORGANISM_SUBSTANCE", 12, 18]]], ["Feed was manufactured according to standard procedures at Kansas State University [13] ( Table 2 ).", [["Feed", "TREATMENT", 0, 4]]], ["In all diets, 1% fat was added before pelleting, with the remaining fat added after pelleting.", [["fat", "ANATOMY", 17, 20], ["fat", "ANATOMY", 68, 71], ["fat", "TISSUE", 17, 20], ["fat", "TISSUE", 68, 71]]], ["Diets were pelleted at a 85\u00b0C conditioning temperature using a 0.40 \u00d7 3.18 cm die and a conditioning retention time of 15 s.", [["a 0.40 \u00d7 3.18 cm die", "TREATMENT", 61, 81], ["a conditioning retention time", "TREATMENT", 86, 115]]], ["Starter diets were crumbled.", [["Starter diets", "TREATMENT", 0, 13]]], ["The hanging feeders were adjusted regularly to maintain optimal height for feed consumption.", [["The hanging feeders", "TREATMENT", 0, 19], ["hanging feeders", "OBSERVATION", 4, 19]]], ["Water was delivered via free-standing 3.8-L poultry founts.", [["free-standing 3.8-L poultry founts", "TREATMENT", 24, 58]]], ["Broilers (6 per pen; 8 pens per treatment) were housed in floor pens (56 \u00d7 122 cm).", [["Broilers", "ANATOMY", 0, 8], ["Broilers", "TREATMENT", 0, 8]]], ["Pens contained soiled litter (softwood shavings used in 3 consecutive experiments), resulting in a high pathogen load environment.", [["litter", "ORGANISM_SUBDIVISION", 22, 28], ["Pens", "TREATMENT", 0, 4], ["softwood shavings", "TREATMENT", 30, 47], ["a high pathogen load environment", "PROBLEM", 97, 129], ["soiled", "OBSERVATION_MODIFIER", 15, 21], ["litter", "OBSERVATION_MODIFIER", 22, 28]]], ["Following removal of broilers from the previous experiments, all pens were raked, allowed to dry (2 d), and caked dry litter was removed.", [["removal", "TREATMENT", 10, 17], ["broilers", "TREATMENT", 21, 29], ["the previous experiments", "TREATMENT", 35, 59], ["all pens", "TREATMENT", 61, 69], ["broilers", "OBSERVATION_MODIFIER", 21, 29]]], ["The remaining litter was mixed with new litter and leveled to an average depth of 10 cm.", [["remaining", "OBSERVATION_MODIFIER", 4, 13], ["litter", "OBSERVATION_MODIFIER", 14, 20], ["mixed", "OBSERVATION_MODIFIER", 25, 30], ["new", "OBSERVATION_MODIFIER", 36, 39], ["litter", "OBSERVATION_MODIFIER", 40, 46], ["average", "OBSERVATION_MODIFIER", 65, 72], ["depth", "OBSERVATION_MODIFIER", 73, 78], ["10 cm", "OBSERVATION_MODIFIER", 82, 87]]], ["Heat lamps maintained average temperatures at bird levels of 32, 29, 27, and 24\u00b0C for wk 1, 2, 3, and 4 to the end, respectively.", [["Heat lamps", "TEST", 0, 10], ["average temperatures", "TEST", 22, 42], ["bird levels", "TEST", 46, 57]]], ["Broilers were maintained on 23L:1D.", [["Broilers", "ANATOMY", 0, 8], ["Broilers", "CELL", 0, 8]]], ["Vaccinations prehatch were half a dose of Marek's and, before shipping, half a dose of Newcastle and Bronchitis.", [["Marek", "ORGANISM", 42, 47], ["Marek", "SPECIES", 42, 47], ["Vaccinations", "TREATMENT", 0, 12], ["Marek's", "TREATMENT", 42, 49], ["shipping", "TREATMENT", 62, 70], ["Newcastle", "TREATMENT", 87, 96], ["Bronchitis", "PROBLEM", 101, 111], ["Bronchitis", "OBSERVATION", 101, 111]]], ["On d 7, all birds were vaccinated with Bursal Disease Vaccine [15] via the water, and on d 14, they were vaccinated with Newcastle-Bronchitis Vaccine [16] by coarse spray.MATERIALS AND METHODSFeed intake and mortality were measured daily.", [["birds", "ORGANISM", 12, 17], ["all birds", "TREATMENT", 8, 17], ["Bursal Disease Vaccine", "TREATMENT", 39, 61], ["Newcastle-Bronchitis Vaccine", "TREATMENT", 121, 149], ["Bursal", "ANATOMY", 39, 45]]], ["Pen weight was measured daily to d 7 and weekly thereafter.", [["Pen weight", "TEST", 0, 10]]], ["Individual BW were measured on d 0.", [["Individual BW", "TEST", 0, 13]]], ["Data were analyzed as a randomized complete block design using the GLM procedures of SAS [17] .", [["a randomized complete block design", "TREATMENT", 22, 56], ["the GLM procedures", "TREATMENT", 63, 81], ["SAS", "TEST", 85, 88]]], ["Pen was the experimental unit, and placement within room of the facility was the blocking criterion.", [["placement", "TREATMENT", 35, 44]]], ["Least squares means were considered significantly different if P < 0.05.RESULTSThe experiment was originally planned for 42 d; however, it was terminated on d 35 due to increasing mortality of control broilers.", [["broilers", "ORGANISM_SUBDIVISION", 201, 209], ["P", "TEST", 63, 64], ["increasing mortality of control broilers", "PROBLEM", 169, 209]]], ["Mortality was the result of a natural challenge occurring in the facility.", [["a natural challenge", "TREATMENT", 28, 47]]], ["Broilers were necropsied by a trained pathologist and confirmed to have necrotic enteritis and cultured positive for Escherichia coli and Salmonella.", [["Broilers", "ANATOMY", 0, 8], ["necrotic enteritis", "DISEASE", 72, 90], ["Broilers", "ORGANISM", 0, 8], ["Escherichia coli", "ORGANISM", 117, 133], ["Escherichia coli", "SPECIES", 117, 133], ["Escherichia coli", "SPECIES", 117, 133], ["necrotic enteritis", "PROBLEM", 72, 90], ["Escherichia coli", "PROBLEM", 117, 133], ["Salmonella", "PROBLEM", 138, 148], ["necrotic", "OBSERVATION_MODIFIER", 72, 80], ["enteritis", "OBSERVATION", 81, 90], ["Escherichia coli", "OBSERVATION", 117, 133]]], ["Furthermore, the broilers were exhibiting rickets as a result of malabsorption from severe necrotic enteritis and had litter in the gizzard.RESULTSNo interactions (P > 0.10) between duration of feeding (continuous or not) or form (powder vs. granular) of SDP were noted (Table 3) .", [["gizzard", "ANATOMY", 132, 139], ["rickets", "DISEASE", 42, 49], ["malabsorption", "DISEASE", 65, 78], ["necrotic enteritis", "DISEASE", 91, 109], ["broilers", "ORGANISM", 17, 25], ["gizzard", "ORGANISM_SUBDIVISION", 132, 139], ["broilers", "SPECIES", 17, 25], ["rickets", "PROBLEM", 42, 49], ["malabsorption", "PROBLEM", 65, 78], ["severe necrotic enteritis", "PROBLEM", 84, 109], ["P", "TEST", 164, 165], ["SDP", "PROBLEM", 255, 258], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["necrotic", "OBSERVATION_MODIFIER", 91, 99], ["enteritis", "OBSERVATION", 100, 109], ["gizzard", "ANATOMY", 132, 139]]], ["Compared with that of control broilers, the addition of SDP improved (P < 0.05) average daily gain (ADG), average daily feed intake (ADFI), and feed effi- Figure 1 ).", [["SDP", "PROBLEM", 56, 59], ["SDP", "OBSERVATION_MODIFIER", 56, 59], ["improved", "OBSERVATION_MODIFIER", 60, 68]]], ["Compared with that of broilers consuming powdered SDP, granulated SDP improved (P < 0.05) ADG and feed efficiency from d 0 to 14 and improved (P = 0.10) ADFI from d 15 to 28 (Table 3) .", [["broilers", "ORGANISM", 22, 30], ["SDP", "SIMPLE_CHEMICAL", 66, 69], ["broilers", "SPECIES", 22, 30], ["broilers", "SPECIES", 22, 30], ["granulated SDP", "PROBLEM", 55, 69], ["ADG and feed efficiency", "TEST", 90, 113], ["ADFI", "TEST", 153, 157], ["granulated", "OBSERVATION_MODIFIER", 55, 65], ["SDP", "OBSERVATION_MODIFIER", 66, 69], ["improved", "OBSERVATION_MODIFIER", 70, 78]]], ["Overall (d 0 to 35; Table 3 ), no differences (P > 0.10) were noted in ADG, ADFI, and feed efficiency due to different plasma forms (granular vs. powder).", [["plasma", "ANATOMY", 119, 125], ["plasma", "ORGANISM_SUBSTANCE", 119, 125], ["P", "TEST", 47, 48], ["ADFI", "TEST", 76, 80], ["feed efficiency", "PROBLEM", 86, 101], ["different plasma forms", "PROBLEM", 109, 131], ["granular vs. powder", "TREATMENT", 133, 152]]], ["Granulation improved BW of broilers when measured on d 14 (P = 0.04), 21 (P = 0.09), and 35 (P = 0.08) compared with broilers consuming powder SDP (Table 4) .RESULTSContinuous feeding of SDP improved (P < 0.05; Table 3 ) ADG, ADFI, and feed efficiency for each period (d 15 to 28, 29 to 35, and 0 to 35) compared with that of broilers when SDP was removed from the diet on d 14.", [["SDP", "CHEMICAL", 340, 343], ["broilers", "ORGANISM", 326, 334], ["SDP", "SIMPLE_CHEMICAL", 340, 343], ["broilers", "SPECIES", 27, 35], ["broilers", "SPECIES", 326, 334], ["Granulation", "PROBLEM", 0, 11], ["d", "TEST", 53, 54], ["P", "TEST", 59, 60], ["P", "TEST", 74, 75], ["improved", "OBSERVATION_MODIFIER", 12, 20]]], ["Body weight was also improved (P < 0.05; Table 4 ) on d 28 and 35 when broilers continued to consume SDP compared with broilers when SDP was removed from the diet on d 14.RESULTSAverage daily feed intake of control broilers was lower than that of SDP-fed broilers (P < 0.05) by d 9 and began to plateau by d 14 ( Figure 2) .", [["Body", "ANATOMY", 0, 4], ["SDP", "CHEMICAL", 101, 104], ["SDP", "CHEMICAL", 133, 136], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["broilers", "ORGANISM", 71, 79], ["broilers", "ORGANISM_SUBDIVISION", 119, 127], ["broilers", "SPECIES", 215, 223], ["broilers", "SPECIES", 119, 127], ["Body weight", "TEST", 0, 11], ["control broilers", "TREATMENT", 207, 223], ["improved", "OBSERVATION_MODIFIER", 21, 29]]], ["Additionally, the removal of SDP from the diet on d 14 (discontinued treatments Powder/ D and Granular/D; Figure 2 ) resulted in ADFI Values represent the mean of 8 replicates per treatment with 6 broilers per pen.", [["SDP", "CHEMICAL", 29, 32], ["SDP", "SIMPLE_CHEMICAL", 29, 32], ["the removal of SDP", "TREATMENT", 14, 32], ["treatments", "TREATMENT", 69, 79], ["ADFI Values", "TEST", 129, 140]]], ["NS = nonsignificant at P > 0.10.", [["NS", "TREATMENT", 0, 2], ["nonsignificant", "OBSERVATION_MODIFIER", 5, 19]]], ["Powder = spray-dried powder plasma (AP 920) [7] ; Granular = spraydried granular plasma (Appetein) [7] .", [["granular plasma", "ANATOMY", 72, 87], ["AP 920", "CHEMICAL", 36, 42], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["Appetein", "SIMPLE_CHEMICAL", 89, 97], ["Powder = spray", "TREATMENT", 0, 14], ["Granular = spraydried granular plasma (Appetein)", "TREATMENT", 50, 98]]], ["2 Contrasts were as follows: 1) control (treatment 1) vs. SDP (treatments 2, 3, 4, and 5); 2) Powder (treatments 2 and 3) vs. Granular (treatments 4 and 5); 3) SDP continuous feeding (treatments 2 and 4) vs. SDP discontinued feeding (treatments 3 and 5); 4) interaction of feeding duration and form of SDP (treatments 3 and 4 vs. 2 and 5).RESULTSplateauing by d 20 but remaining significantly greater (P < 0.05) than control broilers.", [["broilers", "SPECIES", 425, 433], ["SDP (treatments", "TREATMENT", 58, 73], ["Powder (treatments", "TREATMENT", 94, 112], ["Granular (treatments", "TREATMENT", 126, 146], ["SDP continuous feeding (treatments", "TREATMENT", 160, 194], ["feeding (treatments", "TREATMENT", 225, 244], ["SDP (treatments", "TREATMENT", 302, 317], ["significantly", "OBSERVATION_MODIFIER", 379, 392], ["greater", "OBSERVATION_MODIFIER", 393, 400]]], ["Average daily feed intake of broilers consuming SDP to d 35 (continuous treatments Powder/C and Gran- Values represent the mean of 8 replicates per treatment with 6 broilers per pen.", [["broilers", "ORGANISM_SUBDIVISION", 29, 37], ["broilers", "SPECIES", 29, 37], ["continuous treatments Powder/C and Gran", "TREATMENT", 61, 100]]], ["NS = nonsignificant at P > 0.10.", [["NS", "TREATMENT", 0, 2], ["nonsignificant", "OBSERVATION_MODIFIER", 5, 19]]], ["Powder = spray-dried powder plasma (AP 920) [7] ; Granular = spray-dried granular plasma (Appetein) [7] .", [["granular plasma", "ANATOMY", 73, 88], ["AP 920", "CHEMICAL", 36, 42], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["Appetein", "SIMPLE_CHEMICAL", 90, 98], ["Powder = spray-dried powder plasma (AP", "TREATMENT", 0, 38], ["Granular = spray", "TREATMENT", 50, 66]]], ["2 Contrasts were as follows: 1) control (treatment 1) vs. SDP (treatments 2, 3, 4, and 5); 2) Powder (treatments 2 and 3) vs. Granular (treatments 4 and 5); 3) SDP continuous feeding (treatments 2 and 4) vs. SDP discontinued feeding (treatments 3 and 5); 4) interaction of feeding duration and form of SDP (treatments 3 and 4 vs. 2 and 5). ular/C; Figure 2 ) increased throughout the experiment.RESULTSMortality of control broilers began to increase by d 15 of the experiment and continued through- out the experiment (Figure 1 ).", [["broilers", "ORGANISM", 423, 431], ["broilers", "SPECIES", 423, 431], ["SDP (treatments", "TREATMENT", 58, 73], ["Powder (treatments", "TREATMENT", 94, 112], ["Granular (treatments", "TREATMENT", 126, 146], ["SDP continuous feeding (treatments", "TREATMENT", 160, 194], ["feeding (treatments", "TREATMENT", 225, 244], ["SDP (treatments", "TREATMENT", 302, 317], ["control broilers", "TREATMENT", 415, 431], ["increased", "OBSERVATION_MODIFIER", 359, 368]]], ["Spray-dried plasma improved (P < 0.05) liveability, and the effect was independent (P > 0.10) of SDP form (powder or granular) or duration of feeding (continuous or not).DISCUSSIONThe present experiment was conducted to evaluate duration of feeding (continuous vs. discontinuous) and form of SDP (powder vs. granular) on broiler performance in simulated production conditions (using used litter from previous experiments).", [["plasma", "ANATOMY", 12, 18], ["SDP", "CHEMICAL", 292, 295], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["SDP", "SIMPLE_CHEMICAL", 97, 100], ["SDP", "SIMPLE_CHEMICAL", 292, 295], ["Spray", "TREATMENT", 0, 5], ["dried plasma", "PROBLEM", 6, 18], ["feeding (continuous vs. discontinuous)", "TREATMENT", 241, 279], ["SDP (powder", "TREATMENT", 292, 303], ["broiler performance", "TREATMENT", 321, 340], ["simulated production conditions", "PROBLEM", 344, 375]]], ["Consistent with data in previous reports, addition of SDP to the diets of poultry (broilers or turkeys) increased growth rate, feed intake, and feed efficiency compared with control [3, 4, 8] .DISCUSSIONThe relative response to SDP is greater when animals are housed in a high antigen environment [3, 4, 8, 18] .", [["SDP", "CHEMICAL", 54, 57], ["SDP", "SIMPLE_CHEMICAL", 54, 57], ["poultry", "ORGANISM_SUBDIVISION", 74, 81], ["broilers", "ORGANISM_SUBDIVISION", 83, 91], ["broilers", "SPECIES", 83, 91], ["turkeys", "SPECIES", 95, 102], ["poultry", "SPECIES", 74, 81], ["broilers", "SPECIES", 83, 91], ["turkeys", "SPECIES", 95, 102], ["increased growth rate", "PROBLEM", 104, 125], ["greater", "OBSERVATION_MODIFIER", 235, 242]]], ["In this experiment, the environment was contaminated as a result of continued litter use after 3 consecutive experiments, resulting in a high pathogen environment.", [["a high pathogen environment", "PROBLEM", 135, 162]]], ["The high pathogen environment was demonstrated by high chronic mortality (Figure 1 ) of control broilers and a progressively lower growth rate (Figure 3 ) of control broilers in the 4 consecutive experiments.", [["broilers", "SPECIES", 96, 104], ["broilers", "SPECIES", 166, 174], ["broilers", "SPECIES", 96, 104], ["The high pathogen environment", "PROBLEM", 0, 29], ["high chronic mortality", "PROBLEM", 50, 72], ["control broilers", "TREATMENT", 88, 104], ["a progressively lower growth rate", "PROBLEM", 109, 142], ["control broilers", "TREATMENT", 158, 174], ["high", "OBSERVATION_MODIFIER", 4, 8], ["pathogen environment", "OBSERVATION", 9, 29], ["high", "OBSERVATION_MODIFIER", 50, 54], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["progressively", "OBSERVATION_MODIFIER", 111, 124], ["lower", "OBSERVATION_MODIFIER", 125, 130], ["growth", "OBSERVATION_MODIFIER", 131, 137]]], ["In the current experiment, daily feed intake of control broilers increased to d 14 then plateaued after d 14 when mortality began to increase more rapidly.", [["broilers", "ORGANISM_SUBDIVISION", 56, 64], ["broilers", "SPECIES", 56, 64], ["daily feed intake of control broilers", "TREATMENT", 27, 64]]], ["When the immune system is stimulated, metabolism is altered [19, 20, 21] , resulting in reduced feed intake, growth rate, and protein accretion [22, 23, 24, 25] .", [["immune system", "ANATOMY", 9, 22], ["reduced feed intake", "PROBLEM", 88, 107], ["growth rate", "TEST", 109, 120], ["protein accretion", "TEST", 126, 143]]], ["Recent reports indicate that SDP prevents overstimulation of the immune system [26].", [["SDP", "CHEMICAL", 29, 32], ["SDP", "SIMPLE_CHEMICAL", 29, 32], ["SDP", "PROBLEM", 29, 32], ["overstimulation of the immune system", "PROBLEM", 42, 78]]], ["Many researchers have reported an initial growth response to plasma the first week after broiler placement or weaning of pigs but have not been able to detect a significant difference in final BW by the end of the experimental period, 3 to 6 wk later [27, 28, 29] .", [["plasma", "ANATOMY", 61, 67], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["pigs", "ORGANISM", 121, 125], ["pigs", "SPECIES", 121, 125], ["pigs", "SPECIES", 121, 125], ["broiler placement", "TREATMENT", 89, 106], ["weaning of pigs", "TREATMENT", 110, 125], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["difference", "OBSERVATION", 173, 183]]], ["In the present experiment, the performance response to SDP continued throughout the 35-d experiment.", [["SDP", "PROBLEM", 55, 58]]], ["This supports the hypothesis that SDP provides passive protection and prevents overstimulation of the immune system, lessening the effects of immune system activation on feed intake, growth, and protein accretion.", [["immune system", "ANATOMY", 102, 115], ["immune system", "ANATOMY", 142, 155], ["SDP", "CHEMICAL", 34, 37], ["SDP", "SIMPLE_CHEMICAL", 34, 37], ["immune system", "ANATOMICAL_SYSTEM", 102, 115], ["passive protection", "TREATMENT", 47, 65], ["overstimulation of the immune system", "PROBLEM", 79, 115], ["immune system activation", "TREATMENT", 142, 166], ["protein accretion", "PROBLEM", 195, 212], ["protein accretion", "OBSERVATION", 195, 212]]], ["This implies that the growth response to SDP is influenced more by the relative degree of immune stimulation rather than by the relative age of the animal.DISCUSSIONEarly nutrition influences intestinal and immune system development and has been shown to result in improved growth in subsequent phases [30, 31, 32] .", [["intestinal", "ANATOMY", 192, 202], ["immune system", "ANATOMY", 207, 220], ["intestinal", "ORGAN", 192, 202], ["immune stimulation", "TREATMENT", 90, 108], ["immune stimulation", "OBSERVATION", 90, 108], ["improved", "OBSERVATION_MODIFIER", 265, 273], ["growth", "OBSERVATION_MODIFIER", 274, 280]]], ["When included in the diet, SDP has been shown to improve intestinal morphology [33, 34] , digestive enzyme activity [35] , and diet digestibility [36] in pigs and dogs.", [["intestinal", "ANATOMY", 57, 67], ["digestive", "ANATOMY", 90, 99], ["SDP", "CHEMICAL", 27, 30], ["SDP", "SIMPLE_CHEMICAL", 27, 30], ["intestinal", "ORGAN", 57, 67], ["digestive", "ORGAN", 90, 99], ["pigs", "ORGANISM", 154, 158], ["dogs", "ORGANISM", 163, 167], ["pigs", "SPECIES", 154, 158], ["dogs", "SPECIES", 163, 167], ["pigs", "SPECIES", 154, 158], ["digestive enzyme activity", "TEST", 90, 115], ["intestinal", "ANATOMY", 57, 67]]], ["Furthermore, bursal weights were significantly heavier in SDP fed broilers compared with control [37] , indicating an influence on immunocompetence.", [["bursal", "ANATOMY", 13, 19], ["bursal", "ORGAN", 13, 19], ["bursal weights", "PROBLEM", 13, 27], ["an influence on immunocompetence", "PROBLEM", 115, 147], ["bursal", "ANATOMY", 13, 19]]], ["Following the removal of SDP (powder or granular) from the diet on d 14, ADFI (Figure 2 ) plateaued and remained greater than that of the control broilers throughout the experiment.", [["SDP", "CHEMICAL", 25, 28], ["SDP", "SIMPLE_CHEMICAL", 25, 28], ["the removal of SDP (powder", "TREATMENT", 10, 36], ["greater", "OBSERVATION_MODIFIER", 113, 120]]], ["This suggests that early consumption of SDP resulted in a broiler more resistant to the deleterious effects of a high pathogen environment due to improved intestinal health.", [["intestinal", "ANATOMY", 155, 165], ["SDP", "CHEMICAL", 40, 43], ["intestinal", "ORGAN", 155, 165], ["SDP", "PROBLEM", 40, 43], ["a broiler", "PROBLEM", 56, 65], ["a high pathogen environment", "PROBLEM", 111, 138], ["early", "OBSERVATION_MODIFIER", 19, 24], ["consumption", "OBSERVATION_MODIFIER", 25, 36], ["broiler more resistant", "OBSERVATION_MODIFIER", 58, 80], ["intestinal", "ANATOMY", 155, 165]]], ["Similar responses have been reported for pigs.", [["pigs", "ORGANISM", 41, 45], ["pigs", "SPECIES", 41, 45], ["pigs", "SPECIES", 41, 45]]], ["Pigs fed SDP during the nursery phase had improved growth during the finishing phase [38] .DISCUSSIONThis experiment did not involve a planned disease challenge.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["a planned disease challenge", "PROBLEM", 133, 160]]], ["However, there was significant mortality, especially for the control broilers.", [["broilers", "SPECIES", 69, 77], ["significant mortality", "PROBLEM", 19, 40], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["mortality", "OBSERVATION", 31, 40]]], ["After d 17 of the experiment, a postmortem examination by a trained pathologist was performed to determine the cause of mortality on all birds that died.", [["a postmortem examination", "TEST", 30, 54]]], ["Initial results of necropsy determined that broilers were experiencing enlarged spleens, indicative of immune stimulation from the Newcas-CONCLUSIONS AND APPLICATIONS1.", [["spleens", "ANATOMY", 80, 87], ["broilers", "ORGANISM", 44, 52], ["spleens", "ORGAN", 80, 87], ["broilers", "SPECIES", 44, 52], ["broilers", "SPECIES", 44, 52], ["necropsy", "TEST", 19, 27], ["enlarged spleens", "PROBLEM", 71, 87], ["immune stimulation", "PROBLEM", 103, 121], ["enlarged", "OBSERVATION", 71, 79], ["spleens", "ANATOMY", 80, 87], ["indicative of", "UNCERTAINTY", 89, 102], ["immune stimulation", "OBSERVATION", 103, 121]]], ["The results of this experiment confirm data from previous research that SDP improves growth rate, feed intake, and feed conversion of broilers.", [["SDP", "CHEMICAL", 72, 75], ["SDP", "SIMPLE_CHEMICAL", 72, 75], ["broilers", "ORGANISM_SUBDIVISION", 134, 142], ["broilers", "SPECIES", 134, 142], ["this experiment", "TEST", 15, 30]]], ["The response to SDP is dependent on the degree of immune stimulation rather than the relative age of the broiler.", [["SDP", "PROBLEM", 16, 19], ["immune stimulation", "TREATMENT", 50, 68], ["dependent", "OBSERVATION_MODIFIER", 23, 32], ["immune stimulation", "OBSERVATION", 50, 68]]], ["Mortality is reduced in broilers with E. coli-and Salmonella-associated enteritis.", [["enteritis", "DISEASE", 72, 81], ["broilers", "ORGANISM_SUBDIVISION", 24, 32], ["E. coli-and Salmonella", "ORGANISM", 38, 60], ["broilers", "SPECIES", 24, 32], ["broilers", "SPECIES", 24, 32], ["Salmonella", "PROBLEM", 50, 60], ["associated enteritis", "PROBLEM", 61, 81], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["E. coli-and", "OBSERVATION_MODIFIER", 38, 49], ["Salmonella", "OBSERVATION", 50, 60], ["enteritis", "OBSERVATION", 72, 81]]], ["Spray-dried granular plasma is more effective than spray-dried powder plasma. tle vaccine.", [["granular plasma", "ANATOMY", 12, 27], ["plasma", "ANATOMY", 70, 76], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["Spray", "TREATMENT", 0, 5], ["dried granular plasma", "TREATMENT", 6, 27], ["dried powder plasma", "TREATMENT", 57, 76], ["tle vaccine", "TREATMENT", 78, 89], ["more effective", "OBSERVATION_MODIFIER", 31, 45]]], ["Death losses were continually monitored, and results of the necrospy indicated that broilers developed necrotic enteritis and cultured positive for E. coli and Salmonella.", [["Death", "DISEASE", 0, 5], ["necrotic enteritis", "DISEASE", 103, 121], ["broilers", "ORGANISM", 84, 92], ["E. coli", "ORGANISM", 148, 155], ["broilers", "SPECIES", 84, 92], ["E. coli", "SPECIES", 148, 155], ["broilers", "SPECIES", 84, 92], ["E. coli", "SPECIES", 148, 155], ["Death losses", "PROBLEM", 0, 12], ["the necrospy", "TEST", 56, 68], ["necrotic enteritis", "PROBLEM", 103, 121], ["E. coli", "PROBLEM", 148, 155], ["Salmonella", "PROBLEM", 160, 170], ["necrotic", "OBSERVATION_MODIFIER", 103, 111], ["enteritis", "OBSERVATION", 112, 121]]], ["Cultures were performed for Clostridium perfringens; however, it was not isolated.", [["Clostridium perfringens", "DISEASE", 28, 51], ["Clostridium perfringens", "ORGANISM", 28, 51], ["Clostridium perfringens", "SPECIES", 28, 51], ["Clostridium perfringens", "SPECIES", 28, 51], ["Cultures", "TEST", 0, 8], ["Clostridium perfringens", "PROBLEM", 28, 51]]], ["Broilers were also exhibiting rickets due to malabsorption from severe enteritis and had litter in the gizzard.", [["gizzard", "ANATOMY", 103, 110], ["rickets", "DISEASE", 30, 37], ["malabsorption", "DISEASE", 45, 58], ["enteritis", "DISEASE", 71, 80], ["gizzard", "ORGANISM_SUBDIVISION", 103, 110], ["Broilers", "TREATMENT", 0, 8], ["rickets", "PROBLEM", 30, 37], ["malabsorption", "PROBLEM", 45, 58], ["severe enteritis", "PROBLEM", 64, 80], ["malabsorption", "OBSERVATION", 45, 58], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["enteritis", "OBSERVATION", 71, 80], ["gizzard", "ANATOMY", 103, 110]]], ["Analysis of diets revealed no nutrient deficiencies.", [["nutrient deficiencies", "PROBLEM", 30, 51], ["no", "UNCERTAINTY", 27, 29], ["nutrient deficiencies", "OBSERVATION", 30, 51]]], ["The addition of SDP to the drinking water reduced mortality of turkey poults challenged with Pasteurella multocida [5] .", [["SDP", "CHEMICAL", 16, 19], ["SDP", "SIMPLE_CHEMICAL", 16, 19], ["turkey", "ORGANISM", 63, 69], ["poults", "ORGANISM_SUBDIVISION", 70, 76], ["Pasteurella multocida", "ORGANISM", 93, 114], ["turkey", "SPECIES", 63, 69], ["poults", "SPECIES", 70, 76], ["Pasteurella multocida", "SPECIES", 93, 114], ["turkey poults", "SPECIES", 63, 76], ["Pasteurella multocida", "SPECIES", 93, 114], ["SDP", "TREATMENT", 16, 19], ["Pasteurella multocida", "PROBLEM", 93, 114]]], ["In addition, SDP has been shown to reduce morbidity and mortality of animals challenged with Crytosporidium parvum [39], coronavirus [40] , and E. coli [1] in calves; E. coli [33, 41, 42] and Salmonella [43] in pigs; Yersinia ruckeri in trout [44] ; and white spot syndrome virus in shrimp [45] .", [["SDP", "CHEMICAL", 13, 16], ["white spot syndrome virus", "DISEASE", 254, 279], ["SDP", "SIMPLE_CHEMICAL", 13, 16], ["Crytosporidium parvum", "ORGANISM", 93, 114], ["[39]", "ORGANISM", 115, 119], ["coronavirus [40", "ORGANISM", 121, 136], ["E. coli", "ORGANISM", 144, 151], ["calves", "ORGANISM", 159, 165], ["E. coli", "ORGANISM", 167, 174], ["Salmonella [43", "ORGANISM", 192, 206], ["pigs", "ORGANISM", 211, 215], ["Yersinia ruckeri", "ORGANISM", 217, 233], ["trout [44", "ORGANISM", 237, 246], ["white spot syndrome virus", "ORGANISM", 254, 279], ["shrimp", "ORGANISM", 283, 289], ["SDP", "PROTEIN", 13, 16], ["Crytosporidium parvum", "SPECIES", 93, 114], ["coronavirus", "SPECIES", 121, 132], ["E. coli", "SPECIES", 144, 151], ["calves", "SPECIES", 159, 165], ["E. coli", "SPECIES", 167, 174], ["pigs", "SPECIES", 211, 215], ["Yersinia ruckeri", "SPECIES", 217, 233], ["trout", "SPECIES", 237, 242], ["Crytosporidium parvum", "SPECIES", 93, 114], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 167, 174], ["pigs", "SPECIES", 211, 215], ["Yersinia ruckeri", "SPECIES", 217, 233], ["trout", "SPECIES", 237, 242], ["white spot syndrome virus", "SPECIES", 254, 279], ["morbidity", "PROBLEM", 42, 51], ["Crytosporidium parvum", "TEST", 93, 114], ["coronavirus", "PROBLEM", 121, 132], ["E. coli", "TEST", 144, 151], ["E. coli", "TEST", 167, 174], ["Salmonella", "TEST", 192, 202], ["Yersinia ruckeri", "TEST", 217, 233], ["white spot syndrome virus", "PROBLEM", 254, 279], ["calves", "ANATOMY", 159, 165], ["E. coli", "ANATOMY", 167, 174], ["Yersinia ruckeri", "OBSERVATION", 217, 233], ["syndrome virus", "OBSERVATION", 265, 279]]], ["In the present experiment, addition of SDP to the diet reduced mortality of birds housed in a high antigen environment.CONCLUSIONS AND APPLICATIONSCompared with powdered SDP, granulated SDP resulted in further improvements in growth rate and feed efficiency the first 2 wk of the experiment and increased BW from d 14 to the end of the experiment.", [["SDP", "CHEMICAL", 39, 42], ["SDP", "CHEMICAL", 186, 189], ["SDP", "SIMPLE_CHEMICAL", 39, 42], ["SDP", "SIMPLE_CHEMICAL", 186, 189], ["powdered SDP", "TREATMENT", 161, 173], ["granulated SDP", "PROBLEM", 175, 189], ["growth rate", "TEST", 226, 237], ["granulated SDP", "OBSERVATION", 175, 189], ["improvements", "OBSERVATION_MODIFIER", 210, 222], ["growth", "OBSERVATION_MODIFIER", 226, 232]]], ["When fed to pigs, granulated SDP has also been shown to be superior to powdered SDP [6] .", [["SDP", "CHEMICAL", 29, 32], ["pigs", "ORGANISM", 12, 16], ["SDP", "SIMPLE_CHEMICAL", 29, 32], ["pigs", "SPECIES", 12, 16], ["pigs", "SPECIES", 12, 16]]], ["In poultry, coarse ground grains induce gizzard motility, resulting in improved digestibility and feed efficiency [46] .", [["gizzard", "ANATOMY", 40, 47], ["gizzard", "ORGANISM_SUBDIVISION", 40, 47], ["gizzard motility", "PROBLEM", 40, 56], ["gizzard motility", "OBSERVATION", 40, 56]]], ["In broilers, granulated SDP may induce more gizzard motility as well.", [["gizzard", "ANATOMY", 44, 51], ["broilers", "ORGANISM", 3, 11], ["SDP", "SIMPLE_CHEMICAL", 24, 27], ["gizzard", "ORGANISM_SUBDIVISION", 44, 51], ["broilers", "SPECIES", 3, 11], ["granulated SDP", "OBSERVATION", 13, 27], ["more", "OBSERVATION_MODIFIER", 39, 43], ["gizzard motility", "OBSERVATION", 44, 60]]]], "adfa249f4dceff2bd5b326cadeb80a9d330e1cd7": [["IntroductionPorcine epidemic diarrhea (PED) is a devastating swine disease that is characterized by acute enteritis and lethal watery diarrhea followed by severe dehydration leading to death, with a high mortality rate in piglets [6, 26, 28] .", [["diarrhea", "DISEASE", 29, 37], ["PED", "DISEASE", 39, 42], ["swine disease", "DISEASE", 61, 74], ["enteritis", "DISEASE", 106, 115], ["watery diarrhea", "DISEASE", 127, 142], ["dehydration", "DISEASE", 162, 173], ["death", "DISEASE", 185, 190], ["piglets", "ORGANISM", 222, 229], ["swine", "SPECIES", 61, 66], ["piglets", "SPECIES", 222, 229], ["swine", "SPECIES", 61, 66], ["IntroductionPorcine epidemic diarrhea", "PROBLEM", 0, 37], ["a devastating swine disease", "PROBLEM", 47, 74], ["acute enteritis", "PROBLEM", 100, 115], ["lethal watery diarrhea", "PROBLEM", 120, 142], ["severe dehydration", "PROBLEM", 155, 173], ["death", "PROBLEM", 185, 190], ["devastating swine", "OBSERVATION_MODIFIER", 49, 66], ["disease", "OBSERVATION", 67, 74], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["enteritis", "OBSERVATION", 106, 115], ["lethal", "OBSERVATION_MODIFIER", 120, 126], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["dehydration", "OBSERVATION", 162, 173]]], ["The disease was initially recognized in England in 1971 [23] , but the causative agent of this disease, PED virus (PEDV), was later identified in 1978 [25] .", [["PED", "DISEASE", 104, 107], ["PED virus", "ORGANISM", 104, 113], ["PEDV", "SPECIES", 115, 119], ["The disease", "PROBLEM", 0, 11], ["this disease", "PROBLEM", 90, 102], ["PED virus (PEDV", "PROBLEM", 104, 119], ["disease", "OBSERVATION", 4, 11]]], ["PED epidemics were first reported in Asia in 1982, and since then, PED has continued to threaten swine health, causing substantial economic losses in the Asian swine industry [4, 19, 27, 33] .", [["swine", "SPECIES", 97, 102], ["swine", "SPECIES", 160, 165], ["swine", "SPECIES", 97, 102], ["Asian swine", "SPECIES", 154, 165], ["PED epidemics", "PROBLEM", 0, 13], ["substantial", "OBSERVATION_MODIFIER", 119, 130], ["economic", "OBSERVATION_MODIFIER", 131, 139], ["losses", "OBSERVATION", 140, 146]]], ["In 2013, PED outbreaks suddenly occurred in the United States and have swept through the pork industry across the country, raising concerns about control measures for PED prevention [21, 30] .", [["PED", "DISEASE", 167, 170], ["pork", "SPECIES", 89, 93], ["PED prevention", "TREATMENT", 167, 181]]], ["In Korea, PEDV appeared in 1992 [14] ; however, a retrospective study indicated that the virus had been present as early as 1987 [24] .", [["PEDV", "SPECIES", 10, 14], ["PEDV", "PROBLEM", 10, 14], ["a retrospective study", "TEST", 48, 69], ["the virus", "PROBLEM", 85, 94], ["virus", "OBSERVATION", 89, 94]]], ["Although periodic vaccination strategies have been implemented nationwide to control PED in Korean swine herds, PEDV has continually emerged, causing tremendous harm to the productivity of Korean pig farms.IntroductionPEDV, a member of the genus Alphacoronavirus within the family Coronaviridae of the order Nidovirales, is a large, enveloped virus possessing a single-stranded, positive-sense RNA genome of approximately 28 kb with a 5 0 cap and a 3 0 polyadenylated tail [25, 28] .", [["PED", "DISEASE", 85, 88], ["PEDV", "CHEMICAL", 112, 116], ["IntroductionPEDV", "CHEMICAL", 206, 222], ["pig", "ORGANISM", 196, 199], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 308, 319], ["positive-sense RNA genome", "DNA", 379, 404], ["5 0 cap", "DNA", 435, 442], ["swine", "SPECIES", 99, 104], ["pig", "SPECIES", 196, 199], ["swine", "SPECIES", 99, 104], ["PEDV", "SPECIES", 112, 116], ["pig", "SPECIES", 196, 199], ["periodic vaccination strategies", "TREATMENT", 9, 40], ["PEDV", "PROBLEM", 112, 116], ["a large, enveloped virus", "PROBLEM", 324, 348], ["large", "OBSERVATION_MODIFIER", 326, 331], ["tail", "OBSERVATION_MODIFIER", 468, 472]]], ["The PEDV genome is composed of the 5 0 untranslated region (UTR), at least seven open reading frames (ORF1a, ORF1b, and ORF2 through 6), and the 3 0 UTR [13] .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 102, 107], ["ORF1b", "GENE_OR_GENE_PRODUCT", 109, 114], ["PEDV genome", "DNA", 4, 15], ["5 0 untranslated region", "DNA", 35, 58], ["UTR", "DNA", 60, 63], ["open reading frames", "DNA", 81, 100], ["ORF1a", "DNA", 102, 107], ["ORF1b", "DNA", 109, 114], ["ORF2", "DNA", 120, 124], ["3 0 UTR [13", "DNA", 145, 156], ["PEDV", "SPECIES", 4, 8], ["The PEDV genome", "PROBLEM", 0, 15], ["ORF1a", "TEST", 102, 107], ["ORF1b", "TEST", 109, 114], ["PEDV genome", "OBSERVATION", 4, 15]]], ["The two large ORFs 1a and 1b make up the 5 0 two-thirds of the genome and encode the non-structural replicase genes.", [["1b", "GENE_OR_GENE_PRODUCT", 26, 28], ["ORFs 1a and 1b", "DNA", 14, 28], ["5 0 two-thirds of the genome", "DNA", 41, 69], ["non-structural replicase genes", "DNA", 85, 115], ["large", "OBSERVATION_MODIFIER", 8, 13], ["ORFs", "OBSERVATION", 14, 18], ["non-structural", "OBSERVATION", 85, 99], ["replicase genes", "OBSERVATION", 100, 115]]], ["The remaining ORFs in the 3 0 terminal region code for four major structural proteins: the 150-220-kDa glycosylated spike (S) protein, the 20-30-kDa membrane (M) protein, the 7-kDa envelope (E) protein, and the 58-kDa nucleocapsid (N) protein [8, 28] .IntroductionThe S protein of PEDV is a type I membrane glycoprotein composed of 1,383 to 1,386 amino acids (aa), depending on the strain.", [["amino acids", "CHEMICAL", 347, 358], ["amino acids", "CHEMICAL", 347, 358], ["glycosylated spike (S)", "GENE_OR_GENE_PRODUCT", 103, 125], ["PEDV", "GENE_OR_GENE_PRODUCT", 281, 285], ["type I membrane glycoprotein", "GENE_OR_GENE_PRODUCT", 291, 319], ["amino acids", "AMINO_ACID", 347, 358], ["ORFs", "DNA", 14, 18], ["3 0 terminal region", "DNA", 26, 45], ["structural proteins", "PROTEIN", 66, 85], ["150-220-kDa glycosylated spike (S) protein", "PROTEIN", 91, 133], ["20-30-kDa membrane (M) protein", "PROTEIN", 139, 169], ["7-kDa envelope (E) protein", "PROTEIN", 175, 201], ["58-kDa nucleocapsid (N) protein", "PROTEIN", 211, 242], ["S protein", "PROTEIN", 268, 277], ["PEDV", "PROTEIN", 281, 285], ["type I membrane glycoprotein", "PROTEIN", 291, 319], ["The remaining ORFs", "TEST", 0, 18], ["protein", "TEST", 126, 133], ["protein", "TEST", 162, 169], ["protein", "TEST", 194, 201], ["protein", "TEST", 235, 242], ["The S protein", "TEST", 264, 277], ["PEDV", "PROBLEM", 281, 285], ["a type I membrane glycoprotein", "TREATMENT", 289, 319], ["amino acids", "TEST", 347, 358], ["the strain", "PROBLEM", 378, 388], ["ORFs", "OBSERVATION", 14, 18]]], ["It contains a putative signal peptide (aa 1-24), a large extracellular region, a single transmembrane domain (aa 1,334-1,356), and a short cytoplasmic tail.", [["extracellular region", "ANATOMY", 57, 77], ["cytoplasmic tail", "ANATOMY", 139, 155], ["extracellular region", "CELLULAR_COMPONENT", 57, 77], ["cytoplasmic tail", "CELLULAR_COMPONENT", 139, 155], ["extracellular region", "PROTEIN", 57, 77], ["transmembrane domain", "PROTEIN", 88, 108], ["aa 1,334-1,356", "PROTEIN", 110, 124], ["short cytoplasmic tail", "PROTEIN", 133, 155], ["a putative signal peptide", "TEST", 12, 37], ["a large extracellular region", "PROBLEM", 49, 77], ["a single transmembrane domain", "TEST", 79, 108], ["aa", "TEST", 110, 112], ["a short cytoplasmic tail", "PROBLEM", 131, 155], ["large", "OBSERVATION_MODIFIER", 51, 56], ["extracellular", "ANATOMY_MODIFIER", 57, 70], ["region", "ANATOMY_MODIFIER", 71, 77], ["tail", "OBSERVATION_MODIFIER", 151, 155]]], ["Although PEDV has an uncleaved S protein because it lacks a furin cleavage site, the S protein can be divided into S1 (aa 1-735) and S2 (736-the last aa) domains based on homology with S proteins of other coronaviruses [7, 11, 16, 31] .", [["PEDV", "CHEMICAL", 9, 13], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["furin", "GENE_OR_GENE_PRODUCT", 60, 65], ["PEDV", "PROTEIN", 9, 13], ["uncleaved S protein", "PROTEIN", 21, 40], ["furin cleavage site", "PROTEIN", 60, 79], ["S protein", "PROTEIN", 85, 94], ["S1", "PROTEIN", 115, 117], ["S2", "PROTEIN", 133, 135], ["736", "PROTEIN", 137, 140], ["S proteins", "PROTEIN", 185, 195], ["PEDV", "SPECIES", 9, 13], ["PEDV", "PROBLEM", 9, 13], ["an uncleaved S protein", "PROBLEM", 18, 40], ["a furin cleavage site", "PROBLEM", 58, 79], ["the S protein", "TEST", 81, 94], ["aa", "TEST", 119, 121], ["S2", "TEST", 133, 135], ["S proteins", "TEST", 185, 195], ["other coronaviruses", "PROBLEM", 199, 218], ["S1", "ANATOMY", 115, 117], ["S2", "ANATOMY", 133, 135]]], ["Like other coronavirus S proteins, the PEDV S protein is known to play a pivotal role, interacting with the cellular receptor to mediate viral entry and inducing neutralizing antibodies in the natural host [2, 3] .", [["cellular", "ANATOMY", 108, 116], ["coronavirus S proteins", "GENE_OR_GENE_PRODUCT", 11, 33], ["PEDV S", "GENE_OR_GENE_PRODUCT", 39, 45], ["cellular", "CELL", 108, 116], ["coronavirus S proteins", "PROTEIN", 11, 33], ["PEDV S protein", "PROTEIN", 39, 53], ["cellular receptor", "PROTEIN", 108, 125], ["neutralizing antibodies", "PROTEIN", 162, 185], ["other coronavirus S proteins", "PROBLEM", 5, 33], ["the PEDV S protein", "TEST", 35, 53], ["neutralizing antibodies", "TEST", 162, 185], ["coronavirus", "OBSERVATION", 11, 22]]], ["More precisely, previous studies have shown that the S1 domain includes the main neutralizing epitopes and the receptor-binding region [17, 32] .", [["S1 domain", "PROTEIN", 53, 62], ["neutralizing epitopes", "PROTEIN", 81, 102], ["receptor-binding region", "PROTEIN", 111, 134], ["previous studies", "TEST", 16, 32], ["the S1 domain", "PROBLEM", 49, 62], ["S1", "ANATOMY", 53, 55], ["main", "OBSERVATION_MODIFIER", 76, 80], ["neutralizing epitopes", "OBSERVATION", 81, 102]]], ["Furthermore, along with the full-length S gene, the S1 portion is known to be a suitable region for determining genetic relatedness among the different PEDV isolates and for developing differential diagnostic assays [5, 16] .", [["S1", "GENE_OR_GENE_PRODUCT", 52, 54], ["full-length S gene", "DNA", 28, 46], ["S1 portion", "DNA", 52, 62], ["PEDV", "SPECIES", 152, 156], ["diagnostic assays", "TEST", 198, 215], ["S1", "ANATOMY", 52, 54]]], ["Considering these molecular and biological features of the S1 domain, it would be an appropriate target for developing effective vaccines against PEDV.IntroductionIn the present study, therefore, we first synthesized a full-length, codon-optimized PEDV S1 gene and then generated a stable porcine-origin cell line constitutively expressing the recombinant S1 protein.", [["cell line", "ANATOMY", 304, 313], ["PEDV", "CHEMICAL", 146, 150], ["PEDV", "SIMPLE_CHEMICAL", 146, 150], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 248, 255], ["porcine", "ORGANISM", 289, 296], ["cell line", "CELL", 304, 313], ["S1", "GENE_OR_GENE_PRODUCT", 356, 358], ["S1 domain", "PROTEIN", 59, 68], ["PEDV S1 gene", "DNA", 248, 260], ["porcine-origin cell line", "CELL_LINE", 289, 313], ["recombinant S1 protein", "PROTEIN", 344, 366], ["PEDV", "SPECIES", 146, 150], ["effective vaccines", "TREATMENT", 119, 137], ["PEDV", "PROBLEM", 146, 150], ["the present study", "TEST", 166, 183], ["a full-length, codon", "TREATMENT", 217, 237], ["a stable porcine-origin cell line", "TREATMENT", 280, 313], ["stable", "OBSERVATION_MODIFIER", 282, 288], ["origin cell line", "OBSERVATION", 297, 313]]], ["The protective efficiency of a recombinant-S1-protein-based vaccine against PEDV was then evaluated in the natural host.", [["PEDV", "CHEMICAL", 76, 80], ["S1", "GENE_OR_GENE_PRODUCT", 43, 45], ["PEDV", "ORGANISM", 76, 80], ["recombinant-S1-protein", "PROTEIN", 31, 53], ["PEDV", "PROTEIN", 76, 80], ["PEDV", "SPECIES", 76, 80], ["a recombinant-S1-protein-based vaccine", "TREATMENT", 29, 67], ["PEDV", "PROBLEM", 76, 80], ["protective efficiency", "OBSERVATION", 4, 25]]], ["The recombinant S1 protein was capable of inducing an efficient antibody response in immunized rabbits.", [["S1", "GENE_OR_GENE_PRODUCT", 16, 18], ["rabbits", "ORGANISM", 95, 102], ["recombinant S1 protein", "PROTEIN", 4, 26], ["rabbits", "SPECIES", 95, 102], ["rabbits", "SPECIES", 95, 102], ["The recombinant S1 protein", "TEST", 0, 26], ["efficient", "OBSERVATION_MODIFIER", 54, 63], ["antibody response", "OBSERVATION", 64, 81], ["immunized rabbits", "OBSERVATION", 85, 102]]], ["Moreover, immunization with the PEDV S1 protein was found to elicit specific neutralizing antibodies in sows and to protect passively immunized suckling piglets against PEDV challenge.Materials and methodsCells, virus, antibodies, and plasmid HEK-293T cells (CRL-1573) were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's modified Eagle medium (DMEM) with high glucose (Invitrogen, Carlsbad, CA) with 10 % fetal bovine serum (FBS, Invitrogen) and antibiotic-antimycotic solutions (1009; Invitrogen).", [["Cells", "ANATOMY", 205, 210], ["HEK-293T cells", "ANATOMY", 243, 257], ["CRL-1573", "ANATOMY", 259, 267], ["fetal bovine serum", "ANATOMY", 458, 476], ["FBS", "ANATOMY", 478, 481], ["PEDV", "CHEMICAL", 169, 173], ["CRL-1573", "CHEMICAL", 259, 267], ["glucose", "CHEMICAL", 413, 420], ["glucose", "CHEMICAL", 413, 420], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 32, 39], ["sows", "ORGANISM", 104, 108], ["piglets", "ORGANISM", 153, 160], ["PEDV", "ORGANISM", 169, 173], ["Cells", "CELL", 205, 210], ["HEK-293T cells", "CELL", 243, 257], ["CRL-1573", "CELL", 259, 267], ["glucose", "SIMPLE_CHEMICAL", 413, 420], ["bovine", "ORGANISM", 464, 470], ["serum", "ORGANISM_SUBSTANCE", 471, 476], ["FBS", "ORGANISM_SUBSTANCE", 478, 481], ["Invitrogen", "SIMPLE_CHEMICAL", 483, 493], ["PEDV S1 protein", "PROTEIN", 32, 47], ["neutralizing antibodies", "PROTEIN", 77, 100], ["plasmid HEK-293T cells", "CELL_LINE", 235, 257], ["CRL-1573", "CELL_LINE", 259, 267], ["piglets", "SPECIES", 153, 160], ["bovine", "SPECIES", 464, 470], ["PEDV", "SPECIES", 32, 36], ["piglets", "SPECIES", 153, 160], ["PEDV", "SPECIES", 169, 173], ["ATCC", "SPECIES", 327, 331], ["Manassas", "SPECIES", 333, 341], ["bovine", "SPECIES", 464, 470], ["immunization", "TREATMENT", 10, 22], ["the PEDV S1 protein", "TEST", 28, 47], ["specific neutralizing antibodies", "PROBLEM", 68, 100], ["PEDV challenge", "TREATMENT", 169, 183], ["Cells", "TEST", 205, 210], ["virus", "TEST", 212, 217], ["antibodies", "TEST", 219, 229], ["plasmid HEK", "TEST", 235, 246], ["CRL", "TEST", 259, 262], ["ATCC", "TEST", 327, 331], ["Dulbecco", "TEST", 363, 371], ["high glucose", "PROBLEM", 408, 420], ["Invitrogen", "TEST", 422, 432], ["Carlsbad", "TEST", 434, 442], ["CA", "TEST", 444, 446], ["fetal bovine serum", "TEST", 458, 476], ["FBS", "TEST", 478, 481], ["Invitrogen", "TEST", 483, 493], ["antibiotic-antimycotic solutions", "TREATMENT", 499, 531], ["Invitrogen", "TREATMENT", 539, 549]]], ["PK-15 cells were grown in RPMI 1640 medium (Invitrogen) supplemented with 10 % FBS and antibiotic-antimycotic solutions.", [["PK-15 cells", "ANATOMY", 0, 11], ["FBS", "ANATOMY", 79, 82], ["PK-15 cells", "CELL", 0, 11], ["FBS", "ORGANISM_SUBSTANCE", 79, 82], ["PK-15 cells", "CELL_LINE", 0, 11], ["PK", "TEST", 0, 2], ["RPMI", "TEST", 26, 30], ["10 % FBS", "TREATMENT", 74, 82], ["antibiotic", "TREATMENT", 87, 97], ["antimycotic solutions", "TREATMENT", 98, 119]]], ["Vero cells were cultured in alpha minimum essential medium (a-MEM, Invitrogen) with 10 % FBS and antibiotic-antimycotic solutions.", [["Vero cells", "ANATOMY", 0, 10], ["FBS", "ANATOMY", 89, 92], ["Vero cells", "CELL", 0, 10], ["FBS", "ORGANISM_SUBSTANCE", 89, 92], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["Invitrogen", "TEST", 67, 77], ["10 % FBS", "TREATMENT", 84, 92], ["antibiotic-antimycotic solutions", "TREATMENT", 97, 129]]], ["The cells were maintained at 37\u00b0C in a humidified 5 % CO 2 atmosphere.", [["cells", "ANATOMY", 4, 9], ["CO", "CHEMICAL", 54, 56], ["cells", "CELL", 4, 9], ["a humidified 5 % CO 2 atmosphere", "TREATMENT", 37, 69]]], ["The PEDV vaccine strain SM98-1 was obtained from the Korean Animal and Plant Quarantine Agency and propagated in Vero cells as described previously [10] .", [["Vero cells", "ANATOMY", 113, 123], ["SM98-1", "CHEMICAL", 24, 30], ["SM98-1", "CELL", 24, 30], ["Vero cells", "CELL", 113, 123], ["Vero cells", "CELL_LINE", 113, 123], ["PEDV vaccine strain SM98-1", "SPECIES", 4, 30], ["The PEDV vaccine strain SM98", "TEST", 0, 28], ["Plant Quarantine Agency", "TREATMENT", 71, 94], ["propagated in Vero cells", "TREATMENT", 99, 123], ["Vero cells", "OBSERVATION", 113, 123]]], ["Challenge PEDV was prepared from the small intestine of a 4-day-old suckling piglet orally inoculated with small intestine homogenate containing the field virus.", [["small intestine", "ANATOMY", 37, 52], ["piglet", "ANATOMY", 77, 83], ["intestine homogenate", "ANATOMY", 113, 133], ["PEDV", "CHEMICAL", 10, 14], ["PEDV", "SIMPLE_CHEMICAL", 10, 14], ["small intestine", "ORGAN", 37, 52], ["piglet", "ORGANISM", 77, 83], ["intestine homogenate", "ORGANISM_SUBSTANCE", 113, 133], ["piglet", "SPECIES", 77, 83], ["PEDV", "SPECIES", 10, 14], ["piglet", "SPECIES", 77, 83], ["Challenge PEDV", "TREATMENT", 0, 14], ["small intestine homogenate containing the field virus", "PROBLEM", 107, 160], ["small", "OBSERVATION_MODIFIER", 37, 42], ["intestine", "ANATOMY", 43, 52], ["intestine", "ANATOMY", 113, 122], ["field virus", "OBSERVATION", 149, 160]]], ["Small intestine tissues were collected and homogenized in a 10 % suspension with a-MEM using a MagNa Lyser (Roche Diagnostics, Mannheim, Germany) with three repetitions of 15 s at a speed of 7,000 rpm, and suspensions were clarified by centrifugation at 4,500 9 g (Hanil Centrifuge FLETA5, Incheon, Korea).", [["intestine tissues", "ANATOMY", 6, 23], ["Small intestine tissues", "TISSUE", 0, 23], ["Small intestine tissues", "PROBLEM", 0, 23], ["suspensions", "TREATMENT", 206, 217], ["intestine tissues", "ANATOMY", 6, 23]]], ["The clarified supernatant was filtered through a 0.22-lm-pore-size syringe filter (Millipore, Billerica, MA), aliquoted, and stored at -80\u00b0C until use as crude challenge virus.", [["supernatant", "ANATOMY", 14, 25], ["C", "GENE_OR_GENE_PRODUCT", 139, 140], ["a 0.22-lm-pore-size syringe filter", "TREATMENT", 47, 81], ["size", "OBSERVATION_MODIFIER", 62, 66], ["syringe filter", "OBSERVATION", 67, 81]]], ["All of the horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 11, 33], ["HRP", "SIMPLE_CHEMICAL", 35, 38], ["horseradish peroxidase", "PROTEIN", 11, 33], ["HRP", "PROTEIN", 35, 38], ["secondary antibodies", "PROTEIN", 51, 71], ["Santa Cruz Biotechnology", "PROTEIN", 92, 116], ["Santa Cruz", "PROTEIN", 118, 128], ["horseradish", "SPECIES", 11, 22], ["the horseradish peroxidase", "TEST", 7, 33], ["conjugated secondary antibodies", "PROBLEM", 40, 71]]], ["The PEDV S-protein-specific monoclonal antibody (MAb) was a kind gift from Sang-Geon Yeo (Kyungpook National University, Daegu, Korea).", [["PEDV S-protein", "GENE_OR_GENE_PRODUCT", 4, 18], ["PEDV S-protein-specific monoclonal antibody", "PROTEIN", 4, 47], ["MAb", "PROTEIN", 49, 52], ["PEDV", "SPECIES", 4, 8], ["The PEDV S-protein", "TEST", 0, 18], ["specific monoclonal antibody", "TEST", 19, 47]]], ["A plasmid encoding the S1 fragment of severe acute respiratory syndrome coronavirus (SARS-CoV), pCDM8-SARS-CoV-S1-Ig, was kindly provided by Hyeryun Choe (Harvard Medical School, Boston, MA).Construction of expression plasmidsDNA manipulation and cloning were performed according to standard procedures [29] .", [["plasmid", "ANATOMY", 2, 9], ["acute respiratory syndrome coronavirus", "DISEASE", 45, 83], ["SARS", "DISEASE", 85, 89], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 38, 83], ["SARS-CoV", "ORGANISM", 85, 93], ["Ig", "GENE_OR_GENE_PRODUCT", 114, 116], ["plasmid", "DNA", 2, 9], ["S1 fragment", "PROTEIN", 23, 34], ["SARS-CoV-S1-Ig", "DNA", 102, 116], ["severe acute respiratory syndrome coronavirus", "SPECIES", 38, 83], ["SARS-CoV", "SPECIES", 85, 93], ["A plasmid encoding the S1 fragment", "PROBLEM", 0, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 38, 83], ["SARS", "TEST", 85, 89], ["pCDM8", "TEST", 96, 101], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["expression plasmidsDNA manipulation", "TREATMENT", 207, 242], ["plasmid", "OBSERVATION", 2, 9], ["S1 fragment", "OBSERVATION_MODIFIER", 23, 34], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["respiratory syndrome coronavirus", "OBSERVATION", 51, 83]]], ["The E. coli strain DH5a (RBC Bioscience, Taiwan) was used as the host for general cloning.", [["E. coli", "ORGANISM", 4, 11], ["RBC", "CELL", 25, 28], ["E. coli", "SPECIES", 4, 11], ["E. coli", "SPECIES", 4, 11], ["The E. coli strain", "TEST", 0, 18], ["general cloning", "TREATMENT", 74, 89], ["coli strain", "OBSERVATION", 7, 18]]], ["The plasmid encoding the full-length S1 gene of the PEDV field strain KNU-0801, pCDM8-PEDV-S1-Ig, was described previously [17] .", [["plasmid", "ANATOMY", 4, 11], ["KNU-0801", "CHEMICAL", 70, 78], ["S1", "GENE_OR_GENE_PRODUCT", 37, 39], ["KNU-0801", "CELL", 70, 78], ["pCDM8-PEDV-S1-Ig", "GENE_OR_GENE_PRODUCT", 80, 96], ["plasmid", "DNA", 4, 11], ["full-length S1 gene", "DNA", 25, 44], ["KNU-0801, pCDM8-PEDV-S1-Ig", "DNA", 70, 96], ["KNU-0801", "SPECIES", 70, 78], ["The plasmid", "TREATMENT", 0, 11], ["the PEDV field strain KNU", "TEST", 48, 73], ["pCDM8", "TEST", 80, 85]]], ["To construct the plasmids expressing S1 and its variants, the consensus sequence of PEDV S1 was identified based on a multiple alignment of the S aa sequences of PEDV field isolates [16] and utilized to synthesize a full-length, codon-optimized PEDV S1 gene (encoding aa 24-735) according to a method described previously [1] .", [["plasmids", "ANATOMY", 17, 25], ["S1", "GENE_OR_GENE_PRODUCT", 37, 39], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 84, 91], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 245, 252], ["plasmids", "DNA", 17, 25], ["S1", "PROTEIN", 37, 39], ["consensus sequence", "DNA", 62, 80], ["PEDV S1", "DNA", 84, 91], ["S aa sequences", "DNA", 144, 158], ["PEDV S1 gene", "DNA", 245, 257], ["PEDV S1", "PROBLEM", 84, 91], ["PEDV field isolates", "TEST", 162, 181], ["codon", "TEST", 229, 234]]], ["The codon-optimized PEDV S1 gene was cloned into a modified expression vector, pCDM8-Fc, which contains the CD5 signal sequence and the Fc domain of human IgG1 [9] , thereby producing a human Fc-tagged fusion protein, rS1-Ig.", [["PEDV S1", "GENE_OR_GENE_PRODUCT", 20, 27], ["pCDM8-Fc", "GENE_OR_GENE_PRODUCT", 79, 87], ["CD5", "GENE_OR_GENE_PRODUCT", 108, 111], ["human", "ORGANISM", 149, 154], ["IgG1", "GENE_OR_GENE_PRODUCT", 155, 159], ["human", "ORGANISM", 186, 191], ["Fc", "GENE_OR_GENE_PRODUCT", 192, 194], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 218, 224], ["codon-optimized PEDV S1 gene", "DNA", 4, 32], ["modified expression vector", "DNA", 51, 77], ["pCDM8-Fc", "DNA", 79, 87], ["CD5 signal sequence", "DNA", 108, 127], ["Fc domain", "PROTEIN", 136, 145], ["human IgG1 [9]", "PROTEIN", 149, 163], ["human Fc-tagged fusion protein", "PROTEIN", 186, 216], ["rS1", "PROTEIN", 218, 221], ["Ig", "PROTEIN", 222, 224], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 186, 191], ["PEDV", "SPECIES", 20, 24], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 186, 191], ["The codon-optimized PEDV S1 gene", "TREATMENT", 0, 32], ["a modified expression vector", "TREATMENT", 49, 77], ["the CD5 signal sequence", "TEST", 104, 127], ["a human Fc", "TEST", 184, 194]]], ["All of the PEDV S1-truncated variants used in this study were generated using this template with the previously described primer sets [17] .", [["PEDV S1", "GENE_OR_GENE_PRODUCT", 11, 18], ["PEDV S1-truncated variants", "DNA", 11, 37], ["PEDV", "SPECIES", 11, 15], ["this study", "TEST", 46, 56], ["this template", "TREATMENT", 78, 91]]], ["An Fctagged PEDV rS1-Ig fragment obtained from pCDM8-Fc-rS1-Ig was then subcloned into a pFB-Neo retroviral vector (Stratagene, La Jolla, CA) using the SalI and XhoI restriction sites to construct a PEDV rS1-Ig gene expression plasmid, pFB-Neo-PEDV-rS1-Ig.", [["pCDM8-Fc-rS1-Ig", "GENE_OR_GENE_PRODUCT", 47, 62], ["SalI", "GENE_OR_GENE_PRODUCT", 152, 156], ["XhoI", "GENE_OR_GENE_PRODUCT", 161, 165], ["rS1", "GENE_OR_GENE_PRODUCT", 204, 207], ["Ig", "GENE_OR_GENE_PRODUCT", 208, 210], ["pFB", "GENE_OR_GENE_PRODUCT", 236, 239], ["Fctagged PEDV rS1-Ig fragment", "DNA", 3, 32], ["pCDM8", "PROTEIN", 47, 52], ["Fc", "PROTEIN", 53, 55], ["-rS1", "PROTEIN", 55, 59], ["Ig", "PROTEIN", 60, 62], ["pFB-Neo retroviral vector", "DNA", 89, 114], ["SalI and XhoI restriction sites", "DNA", 152, 183], ["PEDV rS1-Ig gene expression plasmid", "DNA", 199, 234], ["pFB", "DNA", 236, 239], ["PEDV", "DNA", 244, 248], ["rS1", "DNA", 249, 252], ["PEDV", "SPECIES", 199, 203], ["An Fctagged PEDV rS1", "TEST", 0, 20], ["Ig fragment", "PROBLEM", 21, 32], ["pCDM8", "TEST", 47, 52], ["a pFB", "TREATMENT", 87, 92], ["Neo retroviral vector", "TREATMENT", 93, 114], ["the SalI and XhoI restriction sites", "TREATMENT", 148, 183], ["a PEDV rS1", "TREATMENT", 197, 207], ["Ig gene expression plasmid", "TREATMENT", 208, 234], ["pFB", "TEST", 236, 239], ["Neo-PEDV", "TREATMENT", 240, 248]]], ["All of the constructed plasmids were verified by nucleotide sequencing.Construction of expression plasmidsGeneration of a stable PK-15 cell line expressing PEDV rS1-IgConstruction of expression plasmidsThe retrovirus gene transfer system (Stratagene) was applied to generate a cell line constitutively expressing the recombinant PEDV rS1-Ig gene or an empty retroviral vector as described elsewhere [16, 22] .", [["plasmids", "ANATOMY", 23, 31], ["PK-15 cell line", "ANATOMY", 129, 144], ["cell line", "ANATOMY", 277, 286], ["nucleotide", "CHEMICAL", 49, 59], ["nucleotide", "CHEMICAL", 49, 59], ["PK-15 cell line", "CELL", 129, 144], ["PEDV", "ORGANISM", 156, 160], ["rS1", "GENE_OR_GENE_PRODUCT", 161, 164], ["retrovirus", "ORGANISM", 206, 216], ["cell line", "CELL", 277, 286], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 334, 340], ["plasmids", "DNA", 23, 31], ["expression plasmids", "DNA", 87, 106], ["PK-15 cell line", "CELL_LINE", 129, 144], ["rS1", "PROTEIN", 161, 164], ["expression plasmids", "DNA", 183, 202], ["recombinant PEDV rS1-Ig gene", "DNA", 317, 345], ["PEDV", "SPECIES", 156, 160], ["PEDV", "SPECIES", 329, 333], ["the constructed plasmids", "TREATMENT", 7, 31], ["nucleotide sequencing", "TEST", 49, 70], ["expression plasmids", "TREATMENT", 87, 106], ["cell line", "TREATMENT", 135, 144], ["PEDV rS1", "TREATMENT", 156, 164], ["expression plasmids", "TREATMENT", 183, 202], ["The retrovirus gene transfer system (Stratagene)", "TREATMENT", 202, 250], ["a cell line", "TREATMENT", 275, 286], ["an empty retroviral vector", "TREATMENT", 349, 375], ["stable", "OBSERVATION_MODIFIER", 122, 128], ["expression plasmids", "OBSERVATION", 183, 202], ["cell line", "OBSERVATION", 277, 286], ["empty retroviral vector", "OBSERVATION", 352, 375]]], ["Antibiotic-resistant continuous cell clones were examined by RT-PCR to verify the presence of the full-length rS1-Ig gene, and the positive clones (PK-rS1-Ig) were then amplified for subsequent analyses.Construction of expression plasmidsImmunofluorescence assay (IFA) PK-rS1-Ig cells were grown on microscope coverslips placed in 6-well tissue culture plates.", [["cell clones", "ANATOMY", 32, 43], ["clones", "ANATOMY", 140, 146], ["rS1-Ig cells", "ANATOMY", 272, 284], ["cell clones", "CELL", 32, 43], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 110, 116], ["PK-rS1-Ig", "GENE_OR_GENE_PRODUCT", 148, 157], ["Antibiotic-resistant continuous cell clones", "CELL_LINE", 0, 43], ["rS1", "DNA", 110, 113], ["Ig gene", "DNA", 114, 121], ["positive clones", "DNA", 131, 146], ["PK", "DNA", 148, 150], ["rS1", "DNA", 151, 154], ["Ig", "DNA", 155, 157], ["rS1-Ig cells", "CELL_LINE", 272, 284], ["Antibiotic", "TREATMENT", 0, 10], ["resistant continuous cell clones", "PROBLEM", 11, 43], ["PCR", "TEST", 64, 67], ["the positive clones", "PROBLEM", 127, 146], ["PK", "TEST", 148, 150], ["expression plasmids", "TEST", 219, 238], ["Immunofluorescence assay", "TEST", 238, 262], ["IFA", "TEST", 264, 267], ["PK", "TEST", 269, 271], ["rS1", "TEST", 272, 275], ["Ig cells", "PROBLEM", 276, 284], ["microscope coverslips", "TEST", 299, 320], ["resistant", "OBSERVATION_MODIFIER", 11, 20], ["continuous cell clones", "OBSERVATION", 21, 43], ["positive clones", "OBSERVATION", 131, 146]]], ["At 48 h post-seeding, the cells were fixed with 4 % paraformaldehyde for 10 min at room temperature (RT) and permeabilized with 0.2 % Triton X-100 in PBS at RT for 10 min.", [["cells", "ANATOMY", 26, 31], ["Triton X-100", "CHEMICAL", 134, 146], ["paraformaldehyde", "CHEMICAL", 52, 68], ["cells", "CELL", 26, 31], ["paraformaldehyde", "SIMPLE_CHEMICAL", 52, 68], ["Triton X-100", "SIMPLE_CHEMICAL", 134, 146], ["the cells", "TREATMENT", 22, 31], ["4 % paraformaldehyde", "TREATMENT", 48, 68], ["0.2 % Triton", "TREATMENT", 128, 140]]], ["The cells were subsequently blocked with 1 % bovine serum albumin (BSA) in PBS for 30 min at RT and then incubated with a goat anti-human IgG antibody conjugated with fluorescein isothiocyanate (FITC) (Santa Cruz Biotechnology).", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 52, 57], ["BSA", "CHEMICAL", 67, 70], ["fluorescein isothiocyanate", "CHEMICAL", 167, 193], ["fluorescein isothiocyanate", "CHEMICAL", 167, 193], ["FITC", "CHEMICAL", 195, 199], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 45, 51], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["albumin", "SIMPLE_CHEMICAL", 58, 65], ["BSA", "SIMPLE_CHEMICAL", 67, 70], ["PBS", "SIMPLE_CHEMICAL", 75, 78], ["goat", "ORGANISM", 122, 126], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 167, 193], ["FITC", "SIMPLE_CHEMICAL", 195, 199], ["goat anti-human IgG antibody", "PROTEIN", 122, 150], ["Santa Cruz Biotechnology", "PROTEIN", 202, 226], ["bovine", "SPECIES", 45, 51], ["goat", "SPECIES", 122, 126], ["goat", "SPECIES", 122, 126], ["1 % bovine serum albumin (BSA)", "TREATMENT", 41, 71], ["a goat anti-human IgG antibody", "TREATMENT", 120, 150], ["fluorescein isothiocyanate", "TREATMENT", 167, 193]]], ["Finally, the cells were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO), and cell staining was visualized using a fluorescent Leica DM IL LED microscope (Leica, Wetzlar, Germany).Construction of expression plasmidsFluorescence-activated cell sorting (FACS) analysis rS1 expression in PK-rS1-Ig cells was analyzed by flow cytometry.", [["cells", "ANATOMY", 13, 18], ["cell", "ANATOMY", 110, 114], ["cell", "ANATOMY", 270, 274], ["PK-rS1-Ig cells", "ANATOMY", 317, 332], ["4 0 ,6-diamidino-2-phenylindole", "CHEMICAL", 44, 75], ["4 0 ,6-diamidino-2-phenylindole", "CHEMICAL", 44, 75], ["DAPI", "CHEMICAL", 77, 81], ["cells", "CELL", 13, 18], ["4 0 ,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 44, 75], ["DAPI", "SIMPLE_CHEMICAL", 77, 81], ["Sigma", "SIMPLE_CHEMICAL", 83, 88], ["St. Louis", "SIMPLE_CHEMICAL", 90, 99], ["MO", "ORGANISM", 101, 103], ["cell", "CELL", 110, 114], ["cell", "CELL", 270, 274], ["rS1", "GENE_OR_GENE_PRODUCT", 299, 302], ["PK-rS1", "GENE_OR_GENE_PRODUCT", 317, 323], ["expression plasmids", "DNA", 228, 247], ["rS1", "DNA", 299, 302], ["PK-rS1-Ig cells", "CELL_LINE", 317, 332], ["diamidino", "TEST", 51, 60], ["cell staining", "PROBLEM", 110, 123], ["a fluorescent Leica DM IL", "TREATMENT", 145, 170], ["activated cell sorting", "TEST", 260, 282], ["rS1 expression", "TEST", 299, 313], ["PK", "TEST", 317, 319], ["rS1", "TEST", 320, 323], ["Ig cells", "TEST", 324, 332], ["flow cytometry", "TEST", 349, 363], ["flow cytometry", "OBSERVATION", 349, 363]]], ["Briefly, cells were trypsinized at 48 h postseeding and centrifuged at 250 9 g (Hanil Centrifuge FLETA 5) for 5 min.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14]]], ["The cell pellet was washed with cold washing buffer (1 % BSA and 0.1 % sodium azide in PBS) and 1 9 10 6 cells were resuspended in 1 % formaldehyde solution in cold wash buffer and fixed at 4\u00b0C in the dark for 30 min, followed by incubation in 0.2 % Triton X-100 in PBS for permeabilization at 37\u00b0C for 15 min.", [["cell pellet", "ANATOMY", 4, 15], ["cells", "ANATOMY", 105, 110], ["sodium azide", "CHEMICAL", 71, 83], ["formaldehyde", "CHEMICAL", 135, 147], ["Triton X-100", "CHEMICAL", 250, 262], ["sodium azide", "CHEMICAL", 71, 83], ["formaldehyde", "CHEMICAL", 135, 147], ["cell", "CELL", 4, 8], ["BSA", "SIMPLE_CHEMICAL", 57, 60], ["sodium azide", "SIMPLE_CHEMICAL", 71, 83], ["cells", "CELL", 105, 110], ["formaldehyde", "SIMPLE_CHEMICAL", 135, 147], ["C", "SIMPLE_CHEMICAL", 192, 193], ["Triton X-100", "SIMPLE_CHEMICAL", 250, 262], ["PBS", "SIMPLE_CHEMICAL", 266, 269], ["The cell pellet", "TREATMENT", 0, 15], ["cold washing buffer", "TREATMENT", 32, 51], ["0.1 % sodium azide in PBS", "TREATMENT", 65, 90], ["cold wash buffer", "TREATMENT", 160, 176], ["permeabilization", "TREATMENT", 274, 290], ["cell pellet", "OBSERVATION", 4, 15]]], ["Following centrifugation, the cell pellet was resuspended in normal mouse IgG1 antibody (Santa Cruz Biotechnology) and incubated at 4\u00b0C for 30 min.", [["cell pellet", "ANATOMY", 30, 41], ["cell", "CELL", 30, 34], ["mouse", "ORGANISM", 68, 73], ["IgG1", "GENE_OR_GENE_PRODUCT", 74, 78], ["normal mouse IgG1 antibody", "PROTEIN", 61, 87], ["Santa Cruz Biotechnology", "PROTEIN", 89, 113], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 68, 73], ["centrifugation", "TREATMENT", 10, 24], ["the cell pellet", "TEST", 26, 41]]], ["The cells were washed and reacted with FITC-conjugated anti-human or anti-mouse IgG secondary antibody at 4\u00b0C for 30 min in the dark.", [["cells", "ANATOMY", 4, 9], ["FITC", "CHEMICAL", 39, 43], ["cells", "CELL", 4, 9], ["FITC", "SIMPLE_CHEMICAL", 39, 43], ["FITC-conjugated anti-human", "PROTEIN", 39, 65], ["anti-mouse IgG secondary antibody", "PROTEIN", 69, 102], ["anti-mouse", "SPECIES", 69, 79], ["FITC-conjugated anti-human", "TREATMENT", 39, 65], ["anti-mouse IgG secondary antibody", "TREATMENT", 69, 102]]], ["The stained cells were washed again and analyzed by FACScan flow cytometry.Construction of expression plasmidsWestern blot analysis HEK 293T cells were transfected with each plasmid using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol and solubilized in lysis buffer at 48 h post-transfection as described previously [22] .", [["cells", "ANATOMY", 12, 17], ["HEK 293T cells", "ANATOMY", 132, 146], ["plasmid", "ANATOMY", 174, 181], ["Lipofectamine 2000", "CHEMICAL", 188, 206], ["cells", "CELL", 12, 17], ["HEK 293T cells", "CELL", 132, 146], ["Invitrogen", "SIMPLE_CHEMICAL", 208, 218], ["stained cells", "CELL_TYPE", 4, 17], ["expression plasmids", "DNA", 91, 110], ["HEK 293T cells", "CELL_LINE", 132, 146], ["The stained cells", "TEST", 0, 17], ["FACScan flow cytometry", "TEST", 52, 74], ["expression plasmids", "TREATMENT", 91, 110], ["cells", "TEST", 141, 146], ["Lipofectamine", "TREATMENT", 188, 201], ["the manufacturer's protocol", "TREATMENT", 233, 260], ["solubilized in lysis buffer", "TREATMENT", 265, 292], ["stained cells", "OBSERVATION", 4, 17]]], ["Cell lysates were also prepared from Vero cells infected with PEDV SM98-1 at a multiplicity of infection (MOI) of 0.1 at the indicated time points using lysis buffer.", [["Cell lysates", "ANATOMY", 0, 12], ["Vero cells", "ANATOMY", 37, 47], ["infection", "DISEASE", 95, 104], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["Vero cells", "CELL", 37, 47], ["PEDV SM98-1", "CELL", 62, 73], ["Vero cells", "CELL_LINE", 37, 47], ["PEDV", "SPECIES", 62, 66], ["Cell lysates", "TEST", 0, 12], ["Vero cells", "PROBLEM", 37, 47], ["PEDV SM98", "TEST", 62, 71], ["infection", "PROBLEM", 95, 104], ["lysis buffer", "TREATMENT", 153, 165], ["infection", "OBSERVATION", 95, 104]]], ["The protein concentrations of the cell lysates were determined using a BCA protein assay (Pierce, Rockford, IL).", [["cell lysates", "ANATOMY", 34, 46], ["cell lysates", "ORGANISM_SUBSTANCE", 34, 46], ["IL", "GENE_OR_GENE_PRODUCT", 108, 110], ["the cell lysates", "TREATMENT", 30, 46], ["a BCA protein assay", "TREATMENT", 69, 88]]], ["PK-rS1-Ig cells were grown at 5 9 10 5 cells/well in a 6-well tissue culture plate, and the protein-containing culture supernatants were harvested on days 1, 2, and 3.", [["rS1-Ig cells", "ANATOMY", 3, 15], ["cells", "ANATOMY", 39, 44], ["tissue", "ANATOMY", 62, 68], ["supernatants", "ANATOMY", 119, 131], ["PK", "GENE_OR_GENE_PRODUCT", 0, 2], ["cells", "CELL", 39, 44], ["tissue", "TISSUE", 62, 68], ["PK-rS1-Ig cells", "CELL_LINE", 0, 15], ["PK", "TEST", 0, 2], ["rS1", "TEST", 3, 6], ["Ig cells", "TEST", 7, 15], ["tissue culture plate", "TEST", 62, 82], ["the protein", "TEST", 88, 99], ["culture supernatants", "TEST", 111, 131]]], ["Soluble proteins were immunoprecipitated with protein A Sepharose CL-4B beads (GE Healthcare, Piscataway, NJ) in the presence of protease inhibitors at 4\u00b0C for 16 h.", [["Soluble proteins", "PROTEIN", 0, 16], ["protein A", "PROTEIN", 46, 55], ["Soluble proteins", "TREATMENT", 0, 16], ["protein A Sepharose CL-4B beads (GE Healthcare", "TREATMENT", 46, 92], ["protease inhibitors", "TREATMENT", 129, 148]]], ["The beads were collected by centrifugation at 5,000 9 g (Eppendorf centrifuge 5415R, Hamburg, Germany) for 5 min at 4\u00b0C and washed three times with 0.5 M NaCl in PBS.", [["beads", "ANATOMY", 4, 9], ["NaCl", "CHEMICAL", 154, 158], ["NaCl", "CHEMICAL", 154, 158], ["C", "SIMPLE_CHEMICAL", 118, 119], ["The beads", "TREATMENT", 0, 9], ["0.5 M NaCl in PBS", "TREATMENT", 148, 165], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["The cell lysates or the beads were mixed with 49 NuPAGE sample buffer (Invitrogen) and boiled at 70\u00b0C for 10 min.", [["cell lysates", "ANATOMY", 4, 16], ["beads", "ANATOMY", 24, 29], ["NuPAGE", "CHEMICAL", 49, 55], ["cell lysates", "CELL", 4, 16], ["The cell lysates", "TREATMENT", 0, 16], ["the beads", "TREATMENT", 20, 29], ["49 NuPAGE sample buffer (Invitrogen)", "TREATMENT", 46, 82], ["cell lysates", "OBSERVATION", 4, 16]]], ["The proteins were separated on a NuPAGE 4-12 % gradient Bis-Tris gel (Invitrogen) under reducing conditions, and electrotransferred onto Immunobilon-P (Millipore).", [["Bis-Tris gel", "CHEMICAL", 56, 68], ["NuPAGE", "CHEMICAL", 33, 39], ["Bis-Tris gel", "CHEMICAL", 56, 68], ["Bis-Tris gel", "SIMPLE_CHEMICAL", 56, 68], ["Invitrogen", "SIMPLE_CHEMICAL", 70, 80], ["a NuPAGE 4-12 % gradient Bis-Tris gel", "TREATMENT", 31, 68]]], ["The membranes were then blocked with 3 % powdered skim milk (BD Biosciences, Belford, MA) in TBS (10 mM Tris-HCl [pH 8.0], 150 mM NaCl) with 0.05 % Tween-20 (TBST) at 4\u00b0C for 2 h and reacted directly with the goat anti-human IgG HRP-conjugated secondary antibody, the anti-S1 rabbit serum or the anti-PEDV S MAb, followed by the corresponding HRP-labeled secondary antibody at a dilution of 1:5,000 for 2 h at 4\u00b0C. Finally, the proteins were visualized using enhanced chemiluminescence (ECL) reagents (GE Healthcare) according to the manufacturer's instructions.Construction of expression plasmidsProtein purification PK-rS1-Ig cells were grown at 5 9 10 5 cells/well in a 6-well tissue culture plate in serum-free medium (OptiPRO SFM; Invitrogen).", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 55, 59], ["serum", "ANATOMY", 283, 288], ["rS1-Ig cells", "ANATOMY", 621, 633], ["cells", "ANATOMY", 657, 662], ["tissue", "ANATOMY", 680, 686], ["serum", "ANATOMY", 704, 709], ["Tris-HCl", "CHEMICAL", 104, 112], ["NaCl", "CHEMICAL", 130, 134], ["Tris-HCl", "CHEMICAL", 104, 112], ["NaCl", "CHEMICAL", 130, 134], ["Tween-20", "CHEMICAL", 148, 156], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["milk", "ORGANISM_SUBSTANCE", 55, 59], ["Tween-20", "SIMPLE_CHEMICAL", 148, 156], ["goat", "ORGANISM", 209, 213], ["HRP", "GENE_OR_GENE_PRODUCT", 229, 232], ["rabbit", "ORGANISM", 276, 282], ["serum", "ORGANISM_SUBSTANCE", 283, 288], ["anti-PEDV S MAb", "GENE_OR_GENE_PRODUCT", 296, 311], ["HRP", "SIMPLE_CHEMICAL", 343, 346], ["PK", "GENE_OR_GENE_PRODUCT", 618, 620], ["cells", "CELL", 657, 662], ["tissue", "TISSUE", 680, 686], ["serum", "ORGANISM_SUBSTANCE", 704, 709], ["goat anti-human IgG HRP", "PROTEIN", 209, 232], ["conjugated secondary antibody", "PROTEIN", 233, 262], ["anti-S1", "PROTEIN", 268, 275], ["anti-PEDV S MAb", "PROTEIN", 296, 311], ["HRP-labeled secondary antibody", "PROTEIN", 343, 373], ["expression plasmids", "DNA", 578, 597], ["PK-rS1-Ig cells", "CELL_LINE", 618, 633], ["goat", "SPECIES", 209, 213], ["rabbit", "SPECIES", 276, 282], ["goat", "SPECIES", 209, 213], ["rabbit", "SPECIES", 276, 282], ["anti-PEDV", "SPECIES", 296, 305], ["3 % powdered skim milk", "TREATMENT", 37, 59], ["pH", "TEST", 114, 116], ["NaCl", "TEST", 130, 134], ["Tween", "TEST", 148, 153], ["the goat anti-human IgG HRP", "TEST", 205, 232], ["conjugated secondary antibody", "PROBLEM", 233, 262], ["the anti-S1 rabbit serum", "TEST", 264, 288], ["the anti-PEDV S MAb", "TREATMENT", 292, 311], ["the corresponding HRP", "TEST", 325, 346], ["the proteins", "TEST", 424, 436], ["enhanced chemiluminescence (ECL) reagents (GE Healthcare", "TREATMENT", 459, 515], ["expression plasmids", "TREATMENT", 578, 597], ["Protein purification", "TEST", 597, 617], ["PK", "TEST", 618, 620], ["rS1", "TEST", 621, 624], ["Ig cells", "TEST", 625, 633], ["serum", "TEST", 704, 709]]], ["At 72 h post-seeding, the protein-containing culture supernatants were harvested and soluble proteins were immunoprecipitated with protein A Sepharose CL-4B beads in the presence of protease inhibitors at 4\u00b0C for 16 h.", [["supernatants", "ANATOMY", 53, 65], ["soluble proteins", "PROTEIN", 85, 101], ["protein A", "PROTEIN", 131, 140], ["the protein", "TEST", 22, 33], ["culture supernatants", "TEST", 45, 65], ["soluble proteins", "TEST", 85, 101], ["protein", "TEST", 131, 138], ["A Sepharose CL", "TEST", 139, 153], ["4B beads", "TREATMENT", 154, 162], ["protease inhibitors", "TREATMENT", 182, 201]]], ["The beads were collected and washed as described above.", [["beads", "ANATOMY", 4, 9], ["The beads", "TREATMENT", 0, 9], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["The samples were subsequently eluted with 50 mM sodium citrate/50 mM glycine (pH 2.0) and neutralized with 1 M Tris-HCl (pH 8.0).", [["samples", "ANATOMY", 4, 11], ["sodium citrate", "CHEMICAL", 48, 62], ["glycine", "CHEMICAL", 69, 76], ["Tris-HCl", "CHEMICAL", 111, 119], ["sodium citrate", "CHEMICAL", 48, 62], ["glycine", "CHEMICAL", 69, 76], ["Tris-HCl", "CHEMICAL", 111, 119], ["sodium citrate", "SIMPLE_CHEMICAL", 48, 62], ["glycine", "SIMPLE_CHEMICAL", 69, 76], ["Tris-HCl", "SIMPLE_CHEMICAL", 111, 119], ["The samples", "TEST", 0, 11], ["50 mM sodium citrate", "TREATMENT", 42, 62], ["pH", "TEST", 78, 80], ["pH", "TEST", 121, 123]]], ["The purified proteins were concentrated with Amicon Ultra centrifugal filters 100K (Millipore).", [["purified proteins", "PROTEIN", 4, 21], ["Amicon Ultra centrifugal filters 100K", "PROTEIN", 45, 82], ["The purified proteins", "TREATMENT", 0, 21], ["Amicon Ultra centrifugal filters", "TREATMENT", 45, 77], ["centrifugal filters", "OBSERVATION", 58, 77]]], ["Protein concentration was measured using a BCA protein assay (Pierce, Rockford, IL) and the final products were analyzed by western blotting to confirm target protein purification.Immunization of rabbitsTwo New Zealand white rabbits were immunized intradermally with 250 lg of purified rS1-Ig resuspended in PBS in the presence of Freund's complete adjuvant and boosted four times with a freshly prepared emulsion of 250 lg immunogen and Freund's incomplete adjuvant at 2-week intervals.", [["intradermally", "ANATOMY", 248, 261], ["IL", "GENE_OR_GENE_PRODUCT", 80, 82], ["rabbits", "ORGANISM", 196, 203], ["rabbits", "ORGANISM", 225, 232], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 286, 292], ["rS1", "PROTEIN", 286, 289], ["Ig", "PROTEIN", 290, 292], ["rabbits", "SPECIES", 196, 203], ["rabbits", "SPECIES", 225, 232], ["rabbits", "SPECIES", 196, 203], ["Zealand white rabbits", "SPECIES", 211, 232], ["Protein concentration", "TEST", 0, 21], ["a BCA protein assay", "TEST", 41, 60], ["the final products", "TREATMENT", 88, 106], ["target protein purification", "TREATMENT", 152, 179], ["Immunization of rabbits", "TREATMENT", 180, 203], ["New Zealand white rabbits", "TREATMENT", 207, 232], ["purified rS1", "TREATMENT", 277, 289], ["Freund's complete adjuvant", "TREATMENT", 331, 357], ["lg immunogen", "TREATMENT", 421, 433]]], ["Pre-immune sera were collected before starting the immunization, and antisera were collected at each boost.Pig inoculation studiesThe in vivo swine experiments described here were performed at the Choongang Vaccine Laboratory Animal Facility under the guidelines established by its Institutional Animal Care and Use Committee.", [["sera", "ANATOMY", 11, 15], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["swine", "SPECIES", 142, 147], ["Pre-immune sera", "TEST", 0, 15], ["the immunization", "TREATMENT", 47, 63], ["antisera", "TREATMENT", 69, 77], ["Pig inoculation studies", "TEST", 107, 130]]], ["A total of eight pregnant sows were obtained from a pig farm with no outbreaks or vaccination with PEDV and randomly divided into four groups of two sows.", [["PEDV", "CHEMICAL", 99, 103], ["sows", "ORGANISM", 26, 30], ["pig", "ORGANISM", 52, 55], ["sows", "ORGANISM", 149, 153], ["sows", "SPECIES", 26, 30], ["pig", "SPECIES", 52, 55], ["pig", "SPECIES", 52, 55], ["PEDV", "SPECIES", 99, 103], ["a pig farm", "TREATMENT", 50, 60], ["outbreaks", "PROBLEM", 69, 78], ["vaccination", "TREATMENT", 82, 93], ["PEDV", "TREATMENT", 99, 103]]], ["All animals were determined to be free of antibodies to PEDV.", [["antibodies", "PROTEIN", 42, 52], ["PEDV", "PROTEIN", 56, 60], ["PEDV", "SPECIES", 56, 60], ["PEDV", "PROBLEM", 56, 60]]], ["The design for the present immunogenicity study involving eight pregnant sows is outlined in Table 1 .", [["sows", "ORGANISM", 73, 77], ["the present immunogenicity study", "TEST", 15, 47]]], ["The sows in group 1 were immunized intramuscularly with attenuated PEDV live vaccine and inactivated PEDV vaccine obtained from Choongang Vaccine Laboratory, in order at 2-week intervals prior to farrowing.", [["intramuscularly", "ANATOMY", 35, 50], ["PEDV", "CHEMICAL", 67, 71], ["PEDV", "CHEMICAL", 101, 105], ["sows", "ORGANISM", 4, 8], ["PEDV", "ORGANISM", 101, 105], ["PEDV", "SPECIES", 67, 71], ["PEDV", "SPECIES", 101, 105], ["attenuated PEDV live vaccine", "TREATMENT", 56, 84]]], ["The pigs in group 2 were immunized intramuscularly with PEDV live vaccine and 400 lg of purified rS1-Ig resuspended in PBS in the presence of an oil-in-water adjuvant, in order at 2-week intervals before farrowing.", [["intramuscularly", "ANATOMY", 35, 50], ["PEDV", "CHEMICAL", 56, 60], ["pigs", "ORGANISM", 4, 8], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 97, 103], ["rS1", "PROTEIN", 97, 100], ["Ig", "PROTEIN", 101, 103], ["pigs", "SPECIES", 4, 8], ["PEDV", "SPECIES", 56, 60], ["The pigs in group 2", "TREATMENT", 0, 19], ["PEDV live vaccine", "TREATMENT", 56, 73], ["purified rS1", "TREATMENT", 88, 100], ["an oil", "TREATMENT", 142, 148], ["water adjuvant", "TREATMENT", 152, 166]]], ["Both the PEDV live and inactivated vaccines were administrated according to the manufacturers' manuals.", [["PEDV", "CHEMICAL", 9, 13], ["PEDV", "SPECIES", 9, 13], ["the PEDV live", "TREATMENT", 5, 18], ["inactivated vaccines", "TREATMENT", 23, 43]]], ["The sows in group 3 and group 4 were inoculated intramuscularly three times at 2-week intervals with 400 lg of purified rS1-Ig mixed with the oil adjuvant or with cell culture medium as a negative control.", [["intramuscularly", "ANATOMY", 48, 63], ["oil", "ANATOMY", 142, 145], ["cell", "ANATOMY", 163, 167], ["rS1-Ig", "CHEMICAL", 120, 126], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 120, 126], ["oil", "ORGANISM_SUBSTANCE", 142, 145], ["cell", "CELL", 163, 167], ["rS1", "PROTEIN", 120, 123], ["Ig", "PROTEIN", 124, 126], ["the oil adjuvant", "TREATMENT", 138, 154], ["cell culture medium", "TEST", 163, 182]]], ["Paired blood samples and colostrum were collected at 3-week intervals before farrowing and at farrowing, at delivery, respectively.", [["blood samples", "ANATOMY", 7, 20], ["colostrum", "ANATOMY", 25, 34], ["blood samples", "ORGANISM_SUBSTANCE", 7, 20], ["colostrum", "ORGANISM_SUBSTANCE", 25, 34], ["Paired blood samples", "TEST", 0, 20], ["colostrum", "TEST", 25, 34], ["blood", "ANATOMY", 7, 12], ["colostrum", "ANATOMY", 25, 34]]], ["One 4-to 5-day-old piglet (8 piglets in total) was selected randomly from each farrowing sow in the immunized and control groups for challenge exposure with virulent PEDV.", [["piglet", "ANATOMY", 19, 25], ["PEDV", "CHEMICAL", 166, 170], ["piglet", "ORGANISM", 19, 25], ["piglets", "ORGANISM", 29, 36], ["PEDV", "ORGANISM", 166, 170], ["piglet", "SPECIES", 19, 25], ["piglets", "SPECIES", 29, 36], ["PEDV", "SPECIES", 166, 170], ["virulent PEDV", "TREATMENT", 157, 170]]], ["Piglets from all groups were challenged orally with 1 ml of small intestine homogenate containing 10 5 TCID 50 /ml of PEDV field virus, equivalent to 10 9.8 viral genome copies per ml, determined using real-time RT-PCR as described previously [12] .", [["intestine", "ANATOMY", 66, 75], ["Piglets", "ORGANISM", 0, 7], ["intestine", "ORGAN", 66, 75], ["homogenate", "ORGANISM_SUBSTANCE", 76, 86], ["PEDV", "ORGANISM", 118, 122], ["Piglets", "SPECIES", 0, 7], ["PEDV field virus", "SPECIES", 118, 134], ["small intestine homogenate", "TREATMENT", 60, 86], ["PEDV field virus", "PROBLEM", 118, 134], ["intestine", "ANATOMY", 66, 75]]], ["Clinical signs of diarrhea and death in challenged piglets were monitored daily throughout the study.", [["diarrhea", "DISEASE", 18, 26], ["death", "DISEASE", 31, 36], ["piglets", "ORGANISM", 51, 58], ["piglets", "SPECIES", 51, 58], ["diarrhea", "PROBLEM", 18, 26], ["death", "PROBLEM", 31, 36], ["the study", "TEST", 91, 100], ["diarrhea", "OBSERVATION", 18, 26]]], ["Stool samples from all groups were collected every day with 16-inch cotton-tipped swabs and subjected to RT-PCR using a TGE/PED Detection Kit (iNtRON Biotechnology, Seongnam, Korea) according to the manufacturer's protocol.", [["Stool samples", "ANATOMY", 0, 13], ["swabs", "ANATOMY", 82, 87], ["Stool samples", "CANCER", 0, 13], ["Stool samples from all groups", "TEST", 0, 29], ["16-inch cotton-tipped swabs", "TREATMENT", 60, 87], ["RT-PCR", "TEST", 105, 111], ["the manufacturer's protocol", "TREATMENT", 195, 222]]], ["All piglets from the vaccinated and control groups were euthanized at 5 days after challenge for post-mortem examination.", [["piglets", "ORGANISM", 4, 11], ["piglets", "SPECIES", 4, 11], ["All piglets", "TREATMENT", 0, 11], ["post-mortem examination", "TEST", 97, 120]]], ["Small-intestinal tissue specimens collected from each piglet ( mm thick) were fixed with 10 % formalin for 24 h at RT and embedded in paraffin according to standard laboratory procedures.", [["intestinal tissue specimens", "ANATOMY", 6, 33], ["piglet", "ANATOMY", 54, 60], ["formalin", "CHEMICAL", 94, 102], ["formalin", "CHEMICAL", 94, 102], ["paraffin", "CHEMICAL", 134, 142], ["Small-intestinal tissue specimens", "TISSUE", 0, 33], ["piglet", "ORGANISM", 54, 60], ["formalin", "SIMPLE_CHEMICAL", 94, 102], ["Small-intestinal tissue specimens", "PROBLEM", 0, 33], ["10 % formalin", "TREATMENT", 89, 102], ["paraffin", "TREATMENT", 134, 142], ["standard laboratory procedures", "TREATMENT", 156, 186], ["intestinal tissue", "ANATOMY", 6, 23]]], ["The formalinfixed paraffin-embedded tissues were cut into 5-to 8-lmthick sections on a microtome, floated on a 40\u00b0C water bath containing distilled water, and transferred onto glass slides.", [["tissues", "ANATOMY", 36, 43], ["sections", "ANATOMY", 73, 81], ["paraffin", "CHEMICAL", 18, 26], ["tissues", "TISSUE", 36, 43], ["The formalinfixed paraffin-embedded tissues", "TREATMENT", 0, 43], ["a microtome", "TREATMENT", 85, 96], ["C water bath", "TREATMENT", 114, 126]]], ["The tissues were then deparaffinized in xylene for 5 min and washed in decreasing concentrations of ethanol (100, 95, 85, 70, and 50 %) for 3 min each.", [["tissues", "ANATOMY", 4, 11], ["xylene", "CHEMICAL", 40, 46], ["ethanol", "CHEMICAL", 100, 107], ["xylene", "CHEMICAL", 40, 46], ["ethanol", "CHEMICAL", 100, 107], ["tissues", "TISSUE", 4, 11], ["xylene", "SIMPLE_CHEMICAL", 40, 46], ["ethanol", "SIMPLE_CHEMICAL", 100, 107], ["tissues", "ANATOMY", 4, 11]]], ["The deparaffinized intestinal tissues sections were subjected to immunofluorescence assay using an N-specific MAb and Alexa Fluor 594-conjugated goat anti-mouse antibody as described above.Serum neutralizationThe presence of PEDV-specific neutralizing antibodies in serum and colostrum samples collected from sows in all groups was determined using a serum neutralization (SN) test in 96-well microtiter plates using PEDV vaccine strain SM98-1 as described previously [15] .", [["intestinal tissues sections", "ANATOMY", 19, 46], ["Serum", "ANATOMY", 189, 194], ["serum", "ANATOMY", 266, 271], ["colostrum samples", "ANATOMY", 276, 293], ["serum", "ANATOMY", 351, 356], ["Alexa Fluor 594", "CHEMICAL", 118, 133], ["PEDV", "CHEMICAL", 225, 229], ["PEDV", "CHEMICAL", 417, 421], ["Alexa Fluor 594", "CHEMICAL", 118, 133], ["intestinal tissues sections", "MULTI-TISSUE_STRUCTURE", 19, 46], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 118, 133], ["Serum", "ORGANISM_SUBSTANCE", 189, 194], ["PEDV", "GENE_OR_GENE_PRODUCT", 225, 229], ["serum", "ORGANISM_SUBSTANCE", 266, 271], ["colostrum samples", "ORGANISM_SUBSTANCE", 276, 293], ["sows", "ORGANISM_SUBDIVISION", 309, 313], ["serum", "ORGANISM_SUBSTANCE", 351, 356], ["N-specific MAb", "PROTEIN", 99, 113], ["Alexa Fluor 594-conjugated goat anti-mouse antibody", "PROTEIN", 118, 169], ["PEDV", "PROTEIN", 225, 229], ["neutralizing antibodies", "PROTEIN", 239, 262], ["goat", "SPECIES", 145, 149], ["Alexa Fluor 594", "SPECIES", 118, 133], ["goat", "SPECIES", 145, 149], ["PEDV", "SPECIES", 225, 229], ["PEDV vaccine strain SM98-1", "SPECIES", 417, 443], ["The deparaffinized intestinal tissues sections", "PROBLEM", 0, 46], ["immunofluorescence assay", "TEST", 65, 89], ["an N-specific MAb", "TREATMENT", 96, 113], ["Alexa Fluor", "TEST", 118, 129], ["conjugated goat anti-mouse antibody", "TREATMENT", 134, 169], ["Serum neutralization", "TEST", 189, 209], ["PEDV", "PROBLEM", 225, 229], ["specific neutralizing antibodies", "TEST", 230, 262], ["serum and colostrum samples", "TEST", 266, 293], ["a serum neutralization", "TEST", 349, 371], ["test", "TEST", 377, 381], ["PEDV vaccine", "TREATMENT", 417, 429], ["intestinal tissues", "ANATOMY", 19, 37], ["PEDV", "OBSERVATION", 225, 229], ["neutralizing", "OBSERVATION_MODIFIER", 239, 251]]], ["Briefly, individual virus stocks were diluted in serum-free a-MEM to make 200 PFU in a 50 ll volume.", [["serum", "ANATOMY", 49, 54], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["individual virus stocks", "TREATMENT", 9, 32], ["serum-free a-MEM", "TREATMENT", 49, 65], ["virus stocks", "OBSERVATION", 20, 32]]], ["The diluted virus was then mixed with 50 ll of twofold dilutions of individual PEDV S1 immunogen a PEDV S1 immunogen PEDV S1 immunogen 4 Placebo Placebo Placebo a Placebo (cell culture medium) and protein (PEDV S1) immunizations were given intramuscularly with the oil-in-water adjuvant b Commercial PEDV live and inactivated vaccines were administrated intramuscularly according to the manufacturers' instructions with the oil-in-water adjuvant inactivated sera in 96-well plates and incubated at 37\u00b0C for 1 h.", [["cell", "ANATOMY", 172, 176], ["intramuscularly", "ANATOMY", 240, 255], ["sera", "ANATOMY", 458, 462], ["Placebo", "CHEMICAL", 163, 170], ["PEDV", "CHEMICAL", 300, 304], ["cell", "CELL", 172, 176], ["sera", "ORGANISM_SUBSTANCE", 458, 462], ["PEDV", "SPECIES", 79, 83], ["PEDV", "SPECIES", 99, 103], ["PEDV", "SPECIES", 117, 121], ["PEDV", "SPECIES", 300, 304], ["The diluted virus", "TREATMENT", 0, 17], ["twofold dilutions", "TREATMENT", 47, 64], ["individual PEDV S1 immunogen", "TREATMENT", 68, 96], ["a PEDV S1 immunogen PEDV S1 immunogen", "TREATMENT", 97, 134], ["Placebo Placebo Placebo", "TREATMENT", 137, 160], ["a Placebo (cell culture medium", "TREATMENT", 161, 191], ["protein (PEDV S1) immunizations", "TREATMENT", 197, 228], ["the oil", "TREATMENT", 261, 268], ["-water adjuvant", "TREATMENT", 271, 286], ["Commercial PEDV live", "TREATMENT", 289, 309], ["inactivated vaccines", "TREATMENT", 314, 334], ["the oil", "TREATMENT", 420, 427], ["water adjuvant", "TREATMENT", 431, 445], ["sera", "TEST", 458, 462]]], ["Next, the mixture was incubated at 37\u00b0C for 1 h, approximately 1 9 10 4 Vero cells in 100 ll of a-MEM were added to each well, and the mixture was maintained at 37\u00b0C in a 5 % CO 2 incubator for 3 to 4 days.", [["cells", "ANATOMY", 77, 82], ["CO 2", "CHEMICAL", 175, 179], ["Vero cells", "CELL", 72, 82], ["Vero cells", "TEST", 72, 82], ["a-MEM", "TREATMENT", 96, 101], ["a 5 % CO 2 incubator", "TREATMENT", 169, 189]]], ["The neutralization titer was calculated as the reciprocal of the highest dilution of serum that inhibited the virus-specific cytopathic effect in both of the duplicate wells.", [["serum", "ANATOMY", 85, 90], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["The neutralization titer", "TEST", 0, 24], ["the virus", "PROBLEM", 106, 115], ["specific cytopathic effect", "PROBLEM", 116, 142], ["neutralization titer", "OBSERVATION", 4, 24], ["virus", "OBSERVATION", 110, 115], ["cytopathic effect", "OBSERVATION", 125, 142]]], ["Results were also visualized by staining the wells with a crystal violet-formaldehyde staining reagent (0.013 % crystal violet, 2.5 % ethanol, and 10 % formaldehyde in 0.01 M PBS) for 1 h at RT.Statistical analysisThe Student's t test was used for all statistical analyses, and p-values of less than 0.05 were considered statistically significant.ResultsGeneration of stable porcine-origin cell lines expressing the full-length, codon-optimized S1 proteinResultsWe have previously constructed a series of expression plasmids encoding the full-length S1-Ig (S1 ).ResultsAlthough expression of this gene could be detected in transiently transfected cells by western blot analysis, its expression level was relatively low and insufficient for further protein purification study (Fig. 1, lane 2) .", [["cell lines", "ANATOMY", 390, 400], ["plasmids", "ANATOMY", 516, 524], ["cells", "ANATOMY", 647, 652], ["crystal violet-formaldehyde", "CHEMICAL", 58, 85], ["crystal violet", "CHEMICAL", 112, 126], ["ethanol", "CHEMICAL", 134, 141], ["formaldehyde", "CHEMICAL", 152, 164], ["formaldehyde", "CHEMICAL", 73, 85], ["ethanol", "CHEMICAL", 134, 141], ["formaldehyde", "CHEMICAL", 152, 164], ["ethanol", "SIMPLE_CHEMICAL", 134, 141], ["formaldehyde", "SIMPLE_CHEMICAL", 152, 164], ["porcine", "ORGANISM", 375, 382], ["cell lines", "CELL", 390, 400], ["Ig", "GENE_OR_GENE_PRODUCT", 553, 555], ["S1", "GENE_OR_GENE_PRODUCT", 557, 559], ["cells", "CELL", 647, 652], ["porcine-origin cell lines", "CELL_LINE", 375, 400], ["codon-optimized S1 proteinResults", "DNA", 429, 462], ["expression plasmids", "DNA", 505, 524], ["S1", "PROTEIN", 550, 552], ["Ig", "PROTEIN", 553, 555], ["S1", "PROTEIN", 557, 559], ["transiently transfected cells", "CELL_LINE", 623, 652], ["a crystal violet", "TEST", 56, 72], ["formaldehyde staining reagent", "TREATMENT", 73, 102], ["crystal violet", "TREATMENT", 112, 126], ["Statistical analysis", "TEST", 194, 214], ["The Student's t test", "TEST", 214, 234], ["all statistical analyses", "TEST", 248, 272], ["p-values", "TEST", 278, 286], ["codon", "TEST", 429, 434], ["expression plasmids", "TREATMENT", 505, 524], ["transiently transfected cells", "PROBLEM", 623, 652], ["western blot analysis", "TEST", 656, 677], ["its expression level", "TEST", 679, 699], ["further protein purification study", "TEST", 740, 774], ["stable", "OBSERVATION_MODIFIER", 368, 374], ["origin cell lines", "OBSERVATION", 383, 400], ["transfected cells", "OBSERVATION", 635, 652]]], ["Thus, to enhance S1 protein expression, we first synthesized the full-length, codon-optimized S1 gene and constructed a panel of expression plasmids encoding the codon-optimized rS1-Ig (S1 ) and two C-terminally truncated S1 variants: rS1 25-543 -Ig and rS1 25-432 -Ig.", [["plasmids", "ANATOMY", 140, 148], ["C", "CHEMICAL", 199, 200], ["S1", "GENE_OR_GENE_PRODUCT", 17, 19], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 178, 184], ["rS1 25-543 -Ig", "GENE_OR_GENE_PRODUCT", 235, 249], ["Ig", "GENE_OR_GENE_PRODUCT", 266, 268], ["S1", "PROTEIN", 17, 19], ["S1 gene", "DNA", 94, 101], ["expression plasmids", "DNA", 129, 148], ["rS1", "PROTEIN", 178, 181], ["Ig", "PROTEIN", 182, 184], ["S1", "PROTEIN", 186, 188], ["C-terminally truncated S1 variants", "DNA", 199, 233], ["rS1 25-543 -Ig and rS1 25-432 -Ig", "DNA", 235, 268], ["codon", "TREATMENT", 78, 83], ["expression plasmids", "TREATMENT", 129, 148], ["the codon", "TEST", 158, 167], ["rS1", "TEST", 235, 238], ["Ig", "TEST", 247, 249], ["rS1", "TEST", 254, 257]]], ["These constructs were independently transfected into HEK-293T cells, and expression of each construct was robustly detectable by western blot analysis using an anti-human IgG secondary antibody (Fig. 1, lanes 3 to 5) , compared with a normal S1 protein (lane 2).", [["HEK-293T cells", "ANATOMY", 53, 67], ["HEK-293T cells", "CELL", 53, 67], ["HEK-293T cells", "CELL_LINE", 53, 67], ["anti-human IgG secondary antibody", "PROTEIN", 160, 193], ["Fig. 1, lanes 3 to 5", "PROTEIN", 195, 215], ["normal S1 protein", "PROTEIN", 235, 252], ["blot analysis", "TEST", 137, 150], ["an anti-human IgG secondary antibody", "TEST", 157, 193]]], ["This result indicates that codon optimization greatly increases the expression level of S1 upon transient transfection.", [["S1", "GENE_OR_GENE_PRODUCT", 88, 90], ["S1", "PROTEIN", 88, 90], ["codon optimization", "PROBLEM", 27, 45], ["transient transfection", "TREATMENT", 96, 118], ["transient", "OBSERVATION_MODIFIER", 96, 105], ["transfection", "OBSERVATION", 106, 118]]], ["Subsequently, to easily produce preparative amounts of the S1 protein, sublines of PK-15 cells were established to stably express the recombinant codon-optimized S1 under the control of a retroviral LTR promoter.", [["sublines", "ANATOMY", 71, 79], ["PK-15 cells", "ANATOMY", 83, 94], ["LTR", "ANATOMY", 199, 202], ["sublines", "CELL", 71, 79], ["PK-15 cells", "CELL", 83, 94], ["retroviral", "ORGANISM", 188, 198], ["LTR", "CELLULAR_COMPONENT", 199, 202], ["S1 protein", "PROTEIN", 59, 69], ["PK-15 cells", "CELL_LINE", 83, 94], ["S1", "PROTEIN", 162, 164], ["retroviral LTR promoter", "DNA", 188, 211], ["retroviral", "SPECIES", 188, 198], ["the S1 protein", "TREATMENT", 55, 69], ["PK-15 cells", "TREATMENT", 83, 94], ["the recombinant codon", "TREATMENT", 130, 151], ["a retroviral LTR promoter", "TREATMENT", 186, 211], ["retroviral LTR", "OBSERVATION", 188, 202]]], ["Ten generated cell clones were initially collected and subjected to RT-PCR and western blotting to identify S1 gene expression at the mRNA and protein level, respectively (data not shown).", [["cell clones", "ANATOMY", 14, 25], ["cell clones", "CELL", 14, 25], ["S1", "GENE_OR_GENE_PRODUCT", 108, 110], ["S1 gene", "DNA", 108, 115], ["Ten generated cell clones", "PROBLEM", 0, 25], ["RT-PCR", "TEST", 68, 74], ["western blotting", "TEST", 79, 95], ["the mRNA", "TEST", 130, 138], ["protein level", "TEST", 143, 156], ["cell clones", "OBSERVATION", 14, 25]]], ["Based on the results of western blot analysis, one PK-rS1-Ig cell clone that consistently expressed the highest level of S1 was chosen for subsequent studies.ResultsTo characterize PK-rS1-Ig cells, intracellular and extracellular expression levels of S1 were examined by immunofluorescence, FACS analysis, and western blotting.", [["cell", "ANATOMY", 61, 65], ["PK-rS1-Ig cells", "ANATOMY", 181, 196], ["intracellular", "ANATOMY", 198, 211], ["extracellular", "ANATOMY", 216, 229], ["PK", "GENE_OR_GENE_PRODUCT", 51, 53], ["PK-rS1", "GENE_OR_GENE_PRODUCT", 181, 187], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 229], ["S1", "GENE_OR_GENE_PRODUCT", 251, 253], ["PK-rS1-Ig cell clone", "CELL_LINE", 51, 71], ["S1", "PROTEIN", 121, 123], ["PK-rS1-Ig cells", "CELL_LINE", 181, 196], ["S1", "PROTEIN", 251, 253], ["western blot analysis", "TEST", 24, 45], ["one PK-rS1", "TEST", 47, 57], ["Ig cell clone", "TEST", 58, 71], ["subsequent studies", "TEST", 139, 157], ["PK", "TEST", 181, 183], ["rS1", "TEST", 184, 187], ["Ig cells", "TEST", 188, 196], ["intracellular and extracellular expression levels of S1", "PROBLEM", 198, 253], ["immunofluorescence", "TEST", 271, 289], ["FACS analysis", "TEST", 291, 304], ["Ig cell clone", "OBSERVATION", 58, 71], ["highest", "OBSERVATION_MODIFIER", 104, 111], ["Ig cells", "OBSERVATION", 188, 196], ["extracellular expression", "OBSERVATION", 216, 240], ["S1", "ANATOMY", 251, 253]]], ["As shown in Fig. 2A , specific cell staining was clearly evident when PK-rS1-Ig cells were reacted with the antihuman IgG antibody, confirming a consistent high expression level of the S1 protein.", [["cell", "ANATOMY", 31, 35], ["PK-rS1-Ig cells", "ANATOMY", 70, 85], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["cell", "CELL", 31, 35], ["PK-rS1", "GENE_OR_GENE_PRODUCT", 70, 76], ["S1", "GENE_OR_GENE_PRODUCT", 185, 187], ["PK-rS1-Ig cells", "CELL_LINE", 70, 85], ["antihuman IgG antibody", "PROTEIN", 108, 130], ["S1 protein", "PROTEIN", 185, 195], ["specific cell staining", "TEST", 22, 44], ["PK", "TEST", 70, 72], ["rS1", "TEST", 73, 76], ["Ig cells", "TEST", 77, 85], ["the antihuman IgG antibody", "TEST", 104, 130], ["cell staining", "OBSERVATION", 31, 44], ["high expression", "OBSERVATION", 156, 171], ["S1", "ANATOMY", 185, 187]]], ["The majority of the cells consistently exhibited specific fluorescent signals, indicating a homogenous population of cells expressing S1 (Fig. 2B) .", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 117, 122], ["cells", "CELL", 20, 25], ["cells", "CELL", 117, 122], ["Fig. 2B", "GENE_OR_GENE_PRODUCT", 138, 145], ["S1", "PROTEIN", 134, 136], ["Fig. 2B", "PROTEIN", 138, 145], ["specific fluorescent signals", "PROBLEM", 49, 77], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["fluorescent signals", "OBSERVATION", 58, 77], ["homogenous", "OBSERVATION_MODIFIER", 92, 102], ["population", "OBSERVATION_MODIFIER", 103, 113]]], ["Time-course western blot analysis using culture supernatants revealed that the PK-rS1-Ig cells stably express and cumulatively secrete high levels of approximately 160-kDa S1 (Fig. 2C ).", [["supernatants", "ANATOMY", 48, 60], ["PK-rS1-Ig cells", "ANATOMY", 79, 94], ["PK-rS1", "GENE_OR_GENE_PRODUCT", 79, 85], ["PK-rS1-Ig cells", "CELL_LINE", 79, 94], ["blot analysis", "TEST", 20, 33], ["culture supernatants", "TEST", 40, 60], ["the PK", "TEST", 75, 81], ["rS1", "TEST", 82, 85], ["Ig cells", "TEST", 86, 94]]], ["In addition, the overall growth kinetics of S1-gene-expressing PK-15 cells were found to be similar to those of the parental PK-15 cells, indicating that S1 expression has no effect on cell growth (data not shown).", [["PK-15 cells", "ANATOMY", 63, 74], ["PK-15 cells", "ANATOMY", 125, 136], ["cell", "ANATOMY", 185, 189], ["S1", "GENE_OR_GENE_PRODUCT", 44, 46], ["PK-15 cells", "CELL", 63, 74], ["PK-15 cells", "CELL", 125, 136], ["S1", "GENE_OR_GENE_PRODUCT", 154, 156], ["cell", "CELL", 185, 189], ["S1", "PROTEIN", 44, 46], ["PK-15 cells", "CELL_LINE", 63, 74], ["parental PK-15 cells", "CELL_LINE", 116, 136], ["S1", "PROTEIN", 154, 156], ["PK", "TEST", 63, 65], ["the parental PK", "TEST", 112, 127], ["S1 expression", "PROBLEM", 154, 167], ["cell growth", "PROBLEM", 185, 196], ["no", "UNCERTAINTY", 172, 174]]], ["Further, the recombinant S1 protein tagged with the human IgG Fc domain expressed in the supernatants of stable PK-rS1-Ig cells was purified using protein A Sepharose beads.", [["supernatants", "ANATOMY", 89, 101], ["PK-rS1-Ig cells", "ANATOMY", 112, 127], ["S1", "GENE_OR_GENE_PRODUCT", 25, 27], ["human", "ORGANISM", 52, 57], ["IgG Fc", "GENE_OR_GENE_PRODUCT", 58, 64], ["PK", "GENE_OR_GENE_PRODUCT", 112, 114], ["recombinant S1 protein", "PROTEIN", 13, 35], ["human IgG Fc domain", "PROTEIN", 52, 71], ["PK-rS1-Ig cells", "CELL_LINE", 112, 127], ["protein A", "PROTEIN", 147, 156], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["the recombinant S1 protein", "TEST", 9, 35], ["the human IgG Fc domain", "TREATMENT", 48, 71], ["protein A Sepharose beads", "TREATMENT", 147, 172], ["stable", "OBSERVATION_MODIFIER", 105, 111], ["Sepharose beads", "OBSERVATION", 157, 172]]], ["The purified S1 protein was detectable at a high level by Ponceau S staining, and this was confirmed by immunoblotting with anti-human IgG antibody (Fig. 2D ).", [["Ponceau S", "CHEMICAL", 58, 67], ["S1", "GENE_OR_GENE_PRODUCT", 13, 15], ["Ponceau S", "GENE_OR_GENE_PRODUCT", 58, 67], ["purified S1 protein", "PROTEIN", 4, 23], ["anti-human IgG antibody", "PROTEIN", 124, 147], ["The purified S1 protein", "TEST", 0, 23], ["immunoblotting", "TEST", 104, 118], ["anti-human IgG antibody", "TEST", 124, 147], ["S1 protein", "OBSERVATION", 13, 23]]], ["Using our purification and concentration procedures, we were able to obtain approximately 15 lg of the S1 protein from 1 ml culture supernatant of PK-rS1-Ig cells cultivated in one well of a 6-well plate for 72 h.", [["supernatant", "ANATOMY", 132, 143], ["PK-rS1-Ig cells", "ANATOMY", 147, 162], ["PK-rS1-Ig cells", "CELL", 147, 162], ["S1 protein", "PROTEIN", 103, 113], ["PK-rS1-Ig cells", "CELL_LINE", 147, 162], ["our purification", "TREATMENT", 6, 22], ["concentration procedures", "TREATMENT", 27, 51], ["the S1 protein", "TEST", 99, 113], ["ml culture", "TEST", 121, 131], ["PK", "TEST", 147, 149], ["rS1", "TEST", 150, 153], ["Ig cells", "TEST", 154, 162]]], ["Antibody response of the recombinant S1 immunogen in rabbits Rabbit antisera were collected before immunization (preimmune) and at each boost at 2-week intervals.", [["rabbits", "ORGANISM", 53, 60], ["Rabbit", "ORGANISM", 61, 67], ["recombinant S1 immunogen", "PROTEIN", 25, 49], ["rabbits", "SPECIES", 53, 60], ["Rabbit", "SPECIES", 61, 67], ["rabbits", "SPECIES", 53, 60], ["Rabbit", "SPECIES", 61, 67], ["Antibody response", "TEST", 0, 17], ["the recombinant S1 immunogen", "TREATMENT", 21, 49], ["rabbits Rabbit antisera", "TREATMENT", 53, 76], ["immunization (preimmune)", "TREATMENT", 99, 123]]], ["The serum samples at 1:10,000 to 1:100,000 dilutions were examined for binding to the recombinant fusion protein rS1-Ig or the authentic S protein by western blot analysis.", [["serum samples", "ANATOMY", 4, 17], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["rS1-Ig", "GENE_OR_GENE_PRODUCT", 113, 119], ["recombinant fusion protein", "PROTEIN", 86, 112], ["rS1", "PROTEIN", 113, 116], ["Ig", "PROTEIN", 117, 119], ["S protein", "PROTEIN", 137, 146], ["The serum samples", "TEST", 0, 17], ["the recombinant fusion protein rS1", "TREATMENT", 82, 116], ["the authentic S protein", "TEST", 123, 146], ["blot analysis", "TEST", 158, 171]]], ["The antiserum collected at the second boost reacted with the purified rS1 protein in a concentration-dependent manner (Fig. 3A, top panel) , similar to the binding capacity of the anti-IgG secondary antibody, which can directly recognize the protein fused to the Fc region of human IgG1 (middle panel).", [["antiserum", "ORGANISM_SUBSTANCE", 4, 13], ["rS1", "GENE_OR_GENE_PRODUCT", 70, 73], ["anti-IgG", "GENE_OR_GENE_PRODUCT", 180, 188], ["human", "ORGANISM", 276, 281], ["IgG1", "GENE_OR_GENE_PRODUCT", 282, 286], ["rS1 protein", "PROTEIN", 70, 81], ["anti-IgG secondary antibody", "PROTEIN", 180, 207], ["Fc region", "PROTEIN", 263, 272], ["human IgG1", "PROTEIN", 276, 286], ["middle panel", "PROTEIN", 288, 300], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["The antiserum", "TREATMENT", 0, 13], ["top panel", "TEST", 128, 137], ["the anti-IgG secondary antibody", "PROBLEM", 176, 207], ["anti-IgG", "OBSERVATION", 180, 188], ["secondary antibody", "OBSERVATION", 189, 207]]], ["The antisera were found to retain nearly equivalent reactivity at the third and fourth boosts (data not shown).", [["equivalent", "OBSERVATION_MODIFIER", 41, 51], ["reactivity", "OBSERVATION", 52, 62]]], ["In contrast, the rabbit antiserum bound weakly to the authentic S protein prepared from cells infected with a PEDV vaccine strain (top panel), whereas an MAb raised against the vaccine strain reacted strongly with the authentic S protein (bottom panel).", [["cells", "ANATOMY", 88, 93], ["PEDV", "CHEMICAL", 110, 114], ["rabbit", "ORGANISM", 17, 23], ["antiserum", "ORGANISM_SUBSTANCE", 24, 33], ["cells", "CELL", 88, 93], ["MAb", "GENE_OR_GENE_PRODUCT", 154, 157], ["S protein", "PROTEIN", 64, 73], ["MAb", "PROTEIN", 154, 157], ["S protein", "PROTEIN", 228, 237], ["rabbit", "SPECIES", 17, 23], ["rabbit", "SPECIES", 17, 23], ["PEDV", "SPECIES", 110, 114], ["the rabbit antiserum bound", "PROBLEM", 13, 39], ["a PEDV vaccine strain", "TREATMENT", 108, 129], ["an MAb", "TREATMENT", 151, 157], ["the vaccine strain", "PROBLEM", 173, 191], ["bottom panel", "TEST", 239, 251]]], ["The rabbit antisera were further tested for their neutralizing activity against the PEDV SM98-1 vaccine strain, which can be grown in Vero cells in the absence of trypsin.", [["Vero cells", "ANATOMY", 134, 144], ["rabbit", "ORGANISM", 4, 10], ["PEDV SM98-1", "ORGANISM", 84, 95], ["Vero cells", "CELL", 134, 144], ["trypsin", "GENE_OR_GENE_PRODUCT", 163, 170], ["Vero cells", "CELL_LINE", 134, 144], ["trypsin", "PROTEIN", 163, 170], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["PEDV SM98-1", "SPECIES", 84, 95], ["The rabbit antisera", "TREATMENT", 0, 19], ["their neutralizing activity", "PROBLEM", 44, 71], ["the PEDV SM98", "TEST", 80, 93], ["1 vaccine strain", "PROBLEM", 94, 110], ["trypsin", "PROBLEM", 163, 170], ["Vero cells", "OBSERVATION", 134, 144]]], ["As shown in Fig. 3B , the antisera collected at the final boost at 1:16 dilution fully protect Vero cells from SM98-1 infection (left panel), whereas pig hyperimmune sera raised against the vaccine virus were highly effective in inhibiting virus infection with neutralizing antibody titers of [1:256 (right panel).", [["Vero cells", "ANATOMY", 95, 105], ["left panel", "ANATOMY", 129, 139], ["sera", "ANATOMY", 166, 170], ["infection", "DISEASE", 118, 127], ["infection", "DISEASE", 246, 255], ["Fig. 3B", "CELL", 12, 19], ["Vero cells", "CELL", 95, 105], ["SM98-1", "GENE_OR_GENE_PRODUCT", 111, 117], ["pig", "ORGANISM", 150, 153], ["hyperimmune", "ORGANISM", 154, 165], ["sera", "ORGANISM_SUBSTANCE", 166, 170], ["Vero cells", "CELL_LINE", 95, 105], ["pig", "SPECIES", 150, 153], ["hyperimmune", "SPECIES", 154, 165], ["SM98-1", "SPECIES", 111, 117], ["pig", "SPECIES", 150, 153], ["the antisera", "TREATMENT", 22, 34], ["Vero cells", "PROBLEM", 95, 105], ["SM98", "TEST", 111, 115], ["1 infection", "PROBLEM", 116, 127], ["left panel", "TEST", 129, 139], ["pig hyperimmune sera", "TREATMENT", 150, 170], ["the vaccine virus", "PROBLEM", 186, 203], ["inhibiting virus infection", "PROBLEM", 229, 255], ["neutralizing antibody titers", "TEST", 261, 289], ["Vero cells", "OBSERVATION", 95, 105], ["left", "ANATOMY_MODIFIER", 129, 133], ["right", "ANATOMY_MODIFIER", 301, 306]]], ["The rabbit sera at the second and third boosts possessed comparable neutralizing activities against the vaccine strain (data not shown).", [["sera", "ANATOMY", 11, 15], ["rabbit", "ORGANISM", 4, 10], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["The rabbit sera", "TREATMENT", 0, 15], ["the vaccine strain", "PROBLEM", 100, 118]]], ["Taken together, our data indicated that the recombinant S1 immunogen elicits potent antibody responses in immunized rabbits.", [["rabbits", "ORGANISM", 116, 123], ["rabbits", "SPECIES", 116, 123], ["rabbits", "SPECIES", 116, 123], ["our data", "TEST", 16, 24], ["the recombinant S1 immunogen", "TREATMENT", 40, 68], ["immunized rabbits", "TREATMENT", 106, 123]]], ["However, the rabbit antisera strongly recognized the homologous S1 protein representing the S protein of field isolates but recognized the heterologous S protein of the PEDV vaccine strain inefficiently, suggesting that there are antigenic differences between the vaccine strain and field PEDVs.Experimental infection of pigs with the recombinant S1 immunogenTo determine the immunogenicity of the S1-based subunit vaccine, pregnant sows assigned to four groups were immunized intramuscularly, as outlined in Table 1 .", [["infection", "DISEASE", 308, 317], ["rabbit", "ORGANISM", 13, 19], ["S1", "GENE_OR_GENE_PRODUCT", 64, 66], ["PEDV vaccine", "ORGANISM", 169, 181], ["pigs", "ORGANISM", 321, 325], ["S1", "GENE_OR_GENE_PRODUCT", 398, 400], ["sows", "ORGANISM", 433, 437], ["homologous S1 protein", "PROTEIN", 53, 74], ["S protein", "PROTEIN", 92, 101], ["heterologous S protein", "PROTEIN", 139, 161], ["recombinant S1 immunogen", "PROTEIN", 335, 359], ["S1", "PROTEIN", 398, 400], ["rabbit", "SPECIES", 13, 19], ["pigs", "SPECIES", 321, 325], ["rabbit", "SPECIES", 13, 19], ["PEDV", "SPECIES", 169, 173], ["pigs", "SPECIES", 321, 325], ["the rabbit antisera", "TEST", 9, 28], ["the homologous S1 protein", "TEST", 49, 74], ["the S protein of field isolates", "PROBLEM", 88, 119], ["the PEDV vaccine strain", "PROBLEM", 165, 188], ["antigenic differences", "PROBLEM", 230, 251], ["the vaccine strain", "TREATMENT", 260, 278], ["Experimental infection of pigs", "PROBLEM", 295, 325], ["the recombinant S1 immunogen", "TREATMENT", 331, 359], ["the S1-based subunit vaccine", "TREATMENT", 394, 422], ["infection", "OBSERVATION", 308, 317]]], ["Serum samples were collected at 6 weeks and 3 weeks prior to farrowing and at delivery and were subjected to a serum neutralization test against the PEDV vaccine strain.", [["Serum samples", "ANATOMY", 0, 13], ["serum", "ANATOMY", 111, 116], ["PEDV", "CHEMICAL", 149, 153], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["PEDV", "ORGANISM", 149, 153], ["PEDV", "SPECIES", 149, 153], ["Serum samples", "TEST", 0, 13], ["a serum neutralization test", "TEST", 109, 136], ["the PEDV vaccine strain", "PROBLEM", 145, 168]]], ["Nonimmunized sows showed only minimal neutralizing antibody titers, whereas immunized sows exhibited gradually increased neutralizing antibody titers, which increased considerably after the final vaccination (Fig. 4) .", [["sows", "ORGANISM", 13, 17], ["sows", "ORGANISM", 86, 90], ["minimal neutralizing antibody titers", "PROBLEM", 30, 66], ["gradually increased neutralizing antibody titers", "PROBLEM", 101, 149], ["the final vaccination", "TREATMENT", 186, 207], ["minimal", "OBSERVATION_MODIFIER", 30, 37], ["neutralizing antibody titers", "OBSERVATION", 38, 66], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["neutralizing antibody titers", "OBSERVATION", 121, 149]]], ["Briefly, sows immunized with two doses of PEDV live and inactivated vaccines at 2-week intervals (group 1) had neutralizing titers of [1:256 at delivery.", [["PEDV", "CHEMICAL", 42, 46], ["sows", "ORGANISM", 9, 13], ["PEDV", "ORGANISM", 42, 46], ["sows", "SPECIES", 9, 13], ["PEDV", "SPECIES", 42, 46], ["PEDV live", "TREATMENT", 42, 51], ["inactivated vaccines", "TREATMENT", 56, 76], ["neutralizing titers", "TEST", 111, 130], ["delivery", "TREATMENT", 144, 152]]], ["In contrast, sows immunized with two doses of PEDV live and S1 protein vaccines (group 2) or three doses of S1 protein vaccine (group 3) at 2-week intervals produced relatively lower neutralizing antibody titers of 1:16 to 1:32 compared to those in group 1.", [["PEDV", "CHEMICAL", 46, 50], ["sows", "ORGANISM", 13, 17], ["sows", "SPECIES", 13, 17], ["PEDV", "SPECIES", 46, 50], ["PEDV live", "TREATMENT", 46, 55], ["S1 protein vaccines", "TREATMENT", 60, 79], ["S1 protein vaccine", "TREATMENT", 108, 126], ["relatively lower neutralizing antibody titers", "PROBLEM", 166, 211]]], ["In addition, colostrum samples from each group were found to have neutralizing antibody titers comparable to those in the corresponding serum samples (Fig. 4B) .", [["colostrum samples", "ANATOMY", 13, 30], ["serum samples", "ANATOMY", 136, 149], ["colostrum samples", "ORGANISM_SUBSTANCE", 13, 30], ["serum samples", "ORGANISM_SUBSTANCE", 136, 149], ["colostrum samples", "TEST", 13, 30], ["neutralizing antibody titers", "PROBLEM", 66, 94], ["the corresponding serum samples", "TEST", 118, 149]]], ["These results were coincident with the rabbit study described above, since the rabbit antisera generated by immunization with the recombinant S1 protein also contained low levels of neutralizing antibodies to the heterologous PEDV vaccine strain.Experimental infection of pigs with the recombinant S1 immunogenLastly, to assess the efficacy of immunization with the S1 protein, eight 4-to 5-day-old neonatal piglets from each sow were arbitrarily selected and challenged orally with wild-type PEDV.", [["infection", "DISEASE", 259, 268], ["rabbit", "ORGANISM", 39, 45], ["rabbit", "ORGANISM", 79, 85], ["S1", "GENE_OR_GENE_PRODUCT", 142, 144], ["PEDV vaccine", "ORGANISM", 226, 238], ["pigs", "ORGANISM", 272, 276], ["piglets", "ORGANISM", 408, 415], ["PEDV", "ORGANISM", 493, 497], ["recombinant S1 protein", "PROTEIN", 130, 152], ["neutralizing antibodies", "PROTEIN", 182, 205], ["recombinant S1 immunogenLastly", "PROTEIN", 286, 316], ["S1 protein", "PROTEIN", 366, 376], ["rabbit", "SPECIES", 39, 45], ["rabbit", "SPECIES", 79, 85], ["pigs", "SPECIES", 272, 276], ["piglets", "SPECIES", 408, 415], ["rabbit", "SPECIES", 39, 45], ["rabbit", "SPECIES", 79, 85], ["PEDV", "SPECIES", 226, 230], ["pigs", "SPECIES", 272, 276], ["PEDV", "SPECIES", 493, 497], ["the rabbit study", "TEST", 35, 51], ["the rabbit antisera", "TEST", 75, 94], ["immunization", "TREATMENT", 108, 120], ["the recombinant S1 protein", "TEST", 126, 152], ["low levels of neutralizing antibodies", "PROBLEM", 168, 205], ["the heterologous PEDV vaccine strain", "PROBLEM", 209, 245], ["Experimental infection of pigs", "PROBLEM", 246, 276], ["immunization", "TREATMENT", 344, 356], ["the S1 protein", "TEST", 362, 376], ["low levels", "OBSERVATION_MODIFIER", 168, 178], ["neutralizing antibodies", "OBSERVATION", 182, 205], ["infection", "OBSERVATION", 259, 268]]], ["Clinical observations of death, diarrhea, and virus shedding in challenged piglets are summarized in Table 2 .", [["death", "DISEASE", 25, 30], ["diarrhea", "DISEASE", 32, 40], ["piglets", "ORGANISM", 75, 82], ["piglets", "SPECIES", 75, 82], ["death", "PROBLEM", 25, 30], ["diarrhea", "PROBLEM", 32, 40], ["virus shedding", "PROBLEM", 46, 60]]], ["In the control group, one piglet died and the other piglet experienced severe watery diarrhea post-challenge.", [["piglet", "ANATOMY", 26, 32], ["watery diarrhea", "DISEASE", 78, 93], ["piglet", "ORGANISM", 26, 32], ["piglet", "ORGANISM", 52, 58], ["piglet", "SPECIES", 26, 32], ["piglet", "SPECIES", 52, 58], ["severe watery diarrhea", "PROBLEM", 71, 93], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["watery", "OBSERVATION_MODIFIER", 78, 84], ["diarrhea", "OBSERVATION", 85, 93]]], ["Although none of the piglets from any of the groups of immunized sows died during the challenge experiment, the number of piglets exhibiting diarrhea after challenge varied depending on the group.", [["diarrhea", "DISEASE", 141, 149], ["piglets", "ORGANISM", 21, 28], ["sows", "ORGANISM", 65, 69], ["piglets", "ORGANISM", 122, 129], ["piglets", "SPECIES", 21, 28], ["piglets", "SPECIES", 122, 129], ["diarrhea", "PROBLEM", 141, 149]]], ["All piglets delivered from group 1 sows showed mild-to-severe diarrhea lasting for the entire experiment at 2 days post-challenge.", [["diarrhea", "DISEASE", 62, 70], ["piglets", "ORGANISM", 4, 11], ["sows", "ORGANISM", 35, 39], ["piglets", "SPECIES", 4, 11], ["All piglets", "TREATMENT", 0, 11], ["mild-to-severe diarrhea", "PROBLEM", 47, 70], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["diarrhea", "OBSERVATION", 62, 70]]], ["In contrast, piglets from sows in groups 2 and 3 experienced only mild diarrhea for 1 or 2 days after challenge or throughout the challenge experiment.", [["diarrhea", "DISEASE", 71, 79], ["piglets", "ORGANISM", 13, 20], ["piglets", "SPECIES", 13, 20], ["mild diarrhea", "PROBLEM", 66, 79], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["diarrhea", "OBSERVATION", 71, 79]]], ["Likewise, all piglets from immunized sows (groups 1, 2, and 3) exhibited mild intestinal lesions, and viral antigens were detected only in their small intestines, whereas the majority of enterocytes over the entire villi in the control piglets (group 4) were affected by PEDV, showing moderate-to-severe villous atrophy (Fig. 5) .", [["intestinal lesions", "ANATOMY", 78, 96], ["small intestines", "ANATOMY", 145, 161], ["enterocytes", "ANATOMY", 187, 198], ["villi", "ANATOMY", 215, 220], ["villous", "ANATOMY", 304, 311], ["intestinal lesions", "DISEASE", 78, 96], ["villous atrophy", "DISEASE", 304, 319], ["piglets", "ORGANISM", 14, 21], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 78, 96], ["small intestines", "ORGAN", 145, 161], ["enterocytes", "CELL", 187, 198], ["villi", "MULTI-TISSUE_STRUCTURE", 215, 220], ["piglets", "ORGANISM", 236, 243], ["villous", "TISSUE", 304, 311], ["viral antigens", "PROTEIN", 102, 116], ["enterocytes", "CELL_TYPE", 187, 198], ["piglets", "SPECIES", 14, 21], ["piglets", "SPECIES", 236, 243], ["PEDV", "SPECIES", 271, 275], ["mild intestinal lesions", "PROBLEM", 73, 96], ["viral antigens", "PROBLEM", 102, 116], ["PEDV", "TEST", 271, 275], ["moderate-to-severe villous atrophy", "PROBLEM", 285, 319], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["intestinal", "ANATOMY", 78, 88], ["lesions", "OBSERVATION", 89, 96], ["viral antigens", "OBSERVATION", 102, 116], ["small intestines", "ANATOMY", 145, 161], ["enterocytes", "ANATOMY", 187, 198], ["moderate", "OBSERVATION_MODIFIER", 285, 293], ["-to-severe", "OBSERVATION_MODIFIER", 293, 303], ["villous", "ANATOMY_MODIFIER", 304, 311], ["atrophy", "OBSERVATION", 312, 319]]], ["Altogether, all immunization methods used in this study were capable of protecting passively immunized neonatal piglets against mortality and severe disease after challenge.", [["piglets", "ORGANISM", 112, 119], ["piglets", "SPECIES", 112, 119], ["all immunization methods", "TREATMENT", 12, 36], ["this study", "TEST", 45, 55], ["severe disease", "PROBLEM", 142, 156], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["disease", "OBSERVATION", 149, 156]]], ["However, immunizations involving at least one dose of PEDV S1 protein vaccine (groups 2 and 3) were more efficacious than immunization of sows with two doses of PEDV live and killed vaccines (group 1) in reducing the overall degree of diarrhea, in terms of the duration and severity, in the suckling piglets.DiscussionPEDV continues to have a severe economic impact in swine-raising countries in Asia and, more recently, in the United States.", [["PEDV", "CHEMICAL", 161, 165], ["diarrhea", "DISEASE", 235, 243], ["PEDV S1", "GENE_OR_GENE_PRODUCT", 54, 61], ["sows", "ORGANISM", 138, 142], ["piglets", "ORGANISM", 300, 307], ["piglets", "SPECIES", 300, 307], ["PEDV", "SPECIES", 54, 58], ["PEDV", "SPECIES", 161, 165], ["immunizations", "TREATMENT", 9, 22], ["PEDV S1 protein vaccine", "TREATMENT", 54, 77], ["immunization", "TREATMENT", 122, 134], ["PEDV live", "TREATMENT", 161, 170], ["diarrhea", "PROBLEM", 235, 243], ["a severe economic impact in swine", "PROBLEM", 341, 374], ["overall degree", "OBSERVATION_MODIFIER", 217, 231], ["diarrhea", "OBSERVATION", 235, 243], ["severe", "OBSERVATION_MODIFIER", 343, 349]]], ["Vaccination against PEDV is an important and effective prevention measure.", [["PEDV", "CHEMICAL", 20, 24], ["PEDV", "SPECIES", 20, 24], ["Vaccination", "TREATMENT", 0, 11], ["PEDV", "PROBLEM", 20, 24]]], ["PEDV entry into host cells is mediated by the S glycoprotein on the viral surface, which interacts with the cellular receptor and induces direct membrane fusion.", [["cells", "ANATOMY", 21, 26], ["surface", "ANATOMY", 74, 81], ["cellular", "ANATOMY", 108, 116], ["membrane", "ANATOMY", 145, 153], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["host cells", "CELL", 16, 26], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 46, 60], ["cellular", "CELL", 108, 116], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["PEDV", "PROTEIN", 0, 4], ["host cells", "CELL_TYPE", 16, 26], ["S glycoprotein", "PROTEIN", 46, 60], ["cellular receptor", "PROTEIN", 108, 125], ["PEDV", "SPECIES", 0, 4], ["PEDV entry into host cells", "PROBLEM", 0, 26], ["the cellular receptor", "TREATMENT", 104, 125], ["direct membrane fusion", "TREATMENT", 138, 160], ["host cells", "OBSERVATION", 16, 26], ["viral surface", "OBSERVATION_MODIFIER", 68, 81], ["membrane fusion", "OBSERVATION", 145, 160]]], ["The PEDV S protein is also responsible for inducing neutralizing antibodies in the natural host and hence is a logical target in the development of effective vaccines.", [["PEDV S", "GENE_OR_GENE_PRODUCT", 4, 10], ["PEDV S protein", "PROTEIN", 4, 18], ["neutralizing antibodies", "PROTEIN", 52, 75], ["PEDV", "SPECIES", 4, 8], ["The PEDV S protein", "TEST", 0, 18], ["inducing neutralizing antibodies", "PROBLEM", 43, 75], ["effective vaccines", "TREATMENT", 148, 166]]], ["Furthermore, the S1 domain is a key functional portion of the S protein, which is associated with viral binding to host-cell receptors and contains neutralizing epitopes [17, 32] .", [["cell", "ANATOMY", 120, 124], ["cell", "CELL", 120, 124], ["S1 domain", "PROTEIN", 17, 26], ["S protein", "PROTEIN", 62, 71], ["host-cell receptors", "PROTEIN", 115, 134], ["the S protein", "TEST", 58, 71], ["viral binding", "PROBLEM", 98, 111], ["host-cell receptors", "TREATMENT", 115, 134], ["neutralizing epitopes", "TREATMENT", 148, 169], ["S1", "ANATOMY", 17, 19]]], ["Therefore, the S1 protein of PEDV is considered to be a potential candidate antigen for vaccination attempts.", [["PEDV", "CHEMICAL", 29, 33], ["S1", "GENE_OR_GENE_PRODUCT", 15, 17], ["PEDV", "GENE_OR_GENE_PRODUCT", 29, 33], ["S1 protein", "PROTEIN", 15, 25], ["PEDV", "PROTEIN", 29, 33], ["PEDV", "SPECIES", 29, 33], ["PEDV", "PROBLEM", 29, 33], ["vaccination attempts", "TREATMENT", 88, 108]]], ["In the present study, the first aim was to stably express the full-length, codon-optimized S1 gene of PEDV in porcine-origin cells and to evaluate the immunogenicity and efficacy of the recombinant S1 protein.", [["cells", "ANATOMY", 125, 130], ["PEDV", "GENE_OR_GENE_PRODUCT", 102, 106], ["porcine", "ORGANISM", 110, 117], ["cells", "CELL", 125, 130], ["S1", "GENE_OR_GENE_PRODUCT", 198, 200], ["codon-optimized S1 gene", "DNA", 75, 98], ["PEDV", "DNA", 102, 106], ["porcine-origin cells", "CELL_TYPE", 110, 130], ["recombinant S1 protein", "PROTEIN", 186, 208], ["porcine", "SPECIES", 110, 117], ["PEDV", "SPECIES", 102, 106], ["the present study", "TEST", 3, 20], ["codon", "TREATMENT", 75, 80], ["PEDV", "PROBLEM", 102, 106], ["the recombinant S1 protein", "PROBLEM", 182, 208], ["PEDV", "OBSERVATION", 102, 106]]], ["Our codon-optimization approach dramatically enhanced the expression level of the gene of interest upon transient transfection using a mammalian expression system.", [["transient transfection", "TREATMENT", 104, 126], ["a mammalian expression system", "TREATMENT", 133, 162]]], ["Subsequently, we were able to successfully generate a stable PK cell line continuously producing large amounts of the codon-optimized S1 protein.", [["PK cell line", "ANATOMY", 61, 73], ["PK cell line", "CELL", 61, 73], ["PK cell line", "CELL_LINE", 61, 73], ["codon-optimized S1 protein", "PROTEIN", 118, 144], ["a stable PK cell line", "TREATMENT", 52, 73], ["stable", "OBSERVATION_MODIFIER", 54, 60], ["PK cell line", "OBSERVATION", 61, 73], ["large", "OBSERVATION_MODIFIER", 97, 102], ["amounts", "OBSERVATION_MODIFIER", 103, 110]]], ["Following the purification and concentration processes, approximately 15-20 lg of the recombinant S1 protein could be consistently harvested from PK-rS1-Ig cells in each well of a 6-well plate.DiscussionSince the antibody response is a critical indicator to assess the effect of a vaccine, we immunized rabbits with the S1-based immunogen prepared from culture supernatants of PK-rS1-Ig cells and determined whether or not they developed humoral immunity.", [["PK-rS1-Ig cells", "ANATOMY", 146, 161], ["supernatants", "ANATOMY", 361, 373], ["PK-rS1-Ig cells", "ANATOMY", 377, 392], ["S1", "GENE_OR_GENE_PRODUCT", 98, 100], ["PK-rS1-Ig cells", "CELL", 146, 161], ["rabbits", "ORGANISM", 303, 310], ["PK-rS1-Ig cells", "CELL", 377, 392], ["recombinant S1 protein", "PROTEIN", 86, 108], ["PK-rS1-Ig cells", "CELL_LINE", 146, 161], ["S1", "PROTEIN", 320, 322], ["PK-rS1-Ig cells", "CELL_LINE", 377, 392], ["rabbits", "SPECIES", 303, 310], ["rabbits", "SPECIES", 303, 310], ["concentration processes", "TEST", 31, 54], ["the recombinant S1 protein", "TEST", 82, 108], ["PK", "TEST", 146, 148], ["a vaccine", "TREATMENT", 279, 288], ["the S1-based immunogen", "TREATMENT", 316, 338], ["culture supernatants", "TEST", 353, 373], ["PK", "TEST", 377, 379], ["Ig cells", "OBSERVATION", 153, 161]]], ["PEDV-specific antibodies were strongly detectable in rabbit sera collected from the second boost, even at the highest dilution (1:100,000), when reacted with the recombinant PEDV-S1 protein purified from S1-expressing PK-rS1-Ig cells.", [["sera", "ANATOMY", 60, 64], ["PK-rS1-Ig cells", "ANATOMY", 218, 233], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["rabbit", "ORGANISM", 53, 59], ["sera", "ORGANISM_SUBSTANCE", 60, 64], ["PEDV-S1", "GENE_OR_GENE_PRODUCT", 174, 181], ["S1", "GENE_OR_GENE_PRODUCT", 204, 206], ["PK", "GENE_OR_GENE_PRODUCT", 218, 220], ["PEDV-specific antibodies", "PROTEIN", 0, 24], ["recombinant PEDV-S1 protein", "PROTEIN", 162, 189], ["S1-expressing PK-rS1-Ig cells", "CELL_LINE", 204, 233], ["rabbit", "SPECIES", 53, 59], ["PEDV", "SPECIES", 0, 4], ["rabbit", "SPECIES", 53, 59], ["PEDV", "TEST", 0, 4], ["specific antibodies", "TEST", 5, 24], ["rabbit sera", "TEST", 53, 64], ["the recombinant PEDV", "TEST", 158, 178], ["S1", "TEST", 204, 206], ["PK", "TEST", 218, 220], ["Ig cells", "OBSERVATION", 225, 233]]], ["In contrast, the binding capacity of the antiserum was dramatically reduced when the authentic S protein in wholecell lysates prepared from cells infected with SM98-1 was used as the antigen for western blotting.", [["wholecell lysates", "ANATOMY", 108, 125], ["cells", "ANATOMY", 140, 145], ["SM98-1", "CHEMICAL", 160, 166], ["antiserum", "ORGANISM_SUBSTANCE", 41, 50], ["wholecell lysates", "ORGANISM_SUBSTANCE", 108, 125], ["cells", "CELL", 140, 145], ["SM98-1", "GENE_OR_GENE_PRODUCT", 160, 166], ["S protein", "PROTEIN", 95, 104], ["SM98", "PROTEIN", 160, 164], ["the antiserum", "TREATMENT", 37, 50], ["the authentic S protein", "TEST", 81, 104], ["wholecell lysates", "TREATMENT", 108, 125], ["SM98", "TEST", 160, 164]]], ["Moreover, the rabbit antisera could completely block infection of SM98-1 only at a serum dilution of 1:16, whereas the pig sera raised against SM98-1 contained high levels of neutralizing antibody against the homogeneous virus ([1:256).", [["serum", "ANATOMY", 83, 88], ["sera", "ANATOMY", 123, 127], ["infection", "DISEASE", 53, 62], ["SM98-1", "CHEMICAL", 66, 72], ["rabbit", "ORGANISM", 14, 20], ["SM98-1", "GENE_OR_GENE_PRODUCT", 66, 72], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["pig", "ORGANISM", 119, 122], ["sera", "ORGANISM_SUBSTANCE", 123, 127], ["SM98-1", "GENE_OR_GENE_PRODUCT", 143, 149], ["SM98", "PROTEIN", 143, 147], ["neutralizing antibody", "PROTEIN", 175, 196], ["rabbit", "SPECIES", 14, 20], ["pig", "SPECIES", 119, 122], ["rabbit", "SPECIES", 14, 20], ["pig", "SPECIES", 119, 122], ["the rabbit antisera", "TEST", 10, 29], ["completely block infection of SM98", "PROBLEM", 36, 70], ["a serum dilution", "TEST", 81, 97], ["the pig sera", "TEST", 115, 127], ["SM98", "TEST", 143, 147], ["high levels of neutralizing antibody", "PROBLEM", 160, 196], ["the homogeneous virus", "PROBLEM", 205, 226], ["infection", "OBSERVATION", 53, 62], ["high levels", "OBSERVATION_MODIFIER", 160, 171], ["neutralizing antibody", "OBSERVATION", 175, 196], ["homogeneous", "OBSERVATION_MODIFIER", 209, 220], ["virus", "OBSERVATION", 221, 226]]], ["Since the PEDV field isolate propagated in the current culture system is unavailable to us, we were unable to test the neutralizing capacity of those antisera against the field virus in this study.", [["the PEDV field isolate", "TEST", 6, 28], ["the current culture system", "TEST", 43, 69], ["those antisera", "TREATMENT", 144, 158], ["this study", "TEST", 186, 196]]], ["However, it is conceivable that rabbit antisera directed against the S1 protein may be more effective in neutralizing infection with the field virus than with SM98-1.", [["infection", "DISEASE", 118, 127], ["rabbit", "ORGANISM", 32, 38], ["antisera directed against the S1", "GENE_OR_GENE_PRODUCT", 39, 71], ["SM98-1", "GENE_OR_GENE_PRODUCT", 159, 165], ["S1 protein", "PROTEIN", 69, 79], ["rabbit", "SPECIES", 32, 38], ["rabbit", "SPECIES", 32, 38], ["rabbit antisera", "TREATMENT", 32, 47], ["the S1 protein", "TEST", 65, 79], ["neutralizing infection", "PROBLEM", 105, 127], ["the field virus", "PROBLEM", 133, 148], ["SM98", "TEST", 159, 163], ["neutralizing", "OBSERVATION_MODIFIER", 105, 117], ["infection", "OBSERVATION", 118, 127]]], ["On the other hand, the weak interaction and neutralizing activity of the anti-S1 rabbit serum against the SM98-1 S protein may be attributed to genetic variations between the S proteins of the vaccine strain and field isolates.", [["serum", "ANATOMY", 88, 93], ["rabbit", "ORGANISM", 81, 87], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["SM98-1 S", "GENE_OR_GENE_PRODUCT", 106, 114], ["anti-S1", "PROTEIN", 73, 80], ["SM98-1 S protein", "PROTEIN", 106, 122], ["S proteins", "PROTEIN", 175, 185], ["rabbit", "SPECIES", 81, 87], ["rabbit", "SPECIES", 81, 87], ["the weak interaction", "PROBLEM", 19, 39], ["the anti-S1 rabbit serum", "TEST", 69, 93], ["the SM98", "TEST", 102, 110], ["genetic variations", "PROBLEM", 144, 162], ["the vaccine strain", "TREATMENT", 189, 207]]], ["Indeed, the Korean field isolates, including the challenge strain used in this study, were found to display a high degree ([10 %) of genetic heterogeneity, especially in the S1 domain, compared with the PEDV vaccine strain SM98-1 [16, 18] .", [["SM98-1", "ORGANISM", 223, 229], ["S1 domain", "PROTEIN", 174, 183], ["the challenge strain", "TREATMENT", 45, 65], ["this study", "TEST", 74, 84], ["genetic heterogeneity", "PROBLEM", 133, 154], ["the PEDV vaccine strain SM98", "TEST", 199, 227], ["high degree", "OBSERVATION_MODIFIER", 110, 121], ["heterogeneity", "OBSERVATION", 141, 154], ["S1 domain", "ANATOMY", 174, 183]]], ["Nevertheless, western blot and virus neutralizing assays showed that the recombinant S1 protein efficiently elicits humoral immune responses against PEDV.DiscussionIn Korea, several management strategies, including vaccination, have been employed to control PEDV in pig farms.", [["PEDV", "CHEMICAL", 258, 262], ["S1", "GENE_OR_GENE_PRODUCT", 85, 87], ["PEDV", "SIMPLE_CHEMICAL", 149, 153], ["PEDV", "SIMPLE_CHEMICAL", 258, 262], ["pig", "ORGANISM", 266, 269], ["recombinant S1 protein", "PROTEIN", 73, 95], ["pig", "SPECIES", 266, 269], ["PEDV", "SPECIES", 149, 153], ["PEDV", "SPECIES", 258, 262], ["pig", "SPECIES", 266, 269], ["western blot", "TEST", 14, 26], ["virus neutralizing assays", "TEST", 31, 56], ["the recombinant S1 protein", "PROBLEM", 69, 95], ["PEDV", "PROBLEM", 149, 153], ["several management strategies", "TREATMENT", 174, 203], ["vaccination", "TREATMENT", 215, 226]]], ["The most highly recommended immunization schedule involves two doses of attenuated live and inactivated killed vaccines in gilts at 2-to 3-week intervals before mating and in pregnant sows at 12 and 14 weeks of gestation.", [["sows", "ORGANISM", 184, 188], ["immunization schedule", "TREATMENT", 28, 49], ["attenuated live", "TREATMENT", 72, 87], ["inactivated killed vaccines", "TREATMENT", 92, 119]]], ["In the present study, we compared the efficacy of this common vaccination protocol and S1 protein-based vaccination.", [["S1 protein", "PROTEIN", 87, 97], ["the present study", "TEST", 3, 20], ["this common vaccination protocol", "TREATMENT", 50, 82], ["S1 protein", "TEST", 87, 97]]], ["Although all of the immunized sows developed neutralizing antibodies against SM98-1, only the sows immunized with live and killed vaccines (group 1) had high neutralizing antibody titers, ranging from 1:32 to 1:1024.", [["sows", "ORGANISM", 30, 34], ["SM98-1", "GENE_OR_GENE_PRODUCT", 77, 83], ["sows", "ORGANISM", 94, 98], ["neutralizing antibodies", "PROTEIN", 45, 68], ["SM98", "PROTEIN", 77, 81], ["sows", "SPECIES", 30, 34], ["sows", "SPECIES", 94, 98], ["neutralizing antibodies", "TEST", 45, 68], ["SM98", "TEST", 77, 81], ["high neutralizing antibody titers", "PROBLEM", 153, 186]]], ["However, consistent with the rabbit immunization study, sows in groups 2 and 3, immunized with at least one dose of the S1-protein-based subunit vaccine, developed weak neutralizing responses to the vaccine virus, with titers ranging from 1:8 to 1:32.", [["rabbit", "ORGANISM", 29, 35], ["S1-protein", "PROTEIN", 120, 130], ["rabbit", "SPECIES", 29, 35], ["rabbit", "SPECIES", 29, 35], ["the rabbit immunization study", "TEST", 25, 54], ["the S1-protein-based subunit vaccine", "TREATMENT", 116, 152], ["weak neutralizing responses", "PROBLEM", 164, 191], ["the vaccine virus", "PROBLEM", 195, 212], ["titers", "TEST", 219, 225], ["consistent with", "UNCERTAINTY", 9, 24]]], ["Successful protection against PEDV is based on the presence of specific neutralizing antibodies in immune sows that are passively transferred to their piglets through colostrum and milk.", [["colostrum", "ANATOMY", 167, 176], ["milk", "ANATOMY", 181, 185], ["PEDV", "CHEMICAL", 30, 34], ["PEDV", "ORGANISM", 30, 34], ["sows", "ORGANISM", 106, 110], ["piglets", "ORGANISM", 151, 158], ["colostrum", "ORGANISM_SUBSTANCE", 167, 176], ["milk", "ORGANISM_SUBSTANCE", 181, 185], ["neutralizing antibodies", "PROTEIN", 72, 95], ["piglets", "SPECIES", 151, 158], ["PEDV", "SPECIES", 30, 34], ["Successful protection", "TREATMENT", 0, 21], ["PEDV", "PROBLEM", 30, 34], ["specific neutralizing antibodies in immune sows", "PROBLEM", 63, 110], ["neutralizing antibodies", "OBSERVATION", 72, 95]]], ["Our data showed that, regardless of vaccination group, all neonatal piglets from immunized sows survived after challenge with virulent PEDV, suggesting that the S1 subunit vaccine provides effective lactogenic immunity to prevent mortality comparable to whole-virus-based vaccines.", [["PEDV", "CHEMICAL", 135, 139], ["piglets", "ORGANISM", 68, 75], ["sows", "ORGANISM", 91, 95], ["whole-virus", "ORGANISM", 254, 265], ["piglets", "SPECIES", 68, 75], ["PEDV", "SPECIES", 135, 139], ["Our data", "TEST", 0, 8], ["vaccination group", "TREATMENT", 36, 53], ["all neonatal piglets", "TREATMENT", 55, 75], ["virulent PEDV", "TREATMENT", 126, 139], ["the S1 subunit vaccine", "TREATMENT", 157, 179], ["effective lactogenic immunity", "TREATMENT", 189, 218], ["whole-virus-based vaccines", "TREATMENT", 254, 280]]], ["However, the S1based vaccination strategies, which produced relatively low neutralizing antibody responses, exhibited more-efficient protection, with respective to the duration and severity of diarrhea, than the common live and killed vaccination procedure.", [["diarrhea", "DISEASE", 193, 201], ["the S1based vaccination strategies", "TREATMENT", 9, 43], ["relatively low neutralizing antibody responses", "PROBLEM", 60, 106], ["diarrhea", "PROBLEM", 193, 201], ["killed vaccination procedure", "TREATMENT", 228, 256], ["diarrhea", "OBSERVATION", 193, 201]]], ["It is therefore plausible that the actual levels of neutralizing antibodies raised against the S1 subunit vaccine are underestimated by the vaccine-virus-based neutralization test.", [["neutralizing antibodies", "PROTEIN", 52, 75], ["neutralizing antibodies", "TREATMENT", 52, 75], ["the S1 subunit vaccine", "TREATMENT", 91, 113], ["the vaccine", "TREATMENT", 136, 147], ["based neutralization test", "TEST", 154, 179]]], ["Thus, improved diagnostic tools are needed to differentiate vaccinal antibodies from those resulting from natural infection with the field virus.", [["infection", "DISEASE", 114, 123], ["vaccinal antibodies", "PROTEIN", 60, 79], ["vaccinal antibodies", "PROBLEM", 60, 79], ["natural infection", "PROBLEM", 106, 123], ["the field virus", "PROBLEM", 129, 144], ["infection", "OBSERVATION", 114, 123]]], ["For this purpose, the recombinant S1 protein purified from PK-rS1-Ig cells could be further used as the diagnostic antigen in an enzyme-linked immunosorbent assay (ELISA), and this aspect is currently under investigation.", [["PK-rS1-Ig cells", "ANATOMY", 59, 74], ["S1", "GENE_OR_GENE_PRODUCT", 34, 36], ["PK", "GENE_OR_GENE_PRODUCT", 59, 61], ["recombinant S1 protein", "PROTEIN", 22, 44], ["PK-rS1-Ig cells", "CELL_LINE", 59, 74], ["the recombinant S1 protein", "TEST", 18, 44], ["PK", "TEST", 59, 61], ["the diagnostic antigen", "TEST", 100, 122], ["an enzyme", "TEST", 126, 135], ["immunosorbent assay", "TEST", 143, 162]]], ["Additionally, it is possible that the full-length S protein may induce stronger immune responses than S1 alone because it contains multiple functional domains and neutralizing epitopes.", [["full-length S protein", "PROTEIN", 38, 59], ["S1", "PROTEIN", 102, 104], ["neutralizing epitopes", "PROTEIN", 163, 184], ["the full-length S protein", "PROBLEM", 34, 59], ["multiple functional domains", "PROBLEM", 131, 158], ["neutralizing epitopes", "PROBLEM", 163, 184], ["multiple", "OBSERVATION_MODIFIER", 131, 139], ["functional domains", "OBSERVATION", 140, 158], ["neutralizing epitopes", "OBSERVATION", 163, 184]]], ["In fact, Meng et al. [20] have recently reported that the full-length PEDV S gene induces a better immune response than the N-terminal half alone, using the recombinant DNA plasmid in a mouse model.", [["N", "CHEMICAL", 124, 125], ["PEDV S", "GENE_OR_GENE_PRODUCT", 70, 76], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["mouse", "ORGANISM", 186, 191], ["PEDV S gene", "DNA", 70, 81], ["N-terminal half", "DNA", 124, 139], ["recombinant DNA plasmid", "DNA", 157, 180], ["mouse", "SPECIES", 186, 191], ["mouse", "SPECIES", 186, 191], ["the recombinant DNA plasmid", "TREATMENT", 153, 180]]], ["However, production of the full-length S protein may be unachievable in our system because its expression may cause cytotoxicity due to the presence of potential fusion activity in the C-terminal portion of the S protein.DiscussionIn conclusion, to the best of our knowledge, this is the first evaluation of the immunological and protective effects triggered by recombinant S1 protein in rabbit and pig models.", [["C", "CHEMICAL", 185, 186], ["S protein", "GENE_OR_GENE_PRODUCT", 211, 220], ["S1", "GENE_OR_GENE_PRODUCT", 374, 376], ["rabbit", "ORGANISM", 388, 394], ["pig", "ORGANISM", 399, 402], ["full-length S protein", "PROTEIN", 27, 48], ["C-terminal portion", "PROTEIN", 185, 203], ["S protein", "PROTEIN", 211, 220], ["recombinant S1 protein", "PROTEIN", 362, 384], ["rabbit", "SPECIES", 388, 394], ["pig", "SPECIES", 399, 402], ["rabbit", "SPECIES", 388, 394], ["pig", "SPECIES", 399, 402], ["length S protein", "TEST", 32, 48], ["cytotoxicity", "PROBLEM", 116, 128], ["potential fusion activity", "PROBLEM", 152, 177], ["the first evaluation", "TEST", 284, 304], ["fusion activity", "OBSERVATION", 162, 177], ["terminal portion", "ANATOMY_MODIFIER", 187, 203]]], ["The results presented here indicate that the recombinant S1 protein can elicit a specific antibody response and induce neutralizing antibodies, suggesting its excellent immunogenicity in the natural host.", [["S1", "GENE_OR_GENE_PRODUCT", 57, 59], ["recombinant S1 protein", "PROTEIN", 45, 67], ["neutralizing antibodies", "PROTEIN", 119, 142], ["the recombinant S1 protein", "PROBLEM", 41, 67], ["a specific antibody response", "PROBLEM", 79, 107], ["neutralizing antibodies", "TEST", 119, 142], ["neutralizing antibodies", "OBSERVATION", 119, 142], ["excellent", "OBSERVATION_MODIFIER", 159, 168], ["immunogenicity", "OBSERVATION", 169, 183]]], ["Furthermore, challenge experiments revealed that the S1protein-based vaccine protected passively immunized suckling piglets against field PEDV.", [["S1protein", "CHEMICAL", 53, 62], ["PEDV", "CHEMICAL", 138, 142], ["S1protein", "SIMPLE_CHEMICAL", 53, 62], ["piglets", "ORGANISM", 116, 123], ["S1protein", "PROTEIN", 53, 62], ["piglets", "SPECIES", 116, 123], ["piglets", "SPECIES", 116, 123], ["PEDV", "SPECIES", 138, 142], ["challenge experiments", "TEST", 13, 34], ["the S1protein-based vaccine", "TREATMENT", 49, 76]]], ["Despite the nationwide use of commercial live and killed PEDV vaccines, swine herds in Korea have continued to experience repeated outbreaks, leading swine practitioners and researchers to question their protective efficacy.", [["swine", "SPECIES", 72, 77], ["PEDV", "SPECIES", 57, 61], ["swine", "SPECIES", 72, 77], ["swine", "SPECIES", 150, 155], ["commercial live", "TREATMENT", 30, 45], ["PEDV vaccines", "TREATMENT", 57, 70]]], ["Based on the present and previous studies, we hypothesize that antigenic and genetic variation between the vaccine virus and field PEDVs responsible for periodic outbreaks in herds may be the cause of the low efficacy or failure of vaccination.", [["PEDVs", "CHEMICAL", 131, 136], ["previous studies", "TEST", 25, 41], ["antigenic and genetic variation", "PROBLEM", 63, 94], ["the vaccine virus", "TREATMENT", 103, 120], ["periodic outbreaks in herds", "PROBLEM", 153, 180], ["the low efficacy", "PROBLEM", 201, 217], ["failure of vaccination", "PROBLEM", 221, 243]]], ["Accordingly, current PEDV vaccines manufactured from cell-adapted viruses should be reassessed to determine their efficacy and improved if necessary.DiscussionAlthough further studies with a larger number of animals will be needed to better evaluate the efficacy of the S1 protein vaccine and to optimize immunization procedures, the recombinant S1 protein has potential for use in improving or developing effective and safe vaccines for PED prevention.", [["cell", "ANATOMY", 53, 57], ["PEDV", "CHEMICAL", 21, 25], ["PED", "DISEASE", 438, 441], ["cell", "CELL", 53, 57], ["S1", "GENE_OR_GENE_PRODUCT", 346, 348], ["recombinant S1 protein", "PROTEIN", 334, 356], ["PEDV", "SPECIES", 21, 25], ["current PEDV vaccines", "TREATMENT", 13, 34], ["cell-adapted viruses", "TREATMENT", 53, 73], ["further studies", "TEST", 168, 183], ["the S1 protein vaccine", "TREATMENT", 266, 288], ["immunization procedures", "TREATMENT", 305, 328], ["safe vaccines", "TREATMENT", 420, 433], ["PED prevention", "TREATMENT", 438, 452]]]], "b40daa05191351fbbb837ef9ac2942cf5e1631b8": [["IntroductionAntibiotics have been used in animal agriculture for growth promotion (sub-therapeutic doses), disease prevention (prophylactic doses) and for the treatment of infection for over 50 years (Turner et al., 2001) .", [["infection", "DISEASE", 172, 181], ["IntroductionAntibiotics", "TREATMENT", 0, 23], ["growth promotion", "TREATMENT", 65, 81], ["sub-therapeutic doses", "TREATMENT", 83, 104], ["disease prevention", "TREATMENT", 107, 125], ["prophylactic doses", "TREATMENT", 127, 145], ["infection", "PROBLEM", 172, 181], ["infection", "OBSERVATION", 172, 181]]], ["However, the use and misuse of infeed antibiotics have led to problems with drug residues in animal products and increased bacterial resistance (Khachatourians, 1998) .", [["infeed antibiotics", "TREATMENT", 31, 49], ["drug residues", "PROBLEM", 76, 89], ["animal products", "TREATMENT", 93, 108], ["increased bacterial resistance", "PROBLEM", 113, 143], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["bacterial resistance", "OBSERVATION", 123, 143]]], ["As a result, the sub-therapeutic use of antibiotics has been totally banned in European countries since January 2006 (Casewell et al., 2003) and other countries are seriously considering a similar ban.", [["antibiotics", "TREATMENT", 40, 51]]], ["Therefore, alternatives to antibiotics are urgently needed.IntroductionA wide range of products have been tested as potential alternatives to antibiotics including organic and inorganic acids (Kim et al., 2005) , oligosaccharides (Flickinger et al., 2003) , probiotics (Kritas and Morrison, 2005; Taras et al., 2007) , herbal extracts (Windisch et al., 2008) and antibodies (Cook, 2004) .", [["extracts", "ANATOMY", 326, 334], ["inorganic acids", "CHEMICAL", 176, 191], ["inorganic acids", "SIMPLE_CHEMICAL", 176, 191], ["antibodies", "PROTEIN", 363, 373], ["antibiotics", "TREATMENT", 27, 38], ["IntroductionA wide range of products", "TREATMENT", 59, 95], ["antibiotics", "TREATMENT", 142, 153], ["organic and inorganic acids", "TREATMENT", 164, 191], ["probiotics", "TREATMENT", 258, 268], ["herbal extracts", "TREATMENT", 319, 334]]], ["Among these, oral immunotherapy (passive immunization) with antibodies is a highly attractive and effective alternative approach due to its high specificity.", [["oral", "ANATOMY", 13, 17], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["antibodies", "PROTEIN", 60, 70], ["oral immunotherapy (passive immunization", "TREATMENT", 13, 53], ["antibodies", "TREATMENT", 60, 70]]], ["Oral administration with antibodies derived from mammalian serum and colostrum and even monoclonal antibodies have been used successfully (Kuhlman et al., 1988) .", [["Oral", "ANATOMY", 0, 4], ["serum", "ANATOMY", 59, 64], ["colostrum", "ANATOMY", 69, 78], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["colostrum", "ORGANISM_SUBSTANCE", 69, 78], ["antibodies", "PROTEIN", 25, 35], ["monoclonal antibodies", "PROTEIN", 88, 109], ["Oral administration", "TREATMENT", 0, 19], ["antibodies", "TREATMENT", 25, 35], ["mammalian serum", "TEST", 49, 64], ["monoclonal antibodies", "TREATMENT", 88, 109]]], ["However, with this technique, it is prohibitively expensive to obtain the large amount of antibody required to prevent and treat disease.IntroductionRecently, chicken egg yolk immunoglobulin, referred to as immunoglobulin Y (IgY) has attracted considerable attention as a means to prevent and control disease as it possesses a large number of advantages compared with treatment with mammalian IgG including cost-effectiveness, convenience and high yield (Carlander et al., 2000) .", [["egg yolk", "ANATOMY", 167, 175], ["chicken", "ORGANISM", 159, 166], ["egg yolk immunoglobulin", "GENE_OR_GENE_PRODUCT", 167, 190], ["immunoglobulin Y", "GENE_OR_GENE_PRODUCT", 207, 223], ["IgY", "GENE_OR_GENE_PRODUCT", 225, 228], ["IgG", "GENE_OR_GENE_PRODUCT", 393, 396], ["chicken egg yolk immunoglobulin", "PROTEIN", 159, 190], ["immunoglobulin Y", "PROTEIN", 207, 223], ["IgY", "PROTEIN", 225, 228], ["mammalian IgG", "PROTEIN", 383, 396], ["chicken", "SPECIES", 159, 166], ["chicken", "SPECIES", 159, 166], ["this technique", "TEST", 14, 28], ["antibody", "TREATMENT", 90, 98], ["disease", "PROBLEM", 129, 136], ["IntroductionRecently", "TREATMENT", 137, 157], ["chicken egg yolk immunoglobulin", "TREATMENT", 159, 190], ["control disease", "PROBLEM", 293, 308], ["treatment", "TREATMENT", 368, 377], ["mammalian IgG", "TREATMENT", 383, 396], ["large", "OBSERVATION_MODIFIER", 74, 79], ["amount", "OBSERVATION_MODIFIER", 80, 86], ["large", "OBSERVATION_MODIFIER", 327, 332]]], ["Under natural conditions, the serum IgY of laying hens is deposited in large quantities in the egg yolk in order to protect the developing embryo from potential pathogens (Janson et al., 1995) .", [["serum", "ANATOMY", 30, 35], ["egg yolk", "ANATOMY", 95, 103], ["embryo", "ANATOMY", 139, 145], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["IgY", "GENE_OR_GENE_PRODUCT", 36, 39], ["hens", "ORGANISM", 50, 54], ["egg yolk", "ORGAN", 95, 103], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 139, 145], ["serum IgY", "PROTEIN", 30, 39], ["the serum IgY", "TEST", 26, 39], ["the egg yolk", "TREATMENT", 91, 103], ["the developing embryo", "PROBLEM", 124, 145], ["potential pathogens", "PROBLEM", 151, 170], ["natural conditions", "OBSERVATION", 6, 24], ["large", "OBSERVATION_MODIFIER", 71, 76], ["quantities", "OBSERVATION_MODIFIER", 77, 87], ["egg yolk", "ANATOMY", 95, 103], ["embryo", "ANATOMY", 139, 145]]], ["Thus, it is possible to immunize the hen against specific foreign pathogens thereby allowing the production of IgY with activity against these specific disease conditions.IntroductionOral administration of specific IgY antibody has been shown to be effective against a variety of intestinal pathogens such as bovine and human rotaviruses, enterotoxigenic Escherichia coli (ETEC), bovine coronavirus, Salmonella spp., Edwardsiella tarda, Yersinia ruckeri, Staphylococcus and Pseudomonas (Mine and Kovacs-Nolan, 2002) .", [["intestinal", "ANATOMY", 280, 290], ["enterotoxigenic Escherichia coli", "DISEASE", 339, 371], ["bovine coronavirus, Salmonella spp.", "DISEASE", 380, 415], ["Edwardsiella tarda", "DISEASE", 417, 435], ["Yersinia ruckeri", "DISEASE", 437, 453], ["hen", "ORGANISM", 37, 40], ["IgY", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgY antibody", "GENE_OR_GENE_PRODUCT", 215, 227], ["intestinal", "ORGAN", 280, 290], ["bovine", "ORGANISM", 309, 315], ["human rotaviruses", "ORGANISM", 320, 337], ["enterotoxigenic Escherichia coli", "ORGANISM", 339, 371], ["ETEC", "ORGANISM", 373, 377], ["bovine coronavirus", "ORGANISM", 380, 398], ["Salmonella spp.", "ORGANISM", 400, 415], ["Edwardsiella tarda", "ORGANISM", 417, 435], ["Yersinia ruckeri", "ORGANISM", 437, 453], ["IgY", "PROTEIN", 111, 114], ["IgY antibody", "PROTEIN", 215, 227], ["hen", "SPECIES", 37, 40], ["bovine", "SPECIES", 309, 315], ["human", "SPECIES", 320, 325], ["rotaviruses", "SPECIES", 326, 337], ["enterotoxigenic Escherichia coli", "SPECIES", 339, 371], ["bovine", "SPECIES", 380, 386], ["coronavirus", "SPECIES", 387, 398], ["Salmonella spp.", "SPECIES", 400, 415], ["Edwardsiella tarda", "SPECIES", 417, 435], ["Yersinia ruckeri", "SPECIES", 437, 453], ["Staphylococcus", "SPECIES", 455, 469], ["hen", "SPECIES", 37, 40], ["bovine", "SPECIES", 309, 315], ["human rotaviruses", "SPECIES", 320, 337], ["Escherichia coli", "SPECIES", 355, 371], ["ETEC", "SPECIES", 373, 377], ["bovine coronavirus", "SPECIES", 380, 398], ["Salmonella spp.", "SPECIES", 400, 415], ["Edwardsiella tarda", "SPECIES", 417, 435], ["Yersinia ruckeri", "SPECIES", 437, 453], ["specific foreign pathogens", "PROBLEM", 49, 75], ["these specific disease conditions", "PROBLEM", 137, 170], ["IntroductionOral administration", "TREATMENT", 171, 202], ["specific IgY antibody", "TEST", 206, 227], ["intestinal pathogens", "PROBLEM", 280, 300], ["bovine and human rotaviruses", "PROBLEM", 309, 337], ["enterotoxigenic Escherichia coli", "PROBLEM", 339, 371], ["ETEC", "PROBLEM", 373, 377], ["bovine coronavirus", "PROBLEM", 380, 398], ["Salmonella spp.", "PROBLEM", 400, 415], ["Edwardsiella tarda", "PROBLEM", 417, 435], ["Yersinia ruckeri", "PROBLEM", 437, 453], ["Staphylococcus", "PROBLEM", 455, 469], ["Pseudomonas", "PROBLEM", 474, 485], ["intestinal", "ANATOMY", 280, 290], ["pathogens", "OBSERVATION", 291, 300], ["Yersinia ruckeri", "OBSERVATION", 437, 453]]], ["This review presents an overview of the potential to use immunotherapy with specific IgY for the prevention and treatment of terrestrial and aquatic animal diseases and speculates on the future of IgY technology.Advantages of IgYThe use of chickens for the production of polyclonal antibodies provides many advantages over production methods using mammals ( Table 1) .", [["aquatic animal diseases", "DISEASE", 141, 164], ["IgYThe", "CHEMICAL", 226, 232], ["IgY", "GENE_OR_GENE_PRODUCT", 85, 88], ["IgY", "GENE_OR_GENE_PRODUCT", 197, 200], ["IgYThe", "SIMPLE_CHEMICAL", 226, 232], ["chickens", "ORGANISM", 240, 248], ["IgY", "PROTEIN", 85, 88], ["polyclonal antibodies", "PROTEIN", 271, 292], ["chickens", "SPECIES", 240, 248], ["chickens", "SPECIES", 240, 248], ["immunotherapy", "TREATMENT", 57, 70], ["specific IgY", "TREATMENT", 76, 88], ["the prevention", "TREATMENT", 93, 107], ["treatment", "TREATMENT", 112, 121], ["terrestrial and aquatic animal diseases", "PROBLEM", 125, 164], ["IgY technology", "TREATMENT", 197, 211], ["chickens", "TREATMENT", 240, 248], ["polyclonal antibodies", "TREATMENT", 271, 292], ["aquatic animal diseases", "OBSERVATION", 141, 164]]], ["The most significant advantage is that the collection of antibodies is non-invasive.", [["antibodies", "PROTEIN", 57, 67]]], ["In contrast to conventional methods where animals are often sacrificed in order to collect a sufficient amount of blood to obtain antibodies, production of antibodies in laying hens requires only the collection of eggs, and the high and longlasting titers produced in chickens reduce the need for frequent booster injections.", [["blood", "ANATOMY", 114, 119], ["eggs", "ANATOMY", 214, 218], ["animals", "ORGANISM", 42, 49], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 214, 218], ["chickens", "ORGANISM", 268, 276], ["antibodies", "PROTEIN", 130, 140], ["antibodies", "PROTEIN", 156, 166], ["chickens", "SPECIES", 268, 276], ["chickens", "SPECIES", 268, 276], ["antibodies", "TREATMENT", 130, 140], ["production of antibodies", "PROBLEM", 142, 166], ["the collection of eggs", "PROBLEM", 196, 218], ["the high and longlasting titers", "PROBLEM", 224, 255], ["frequent booster injections", "TREATMENT", 297, 324], ["high", "OBSERVATION_MODIFIER", 228, 232]]], ["Another advantage is that due to the phylogenetic distance between chickens and mammals, chickens often more successfully produce antibodies against highly conserved mammalian proteins than do other mammals and require much less antigen to induce an efficient immune response.Advantages of IgYA hen can be considered as a small \"factory\" for antibody production.", [["chickens", "ORGANISM", 67, 75], ["chickens", "ORGANISM", 89, 97], ["IgYA hen", "ORGANISM", 290, 298], ["antibodies", "PROTEIN", 130, 140], ["mammalian proteins", "PROTEIN", 166, 184], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 89, 97], ["hen", "SPECIES", 295, 298], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 89, 97], ["hen", "SPECIES", 295, 298], ["antibody production", "PROBLEM", 342, 361]]], ["A hen usually lays about 300 eggs per year and the egg yolk (15 ml) contains 50-100 mg of IgY of which 2 to 10% are specific antibodies (Rose et al., 1974) .", [["egg yolk", "ANATOMY", 51, 59], ["hen", "ORGANISM", 2, 5], ["egg yolk", "ORGANISM_SUBSTANCE", 51, 59], ["IgY", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgY", "PROTEIN", 90, 93], ["hen", "SPECIES", 2, 5], ["the egg yolk", "TREATMENT", 47, 59]]], ["Therefore, one immunized hen produces more than 22,500 mg of IgY per year which is equivalent to the production of 4.3 rabbits over the course of a year (Schade et al., 2005) .", [["hen", "ORGANISM", 25, 28], ["IgY", "GENE_OR_GENE_PRODUCT", 61, 64], ["rabbits", "ORGANISM", 119, 126], ["IgY", "PROTEIN", 61, 64], ["hen", "SPECIES", 25, 28], ["rabbits", "SPECIES", 119, 126], ["hen", "SPECIES", 25, 28], ["rabbits", "SPECIES", 119, 126]]], ["The maintenance costs for keeping hens are also lower than those for mammals such as rabbits (Schade et al., 2005) .", [["rabbits", "ORGANISM", 85, 92], ["rabbits", "SPECIES", 85, 92], ["rabbits", "SPECIES", 85, 92], ["maintenance", "OBSERVATION_MODIFIER", 4, 15], ["costs", "OBSERVATION", 16, 21]]], ["Therefore, egg yolk provides a more hygienic, cost-efficient, convenient and rich source of antibodies compared with the traditional method of obtaining antibodies from mammalian serum.", [["egg yolk", "ANATOMY", 11, 19], ["serum", "ANATOMY", 179, 184], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 11, 19], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["antibodies", "PROTEIN", 92, 102], ["antibodies", "PROTEIN", 153, 163], ["egg yolk", "PROBLEM", 11, 19], ["antibodies", "PROBLEM", 92, 102], ["mammalian serum", "TEST", 169, 184]]], ["In contrast to antibiotics, the use of IgY is environmentally-friendly and elicits no undesirable side effects, disease resistance or toxic residues (Coleman, 1999) .Structure and function of chicken IgYInitially, IgY antibodies were thought to be similar to IgG immunoglobulins, whereas they are now considered to be an evolutionary ancestor to mammalian IgG and IgE and also to IgA (Warr et al., 1995) .", [["IgY", "GENE_OR_GENE_PRODUCT", 39, 42], ["chicken", "ORGANISM", 192, 199], ["IgYInitially", "GENE_OR_GENE_PRODUCT", 200, 212], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 214, 228], ["IgG immunoglobulins", "GENE_OR_GENE_PRODUCT", 259, 278], ["IgG", "GENE_OR_GENE_PRODUCT", 356, 359], ["IgE", "GENE_OR_GENE_PRODUCT", 364, 367], ["IgA", "GENE_OR_GENE_PRODUCT", 380, 383], ["IgY", "PROTEIN", 39, 42], ["chicken IgYInitially", "PROTEIN", 192, 212], ["IgY antibodies", "PROTEIN", 214, 228], ["IgG immunoglobulins", "PROTEIN", 259, 278], ["mammalian IgG", "PROTEIN", 346, 359], ["IgE", "PROTEIN", 364, 367], ["IgA", "PROTEIN", 380, 383], ["chicken", "SPECIES", 192, 199], ["chicken", "SPECIES", 192, 199], ["antibiotics", "TREATMENT", 15, 26], ["undesirable side effects", "PROBLEM", 86, 110], ["disease resistance", "PROBLEM", 112, 130], ["chicken IgYInitially", "PROBLEM", 192, 212], ["IgY antibodies", "TEST", 214, 228], ["IgG immunoglobulins", "TEST", 259, 278], ["toxic", "OBSERVATION_MODIFIER", 134, 139], ["function", "OBSERVATION_MODIFIER", 180, 188]]], ["Although chicken IgY is the functional equivalent of mammalian IgG, there are some profound differences in their structure.", [["chicken", "ORGANISM", 9, 16], ["IgY", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgG", "GENE_OR_GENE_PRODUCT", 63, 66], ["chicken IgY", "PROTEIN", 9, 20], ["mammalian IgG", "PROTEIN", 53, 66], ["chicken", "SPECIES", 9, 16], ["chicken", "SPECIES", 9, 16], ["mammalian IgG", "TREATMENT", 53, 66], ["some", "OBSERVATION_MODIFIER", 78, 82], ["profound", "OBSERVATION_MODIFIER", 83, 91], ["differences", "OBSERVATION_MODIFIER", 92, 103]]], ["The general structure of the IgY molecule is the same as the IgG molecule with two heavy (H) chains and two light (L) chains but IgY has a molecular mass of 180 kDa which is larger than that of mammalian IgG (150 kDa) (Fig. 1) .", [["IgY", "GENE_OR_GENE_PRODUCT", 29, 32], ["IgY", "GENE_OR_GENE_PRODUCT", 129, 132], ["IgG", "GENE_OR_GENE_PRODUCT", 204, 207], ["IgY molecule", "PROTEIN", 29, 41], ["IgG molecule", "PROTEIN", 61, 73], ["heavy (H) chains", "PROTEIN", 83, 99], ["light (L) chains", "PROTEIN", 108, 124], ["IgY", "PROTEIN", 129, 132], ["mammalian IgG", "PROTEIN", 194, 207], ["150 kDa", "PROTEIN", 209, 216], ["two light (L) chains", "TREATMENT", 104, 124], ["a molecular mass", "PROBLEM", 137, 153], ["mammalian IgG", "TEST", 194, 207], ["IgY molecule", "OBSERVATION", 29, 41], ["heavy", "OBSERVATION_MODIFIER", 83, 88], ["mass", "OBSERVATION", 149, 153], ["180 kDa", "OBSERVATION_MODIFIER", 157, 164], ["larger", "OBSERVATION_MODIFIER", 174, 180]]], ["The molecular mass (67-70 kDa) of the H chain in IgY is larger than the H chain from mammals (50 kDa).", [["H", "CHEMICAL", 38, 39], ["H", "CHEMICAL", 72, 73], ["H chain", "GENE_OR_GENE_PRODUCT", 38, 45], ["IgY", "GENE_OR_GENE_PRODUCT", 49, 52], ["H chain", "PROTEIN", 38, 45], ["IgY", "PROTEIN", 49, 52], ["H chain", "PROTEIN", 72, 79], ["The molecular mass", "PROBLEM", 0, 18], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["chain", "OBSERVATION_MODIFIER", 40, 45], ["IgY", "ANATOMY", 49, 52], ["larger", "OBSERVATION_MODIFIER", 56, 62]]], ["The greater molecular mass of IgY is due to an increased number of heavy-chain constant domains and carbohydrate chains (Warr et al., 1995) .", [["carbohydrate", "CHEMICAL", 100, 112], ["IgY", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgY", "PROTEIN", 30, 33], ["heavy-chain constant domains", "PROTEIN", 67, 95], ["carbohydrate chains", "PROTEIN", 100, 119], ["The greater molecular mass of IgY", "PROBLEM", 0, 33], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["molecular", "OBSERVATION_MODIFIER", 12, 21], ["mass", "OBSERVATION", 22, 26], ["due to", "UNCERTAINTY", 37, 43], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["heavy", "OBSERVATION_MODIFIER", 67, 72], ["chain", "OBSERVATION_MODIFIER", 73, 78], ["constant", "OBSERVATION_MODIFIER", 79, 87], ["carbohydrate chains", "OBSERVATION", 100, 119]]], ["IgG has 3 C regions (C \u03b3 1-C \u03b3 3), while IgY has 4 C regions (C \u03c5 1-C \u03c5 4) and the presence of one additional C region with its two corresponding carbohydrate chains logically results in a greater molecular mass of IgY compared with IgG.Structure and function of chicken IgYOther differences in structure include the fact that the hinged region of IgY is much less flexible compared with mammalian IgG.", [["carbohydrate", "CHEMICAL", 146, 158], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["C \u03b3 1-C \u03b3 3", "GENE_OR_GENE_PRODUCT", 21, 32], ["IgY", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgY", "GENE_OR_GENE_PRODUCT", 215, 218], ["IgG", "GENE_OR_GENE_PRODUCT", 233, 236], ["chicken", "ORGANISM", 263, 270], ["IgYOther", "GENE_OR_GENE_PRODUCT", 271, 279], ["IgY", "GENE_OR_GENE_PRODUCT", 348, 351], ["IgG", "GENE_OR_GENE_PRODUCT", 398, 401], ["IgG", "PROTEIN", 0, 3], ["C regions", "PROTEIN", 10, 19], ["C \u03b3 1-C \u03b3 3", "DNA", 21, 32], ["IgY", "PROTEIN", 41, 44], ["4 C regions", "DNA", 49, 60], ["C region", "PROTEIN", 110, 118], ["carbohydrate chains", "PROTEIN", 146, 165], ["IgY", "PROTEIN", 215, 218], ["IgG", "PROTEIN", 233, 236], ["chicken IgYOther", "PROTEIN", 263, 279], ["IgY", "PROTEIN", 348, 351], ["mammalian IgG", "PROTEIN", 388, 401], ["chicken", "SPECIES", 263, 270], ["chicken", "SPECIES", 263, 270], ["IgG", "TEST", 0, 3], ["3 C regions", "PROBLEM", 8, 19], ["C", "TEST", 21, 22], ["\u03b3", "TEST", 23, 24], ["IgY", "TEST", 41, 44], ["C regions", "TEST", 51, 60], ["C", "TEST", 62, 63], ["one additional C region", "PROBLEM", 95, 118], ["a greater molecular mass of IgY", "PROBLEM", 187, 218], ["IgG", "TEST", 233, 236], ["mammalian IgG", "TREATMENT", 388, 401], ["greater", "OBSERVATION_MODIFIER", 189, 196], ["molecular", "OBSERVATION_MODIFIER", 197, 206], ["mass", "OBSERVATION", 207, 211], ["function", "OBSERVATION_MODIFIER", 251, 259], ["hinged", "OBSERVATION", 331, 337]]], ["It has also been suggested that IgY is a more hydrophobic molecule than IgG (Davalos-Pantoja et al., 2000) .", [["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgG", "GENE_OR_GENE_PRODUCT", 72, 75], ["IgY", "PROTEIN", 32, 35], ["IgG", "PROTEIN", 72, 75]]], ["Finally, IgY has an isoelectric point of pH 5.7-7.6, whereas that of IgG lies between 6.1 and 8.5 (Davalos-Pantoja et al., 2000; Sun et al., 2001) .", [["IgY", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgY", "PROTEIN", 9, 12], ["IgG", "PROTEIN", 69, 72], ["pH", "TEST", 41, 43], ["IgG", "TEST", 69, 72]]], ["Unlike mammalian IgG, IgY does not fix mammalian complement and does not interact with mammalian Fc and complement receptors (Carlander et al., 2000) .", [["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgY", "GENE_OR_GENE_PRODUCT", 22, 25], ["Fc", "GENE_OR_GENE_PRODUCT", 97, 99], ["complement receptors", "GENE_OR_GENE_PRODUCT", 104, 124], ["mammalian IgG", "PROTEIN", 7, 20], ["IgY", "PROTEIN", 22, 25], ["mammalian complement", "PROTEIN", 39, 59], ["mammalian Fc", "PROTEIN", 87, 99], ["complement receptors", "PROTEIN", 104, 124], ["IgG", "OBSERVATION", 17, 20]]], ["As well, IgY does not bind to protein A, protein G or rheumatoid factor, so no false positives are obtained on immunoassay which is a problem with IgG-based mammalian assays (Davalos-Pantoja et al., 2000) .", [["IgY", "GENE_OR_GENE_PRODUCT", 9, 12], ["protein A", "GENE_OR_GENE_PRODUCT", 30, 39], ["protein G", "GENE_OR_GENE_PRODUCT", 41, 50], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 54, 71], ["IgG", "GENE_OR_GENE_PRODUCT", 147, 150], ["IgY", "PROTEIN", 9, 12], ["protein A", "PROTEIN", 30, 39], ["protein G", "PROTEIN", 41, 50], ["rheumatoid factor", "PROTEIN", 54, 71], ["IgG", "PROTEIN", 147, 150], ["rheumatoid factor", "PROBLEM", 54, 71], ["false positives", "PROBLEM", 79, 94], ["immunoassay", "TEST", 111, 122], ["IgG", "TEST", 147, 150]]], ["These differences provide significant advantages to the application of IgY technology in many areas of research such as diagnostics (Erhard et al., 2000) , antibioticalternative therapy (Carlander et al., 2000) and xenotransplantation (Fryer et al., 1999) .Storage stability of IgYThe stability of IgY during storage is reasonably good under specified conditions.", [["IgYThe", "SIMPLE_CHEMICAL", 278, 284], ["IgY", "GENE_OR_GENE_PRODUCT", 298, 301], ["IgY", "PROTEIN", 298, 301], ["IgY technology", "TREATMENT", 71, 85], ["antibioticalternative therapy", "TREATMENT", 156, 185], ["xenotransplantation", "TREATMENT", 215, 234], ["stability", "OBSERVATION_MODIFIER", 265, 274], ["stability", "OBSERVATION_MODIFIER", 285, 294]]], ["IgY solutions may be stored at 4\u00b0C for periods ranging from months to a few years provided 0.02% NaN 3 , 0.03% w/v thimerosal or 50 \u03bcg/ml gentamicin has been added to retard microbial growth (Schade et al., 2005) .", [["thimerosal", "CHEMICAL", 115, 125], ["gentamicin", "CHEMICAL", 138, 148], ["thimerosal", "CHEMICAL", 115, 125], ["gentamicin", "CHEMICAL", 138, 148], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["C", "GENE_OR_GENE_PRODUCT", 33, 34], ["thimerosal", "SIMPLE_CHEMICAL", 115, 125], ["gentamicin", "SIMPLE_CHEMICAL", 138, 148], ["IgY solutions", "TREATMENT", 0, 13], ["v thimerosal", "TREATMENT", 113, 125], ["gentamicin", "TREATMENT", 138, 148]]], ["Dried IgY preparations were stored for five to ten years at 4\u00b0C without significant loss of antibody activity and the preparations also retained activity for six months at room temperature and for one month at 37\u00b0C (Larsson et al., 1993) .", [["loss of antibody activity", "DISEASE", 84, 109], ["C", "GENE_OR_GENE_PRODUCT", 62, 63], ["Dried IgY preparations", "TREATMENT", 0, 22], ["significant loss of antibody activity", "PROBLEM", 72, 109], ["without", "UNCERTAINTY", 64, 71], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["loss", "OBSERVATION", 84, 88], ["antibody activity", "OBSERVATION", 92, 109]]], ["While lyophilization minimizes bacterial growth and maintains better structural integrity of purified IgY, spray-drying is more economical .", [["IgY", "GENE_OR_GENE_PRODUCT", 102, 105], ["purified IgY", "PROTEIN", 93, 105], ["bacterial growth", "PROBLEM", 31, 47], ["purified IgY", "TREATMENT", 93, 105], ["spray", "TREATMENT", 107, 112], ["bacterial", "OBSERVATION_MODIFIER", 31, 40], ["growth", "OBSERVATION_MODIFIER", 41, 47]]], ["Collectively, these unique biological attributes make IgY an effective natural food antimicrobial system and immunotherapeutic agent.Mode of actionThe exact mechanisms through which IgY counteracts pathogen activity have not been determined.", [["IgY", "GENE_OR_GENE_PRODUCT", 54, 57], ["IgY", "GENE_OR_GENE_PRODUCT", 182, 185], ["IgY", "PROTEIN", 182, 185], ["immunotherapeutic agent", "TREATMENT", 109, 132]]], ["However, several mechanisms have been proposed to express how specific IgY counteracts pathogen activity and these are outlined below.Mode of action(i) Agglutination.", [["IgY", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgY", "PROTEIN", 71, 74]]], ["Tsubokura et al. (1997) suggested that the inhibition of bacterial growth or colonization observed as a result of treatment with IgY can be the result of bacterial agglutination, causing a reduction in CFU rather than actual direct effects on individual bacteria.", [["IgY", "GENE_OR_GENE_PRODUCT", 129, 132], ["IgY", "PROTEIN", 129, 132], ["bacterial growth", "PROBLEM", 57, 73], ["colonization", "PROBLEM", 77, 89], ["treatment", "TREATMENT", 114, 123], ["IgY", "TREATMENT", 129, 132], ["bacterial agglutination", "PROBLEM", 154, 177], ["a reduction in CFU", "PROBLEM", 187, 205], ["individual bacteria", "PROBLEM", 243, 262], ["bacterial agglutination", "OBSERVATION", 154, 177], ["reduction", "OBSERVATION_MODIFIER", 189, 198]]], ["Although agglutination may be one mediator of growth inhibition, it is unlikely to be the most important mediator because cross-linking of bacteria is precluded by the steric hindrance of the two Fab arms of IgY (Gallagher and Voss, 1974) . (ii) Adherence-blockade.", [["IgY", "GENE_OR_GENE_PRODUCT", 208, 211], ["Fab arms", "PROTEIN", 196, 204], ["IgY", "PROTEIN", 208, 211], ["agglutination", "PROBLEM", 9, 22], ["cross-linking of bacteria", "PROBLEM", 122, 147], ["Adherence-blockade", "TREATMENT", 246, 264], ["may be", "UNCERTAINTY", 23, 29], ["unlikely to be", "UNCERTAINTY", 71, 85], ["bacteria", "OBSERVATION", 139, 147], ["steric hindrance", "OBSERVATION", 168, 184]]], ["Several in vitro studies have suggested that inhibition of adhesion is the dominant mechanism by which specific IgY counteracts pathogen activity (Jin et al. 1998; Lee et al. 2002) .", [["IgY", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgY", "PROTEIN", 112, 115], ["Several in vitro studies", "TEST", 0, 24], ["inhibition of adhesion", "PROBLEM", 45, 67]]], ["Jin et al. (1998) showed that IgY functions to prevent the adherence of E. coli K88 to the intestinal mucus of piglets.", [["intestinal mucus", "ANATOMY", 91, 107], ["IgY", "GENE_OR_GENE_PRODUCT", 30, 33], ["E. coli K88", "ORGANISM", 72, 83], ["intestinal mucus", "ORGAN", 91, 107], ["piglets", "ORGANISM", 111, 118], ["IgY", "PROTEIN", 30, 33], ["E. coli", "SPECIES", 72, 79], ["piglets", "SPECIES", 111, 118], ["E. coli", "SPECIES", 72, 79], ["IgY functions", "TREATMENT", 30, 43], ["E. coli K88", "TREATMENT", 72, 83], ["E. coli", "OBSERVATION", 72, 79], ["intestinal mucus", "ANATOMY", 91, 107]]], ["Particular components exposed on the Gram-negative bacteria surface such as outer membrane protein, lipopolysaccharide, fimbriae (or pili), and flagella, which are crucial factors for bacterial colonization, may be recognized and bound by related polyclonal antibody such as IgY (Sim et al., 2000) .", [["surface", "ANATOMY", 60, 67], ["outer membrane", "ANATOMY", 76, 90], ["flagella", "ANATOMY", 144, 152], ["lipopolysaccharide", "CHEMICAL", 100, 118], ["outer membrane", "CELLULAR_COMPONENT", 76, 90], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 100, 118], ["fimbriae", "GENE_OR_GENE_PRODUCT", 120, 128], ["pili", "GENE_OR_GENE_PRODUCT", 133, 137], ["flagella", "CELLULAR_COMPONENT", 144, 152], ["IgY", "GENE_OR_GENE_PRODUCT", 275, 278], ["outer membrane protein", "PROTEIN", 76, 98], ["fimbriae", "PROTEIN", 120, 128], ["pili", "PROTEIN", 133, 137], ["flagella", "PROTEIN", 144, 152], ["polyclonal antibody", "PROTEIN", 247, 266], ["IgY", "PROTEIN", 275, 278], ["Particular components", "PROBLEM", 0, 21], ["the Gram-negative bacteria surface", "PROBLEM", 33, 67], ["outer membrane protein", "TEST", 76, 98], ["lipopolysaccharide", "PROBLEM", 100, 118], ["fimbriae", "PROBLEM", 120, 128], ["flagella", "PROBLEM", 144, 152], ["crucial factors", "PROBLEM", 164, 179], ["bacterial colonization", "PROBLEM", 184, 206], ["polyclonal antibody", "TEST", 247, 266], ["bacteria", "OBSERVATION", 51, 59], ["outer", "ANATOMY_MODIFIER", 76, 81], ["membrane protein", "OBSERVATION", 82, 98]]], ["This binding may block or impair the functions of growth-related bacterial components and lead to bacterial growth inhibition.", [["bacterial components", "PROBLEM", 65, 85], ["bacterial growth inhibition", "PROBLEM", 98, 125], ["bacterial components", "OBSERVATION", 65, 85]]], ["It is also possible that specific IgY binding to bacteria could alter cellular signaling cascades that could result in decreased toxin production and release. (iii) Opsonization followed by phagocytosis.", [["cellular", "ANATOMY", 70, 78], ["IgY", "GENE_OR_GENE_PRODUCT", 34, 37], ["cellular", "CELL", 70, 78], ["toxin", "SIMPLE_CHEMICAL", 129, 134], ["IgY", "PROTEIN", 34, 37], ["toxin", "PROTEIN", 129, 134], ["specific IgY binding", "PROBLEM", 25, 45], ["bacteria", "PROBLEM", 49, 57], ["cellular signaling cascades", "PROBLEM", 70, 97], ["decreased toxin production", "PROBLEM", 119, 145], ["phagocytosis", "PROBLEM", 190, 202], ["also possible", "UNCERTAINTY", 6, 19], ["signaling cascades", "OBSERVATION", 79, 97], ["decreased", "OBSERVATION_MODIFIER", 119, 128]]], ["Nie et al. (2004) determined that IgY improved the phagocytosis of S. aureus by neutrophils.", [["neutrophils", "ANATOMY", 80, 91], ["IgY", "GENE_OR_GENE_PRODUCT", 34, 37], ["S. aureus", "ORGANISM", 67, 76], ["neutrophils", "CELL", 80, 91], ["IgY", "PROTEIN", 34, 37], ["neutrophils", "CELL_TYPE", 80, 91], ["S. aureus", "SPECIES", 67, 76], ["S. aureus", "SPECIES", 67, 76], ["S. aureus", "PROBLEM", 67, 76], ["neutrophils", "TEST", 80, 91], ["aureus", "OBSERVATION", 70, 76]]], ["Similarly, Zhen et al. (2008b) showed that phagocytic activity of E. coli by either milk macrophages or by polymorphonuclear neutrophil leukocytes increased significantly in the presence of IgY.", [["milk macrophages", "ANATOMY", 84, 100], ["polymorphonuclear neutrophil leukocytes", "ANATOMY", 107, 146], ["E. coli", "ORGANISM", 66, 73], ["milk macrophages", "CELL", 84, 100], ["polymorphonuclear neutrophil leukocytes", "CELL", 107, 146], ["IgY", "GENE_OR_GENE_PRODUCT", 190, 193], ["milk macrophages", "CELL_TYPE", 84, 100], ["polymorphonuclear neutrophil leukocytes", "CELL_TYPE", 107, 146], ["IgY", "PROTEIN", 190, 193], ["E. coli", "SPECIES", 66, 73], ["E. coli", "SPECIES", 66, 73], ["E. coli", "PROBLEM", 66, 73], ["polymorphonuclear neutrophil leukocytes", "TEST", 107, 146], ["phagocytic activity", "OBSERVATION", 43, 62], ["E. coli", "OBSERVATION", 66, 73], ["polymorphonuclear neutrophil leukocytes", "OBSERVATION", 107, 146]]], ["These results suggest that IgY enhanced phagocytic activity.", [["IgY", "GENE_OR_GENE_PRODUCT", 27, 30], ["IgY", "PROTEIN", 27, 30], ["IgY enhanced phagocytic activity", "PROBLEM", 27, 59], ["phagocytic activity", "OBSERVATION", 40, 59]]], ["Structural alterations were observed on the surface of S. typhimurium and E. coli O111 (Zhen et al., 2008b) by binding with specific IgY.", [["surface", "ANATOMY", 44, 51], ["surface", "CELLULAR_COMPONENT", 44, 51], ["S. typhimurium", "ORGANISM", 55, 69], ["E. coli", "ORGANISM", 74, 81], ["O111", "ORGANISM", 82, 86], ["IgY", "GENE_OR_GENE_PRODUCT", 133, 136], ["IgY", "PROTEIN", 133, 136], ["S. typhimurium", "SPECIES", 55, 69], ["E. coli", "SPECIES", 74, 81], ["S. typhimurium", "SPECIES", 55, 69], ["E. coli", "SPECIES", 74, 81], ["Structural alterations", "PROBLEM", 0, 22], ["E. coli", "PROBLEM", 74, 81], ["alterations", "OBSERVATION", 11, 22]]], ["These changes could be explained by the variation of the electron cloud and/or electric field on the bacterial surface , resulting in greater vulnerability of the bacterial cells to phagocytosis. (iv) Toxin neutralization.", [["surface", "ANATOMY", 111, 118], ["cells", "ANATOMY", 173, 178], ["electron", "SIMPLE_CHEMICAL", 57, 65], ["bacterial surface", "CELLULAR_COMPONENT", 101, 118], ["cells", "CELL", 173, 178], ["Toxin", "GENE_OR_GENE_PRODUCT", 201, 206], ["bacterial cells", "CELL_TYPE", 163, 178], ["the electron cloud", "PROBLEM", 53, 71], ["the bacterial surface", "TEST", 97, 118], ["the bacterial cells", "PROBLEM", 159, 178], ["Toxin neutralization", "TREATMENT", 201, 221], ["could be explained", "UNCERTAINTY", 14, 32], ["electron cloud", "OBSERVATION", 57, 71], ["bacterial surface", "OBSERVATION_MODIFIER", 101, 118], ["greater", "OBSERVATION_MODIFIER", 134, 141], ["vulnerability", "OBSERVATION_MODIFIER", 142, 155], ["bacterial cells", "OBSERVATION", 163, 178]]], ["S. aureus capsular is a major virulence factor involved in the onset of bovine mastitis.", [["bovine mastitis", "DISEASE", 72, 87], ["S. aureus", "ORGANISM", 0, 9], ["bovine", "ORGANISM", 72, 78], ["S. aureus", "SPECIES", 0, 9], ["bovine", "SPECIES", 72, 78], ["S. aureus", "SPECIES", 0, 9], ["bovine", "SPECIES", 72, 78], ["S. aureus capsular", "PROBLEM", 0, 18], ["a major virulence factor", "PROBLEM", 22, 46], ["bovine mastitis", "PROBLEM", 72, 87], ["aureus", "OBSERVATION", 3, 9], ["capsular", "OBSERVATION_MODIFIER", 10, 18], ["bovine mastitis", "OBSERVATION", 72, 87]]], ["Wang et al. (2011) studied the effectiveness of IgY against encapsulated S. aureus.", [["IgY", "ORGANISM", 48, 51], ["S. aureus", "ORGANISM", 73, 82], ["IgY", "PROTEIN", 48, 51], ["S. aureus", "SPECIES", 73, 82], ["S. aureus", "SPECIES", 73, 82], ["IgY", "TREATMENT", 48, 51], ["encapsulated S. aureus", "PROBLEM", 60, 82], ["aureus", "OBSERVATION", 76, 82]]], ["Their results showed that IgY could prevent S. aureus internalization by mammary epithelial cells suggesting toxin neutralization activity, rather than direct growth inhibition as the means through which IgY acts to control mastitis.Applications for IgY administrationThe potential applications for using orally administered IgY in the control of enteric and non-enteric infections of either bacterial or viral origin in humans and animals have been studied at length and are summarized in Tables 2 and 3 .Bovine mastitisBovine mastitis is a costly disease for the dairy industry.", [["mammary epithelial cells", "ANATOMY", 73, 97], ["mastitis", "DISEASE", 224, 232], ["infections", "DISEASE", 371, 381], ["mastitis", "DISEASE", 513, 521], ["Bovine mastitis", "DISEASE", 521, 536], ["IgY", "GENE_OR_GENE_PRODUCT", 26, 29], ["S. aureus", "ORGANISM", 44, 53], ["mammary epithelial cells", "CELL", 73, 97], ["IgY", "GENE_OR_GENE_PRODUCT", 204, 207], ["IgY", "GENE_OR_GENE_PRODUCT", 250, 253], ["IgY", "GENE_OR_GENE_PRODUCT", 325, 328], ["humans", "ORGANISM", 421, 427], ["Bovine", "ORGANISM", 506, 512], ["Bovine", "ORGANISM", 521, 527], ["IgY", "PROTEIN", 26, 29], ["mammary epithelial cells", "CELL_TYPE", 73, 97], ["IgY", "PROTEIN", 204, 207], ["IgY", "PROTEIN", 250, 253], ["IgY", "PROTEIN", 325, 328], ["S. aureus", "SPECIES", 44, 53], ["humans", "SPECIES", 421, 427], ["Bovine", "SPECIES", 506, 512], ["Bovine", "SPECIES", 521, 527], ["S. aureus", "SPECIES", 44, 53], ["humans", "SPECIES", 421, 427], ["Bovine mastitis", "SPECIES", 506, 521], ["Bovine", "SPECIES", 521, 527], ["IgY", "TREATMENT", 26, 29], ["S. aureus internalization", "PROBLEM", 44, 69], ["mammary epithelial cells", "PROBLEM", 73, 97], ["toxin neutralization activity", "PROBLEM", 109, 138], ["direct growth inhibition", "PROBLEM", 152, 176], ["mastitis", "PROBLEM", 224, 232], ["IgY administration", "TREATMENT", 250, 268], ["The potential applications", "TREATMENT", 268, 294], ["orally administered IgY", "TREATMENT", 305, 328], ["enteric and non-enteric infections", "TREATMENT", 347, 381], ["Bovine mastitis", "PROBLEM", 506, 521], ["Bovine mastitis", "PROBLEM", 521, 536], ["a costly disease", "PROBLEM", 540, 556], ["aureus", "OBSERVATION", 47, 53], ["mammary", "ANATOMY", 73, 80], ["epithelial cells", "OBSERVATION", 81, 97], ["neutralization activity", "OBSERVATION", 115, 138], ["mastitis", "OBSERVATION", 224, 232], ["enteric", "ANATOMY", 347, 354], ["bacterial", "OBSERVATION_MODIFIER", 392, 401], ["viral origin", "OBSERVATION", 405, 417], ["mastitis", "OBSERVATION", 513, 521], ["mastitis", "OBSERVATION", 528, 536]]], ["In the United States alone, the annual costs of mastitis have been estimated to be US).", [["mastitis", "DISEASE", 48, 56], ["mastitis", "PROBLEM", 48, 56], ["mastitis", "OBSERVATION", 48, 56]]], ["Numerous pathogens can cause mastitis and these can be classified into contagious pathogens (primary Staphylococcus aureus and Streptococcus agalactiae) or environmental pathogens (primary E. coli; Riffon et al., 2001) .Bovine mastitisIn our research, we have reported that specific IgY produced by hens immunized with S. aureus and/or E. coli was effective in controlling experimental and clinical mastitis (Zhen et al., 2008a,b; ).", [["mastitis", "DISEASE", 29, 37], ["primary Staphylococcus aureus", "DISEASE", 93, 122], ["Streptococcus agalactiae", "DISEASE", 127, 151], ["mastitis", "DISEASE", 227, 235], ["mastitis", "DISEASE", 399, 407], ["Staphylococcus aureus", "ORGANISM", 101, 122], ["Streptococcus agalactiae", "ORGANISM", 127, 151], ["E. coli", "ORGANISM", 189, 196], ["Bovine", "ORGANISM", 220, 226], ["IgY", "GENE_OR_GENE_PRODUCT", 283, 286], ["hens", "ORGANISM", 299, 303], ["S. aureus", "ORGANISM", 319, 328], ["E. coli", "ORGANISM", 336, 343], ["IgY", "PROTEIN", 283, 286], ["Staphylococcus aureus", "SPECIES", 101, 122], ["Streptococcus agalactiae", "SPECIES", 127, 151], ["E. coli", "SPECIES", 189, 196], ["Bovine", "SPECIES", 220, 226], ["S. aureus", "SPECIES", 319, 328], ["E. coli", "SPECIES", 336, 343], ["Staphylococcus aureus", "SPECIES", 101, 122], ["Streptococcus agalactiae", "SPECIES", 127, 151], ["E. coli", "SPECIES", 189, 196], ["Bovine mastitis", "SPECIES", 220, 235], ["hens", "SPECIES", 299, 303], ["S. aureus", "SPECIES", 319, 328], ["E. coli", "SPECIES", 336, 343], ["Numerous pathogens", "PROBLEM", 0, 18], ["mastitis", "PROBLEM", 29, 37], ["contagious pathogens", "PROBLEM", 71, 91], ["primary Staphylococcus aureus", "PROBLEM", 93, 122], ["Streptococcus agalactiae", "PROBLEM", 127, 151], ["environmental pathogens", "PROBLEM", 156, 179], ["primary E. coli", "PROBLEM", 181, 196], ["Bovine mastitis", "PROBLEM", 220, 235], ["S. aureus", "PROBLEM", 319, 328], ["E. coli", "PROBLEM", 336, 343], ["clinical mastitis", "PROBLEM", 390, 407], ["pathogens", "OBSERVATION", 9, 18], ["mastitis", "OBSERVATION", 29, 37], ["Streptococcus agalactiae", "OBSERVATION", 127, 151], ["mastitis", "OBSERVATION", 227, 235], ["aureus", "OBSERVATION", 322, 328], ["E. coli", "OBSERVATION", 336, 343], ["mastitis", "OBSERVATION", 399, 407]]], ["An in vitro study conducted in our laboratory indicated that IgY could inhibit the growth of bacteria by altering the bacterial cell surface thereby reducing the ability of bacteria to adhere to mammary epithelial cells (Zhen et al., 2008b) .", [["cell surface", "ANATOMY", 128, 140], ["mammary epithelial cells", "ANATOMY", 195, 219], ["IgY", "GENE_OR_GENE_PRODUCT", 61, 64], ["cell surface", "CELLULAR_COMPONENT", 128, 140], ["mammary epithelial cells", "CELL", 195, 219], ["IgY", "PROTEIN", 61, 64], ["mammary epithelial cells", "CELL_TYPE", 195, 219], ["An in vitro study", "TEST", 0, 17], ["the growth of bacteria", "PROBLEM", 79, 101], ["altering the bacterial cell surface", "PROBLEM", 105, 140], ["bacteria", "PROBLEM", 173, 181], ["growth", "OBSERVATION_MODIFIER", 83, 89], ["bacteria", "OBSERVATION", 93, 101], ["bacterial cell", "OBSERVATION", 118, 132], ["mammary", "ANATOMY", 195, 202], ["epithelial cells", "OBSERVATION", 203, 219]]], ["In a further study, the efficacy of specific IgY to reduce clinical and experimental mastitis caused by S. aureus was demonstrated by improving milk quality through a decrease in somatic cell and bacterial counts in milk ).", [["milk", "ANATOMY", 144, 148], ["somatic cell", "ANATOMY", 179, 191], ["milk", "ANATOMY", 216, 220], ["mastitis", "DISEASE", 85, 93], ["IgY", "GENE_OR_GENE_PRODUCT", 45, 48], ["S. aureus", "ORGANISM", 104, 113], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["somatic cell", "CELL", 179, 191], ["milk", "ORGANISM_SUBSTANCE", 216, 220], ["IgY", "PROTEIN", 45, 48], ["S. aureus", "SPECIES", 104, 113], ["S. aureus", "SPECIES", 104, 113], ["a further study", "TEST", 3, 18], ["specific IgY", "TREATMENT", 36, 48], ["clinical and experimental mastitis", "PROBLEM", 59, 93], ["S. aureus", "PROBLEM", 104, 113], ["a decrease in somatic cell", "PROBLEM", 165, 191], ["bacterial counts", "TEST", 196, 212], ["mastitis", "OBSERVATION", 85, 93], ["aureus", "OBSERVATION", 107, 113], ["somatic cell", "OBSERVATION", 179, 191], ["bacterial counts", "OBSERVATION", 196, 212]]], ["The cure rates resulting from the use of IgY for clinical and experimental mastitis were dramatically higher than for untreated animals (Table 4 ).", [["mastitis", "DISEASE", 75, 83], ["IgY", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgY", "PROTEIN", 41, 44], ["IgY", "TREATMENT", 41, 44], ["clinical and experimental mastitis", "PROBLEM", 49, 83], ["mastitis", "OBSERVATION", 75, 83]]], ["Although conducted with very few animals, these From Narat, 2003. studies indicate that specific IgY has considerable potential as a therapeutic treatment for mastitis in dairy cows.Diarrhea in pigletsEnterotoxigenic E. coli (ETEC) is by far the most common cause of enteric colibacillosis encountered in neonatal and post-weaned pigs .", [["mastitis", "DISEASE", 159, 167], ["Diarrhea", "DISEASE", 182, 190], ["enteric colibacillosis", "DISEASE", 267, 289], ["IgY", "GENE_OR_GENE_PRODUCT", 97, 100], ["piglets", "ORGANISM", 194, 201], ["Enterotoxigenic E. coli", "ORGANISM", 201, 224], ["ETEC", "ORGANISM", 226, 230], ["pigs", "ORGANISM", 330, 334], ["IgY", "PROTEIN", 97, 100], ["cows", "SPECIES", 177, 181], ["piglets", "SPECIES", 194, 201], ["E. coli", "SPECIES", 217, 224], ["pigs", "SPECIES", 330, 334], ["E. coli", "SPECIES", 217, 224], ["ETEC", "SPECIES", 226, 230], ["pigs", "SPECIES", 330, 334], ["studies", "TEST", 66, 73], ["a therapeutic treatment", "TREATMENT", 131, 154], ["mastitis", "PROBLEM", 159, 167], ["Diarrhea", "PROBLEM", 182, 190], ["pigletsEnterotoxigenic E. coli", "PROBLEM", 194, 224], ["enteric colibacillosis", "PROBLEM", 267, 289], ["very", "OBSERVATION_MODIFIER", 24, 28], ["few", "OBSERVATION_MODIFIER", 29, 32], ["Enterotoxigenic", "OBSERVATION_MODIFIER", 201, 216], ["E. coli", "OBSERVATION_MODIFIER", 217, 224], ["enteric", "ANATOMY", 267, 274], ["colibacillosis", "OBSERVATION", 275, 289]]], ["The strains of E. coli associated with intestinal colonization which cause severe diarrhea are the K88, K99 and 987P fimbrial adhesins.", [["intestinal", "ANATOMY", 39, 49], ["diarrhea", "DISEASE", 82, 90], ["E. coli", "ORGANISM", 15, 22], ["intestinal", "ORGAN", 39, 49], ["987P fimbrial adhesins", "GENE_OR_GENE_PRODUCT", 112, 134], ["K88, K99 and 987P fimbrial adhesins", "PROTEIN", 99, 134], ["E. coli", "SPECIES", 15, 22], ["E. coli", "SPECIES", 15, 22], ["E. coli", "PROBLEM", 15, 22], ["intestinal colonization", "PROBLEM", 39, 62], ["severe diarrhea", "PROBLEM", 75, 90], ["the K88", "TREATMENT", 95, 102], ["E. coli", "OBSERVATION", 15, 22], ["intestinal", "ANATOMY", 39, 49], ["colonization", "OBSERVATION", 50, 62], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["diarrhea", "OBSERVATION", 82, 90]]], ["Among the ETEC, those expressing the K88+ fimbrial antigen are the most prevalent forms causing E. coli infection world-wide (Rapacz and Hasler-Rapacz, 1986 ).", [["E. coli infection", "DISEASE", 96, 113], ["K88", "GENE_OR_GENE_PRODUCT", 37, 40], ["fimbrial antigen", "GENE_OR_GENE_PRODUCT", 42, 58], ["E. coli", "ORGANISM", 96, 103], ["K88", "PROTEIN", 37, 40], ["fimbrial antigen", "PROTEIN", 42, 58], ["E. coli", "SPECIES", 96, 103], ["E. coli", "SPECIES", 96, 103], ["the K88+ fimbrial antigen", "PROBLEM", 33, 58], ["E. coli infection", "PROBLEM", 96, 113], ["most prevalent", "OBSERVATION_MODIFIER", 67, 81], ["coli infection", "OBSERVATION", 99, 113]]], ["It has been estimated that K88+ ETEC are responsible for more than half of the piglet mortality which occurs each year (Waters and Sellwood, 1982) , causing significant economic loss for the pig industry.Diarrhea in pigletsIgY is recognized as an alternative source of antibodies for the prevention of ETEC coli infection because it has been found to inhibit binding of E. coli to the intestinal mucosa (Jin et al., 1998) .", [["piglet", "ANATOMY", 79, 85], ["intestinal mucosa", "ANATOMY", 385, 402], ["Diarrhea", "DISEASE", 204, 212], ["ETEC coli infection", "DISEASE", 302, 321], ["K88+ ETEC", "GENE_OR_GENE_PRODUCT", 27, 36], ["piglet", "ORGANISM", 79, 85], ["pig", "ORGANISM", 191, 194], ["piglets", "ORGANISM", 216, 223], ["IgY", "ORGANISM", 223, 226], ["ETEC coli", "ORGANISM", 302, 311], ["E. coli", "ORGANISM", 370, 377], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 385, 402], ["antibodies", "PROTEIN", 269, 279], ["pig", "SPECIES", 191, 194], ["piglets", "SPECIES", 216, 223], ["ETEC coli", "SPECIES", 302, 311], ["E. coli", "SPECIES", 370, 377], ["pig", "SPECIES", 191, 194], ["piglets", "SPECIES", 216, 223], ["ETEC coli", "SPECIES", 302, 311], ["E. coli", "SPECIES", 370, 377], ["K88", "PROBLEM", 27, 30], ["ETEC", "PROBLEM", 32, 36], ["significant economic loss", "PROBLEM", 157, 182], ["the pig industry", "TREATMENT", 187, 203], ["Diarrhea in pigletsIgY", "PROBLEM", 204, 226], ["antibodies", "TREATMENT", 269, 279], ["ETEC coli infection", "PROBLEM", 302, 321], ["E. coli", "PROBLEM", 370, 377], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["economic loss", "OBSERVATION", 169, 182], ["E. coli", "OBSERVATION", 370, 377], ["intestinal mucosa", "ANATOMY", 385, 402]]], ["IgY has been orally administered to piglets and offers a potential prophylactic and therapeutic approach for controlling E. coli-induced diarrhea.", [["diarrhea", "DISEASE", 137, 145], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["piglets", "ORGANISM", 36, 43], ["IgY", "PROTEIN", 0, 3], ["piglets", "SPECIES", 36, 43], ["E. coli-induced diarrhea", "SPECIES", 121, 145], ["IgY", "TREATMENT", 0, 3], ["a potential prophylactic", "TREATMENT", 55, 79], ["therapeutic approach", "TREATMENT", 84, 104], ["E. coli-induced diarrhea", "PROBLEM", 121, 145]]], ["Yokoyama et al. (1992) showed that orally administered IgY generated against E. coli K88, K99, or 987P fimbriae was protective against infection from each of the three homologous strains of E. coli in a dose-dependent manner.", [["infection", "DISEASE", 135, 144], ["IgY", "GENE_OR_GENE_PRODUCT", 55, 58], ["E. coli", "ORGANISM", 77, 84], ["K88", "ORGANISM", 85, 88], ["K99", "GENE_OR_GENE_PRODUCT", 90, 93], ["987P fimbriae", "GENE_OR_GENE_PRODUCT", 98, 111], ["E. coli", "ORGANISM", 190, 197], ["IgY", "PROTEIN", 55, 58], ["E. coli", "SPECIES", 77, 84], ["E. coli", "SPECIES", 190, 197], ["E. coli", "SPECIES", 77, 84], ["E. coli", "SPECIES", 190, 197], ["orally administered IgY", "TREATMENT", 35, 58], ["E. coli K88", "TREATMENT", 77, 88], ["infection", "PROBLEM", 135, 144], ["E. coli", "PROBLEM", 190, 197], ["infection", "OBSERVATION", 135, 144], ["E. coli", "OBSERVATION", 190, 197]]], ["E. coli K88, K99, and 987P strains adhered equally to porcine epithelial cells from the duodenum and ileum but failed to so in the presence of homologous anti-fimbrial IgY.Diarrhea in pigletsA group of researchers at the University of Manitoba (Winnipeg, Canada) have carried out some excellent studies on the passive protective effect of IgY against ETEC K88 fimbriae in the control of neonatal and early-weaned piglets in vitro and in vivo (Jin et al., 1998; Marquardt et al., 1999) .", [["epithelial cells", "ANATOMY", 62, 78], ["duodenum", "ANATOMY", 88, 96], ["ileum", "ANATOMY", 101, 106], ["Diarrhea", "DISEASE", 172, 180], ["E. coli", "ORGANISM", 0, 7], ["K88", "ORGANISM", 8, 11], ["K99", "CELL", 13, 16], ["porcine", "ORGANISM", 54, 61], ["epithelial cells", "CELL", 62, 78], ["duodenum", "ORGAN", 88, 96], ["ileum", "ORGAN", 101, 106], ["IgY", "GENE_OR_GENE_PRODUCT", 168, 171], ["piglets", "ORGANISM", 184, 191], ["IgY", "GENE_OR_GENE_PRODUCT", 339, 342], ["ETEC K88 fimbriae", "GENE_OR_GENE_PRODUCT", 351, 368], ["piglets", "ORGANISM", 413, 420], ["porcine epithelial cells", "CELL_TYPE", 54, 78], ["anti-fimbrial IgY", "PROTEIN", 154, 171], ["IgY", "PROTEIN", 339, 342], ["ETEC K88 fimbriae", "PROTEIN", 351, 368], ["E. coli", "SPECIES", 0, 7], ["porcine", "SPECIES", 54, 61], ["piglets", "SPECIES", 184, 191], ["piglets", "SPECIES", 413, 420], ["E. coli", "SPECIES", 0, 7], ["porcine", "SPECIES", 54, 61], ["ETEC", "SPECIES", 351, 355], ["E. coli K88", "TEST", 0, 11], ["K99", "TEST", 13, 16], ["P strains", "PROBLEM", 25, 34], ["homologous anti-fimbrial IgY", "TREATMENT", 143, 171], ["Diarrhea", "PROBLEM", 172, 180], ["the passive protective effect", "TREATMENT", 306, 335], ["IgY", "TREATMENT", 339, 342], ["ETEC K88 fimbriae", "TREATMENT", 351, 368], ["coli K88", "OBSERVATION", 3, 11], ["epithelial cells", "OBSERVATION", 62, 78], ["duodenum", "ANATOMY", 88, 96], ["ileum", "ANATOMY", 101, 106], ["piglets", "ANATOMY", 184, 191]]], ["In an animal feeding study, 21-day old pigs were challenged with 5 ml of ETEC K88 at a dose of 10 12 CFU ml \u2212 1 per piglet.", [["piglet", "ANATOMY", 116, 122], ["ETEC K88", "CHEMICAL", 73, 81], ["pigs", "ORGANISM", 39, 43], ["ETEC", "ORGANISM", 73, 77], ["K88", "SIMPLE_CHEMICAL", 78, 81], ["piglet", "ORGANISM", 116, 122], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 39, 43], ["ETEC", "SPECIES", 73, 77], ["an animal feeding study", "TEST", 3, 26], ["ETEC K88", "TREATMENT", 73, 81]]], ["IgY was administered to piglets three times a day for two days.", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["piglets", "ORGANISM", 24, 31], ["IgY", "PROTEIN", 0, 3], ["piglets", "SPECIES", 24, 31], ["IgY", "TREATMENT", 0, 3]]], ["Control piglets (treated with IgY from non-immunized hens) developed severe diarrhea within 12 h and 30% of the pigs died.", [["diarrhea", "DISEASE", 76, 84], ["piglets", "ORGANISM", 8, 15], ["pigs", "ORGANISM", 112, 116], ["IgY", "PROTEIN", 30, 33], ["piglets", "SPECIES", 8, 15], ["pigs", "SPECIES", 112, 116], ["pigs", "SPECIES", 112, 116], ["IgY", "TREATMENT", 30, 33], ["severe diarrhea", "PROBLEM", 69, 84], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["diarrhea", "OBSERVATION", 76, 84]]], ["In contrast, the pigs given IgY from immunized hens exhibited no signs of diarrhea when observed 24 and 48 h after treatment (Table 5) .", [["diarrhea", "DISEASE", 74, 82], ["pigs", "ORGANISM", 17, 21], ["IgY", "GENE_OR_GENE_PRODUCT", 28, 31], ["IgY", "PROTEIN", 28, 31], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 17, 21], ["the pigs", "TREATMENT", 13, 21], ["diarrhea", "PROBLEM", 74, 82], ["no signs of", "UNCERTAINTY", 62, 73], ["diarrhea", "OBSERVATION", 74, 82]]], ["Furthermore, the field study showed the suppression of the incidence and severity of diarrhea in 14-18-day-old weaned piglets fed specific IgY powder, which was much lower than in those fed a commercial diet containing an antibiotic.", [["diarrhea", "DISEASE", 85, 93], ["piglets", "ORGANISM", 118, 125], ["IgY", "ORGANISM", 139, 142], ["piglets", "SPECIES", 118, 125], ["the field study", "TEST", 13, 28], ["diarrhea", "PROBLEM", 85, 93], ["specific IgY powder", "TREATMENT", 130, 149], ["an antibiotic", "TREATMENT", 219, 232], ["diarrhea", "OBSERVATION", 85, 93]]], ["The number of pigs in this study was not large and it would be desirable to repeat this study with a greater number of animals.", [["pigs", "ORGANISM", 14, 18], ["pigs", "SPECIES", 14, 18], ["pigs", "SPECIES", 14, 18], ["this study", "TEST", 22, 32], ["this study", "TEST", 83, 93], ["pigs", "OBSERVATION", 14, 18], ["large", "OBSERVATION", 41, 46]]], ["Table 3 Investigations on the use of specific IgY in the control of non-enteric diseases.PathogensEffects of IgY Ref.Streptococcus mutansProtecting rats from S. mutans-induced dental caries Hamada et al. (1991) Snake \u204e p b 0.05 compared with no treatment in the same group. a Ten milliliters of IgY, at a concentration of 20 mg ml \u2212 1 , or penicillin, at a concentration of 100 mg ml \u2212 1 , were infused into the mammary glands immediately after the cow's morning and evening milking for six consecutive days. b Mammary glands selected for clinical mastitis treatment met the following criteria:Streptococcus mutansobvious clinical signs of mastitis were detected, S. aureus counts of the milk samples were 100-200 CFU ml \u2212 1 , somatic cell counts were more than 5 \u00d7 10 5 cells ml \u2212 1 . c Mammary glands selected for inducing experimental mastitis met the following criteria: no clinical signs of mastitis were detected, S. aureus counts of the milk were less than 10 CFU ml \u2212 1 and no other bacteria were detected, somatic cell counts were less than 1 \u00d7 10 5 CFU ml \u2212 1 .", [["mammary glands", "ANATOMY", 412, 426], ["Mammary glands", "ANATOMY", 511, 525], ["milk samples", "ANATOMY", 688, 700], ["somatic cell", "ANATOMY", 727, 739], ["cells", "ANATOMY", 771, 776], ["Mammary glands", "ANATOMY", 788, 802], ["milk", "ANATOMY", 944, 948], ["somatic cell", "ANATOMY", 1015, 1027], ["non-enteric diseases", "DISEASE", 68, 88], ["caries", "DISEASE", 183, 189], ["penicillin", "CHEMICAL", 340, 350], ["mastitis", "DISEASE", 548, 556], ["mastitis", "DISEASE", 640, 648], ["mastitis", "DISEASE", 838, 846], ["mastitis", "DISEASE", 896, 904], ["penicillin", "CHEMICAL", 340, 350], ["IgY", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgY", "GENE_OR_GENE_PRODUCT", 109, 112], ["Streptococcus mutans", "ORGANISM", 117, 137], ["rats", "ORGANISM", 148, 152], ["S. mutans", "ORGANISM", 158, 167], ["IgY", "GENE_OR_GENE_PRODUCT", 295, 298], ["penicillin", "SIMPLE_CHEMICAL", 340, 350], ["mammary glands", "ORGAN", 412, 426], ["Mammary glands", "ORGAN", 511, 525], ["Streptococcus mutansobvious", "ORGANISM", 594, 621], ["S. aureus", "ORGANISM", 664, 673], ["milk samples", "ORGANISM_SUBSTANCE", 688, 700], ["somatic cell", "CELL", 727, 739], ["Mammary glands", "ORGAN", 788, 802], ["S. aureus", "ORGANISM", 920, 929], ["milk", "ORGANISM_SUBSTANCE", 944, 948], ["somatic cell", "CELL", 1015, 1027], ["IgY", "PROTEIN", 46, 49], ["IgY Ref", "PROTEIN", 109, 116], ["IgY", "PROTEIN", 295, 298], ["Streptococcus mutans", "SPECIES", 117, 137], ["rats", "SPECIES", 148, 152], ["S. mutans", "SPECIES", 158, 167], ["cow", "SPECIES", 449, 452], ["S. aureus", "SPECIES", 664, 673], ["milk", "SPECIES", 688, 692], ["S. aureus", "SPECIES", 920, 929], ["milk", "SPECIES", 944, 948], ["Streptococcus mutans", "SPECIES", 117, 137], ["S. mutans", "SPECIES", 158, 167], ["cow", "SPECIES", 449, 452], ["S. aureus", "SPECIES", 664, 673], ["S. aureus", "SPECIES", 920, 929], ["specific IgY", "TREATMENT", 37, 49], ["non-enteric diseases", "PROBLEM", 68, 88], ["Streptococcus mutans", "PROBLEM", 117, 137], ["treatment", "TREATMENT", 245, 254], ["IgY", "TREATMENT", 295, 298], ["penicillin", "TREATMENT", 340, 350], ["clinical mastitis treatment", "TREATMENT", 539, 566], ["Streptococcus", "PROBLEM", 594, 607], ["mastitis", "PROBLEM", 640, 648], ["S. aureus counts", "TEST", 664, 680], ["the milk samples", "TEST", 684, 700], ["somatic cell counts", "TEST", 727, 746], ["experimental mastitis", "PROBLEM", 825, 846], ["mastitis", "PROBLEM", 896, 904], ["S. aureus counts", "TEST", 920, 936], ["the milk", "TEST", 940, 948], ["other bacteria", "PROBLEM", 985, 999], ["somatic cell counts", "TEST", 1015, 1034], ["non-enteric diseases", "OBSERVATION", 68, 88], ["mammary glands", "ANATOMY", 412, 426], ["glands", "ANATOMY", 519, 525], ["mastitis", "OBSERVATION", 640, 648], ["Mammary glands", "ANATOMY", 788, 802], ["mastitis", "OBSERVATION", 838, 846], ["mastitis", "OBSERVATION", 896, 904]]], ["Experimental mastitis was induced by mammary infusion with 10 7 CFU ml \u2212 1 of S. aureus. a All the 21-day-old piglets were challenged orally two times (at 0 and 5 h) with a dose of 10 12 CFU ml \u2212 1 of viable organism per piglet.", [["mammary", "ANATOMY", 37, 44], ["piglet", "ANATOMY", 221, 227], ["mastitis", "DISEASE", 13, 21], ["mammary", "ORGAN", 37, 44], ["S. aureus", "ORGANISM", 78, 87], ["piglets", "ORGANISM", 110, 117], ["piglet", "ORGANISM", 221, 227], ["S. aureus", "SPECIES", 78, 87], ["piglets", "SPECIES", 110, 117], ["S. aureus", "SPECIES", 78, 87], ["Experimental mastitis", "PROBLEM", 0, 21], ["mammary infusion", "TREATMENT", 37, 53], ["S. aureus", "PROBLEM", 78, 87], ["mastitis", "OBSERVATION", 13, 21], ["mammary", "ANATOMY", 37, 44], ["aureus", "OBSERVATION", 81, 87]]], ["Piglets in the E. coli challenged + IgY group were treated with 0.5 g of egg yolk antibodies, three times a day (\u2212 1, 4 and 9 h after the first ETEC challenge) for the first day and once a day for the next two days after the first ETEC challenge. b FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrhea; 3, severe diarrhea.", [["egg yolk", "ANATOMY", 73, 81], ["soft feces", "ANATOMY", 309, 319], ["diarrhea", "DISEASE", 329, 337], ["diarrhea", "DISEASE", 349, 357], ["Piglets", "ORGANISM", 0, 7], ["E. coli", "ORGANISM", 15, 22], ["IgY", "GENE_OR_GENE_PRODUCT", 36, 39], ["egg yolk antibodies", "PROTEIN", 73, 92], ["Piglets", "SPECIES", 0, 7], ["E. coli", "SPECIES", 15, 22], ["E. coli", "SPECIES", 15, 22], ["Piglets", "TREATMENT", 0, 7], ["the E. coli", "TREATMENT", 11, 22], ["IgY group", "TREATMENT", 36, 45], ["egg yolk antibodies", "TREATMENT", 73, 92], ["the first ETEC challenge", "TREATMENT", 221, 245], ["b FC score", "TEST", 247, 257], ["the mean fecal consistency score", "TEST", 261, 293], ["mild diarrhea", "PROBLEM", 324, 337], ["severe diarrhea", "PROBLEM", 342, 357], ["normal", "OBSERVATION", 298, 304], ["soft feces", "OBSERVATION_MODIFIER", 309, 319], ["mild", "OBSERVATION_MODIFIER", 324, 328], ["diarrhea", "OBSERVATION", 329, 337], ["severe", "OBSERVATION_MODIFIER", 342, 348], ["diarrhea", "OBSERVATION", 349, 357]]], ["Pigs with a fecal score of \u22641 were considered not to have diarrhea.Table 2Investigations on the use of specific IgY for the control of enteric diseases.", [["fecal", "ANATOMY", 12, 17], ["diarrhea", "DISEASE", 58, 66], ["enteric diseases", "DISEASE", 135, 151], ["Pigs", "ORGANISM", 0, 4], ["fecal", "ORGANISM_SUBSTANCE", 12, 17], ["IgY", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgY", "PROTEIN", 112, 115], ["Pigs", "SPECIES", 0, 4], ["a fecal score", "TEST", 10, 23], ["diarrhea", "PROBLEM", 58, 66], ["specific IgY", "TREATMENT", 103, 115], ["enteric diseases", "PROBLEM", 135, 151], ["enteric", "ANATOMY", 135, 142], ["diseases", "OBSERVATION", 143, 151]]], ["From Mine and Kovacs-Nolan (2002) .PathogensEffects of IgY Ref.RotavirusProtecting calves from bovine rotavirus-induced diarrhea Kuroki et al. (1994) Preventing murine rotavirus in mice Yolken et al. (1988) Preventing human rotavirus-induced gastroenteritis in mice Ebina (1996) Prevention and treatment of rotavirus-induced gastroenteritis in murine model Hatta et al. (1993) (1996) ETEC can cause severe diarrhea in young animals by proliferation in the small intestine and through the production of two types of enterotoxins including a heat-labile enterotoxin (LT) and a family of heat-stable enterotoxins (ST) that includes STa and STb (Dubreuil, 1997) .", [["small intestine", "ANATOMY", 456, 471], ["Rotavirus", "DISEASE", 63, 72], ["diarrhea", "DISEASE", 120, 128], ["rotavirus-induced gastroenteritis", "DISEASE", 224, 257], ["rotavirus-induced gastroenteritis", "DISEASE", 307, 340], ["ETEC", "CHEMICAL", 384, 388], ["diarrhea", "DISEASE", 406, 414], ["IgY", "GENE_OR_GENE_PRODUCT", 55, 58], ["Rotavirus", "ORGANISM", 63, 72], ["calves", "ORGANISM", 83, 89], ["bovine", "ORGANISM", 95, 101], ["rotavirus", "ORGANISM", 102, 111], ["murine", "ORGANISM", 161, 167], ["rotavirus", "ORGANISM", 168, 177], ["mice", "ORGANISM", 181, 185], ["human", "ORGANISM", 218, 223], ["rotavirus", "ORGANISM", 224, 233], ["mice", "ORGANISM", 261, 265], ["rotavirus", "ORGANISM", 307, 316], ["murine", "ORGANISM", 344, 350], ["small intestine", "ORGAN", 456, 471], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 552, 563], ["LT", "GENE_OR_GENE_PRODUCT", 565, 567], ["STa", "GENE_OR_GENE_PRODUCT", 629, 632], ["STb", "GENE_OR_GENE_PRODUCT", 637, 640], ["IgY Ref", "PROTEIN", 55, 62], ["enterotoxins", "PROTEIN", 515, 527], ["heat-labile enterotoxin", "PROTEIN", 540, 563], ["LT", "PROTEIN", 565, 567], ["enterotoxins", "PROTEIN", 597, 609], ["ST", "PROTEIN", 611, 613], ["calves", "SPECIES", 83, 89], ["bovine", "SPECIES", 95, 101], ["murine", "SPECIES", 161, 167], ["mice", "SPECIES", 181, 185], ["human", "SPECIES", 218, 223], ["mice", "SPECIES", 261, 265], ["murine", "SPECIES", 344, 350], ["Rotavirus", "SPECIES", 63, 72], ["mice", "SPECIES", 181, 185], ["human", "SPECIES", 218, 223], ["mice", "SPECIES", 261, 265], ["Rotavirus", "PROBLEM", 63, 72], ["bovine rotavirus", "PROBLEM", 95, 111], ["diarrhea", "PROBLEM", 120, 128], ["human rotavirus", "PROBLEM", 218, 233], ["gastroenteritis", "PROBLEM", 242, 257], ["treatment", "TREATMENT", 294, 303], ["rotavirus", "PROBLEM", 307, 316], ["gastroenteritis", "PROBLEM", 325, 340], ["ETEC", "PROBLEM", 384, 388], ["severe diarrhea", "PROBLEM", 399, 414], ["proliferation in the small intestine", "PROBLEM", 435, 471], ["enterotoxins", "PROBLEM", 515, 527], ["a heat-labile enterotoxin", "PROBLEM", 538, 563], ["gastroenteritis", "OBSERVATION", 325, 340], ["severe", "OBSERVATION_MODIFIER", 399, 405], ["diarrhea", "OBSERVATION", 406, 414], ["small intestine", "ANATOMY", 456, 471]]], ["These enterotoxins are crucial virulence factors and therefore effective programs for immunological protection against ETECmediated diarrhea should include antitoxic immunity (Cardenas and Clements, 1993) .", [["diarrhea", "DISEASE", 132, 140], ["enterotoxins", "PROTEIN", 6, 18], ["virulence factors", "PROTEIN", 31, 48], ["These enterotoxins", "PROBLEM", 0, 18], ["crucial virulence factors", "PROBLEM", 23, 48], ["effective programs", "TREATMENT", 63, 81], ["immunological protection", "TREATMENT", 86, 110], ["ETECmediated diarrhea", "PROBLEM", 119, 140]]], ["Because of their small size, enterotoxins STa and STb are poorly immunogenic, but they can attain immunogenicity when coupled chemically or genetically to an appropriate carrier (Clements, 1990; Dubreuil et al., 1996) .RotavirusAntitoxinic antibodies were shown to be important in the prevention of E. coli-induced diarrhea.", [["STa", "CHEMICAL", 42, 45], ["STb", "CHEMICAL", 50, 53], ["diarrhea", "DISEASE", 315, 323], ["STa", "GENE_OR_GENE_PRODUCT", 42, 45], ["STb", "GENE_OR_GENE_PRODUCT", 50, 53], ["Rotavirus", "ORGANISM", 219, 228], ["enterotoxins", "PROTEIN", 29, 41], ["STb", "PROTEIN", 50, 53], ["RotavirusAntitoxinic antibodies", "PROTEIN", 219, 250], ["Rotavirus", "SPECIES", 219, 228], ["E. coli-induced diarrhea", "SPECIES", 299, 323], ["their small size", "PROBLEM", 11, 27], ["enterotoxins STa", "PROBLEM", 29, 45], ["STb", "PROBLEM", 50, 53], ["poorly immunogenic", "PROBLEM", 58, 76], ["RotavirusAntitoxinic antibodies", "TREATMENT", 219, 250], ["E. coli-induced diarrhea", "PROBLEM", 299, 323], ["small", "OBSERVATION_MODIFIER", 17, 22], ["size", "OBSERVATION_MODIFIER", 23, 27], ["poorly immunogenic", "OBSERVATION_MODIFIER", 58, 76], ["coli-induced", "OBSERVATION_MODIFIER", 302, 314], ["diarrhea", "OBSERVATION", 315, 323]]], ["Considering the limited number of classes of enterotoxins, enterotoxin-based vaccines should provide broad-spectrum protection against various ETEC.", [["enterotoxin", "CHEMICAL", 59, 70], ["ETEC", "DISEASE", 143, 147], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 59, 70], ["enterotoxins", "PROTEIN", 45, 57], ["enterotoxin", "PROTEIN", 59, 70], ["ETEC", "SPECIES", 143, 147], ["enterotoxins", "PROBLEM", 45, 57], ["enterotoxin-based vaccines", "TREATMENT", 59, 85], ["broad-spectrum protection", "TREATMENT", 101, 126], ["various ETEC", "PROBLEM", 135, 147]]], ["In order to make the useful toxoids, polyvalent enterotoxin STa-LTB-STb DNA and protein vaccines endowing immunogenicity to both STa and STb were constructed .", [["STa", "CHEMICAL", 60, 63], ["STa", "GENE_OR_GENE_PRODUCT", 60, 63], ["STb", "ORGANISM", 68, 71], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["STa", "GENE_OR_GENE_PRODUCT", 129, 132], ["STb", "GENE_OR_GENE_PRODUCT", 137, 140], ["polyvalent enterotoxin STa-LTB-STb DNA", "DNA", 37, 75], ["STa", "DNA", 129, 132], ["STb", "DNA", 137, 140], ["the useful toxoids", "TREATMENT", 17, 35], ["polyvalent enterotoxin STa", "TREATMENT", 37, 63], ["LTB", "TEST", 64, 67], ["STb DNA", "TREATMENT", 68, 75], ["protein vaccines", "TREATMENT", 80, 96]]], ["We immunized laying hens with DNA vaccines and obtained antitoxic antibodies from egg yolks and this was confirmed by indirect ELISA.", [["egg yolks", "ANATOMY", 82, 91], ["hens", "ORGANISM", 20, 24], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["egg yolks", "ORGANISM_SUBSTANCE", 82, 91], ["antitoxic antibodies", "PROTEIN", 56, 76], ["DNA vaccines", "TREATMENT", 30, 42], ["antitoxic antibodies", "TREATMENT", 56, 76], ["egg yolks", "TREATMENT", 82, 91]]], ["The polyvalent DNA vaccine pCI-STa-LTB-STb expressed the STa-LTB-STb fusion peptide in vitro in cultured Hela cells.", [["Hela cells", "ANATOMY", 105, 115], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["STa", "GENE_OR_GENE_PRODUCT", 57, 60], ["LTB", "GENE_OR_GENE_PRODUCT", 61, 64], ["STb", "GENE_OR_GENE_PRODUCT", 65, 68], ["Hela cells", "CELL", 105, 115], ["pCI", "PROTEIN", 27, 30], ["STa-LTB", "DNA", 31, 38], ["STb", "DNA", 39, 42], ["STa", "PROTEIN", 57, 60], ["LTB", "PROTEIN", 61, 64], ["STb", "PROTEIN", 65, 68], ["cultured Hela cells", "CELL_LINE", 96, 115], ["The polyvalent DNA vaccine pCI", "TREATMENT", 0, 30], ["STa-LTB", "TEST", 31, 38], ["STb", "PROBLEM", 39, 42], ["the STa", "TEST", 53, 60], ["LTB", "PROBLEM", 61, 64], ["STb fusion peptide", "TREATMENT", 65, 83], ["vitro in cultured Hela cells", "TREATMENT", 87, 115], ["LTB", "ANATOMY", 61, 64], ["Hela cells", "OBSERVATION", 105, 115]]], ["These egg yolk antibodies were able to neutralize the biological activity of ST and LT (You, 2011) .", [["egg yolk", "ANATOMY", 6, 14], ["egg yolk", "ORGANISM_SUBSTANCE", 6, 14], ["egg yolk antibodies", "PROTEIN", 6, 25], ["These egg yolk antibodies", "TEST", 0, 25], ["LT", "ANATOMY", 84, 86]]], ["Therefore, the trivalent fusion enterotoxin STa-LTB-STb has the potential to serve as a useful toxin-based vaccine which can provide broad protection against ETEC-induced diarrhea.Diarrhea in calvesNeonatal calf diarrhea caused by bovine rotavirus (BRV) is a common disease and causes high mortality in cattle (Lee et al., 1995) .", [["STa-", "CHEMICAL", 44, 48], ["STb", "CHEMICAL", 52, 55], ["ETEC", "CHEMICAL", 158, 162], ["diarrhea", "DISEASE", 171, 179], ["Diarrhea", "DISEASE", 180, 188], ["Neonatal calf diarrhea", "DISEASE", 198, 220], ["bovine rotavirus (BRV)", "DISEASE", 231, 253], ["STa-LTB-STb", "SIMPLE_CHEMICAL", 44, 55], ["ETEC", "ORGANISM", 158, 162], ["calves", "ORGANISM", 192, 198], ["calf", "ORGANISM_SUBDIVISION", 207, 211], ["bovine rotavirus", "ORGANISM", 231, 247], ["cattle", "ORGANISM", 303, 309], ["LTB", "PROTEIN", 48, 51], ["STb", "PROTEIN", 52, 55], ["calves", "SPECIES", 192, 198], ["calf", "SPECIES", 207, 211], ["bovine", "SPECIES", 231, 237], ["rotavirus", "SPECIES", 238, 247], ["cattle", "SPECIES", 303, 309], ["ETEC", "SPECIES", 158, 162], ["bovine rotavirus", "SPECIES", 231, 247], ["BRV", "SPECIES", 249, 252], ["cattle", "SPECIES", 303, 309], ["the trivalent fusion enterotoxin", "TREATMENT", 11, 43], ["a useful toxin-based vaccine", "TREATMENT", 86, 114], ["ETEC", "PROBLEM", 158, 162], ["diarrhea", "PROBLEM", 171, 179], ["Diarrhea", "PROBLEM", 180, 188], ["Neonatal calf diarrhea", "PROBLEM", 198, 220], ["bovine rotavirus (BRV", "PROBLEM", 231, 252], ["a common disease", "PROBLEM", 257, 273], ["diarrhea", "OBSERVATION", 171, 179], ["calf", "ANATOMY", 207, 211], ["diarrhea", "OBSERVATION", 212, 220], ["bovine rotavirus", "OBSERVATION", 231, 247], ["common", "OBSERVATION_MODIFIER", 259, 265], ["disease", "OBSERVATION", 266, 273], ["high", "OBSERVATION_MODIFIER", 285, 289], ["mortality", "OBSERVATION_MODIFIER", 290, 299]]], ["Anti-BRV IgY has been shown to successfully provide protection against BRV infection in calves (Kuroki et al., 1994) .Diarrhea in calvesBovine corona virus (BCV) is an important enteric pathogen that is responsible for both neonatal calf diarrhea and acute diarrhea in adult cattle.", [["BRV infection", "DISEASE", 71, 84], ["Diarrhea", "DISEASE", 118, 126], ["diarrhea", "DISEASE", 238, 246], ["diarrhea", "DISEASE", 257, 265], ["IgY", "GENE_OR_GENE_PRODUCT", 9, 12], ["BRV", "CANCER", 71, 74], ["calves", "ORGANISM", 88, 94], ["calves", "ORGANISM", 130, 136], ["Bovine corona virus", "ORGANISM", 136, 155], ["BCV", "ORGANISM", 157, 160], ["calf", "ORGANISM_SUBDIVISION", 233, 237], ["cattle", "ORGANISM", 275, 281], ["Anti-BRV IgY", "PROTEIN", 0, 12], ["calves", "SPECIES", 88, 94], ["calves", "SPECIES", 130, 136], ["Bovine corona virus", "SPECIES", 136, 155], ["calf", "SPECIES", 233, 237], ["cattle", "SPECIES", 275, 281], ["Anti-BRV", "SPECIES", 0, 8], ["BRV", "SPECIES", 71, 74], ["calves", "SPECIES", 88, 94], ["Bovine corona virus", "SPECIES", 136, 155], ["BCV", "SPECIES", 157, 160], ["cattle", "SPECIES", 275, 281], ["Anti-BRV IgY", "TREATMENT", 0, 12], ["BRV infection in calves", "PROBLEM", 71, 94], ["Diarrhea in calvesBovine corona virus", "PROBLEM", 118, 155], ["an important enteric pathogen", "PROBLEM", 165, 194], ["neonatal calf diarrhea", "PROBLEM", 224, 246], ["acute diarrhea", "PROBLEM", 251, 265], ["infection", "OBSERVATION", 75, 84], ["corona virus", "OBSERVATION", 143, 155], ["pathogen", "OBSERVATION", 186, 194], ["responsible for", "UNCERTAINTY", 203, 218], ["calf", "ANATOMY", 233, 237], ["diarrhea", "OBSERVATION", 238, 246], ["acute", "OBSERVATION_MODIFIER", 251, 256], ["diarrhea", "OBSERVATION", 257, 265]]], ["BCV may be more severe than BRV as it replicates in the epithelium of both the small and large intestine whereas BRV infects only the small intestine.", [["epithelium", "ANATOMY", 56, 66], ["intestine", "ANATOMY", 95, 104], ["small intestine", "ANATOMY", 134, 149], ["BCV", "ORGANISM", 0, 3], ["epithelium", "TISSUE", 56, 66], ["intestine", "ORGAN", 95, 104], ["small intestine", "ORGAN", 134, 149], ["BCV", "SPECIES", 0, 3], ["BRV", "SPECIES", 28, 31], ["BRV", "SPECIES", 113, 116], ["may be", "UNCERTAINTY", 4, 10], ["more severe", "OBSERVATION_MODIFIER", 11, 22], ["epithelium", "ANATOMY_MODIFIER", 56, 66], ["both", "ANATOMY_MODIFIER", 70, 74], ["small", "ANATOMY_MODIFIER", 79, 84], ["large intestine", "ANATOMY", 89, 104], ["BRV infects", "OBSERVATION", 113, 124], ["small intestine", "ANATOMY", 134, 149]]], ["Ikemori et al. (1997) examined the efficacy of specific IgY antibodies and cow colostrum antibodies to BCV-induced diarrhea in calves.", [["diarrhea", "DISEASE", 115, 123], ["IgY", "ORGANISM", 56, 59], ["cow", "ORGANISM", 75, 78], ["colostrum", "ORGANISM_SUBSTANCE", 79, 88], ["BCV", "ORGANISM", 103, 106], ["calves", "ORGANISM", 127, 133], ["IgY antibodies", "PROTEIN", 56, 70], ["cow colostrum antibodies", "PROTEIN", 75, 99], ["cow", "SPECIES", 75, 78], ["calves", "SPECIES", 127, 133], ["cow", "SPECIES", 75, 78], ["BCV", "SPECIES", 103, 106], ["specific IgY antibodies", "TEST", 47, 70], ["cow colostrum antibodies", "TEST", 75, 99], ["BCV", "TEST", 103, 106], ["diarrhea in calves", "PROBLEM", 115, 133], ["diarrhea", "OBSERVATION", 115, 123], ["calves", "ANATOMY", 127, 133]]], ["They found that control calves which received no antibodies developed severe diarrhea resulting in all calves dying within 6 days of BCV challenge whereas calves treated with milk containing egg yolk or colostrum had positive weight gains and none of these calves died (Table 6 ).", [["milk", "ANATOMY", 175, 179], ["egg yolk", "ANATOMY", 191, 199], ["colostrum", "ANATOMY", 203, 212], ["diarrhea", "DISEASE", 77, 85], ["weight gains", "DISEASE", 226, 238], ["calves", "ORGANISM", 24, 30], ["calves", "ORGANISM", 103, 109], ["BCV", "ORGANISM", 133, 136], ["calves", "ORGANISM", 155, 161], ["milk", "ORGANISM_SUBSTANCE", 175, 179], ["egg yolk", "ORGANISM_SUBSTANCE", 191, 199], ["colostrum", "ORGANISM_SUBSTANCE", 203, 212], ["calves", "ORGANISM", 257, 263], ["antibodies", "PROTEIN", 49, 59], ["calves", "SPECIES", 24, 30], ["calves", "SPECIES", 103, 109], ["calves", "SPECIES", 155, 161], ["milk", "SPECIES", 175, 179], ["calves", "SPECIES", 257, 263], ["BCV", "SPECIES", 133, 136], ["calves", "SPECIES", 155, 161], ["antibodies", "PROBLEM", 49, 59], ["severe diarrhea", "PROBLEM", 70, 85], ["BCV challenge", "TREATMENT", 133, 146], ["positive weight gains", "PROBLEM", 217, 238], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["diarrhea", "OBSERVATION", 77, 85]]], ["This study was conducted with very few animals and a larger study should be conducted to confirm these findings.", [["This study", "TEST", 0, 10], ["a larger study", "TEST", 51, 65]]], ["However, these results do indicate that orally administered egg yolk or colostral antibodies have the potential to passively protect calves against BCV infection and the effect of IgY was higher than that of colostrum alone indicating that the passive immunization strategy with IgY provided a more efficacious alternative to existing treatments for BCV.", [["egg yolk", "ANATOMY", 60, 68], ["colostrum", "ANATOMY", 208, 217], ["BCV infection", "DISEASE", 148, 161], ["egg yolk", "ORGANISM_SUBSTANCE", 60, 68], ["colostral antibodies", "GENE_OR_GENE_PRODUCT", 72, 92], ["calves", "ORGANISM", 133, 139], ["BCV", "ORGANISM", 148, 151], ["IgY", "GENE_OR_GENE_PRODUCT", 180, 183], ["colostrum", "ORGANISM_SUBSTANCE", 208, 217], ["BCV", "ORGANISM", 350, 353], ["colostral antibodies", "PROTEIN", 72, 92], ["IgY", "PROTEIN", 180, 183], ["IgY", "PROTEIN", 279, 282], ["calves", "SPECIES", 133, 139], ["calves", "SPECIES", 133, 139], ["BCV", "SPECIES", 148, 151], ["BCV", "SPECIES", 350, 353], ["orally administered egg yolk", "TREATMENT", 40, 68], ["colostral antibodies", "PROBLEM", 72, 92], ["BCV infection", "PROBLEM", 148, 161], ["IgY", "TREATMENT", 180, 183], ["the passive immunization strategy", "TREATMENT", 240, 273], ["IgY", "TREATMENT", 279, 282], ["existing treatments", "TREATMENT", 326, 345], ["BCV", "PROBLEM", 350, 353], ["infection", "OBSERVATION", 152, 161]]], ["The passive protective effects of using anti-ETEC IgY administration on fatal enteric colibacillosis in neonatal calves have also been studied .", [["enteric colibacillosis", "DISEASE", 78, 100], ["anti-ETEC IgY", "GENE_OR_GENE_PRODUCT", 40, 53], ["calves", "ORGANISM", 113, 119], ["anti-ETEC IgY", "PROTEIN", 40, 53], ["calves", "SPECIES", 113, 119], ["The passive protective effects", "TREATMENT", 0, 30], ["anti-ETEC IgY administration", "TREATMENT", 40, 68], ["fatal enteric colibacillosis in neonatal calves", "TREATMENT", 72, 119], ["passive protective", "OBSERVATION_MODIFIER", 4, 22], ["colibacillosis", "OBSERVATION", 86, 100]]], ["Calves fed milk containing IgY had only transient diarrhea, 100% survival and exhibited good body weight gains during the course of the study.", [["milk", "ANATOMY", 11, 15], ["body", "ANATOMY", 93, 97], ["diarrhea", "DISEASE", 50, 58], ["Calves", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 11, 15], ["IgY", "ORGANISM_SUBSTANCE", 27, 30], ["body", "ORGANISM_SUBDIVISION", 93, 97], ["IgY", "PROTEIN", 27, 30], ["Calves", "SPECIES", 0, 6], ["milk", "SPECIES", 11, 15], ["Calves", "SPECIES", 0, 6], ["transient diarrhea", "PROBLEM", 40, 58], ["the study", "TEST", 132, 141], ["transient", "OBSERVATION_MODIFIER", 40, 49], ["diarrhea", "OBSERVATION", 50, 58]]], ["In contrast, the controls which received no antibody had severe diarrhea and all died within 6 days of infection.SalmonellosisSalmonella infections are thought to be responsible for a variety of acute and chronic diseases of poultry.", [["diarrhea", "DISEASE", 64, 72], ["infection", "DISEASE", 103, 112], ["Salmonellosis", "CHEMICAL", 113, 126], ["Salmonella infections", "DISEASE", 126, 147], ["SalmonellosisSalmonella", "ORGANISM", 113, 136], ["Salmonella", "SPECIES", 126, 136], ["severe diarrhea", "PROBLEM", 57, 72], ["infection", "PROBLEM", 103, 112], ["SalmonellosisSalmonella infections", "PROBLEM", 113, 147], ["acute and chronic diseases of poultry", "PROBLEM", 195, 232], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["diarrhea", "OBSERVATION", 64, 72], ["infection", "OBSERVATION", 103, 112], ["infections", "OBSERVATION", 137, 147], ["thought to be responsible for", "UNCERTAINTY", 152, 181], ["variety", "OBSERVATION_MODIFIER", 184, 191], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["chronic", "OBSERVATION_MODIFIER", 205, 212], ["diseases", "OBSERVATION", 213, 221], ["poultry", "OBSERVATION_MODIFIER", 225, 232]]], ["It has been shown that specific IgY against Salmonella enteritidis or Salmonella typhimurium inhibits bacterial growth in vitro .", [["Salmonella enteritidis", "DISEASE", 44, 66], ["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["Salmonella enteritidis", "ORGANISM", 44, 66], ["Salmonella typhimurium", "ORGANISM", 70, 92], ["IgY", "PROTEIN", 32, 35], ["Salmonella enteritidis", "SPECIES", 44, 66], ["Salmonella typhimurium", "SPECIES", 70, 92], ["Salmonella enteritidis", "SPECIES", 44, 66], ["Salmonella typhimurium", "SPECIES", 70, 92], ["Salmonella enteritidis", "PROBLEM", 44, 66], ["Salmonella typhimurium", "PROBLEM", 70, 92], ["bacterial growth in vitro", "PROBLEM", 102, 127], ["bacterial", "OBSERVATION_MODIFIER", 102, 111], ["growth", "OBSERVATION_MODIFIER", 112, 118]]], ["Studies have demonstrated that egg derived anti-S. entritidis IgY antibody had a beneficial effect in reducing the colonization of Salmonella in market-aged broilers (Rahimi et al., 2007b; Tellez et al., 2001) (Table 7) .", [["egg", "ORGANISM_SUBDIVISION", 31, 34], ["anti-S. entritidis", "ORGANISM", 43, 61], ["IgY", "ORGANISM", 62, 65], ["broilers", "ORGANISM", 157, 165], ["egg derived anti-S. entritidis IgY antibody", "PROTEIN", 31, 74], ["anti-S. entritidis", "SPECIES", 43, 61], ["broilers", "SPECIES", 157, 165], ["anti-S. entritidis", "SPECIES", 43, 61], ["Salmonella", "SPECIES", 131, 141], ["Studies", "TEST", 0, 7], ["egg", "TEST", 31, 34], ["anti-S. entritidis IgY antibody", "TEST", 43, 74]]], ["Whether or not this translates into improvements in broiler performance has not been determined.SalmonellosisThe use of whole egg powder (containing antibody) as a feed additive may be an alternative way to reduce the rate of Salmonella contamination of eggs.", [["eggs", "ANATOMY", 254, 258], ["Salmonellosis", "DISEASE", 96, 109], ["egg powder", "ORGANISM_SUBSTANCE", 126, 136], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 254, 258], ["Salmonella", "SPECIES", 226, 236], ["broiler performance", "TEST", 52, 71], ["Salmonellosis", "TREATMENT", 96, 109], ["whole egg powder (containing antibody", "TREATMENT", 120, 157], ["a feed additive", "TREATMENT", 162, 177], ["Salmonella contamination of eggs", "PROBLEM", 226, 258]]], ["Gurtler et al. (2004) found that in the experimental group, 13.3% of the eggs were Salmonella positive, which was significantly lower than the 29.4% Salmonella-positive eggs in the control group (p \u2264 0.001) (Table 8) .", [["eggs", "ANATOMY", 73, 77], ["eggs", "ANATOMY", 169, 173], ["eggs", "ORGANISM", 73, 77], ["Salmonella", "SPECIES", 83, 93], ["the eggs", "TEST", 69, 77], ["Salmonella positive", "PROBLEM", 83, 102], ["Salmonella", "TEST", 149, 159]]], ["However, it must be pointed out that the majority of the Salmonella was found on the shell and there were only modest differences in Salmonella numbers in the albumen and yolk.", [["albumen", "ANATOMY", 159, 166], ["yolk", "ANATOMY", 171, 175], ["Salmonella", "ORGANISM", 57, 67], ["albumen", "ORGANISM_SUBSTANCE", 159, 166], ["yolk", "ORGANISM_SUBSTANCE", 171, 175], ["Salmonella", "SPECIES", 57, 67], ["Salmonella", "SPECIES", 133, 143], ["the Salmonella", "PROBLEM", 53, 67], ["modest differences in Salmonella numbers", "PROBLEM", 111, 151], ["Salmonella", "OBSERVATION", 57, 67], ["modest", "OBSERVATION_MODIFIER", 111, 117], ["differences", "OBSERVATION_MODIFIER", 118, 129], ["Salmonella numbers", "OBSERVATION", 133, 151]]], ["Whether or not this translates into any less health risk for consumers of egg products is not known at this time.CampylobacteriosisCampylobacter jejuni has become a major concern to the commercial broiler, turkey and commercial egg-producing f locks in all countries.", [["Campylobacter jejuni", "DISEASE", 131, 151], ["egg", "ORGANISM", 74, 77], ["Campylobacteriosis", "ORGANISM", 113, 131], ["Campylobacter jejuni", "ORGANISM", 131, 151], ["turkey", "ORGANISM", 206, 212], ["egg", "ORGANISM_SUBDIVISION", 228, 231], ["Campylobacter jejuni", "SPECIES", 131, 151], ["turkey", "SPECIES", 206, 212], ["Campylobacter jejuni", "SPECIES", 131, 151], ["turkey", "SPECIES", 206, 212], ["egg products", "TREATMENT", 74, 86], ["CampylobacteriosisCampylobacter jejuni", "PROBLEM", 113, 151], ["Campylobacter jejuni", "OBSERVATION", 131, 151]]], ["Tsubokura et al. (1997) used egg yolk antibodies for prophylactic and therapeutic applications in Campylobacter-infected chickens.", [["egg yolk", "ANATOMY", 29, 37], ["Campylobacter-infected", "DISEASE", 98, 120], ["chickens", "ORGANISM", 121, 129], ["egg yolk antibodies", "PROTEIN", 29, 48], ["chickens", "SPECIES", 121, 129], ["chickens", "SPECIES", 121, 129], ["egg yolk antibodies", "TREATMENT", 29, 48], ["prophylactic", "TREATMENT", 53, 65], ["therapeutic applications", "TREATMENT", 70, 94], ["Campylobacter", "PROBLEM", 98, 111], ["infected chickens", "PROBLEM", 112, 129], ["infected chickens", "OBSERVATION", 112, 129]]], ["In a prophylaxis experiment, it was found that these antibodies caused a 99% decrease in the number of Campylobacter observed, whereas in a therapy trial (antibodies were given after establishment of the infection), the number of bacteria in the feces was 80-95% lower.", [["feces", "ANATOMY", 246, 251], ["infection", "DISEASE", 204, 213], ["feces", "ORGANISM_SUBDIVISION", 246, 251], ["antibodies", "PROTEIN", 53, 63], ["antibodies", "PROTEIN", 155, 165], ["a prophylaxis experiment", "TREATMENT", 3, 27], ["these antibodies", "TEST", 47, 63], ["a 99% decrease", "PROBLEM", 71, 85], ["Campylobacter", "PROBLEM", 103, 116], ["a therapy trial (antibodies", "TREATMENT", 138, 165], ["the infection", "PROBLEM", 200, 213], ["bacteria", "PROBLEM", 230, 238], ["decrease", "OBSERVATION_MODIFIER", 77, 85], ["Campylobacter", "OBSERVATION", 103, 116], ["infection", "OBSERVATION", 204, 213], ["bacteria", "OBSERVATION_MODIFIER", 230, 238], ["feces", "ANATOMY", 246, 251]]], ["Unfortunately, bird performance was not monitored in this study.Infectious bursal diseaseInfectious bursal disease (IBD) is an acute, highly contagious disease of young chickens caused by IBD virus (Chettle et al., 1989) .", [["bursal", "ANATOMY", 75, 81], ["bursal", "ANATOMY", 100, 106], ["bursal diseaseInfectious bursal disease", "DISEASE", 75, 114], ["IBD", "DISEASE", 116, 119], ["chickens", "ORGANISM", 169, 177], ["chickens", "SPECIES", 169, 177], ["Infectious bursal diseaseInfectious bursal disease (IBD)", "SPECIES", 64, 120], ["chickens", "SPECIES", 169, 177], ["IBD virus", "SPECIES", 188, 197], ["bird performance", "TEST", 15, 31], ["this study", "TEST", 53, 63], ["Infectious bursal diseaseInfectious bursal disease (IBD", "PROBLEM", 64, 119], ["highly contagious disease", "PROBLEM", 134, 159], ["young chickens", "PROBLEM", 163, 177], ["IBD virus", "PROBLEM", 188, 197], ["bursal", "ANATOMY", 100, 106], ["disease", "OBSERVATION", 107, 114], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["highly", "OBSERVATION_MODIFIER", 134, 140], ["contagious", "OBSERVATION_MODIFIER", 141, 151], ["young chickens", "OBSERVATION", 163, 177], ["IBD virus", "OBSERVATION", 188, 197]]], ["Early sub-clinical infections which usually result in immunosuppression are the most important form of this disease because of the large economic loss that results from their presence.", [["infections", "DISEASE", 19, 29], ["Early sub-clinical infections", "PROBLEM", 0, 29], ["immunosuppression", "TREATMENT", 54, 71], ["this disease", "PROBLEM", 103, 115], ["the large economic loss", "PROBLEM", 127, 150], ["sub-", "OBSERVATION_MODIFIER", 6, 10], ["infections", "OBSERVATION", 19, 29], ["large", "OBSERVATION_MODIFIER", 131, 136], ["economic loss", "OBSERVATION", 137, 150]]], ["Chickens immunosuppressed by early IBD infections do not respond well to vaccination Table 6 Clinical response of calves to challenge exposure with bovine coronavirus and subsequent treatment with egg yolk powder.", [["yolk", "ANATOMY", 201, 205], ["IBD infections", "DISEASE", 35, 49], ["Chickens", "ORGANISM", 0, 8], ["calves", "ORGANISM", 114, 120], ["bovine", "ORGANISM", 148, 154], ["coronavirus", "ORGANISM", 155, 166], ["egg yolk powder", "ORGANISM_SUBSTANCE", 197, 212], ["Chickens", "SPECIES", 0, 8], ["calves", "SPECIES", 114, 120], ["bovine", "SPECIES", 148, 154], ["Chickens", "SPECIES", 0, 8], ["calves", "SPECIES", 114, 120], ["bovine coronavirus", "SPECIES", 148, 166], ["Chickens immunosuppressed", "PROBLEM", 0, 25], ["early IBD infections", "PROBLEM", 29, 49], ["vaccination Table", "TREATMENT", 73, 90], ["bovine coronavirus", "TREATMENT", 148, 166], ["subsequent treatment", "TREATMENT", 171, 191], ["egg yolk powder", "TREATMENT", 197, 212], ["early", "OBSERVATION_MODIFIER", 29, 34], ["IBD", "OBSERVATION", 35, 38]]], ["From Ikemori et al. (1997) . and show increased susceptibility to other diseases such as bacterial infection with E. coli or viral infections like bronchitis or inclusion body hepatitis (Muhammad et al., 1996) .", [["body", "ANATOMY", 171, 175], ["bacterial infection", "DISEASE", 89, 108], ["viral infections", "DISEASE", 125, 141], ["bronchitis", "DISEASE", 147, 157], ["inclusion body hepatitis", "DISEASE", 161, 185], ["E. coli", "ORGANISM", 114, 121], ["body", "ORGANISM_SUBDIVISION", 171, 175], ["E. coli", "SPECIES", 114, 121], ["E. coli", "SPECIES", 114, 121], ["increased susceptibility to other diseases", "PROBLEM", 38, 80], ["bacterial infection", "PROBLEM", 89, 108], ["E. coli", "PROBLEM", 114, 121], ["viral infections", "PROBLEM", 125, 141], ["bronchitis", "PROBLEM", 147, 157], ["inclusion body hepatitis", "PROBLEM", 161, 185], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["susceptibility", "OBSERVATION_MODIFIER", 48, 62], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["infection", "OBSERVATION", 99, 108], ["E. coli", "OBSERVATION_MODIFIER", 114, 121], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infections", "OBSERVATION", 131, 141], ["bronchitis", "OBSERVATION", 147, 157], ["body hepatitis", "OBSERVATION", 171, 185]]], ["Antibiotic therapy is the most readily-available approach for controlling IBD-induced secondary bacterial infections in affected flocks.", [["IBD", "DISEASE", 74, 77], ["bacterial infections", "DISEASE", 96, 116], ["Antibiotic therapy", "TREATMENT", 0, 18], ["controlling IBD", "PROBLEM", 62, 77], ["secondary bacterial infections", "PROBLEM", 86, 116], ["affected flocks", "PROBLEM", 120, 135], ["secondary", "OBSERVATION_MODIFIER", 86, 95], ["bacterial infections", "OBSERVATION", 96, 116], ["affected flocks", "OBSERVATION", 120, 135]]], ["It has been shown that specific IgY has a great potential as an alternative to antibiotics for IBD.", [["IBD", "DISEASE", 95, 98], ["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgY", "PROTEIN", 32, 35], ["antibiotics", "TREATMENT", 79, 90], ["IBD", "PROBLEM", 95, 98]]], ["Muhammad et al. (2001) demonstrated that yolks from hyperimmunized hens can be used to control IBD in commercial laying hens.", [["yolks", "ANATOMY", 41, 46], ["IBD", "DISEASE", 95, 98], ["yolks", "ORGANISM_SUBSTANCE", 41, 46], ["hens", "ORGANISM", 67, 71], ["hyperimmunized hens", "TREATMENT", 52, 71]]], ["The IBD infected broilers (28 days old) treated with the yolk induced 80% recovery while all the control (untreated) birds died.Newcastle diseaseNewcastle disease is a severe viral infection causing a respiratory nervous disorder in several species of poultry including chickens and turkeys.", [["yolk", "ANATOMY", 57, 61], ["respiratory nervous", "ANATOMY", 201, 220], ["IBD infected", "DISEASE", 4, 16], ["Newcastle diseaseNewcastle disease", "DISEASE", 128, 162], ["viral infection", "DISEASE", 175, 190], ["respiratory nervous disorder", "DISEASE", 201, 229], ["broilers", "ORGANISM", 17, 25], ["yolk", "ORGANISM_SUBSTANCE", 57, 61], ["birds", "ORGANISM", 117, 122], ["Newcastle diseaseNewcastle", "ORGANISM", 128, 154], ["nervous", "ANATOMICAL_SYSTEM", 213, 220], ["poultry", "ORGANISM_SUBDIVISION", 252, 259], ["chickens", "ORGANISM", 270, 278], ["turkeys", "ORGANISM", 283, 290], ["broilers", "SPECIES", 17, 25], ["poultry", "SPECIES", 252, 259], ["chickens", "SPECIES", 270, 278], ["turkeys", "SPECIES", 283, 290], ["broilers", "SPECIES", 17, 25], ["Newcastle diseaseNewcastle", "SPECIES", 128, 154], ["poultry", "SPECIES", 252, 259], ["chickens", "SPECIES", 270, 278], ["turkeys", "SPECIES", 283, 290], ["The IBD infected broilers", "PROBLEM", 0, 25], ["the yolk", "TREATMENT", 53, 61], ["Newcastle diseaseNewcastle disease", "PROBLEM", 128, 162], ["a severe viral infection", "PROBLEM", 166, 190], ["a respiratory nervous disorder", "PROBLEM", 199, 229], ["IBD", "OBSERVATION_MODIFIER", 4, 7], ["infected", "OBSERVATION", 8, 16], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["viral", "OBSERVATION_MODIFIER", 175, 180], ["infection", "OBSERVATION", 181, 190], ["respiratory nervous disorder", "OBSERVATION", 201, 229]]], ["This disease is endemic in commercial poultry from many countries and can cause great economic loss due to high mortality rates (Lancaster, 1976) .", [["This disease", "PROBLEM", 0, 12], ["great economic loss", "PROBLEM", 80, 99], ["high mortality rates", "PROBLEM", 107, 127], ["disease", "OBSERVATION", 5, 12], ["endemic", "OBSERVATION_MODIFIER", 16, 23]]], ["Vaccination has been used to prevent this disease in endemic areas, but vaccines are not always effective and vaccinated flocks may still be infected.", [["Vaccination", "TREATMENT", 0, 11], ["this disease in endemic areas", "PROBLEM", 37, 66], ["vaccines", "TREATMENT", 72, 80], ["vaccinated flocks", "PROBLEM", 110, 127], ["infected", "PROBLEM", 141, 149], ["endemic", "OBSERVATION_MODIFIER", 53, 60], ["infected", "OBSERVATION", 141, 149]]], ["When outbreaks of Newcastle disease occur in a commercial poultry flock, antibiotics may be given to prevent secondary bacterial infections which are usually triggered by this disease.", [["Newcastle disease", "DISEASE", 18, 35], ["bacterial infections", "DISEASE", 119, 139], ["Newcastle disease", "PROBLEM", 18, 35], ["a commercial poultry flock", "TREATMENT", 45, 71], ["antibiotics", "TREATMENT", 73, 84], ["secondary bacterial infections", "PROBLEM", 109, 139], ["this disease", "PROBLEM", 171, 183], ["Newcastle disease", "OBSERVATION", 18, 35], ["bacterial", "OBSERVATION_MODIFIER", 119, 128], ["infections", "OBSERVATION", 129, 139]]], ["It has been shown that egg yolk antibodies conferred protection in chickens against Newcastle disease (Box et al., 1969; Wills and Luginbuhl, 1963) .", [["egg yolk", "ANATOMY", 23, 31], ["Newcastle disease", "DISEASE", 84, 101], ["egg yolk", "ORGANISM_SUBSTANCE", 23, 31], ["chickens", "ORGANISM", 67, 75], ["egg yolk antibodies", "PROTEIN", 23, 42], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 67, 75], ["egg yolk antibodies", "TREATMENT", 23, 42], ["Newcastle disease", "PROBLEM", 84, 101], ["egg yolk antibodies", "OBSERVATION", 23, 42]]], ["Wills and Luginbuhl (1963) have found that subcutaneous administration of egg yolk containing high levels of IgY antibody specific to Newcastle disease protected 80% of the birds during a four-week study period.Shrimp white spot syndrome virusWhite spot syndrome virus (WSSV) is a virulent pathogen causing high mortality and significant economic loss in cultured shrimp operations worldwide (Wongteerasupaya et al., 1995) .", [["subcutaneous", "ANATOMY", 43, 55], ["egg yolk", "ANATOMY", 74, 82], ["Newcastle disease", "DISEASE", 134, 151], ["virusWhite spot syndrome", "DISEASE", 238, 262], ["egg yolk", "ORGANISM_SUBSTANCE", 74, 82], ["IgY", "GENE_OR_GENE_PRODUCT", 109, 112], ["birds", "ORGANISM", 173, 178], ["Shrimp white spot syndrome virusWhite spot syndrome virus", "GENE_OR_GENE_PRODUCT", 211, 268], ["WSSV", "ORGANISM", 270, 274], ["IgY antibody", "PROTEIN", 109, 121], ["Shrimp white spot syndrome virusWhite spot syndrome virus", "SPECIES", 211, 268], ["WSSV", "SPECIES", 270, 274], ["subcutaneous administration of egg yolk", "TREATMENT", 43, 82], ["IgY antibody", "PROBLEM", 109, 121], ["Newcastle disease", "PROBLEM", 134, 151], ["Shrimp white spot syndrome", "PROBLEM", 211, 237], ["virusWhite spot syndrome virus (WSSV", "PROBLEM", 238, 274], ["a virulent pathogen", "PROBLEM", 279, 298], ["high mortality", "PROBLEM", 307, 321], ["significant economic loss", "PROBLEM", 326, 351], ["subcutaneous", "ANATOMY", 43, 55], ["spot syndrome", "OBSERVATION", 224, 237], ["spot syndrome", "OBSERVATION", 249, 262], ["virulent", "OBSERVATION_MODIFIER", 281, 289], ["high mortality", "OBSERVATION_MODIFIER", 307, 321], ["significant", "OBSERVATION_MODIFIER", 326, 337], ["economic loss", "OBSERVATION", 338, 351], ["shrimp operations", "OBSERVATION", 364, 381]]], ["However, shrimp may exhibit a quasiimmune response which possibly shows WSSV-specific effects (Witteveldt et al., 2004; Wu et al., 2002) .", [["shrimp", "ORGANISM", 9, 15], ["a quasiimmune response", "PROBLEM", 28, 50], ["WSSV", "PROBLEM", 72, 76]]], ["WSSV can be neutralized by chicken IgY produced against a truncated fusion protein of VP28 and VP19 (Kim et al., 2004) and therefore, passive immunization with IgY against WSSV has potential for immunotherapeutic application to prevent WSSV infection in shrimp.Shrimp white spot syndrome virusSome researchers have demonstrated passive immunization by anti-viral egg yolk antibodies (IgY) (Arasteh et al., 2004; Kweon et al., 2000) .", [["WSSV infection", "DISEASE", 236, 250], ["WSSV", "ORGANISM", 0, 4], ["chicken", "ORGANISM", 27, 34], ["IgY", "GENE_OR_GENE_PRODUCT", 35, 38], ["VP28", "GENE_OR_GENE_PRODUCT", 86, 90], ["VP19", "GENE_OR_GENE_PRODUCT", 95, 99], ["IgY", "GENE_OR_GENE_PRODUCT", 160, 163], ["WSSV", "ORGANISM", 172, 176], ["WSSV", "ORGANISM", 236, 240], ["shrimp", "ORGANISM", 254, 260], ["Shrimp white spot syndrome virus", "ORGANISM", 261, 293], ["chicken IgY", "PROTEIN", 27, 38], ["truncated fusion protein", "PROTEIN", 58, 82], ["VP28", "PROTEIN", 86, 90], ["VP19", "PROTEIN", 95, 99], ["IgY", "PROTEIN", 160, 163], ["anti-viral egg yolk antibodies", "PROTEIN", 352, 382], ["IgY", "PROTEIN", 384, 387], ["chicken", "SPECIES", 27, 34], ["shrimp", "SPECIES", 254, 260], ["WSSV", "SPECIES", 0, 4], ["chicken", "SPECIES", 27, 34], ["WSSV", "SPECIES", 172, 176], ["WSSV", "SPECIES", 236, 240], ["Shrimp white spot syndrome virus", "SPECIES", 261, 293], ["WSSV", "PROBLEM", 0, 4], ["a truncated fusion protein", "PROBLEM", 56, 82], ["VP28", "TEST", 86, 90], ["VP19", "TEST", 95, 99], ["passive immunization", "TREATMENT", 134, 154], ["IgY", "TREATMENT", 160, 163], ["immunotherapeutic application", "TREATMENT", 195, 224], ["WSSV infection", "PROBLEM", 236, 250], ["Shrimp white spot syndrome virus", "PROBLEM", 261, 293], ["passive immunization", "TREATMENT", 328, 348], ["anti-viral egg yolk antibodies", "TREATMENT", 352, 382], ["infection", "OBSERVATION", 241, 250], ["spot syndrome", "OBSERVATION", 274, 287]]], ["However, our research work (Lu et al., 2008) represents the first report of the passive immunization of shrimp with IgY obtained from the egg yolk of chickens vaccinated with a DNA vaccine comprising genes encoding structural proteins of WSSV or with inactivated WSSV.", [["egg yolk", "ANATOMY", 138, 146], ["shrimp", "ORGANISM", 104, 110], ["IgY", "GENE_OR_GENE_PRODUCT", 116, 119], ["egg yolk", "ORGAN", 138, 146], ["chickens", "ORGANISM", 150, 158], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["WSSV", "ORGANISM", 238, 242], ["WSSV", "ORGANISM", 263, 267], ["IgY", "PROTEIN", 116, 119], ["structural proteins", "PROTEIN", 215, 234], ["chickens", "SPECIES", 150, 158], ["chickens", "SPECIES", 150, 158], ["WSSV", "SPECIES", 238, 242], ["WSSV", "SPECIES", 263, 267], ["the passive immunization of shrimp", "TREATMENT", 76, 110], ["IgY", "TREATMENT", 116, 119], ["the egg yolk", "TREATMENT", 134, 146], ["chickens vaccinated", "TREATMENT", 150, 169], ["a DNA vaccine", "TREATMENT", 175, 188], ["inactivated WSSV", "PROBLEM", 251, 267]]], ["Our work showed that IgY antibodies have a high affinity for WSSV and maintained good biological and neutralization activity especially when induced by the traditional inactivated vaccine.", [["IgY antibodies", "GENE_OR_GENE_PRODUCT", 21, 35], ["WSSV", "ORGANISM", 61, 65], ["IgY antibodies", "PROTEIN", 21, 35], ["WSSV", "SPECIES", 61, 65], ["Our work", "TEST", 0, 8], ["IgY antibodies", "TEST", 21, 35], ["WSSV", "PROBLEM", 61, 65], ["the traditional inactivated vaccine", "TREATMENT", 152, 187], ["good", "OBSERVATION_MODIFIER", 81, 85], ["neutralization activity", "OBSERVATION", 101, 124]]], ["IgY antibody induced by the DNA vaccine was also able to neutralize disease in shrimp experimentally challenged with WSSV but was still inferior to inactivated WSSV (Lu et al., 2008) .", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["shrimp", "ORGANISM", 79, 85], ["WSSV", "ORGANISM", 117, 121], ["WSSV", "ORGANISM", 160, 164], ["IgY antibody", "PROTEIN", 0, 12], ["WSSV", "SPECIES", 117, 121], ["WSSV", "SPECIES", 160, 164], ["IgY antibody", "TEST", 0, 12], ["the DNA vaccine", "TREATMENT", 24, 39], ["neutralize disease", "PROBLEM", 57, 75], ["WSSV", "PROBLEM", 117, 121]]], ["Using specific IgY from hens immunized with inactivated WSSV and DNA vaccine to neutralize WSSV, the challenged shrimp had 73.3 and 33.3% survival, respectively (Fig. 2) .", [["IgY", "GENE_OR_GENE_PRODUCT", 15, 18], ["hens", "ORGANISM", 24, 28], ["WSSV", "ORGANISM", 56, 60], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["WSSV", "ORGANISM", 91, 95], ["shrimp", "ORGANISM", 112, 118], ["IgY", "PROTEIN", 15, 18], ["hens", "SPECIES", 24, 28], ["WSSV", "SPECIES", 56, 60], ["WSSV", "SPECIES", 91, 95], ["specific IgY", "TREATMENT", 6, 18], ["inactivated WSSV", "TREATMENT", 44, 60], ["DNA vaccine", "TREATMENT", 65, 76]]], ["As well, the effectiveness of IgY provided by intramuscular injection, oral administration, and immersion was investigated in crayfish (Procambius clarkiaii) challenged with WSSV (Lu et al., 2009) .", [["intramuscular", "ANATOMY", 46, 59], ["oral", "ANATOMY", 71, 75], ["IgY", "GENE_OR_GENE_PRODUCT", 30, 33], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 59], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["crayfish", "ORGANISM", 126, 134], ["Procambius clarkiaii", "ORGANISM", 136, 156], ["WSSV", "ORGANISM", 174, 178], ["IgY", "PROTEIN", 30, 33], ["Procambius clarkiaii", "SPECIES", 136, 156], ["Procambius clarkiaii", "SPECIES", 136, 156], ["WSSV", "SPECIES", 174, 178], ["IgY", "TREATMENT", 30, 33], ["intramuscular injection", "TREATMENT", 46, 69], ["oral administration", "TREATMENT", 71, 90]]], ["Our results showed that immunization of specific IgY antibodies through intramuscular injection, oral administration or immersion were all effective means of protecting crayfish against WSSV.", [["intramuscular", "ANATOMY", 72, 85], ["oral", "ANATOMY", 97, 101], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 49, 63], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["oral", "ORGANISM_SUBDIVISION", 97, 101], ["crayfish", "ORGANISM", 169, 177], ["WSSV", "ORGANISM", 186, 190], ["IgY antibodies", "PROTEIN", 49, 63], ["WSSV", "SPECIES", 186, 190], ["immunization", "TREATMENT", 24, 36], ["specific IgY antibodies", "TREATMENT", 40, 63], ["intramuscular injection", "TREATMENT", 72, 95], ["oral administration", "TREATMENT", 97, 116], ["WSSV", "PROBLEM", 186, 190]]], ["Unfortunately, these are labor intensive techniques and may have limited application under commercial aquaculture conditions where crayfish are raised in the ocean.Shrimp white spot syndrome virusEgg yolk antibodies can be harvested in a more cost efficient and convenient manner compared with production of antibody from mammals (Mine and Kovacs-Nolan, 2002) .", [["Egg yolk", "ANATOMY", 196, 204], ["Shrimp white spot syndrome virus", "ORGANISM", 164, 196], ["Egg yolk antibodies", "PROTEIN", 196, 215], ["Shrimp white spot syndrome virus", "SPECIES", 164, 196], ["labor intensive techniques", "TREATMENT", 25, 51], ["Shrimp white spot syndrome virus", "PROBLEM", 164, 196], ["Egg yolk antibodies", "PROBLEM", 196, 215], ["spot syndrome", "OBSERVATION", 177, 190], ["virus", "OBSERVATION", 191, 196]]], ["IgY in egg yolk could be prepared in different forms such as egg yolk powder, purified powder and liquor which may provide a feasible and significant way forward in research using antibodies against WSSV.Y. ruckeriThe effectiveness of IgY in passive immunization of rainbow trout against Y. ruckeri infection has been studied .", [["egg yolk", "ANATOMY", 7, 15], ["egg yolk", "ANATOMY", 61, 69], ["Y. ruckeri infection", "DISEASE", 288, 308], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["egg yolk", "ORGANISM_SUBSTANCE", 7, 15], ["egg yolk powder", "ORGANISM_SUBSTANCE", 61, 76], ["WSSV", "ORGANISM", 199, 203], ["Y. ruckeri", "ORGANISM", 204, 214], ["IgY", "GENE_OR_GENE_PRODUCT", 235, 238], ["rainbow trout", "ORGANISM", 266, 279], ["Y. ruckeri", "ORGANISM", 288, 298], ["IgY", "PROTEIN", 0, 3], ["antibodies", "PROTEIN", 180, 190], ["IgY", "PROTEIN", 235, 238], ["Y. ruckeri", "SPECIES", 204, 214], ["rainbow trout", "SPECIES", 266, 279], ["Y. ruckeri", "SPECIES", 288, 298], ["WSSV", "SPECIES", 199, 203], ["Y. ruckeri", "SPECIES", 204, 214], ["rainbow trout", "SPECIES", 266, 279], ["Y. ruckeri", "SPECIES", 288, 298], ["IgY in egg yolk", "TREATMENT", 0, 15], ["egg yolk powder", "TREATMENT", 61, 76], ["purified powder and liquor", "TREATMENT", 78, 104], ["WSSV", "PROBLEM", 199, 203], ["IgY", "TREATMENT", 235, 238], ["passive immunization", "TREATMENT", 242, 262], ["ruckeri infection", "PROBLEM", 291, 308], ["ruckeri", "OBSERVATION", 207, 214], ["infection", "OBSERVATION", 299, 308]]], ["Y. ruckeri is the aetiological agent of enteric red mouth disease, a systemic bacterial septicaemia, principally affecting farmed rainbow trout, Oncorhynchus mykiss (Stevenson et al., 1993) .", [["red mouth", "ANATOMY", 48, 57], ["Y. ruckeri", "DISEASE", 0, 10], ["enteric red mouth disease", "DISEASE", 40, 65], ["bacterial septicaemia", "DISEASE", 78, 99], ["Y. ruckeri", "ORGANISM", 0, 10], ["mouth", "ORGAN", 52, 57], ["rainbow trout", "ORGANISM", 130, 143], ["Oncorhynchus mykiss", "ORGANISM", 145, 164], ["Y. ruckeri", "SPECIES", 0, 10], ["rainbow trout", "SPECIES", 130, 143], ["Oncorhynchus mykiss", "SPECIES", 145, 164], ["Y. ruckeri", "SPECIES", 0, 10], ["farmed rainbow trout", "SPECIES", 123, 143], ["Oncorhynchus mykiss", "SPECIES", 145, 164], ["enteric red mouth disease", "PROBLEM", 40, 65], ["a systemic bacterial septicaemia", "PROBLEM", 67, 99], ["ruckeri", "OBSERVATION", 3, 10], ["enteric", "ANATOMY", 40, 47], ["red mouth disease", "OBSERVATION", 48, 65], ["systemic", "OBSERVATION_MODIFIER", 69, 77], ["bacterial", "OBSERVATION_MODIFIER", 78, 87], ["septicaemia", "OBSERVATION", 88, 99]]], ["Y. ruckeri could persist for long periods in carrier fish and are shed in feces, representing a continuing source of infection.", [["feces", "ANATOMY", 74, 79], ["infection", "DISEASE", 117, 126], ["Y. ruckeri", "ORGANISM", 0, 10], ["fish", "ORGANISM_SUBDIVISION", 53, 57], ["feces", "ORGANISM_SUBDIVISION", 74, 79], ["Y. ruckeri", "SPECIES", 0, 10], ["Y. ruckeri", "SPECIES", 0, 10], ["infection", "PROBLEM", 117, 126], ["ruckeri", "OBSERVATION", 3, 10], ["infection", "OBSERVATION", 117, 126]]], ["If a population of asymptomatic carrier fish could be adequately cleared by oral administration of anti-Y. ruckeri antibody, such treatment might be a cost-effective alternative approach to the slaughter of a stock of fish with a potential health risk.", [["oral", "ANATOMY", 76, 80], ["fish", "ORGANISM", 40, 44], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["anti-Y. ruckeri", "ORGANISM", 99, 114], ["fish", "ORGANISM", 218, 222], ["anti-Y. ruckeri antibody", "PROTEIN", 99, 123], ["anti-Y. ruckeri", "SPECIES", 99, 114], ["asymptomatic carrier fish", "PROBLEM", 19, 44], ["anti-Y. ruckeri antibody", "TREATMENT", 99, 123], ["such treatment", "TREATMENT", 125, 139]]], ["Rainbow trout fed with anti-Y. ruckeri IgY, 2 h before an immersion challenge with Y. ruckeri, showed a lower mortality rate after 8 days than did fish fed unsupplemented IgY feed before the challenge .", [["anti-Y. ruckeri IgY", "ORGANISM", 23, 42], ["Y. ruckeri", "ORGANISM", 83, 93], ["fish", "ORGANISM", 147, 151], ["Rainbow trout", "SPECIES", 0, 13], ["anti-Y. ruckeri", "SPECIES", 23, 38], ["Y. ruckeri", "SPECIES", 83, 93], ["Rainbow trout", "SPECIES", 0, 13], ["anti-Y. ruckeri", "SPECIES", 23, 38], ["Y. ruckeri", "SPECIES", 83, 93], ["IgY", "SPECIES", 171, 174], ["an immersion challenge", "TREATMENT", 55, 77]]], ["The fish fed IgY also appeared to have fewer infections after 8 days, based on organ and intestinal cultures.", [["organ", "ANATOMY", 79, 84], ["intestinal cultures", "ANATOMY", 89, 108], ["infections", "DISEASE", 45, 55], ["fish", "ORGANISM", 4, 8], ["IgY", "GENE_OR_GENE_PRODUCT", 13, 16], ["organ", "ORGAN", 79, 84], ["intestinal cultures", "CELL", 89, 108], ["IgY", "PROTEIN", 13, 16], ["fewer infections", "PROBLEM", 39, 55], ["organ and intestinal cultures", "TEST", 79, 108], ["fewer", "OBSERVATION_MODIFIER", 39, 44], ["infections", "OBSERVATION", 45, 55], ["intestinal", "ANATOMY", 89, 99]]], ["In a subsequent trial, the IgY-fed fish had lower mortality than fish receiving unsupplemented IgY feed .", [["IgY", "ORGANISM", 27, 30], ["fish", "ORGANISM", 35, 39], ["fish", "ORGANISM", 65, 69], ["IgY", "PROTEIN", 27, 30], ["unsupplemented IgY feed", "TREATMENT", 80, 103]]], ["The percentage of IgY-fed fish carrying Y. ruckeri in their intestinal samples appeared to be lower than in the untreated controls, regardless of whether the IgY containing feed was given before or after the challenge.", [["intestinal samples", "ANATOMY", 60, 78], ["IgY", "GENE_OR_GENE_PRODUCT", 18, 21], ["fish", "ORGANISM", 26, 30], ["Y. ruckeri", "ORGANISM", 40, 50], ["intestinal samples", "ORGAN", 60, 78], ["IgY", "GENE_OR_GENE_PRODUCT", 158, 161], ["IgY", "PROTEIN", 18, 21], ["IgY", "PROTEIN", 158, 161], ["Y. ruckeri", "SPECIES", 40, 50], ["Y. ruckeri", "SPECIES", 40, 50], ["the IgY containing feed", "TREATMENT", 154, 177], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["intestinal", "ANATOMY", 60, 70]]], ["The oral administration of specific IgY against fish pathogens could provide an alternative method to antibiotics and chemotherapy for prevention of bacterial diseases of fish in fish farm.E. tardaE. tarda is another important fish pathogen which is spread by infection through the intestinal mucosa (Noga, 1996) .", [["oral", "ANATOMY", 4, 8], ["intestinal mucosa", "ANATOMY", 282, 299], ["bacterial diseases", "DISEASE", 149, 167], ["tarda", "DISEASE", 200, 205], ["infection", "DISEASE", 260, 269], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["IgY", "GENE_OR_GENE_PRODUCT", 36, 39], ["fish", "ORGANISM", 48, 52], ["fish", "ORGANISM", 171, 175], ["fish", "ORGANISM", 179, 183], ["E. tardaE", "ORGANISM", 189, 198], ["fish", "ORGANISM", 227, 231], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 282, 299], ["IgY", "PROTEIN", 36, 39], ["E. tardaE", "SPECIES", 189, 198], ["tarda", "SPECIES", 200, 205], ["The oral administration", "TREATMENT", 0, 23], ["specific IgY", "TREATMENT", 27, 39], ["fish pathogens", "PROBLEM", 48, 62], ["an alternative method to antibiotics", "TREATMENT", 77, 113], ["chemotherapy", "TREATMENT", 118, 130], ["bacterial diseases", "PROBLEM", 149, 167], ["tarda", "PROBLEM", 200, 205], ["fish pathogen", "PROBLEM", 227, 240], ["bacterial diseases", "OBSERVATION", 149, 167], ["important fish", "OBSERVATION_MODIFIER", 217, 231], ["pathogen", "OBSERVATION", 232, 240], ["infection", "OBSERVATION", 260, 269], ["intestinal mucosa", "ANATOMY", 282, 299]]], ["Edwardsiellosis in Japanese eels has become a serious problem for the eel farming industry (Wakabayashi and Egusa, 1973) .", [["Edwardsiellosis", "CHEMICAL", 0, 15], ["eel", "ORGANISM", 70, 73], ["Japanese eels", "SPECIES", 19, 32], ["Edwardsiellosis", "PROBLEM", 0, 15], ["a serious problem", "PROBLEM", 44, 61]]], ["Egg yolk antibodies have been investigated for the prevention of this infectious disease because the use and misuse of antibiotics has led to growing problems with drug residues in fish products and increased bacterial resistance (Gutierrez et al., 1993; Hatta et al., 1994) .", [["Egg yolk", "ANATOMY", 0, 8], ["infectious disease", "DISEASE", 70, 88], ["Egg yolk antibodies", "GENE_OR_GENE_PRODUCT", 0, 19], ["fish", "ORGANISM", 181, 185], ["Egg yolk antibodies", "PROTEIN", 0, 19], ["Egg yolk antibodies", "TEST", 0, 19], ["this infectious disease", "PROBLEM", 65, 88], ["antibiotics", "TREATMENT", 119, 130], ["growing problems", "PROBLEM", 142, 158], ["drug residues", "PROBLEM", 164, 177], ["increased bacterial resistance", "PROBLEM", 199, 229], ["infectious", "OBSERVATION", 70, 80], ["increased", "OBSERVATION_MODIFIER", 199, 208], ["bacterial resistance", "OBSERVATION", 209, 229]]], ["Anti-E. tarda IgY were simultaneously administered orally to Japanese eels (Anguilla From Lu et al., 2008. japonica) with the pathogenic bacteria (10 5 -10 6 CFU per fish).", [["Anti-E. tarda", "ORGANISM", 0, 13], ["IgY", "GENE_OR_GENE_PRODUCT", 14, 17], ["japonica", "ORGANISM", 107, 115], ["Anti-E. tarda IgY", "PROTEIN", 0, 17], ["japonica", "SPECIES", 107, 115], ["Anti-E. tarda", "SPECIES", 0, 13], ["Japanese eels", "SPECIES", 61, 74], ["japonica", "SPECIES", 107, 115], ["Anti-E. tarda IgY", "TREATMENT", 0, 17], ["the pathogenic bacteria", "PROBLEM", 122, 145], ["pathogenic", "OBSERVATION_MODIFIER", 126, 136], ["bacteria", "OBSERVATION", 137, 145]]], ["The non-treated infected eels died within 15 days whereas the eels receiving IgY survived and no disease symptoms were observed, suggesting that anti-E. tarda IgY is effective in preventing edwardsiellosis (Gutierrez et al., 1993) .", [["edwardsiellosis", "DISEASE", 190, 205], ["eels", "ORGANISM", 25, 29], ["eels", "ORGANISM", 62, 66], ["IgY", "GENE_OR_GENE_PRODUCT", 77, 80], ["anti-E. tarda IgY", "ORGANISM", 145, 162], ["IgY", "PROTEIN", 77, 80], ["anti-E. tarda", "SPECIES", 145, 158], ["The non-treated infected eels", "PROBLEM", 0, 29], ["IgY", "TREATMENT", 77, 80], ["disease symptoms", "PROBLEM", 97, 113], ["anti-E. tarda IgY", "TREATMENT", 145, 162], ["edwardsiellosis", "PROBLEM", 190, 205], ["non-treated", "OBSERVATION_MODIFIER", 4, 15], ["infected", "OBSERVATION", 16, 24]]], ["Again limited numbers of eels were used in this study and a repeat with greater numbers would certainly be welcomed.Limitations of IgY technologyThere are limitations to the use of IgY for oral passive immunotherapy due to its susceptibility to proteolysis.", [["oral", "ANATOMY", 189, 193], ["eels", "ORGANISM", 25, 29], ["IgY", "GENE_OR_GENE_PRODUCT", 131, 134], ["IgY", "GENE_OR_GENE_PRODUCT", 181, 184], ["oral", "ORGANISM_SUBDIVISION", 189, 193], ["IgY", "PROTEIN", 181, 184], ["this study", "TEST", 43, 53], ["a repeat", "TEST", 58, 66], ["IgY", "TREATMENT", 181, 184], ["oral passive immunotherapy", "TREATMENT", 189, 215], ["its susceptibility to proteolysis", "PROBLEM", 223, 256]]], ["IgY is fairly resistant to digestion by intestinal proteases Shimizu et al., 1988) .", [["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["intestinal", "ORGAN", 40, 50], ["IgY", "PROTEIN", 0, 3], ["intestinal", "ANATOMY", 40, 50]]], ["However, it was found that the activity of IgY was decreased at pH 3.5 and completely lost at pH 3.0 (Shimizu et al., 1988) .", [["IgY", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgY", "PROTEIN", 43, 46], ["the activity of IgY", "PROBLEM", 27, 46], ["pH", "TEST", 64, 66], ["pH", "TEST", 94, 96]]], ["IgY has a serum half-life of 1.85 days in newborn pigs.", [["serum", "ANATOMY", 10, 15], ["IgY", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["pigs", "ORGANISM", 50, 54], ["IgY", "PROTEIN", 0, 3], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 50, 54]]], ["This is shorter than the reported serum half-life of 12 to 14 days for homologous IgG (colostral antibodies).", [["serum", "ANATOMY", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 82, 85], ["colostral antibodies", "GENE_OR_GENE_PRODUCT", 87, 107], ["homologous IgG", "PROTEIN", 71, 85], ["colostral antibodies", "PROTEIN", 87, 107], ["homologous IgG (colostral antibodies", "TEST", 71, 107], ["shorter", "OBSERVATION_MODIFIER", 8, 15]]], ["The fraction of IgY absorbed into the circulation when administered in pigs decreased with increasing age of pigs .Limitations of IgY technologySince the primary target site of IgY is the small intestine, in order for it to function it is essential to find an effective method to protect IgY against peptic digestion and acidity in the stomach.", [["small intestine", "ANATOMY", 188, 203], ["peptic", "ANATOMY", 300, 306], ["stomach", "ANATOMY", 336, 343], ["IgY", "GENE_OR_GENE_PRODUCT", 16, 19], ["pigs", "ORGANISM", 71, 75], ["pigs", "ORGANISM", 109, 113], ["IgY", "GENE_OR_GENE_PRODUCT", 130, 133], ["IgY", "GENE_OR_GENE_PRODUCT", 177, 180], ["small intestine", "ORGAN", 188, 203], ["IgY", "GENE_OR_GENE_PRODUCT", 288, 291], ["stomach", "ORGAN", 336, 343], ["IgY", "PROTEIN", 16, 19], ["IgY", "PROTEIN", 177, 180], ["IgY", "PROTEIN", 288, 291], ["pigs", "SPECIES", 71, 75], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 71, 75], ["pigs", "SPECIES", 109, 113], ["an effective method", "TREATMENT", 257, 276], ["peptic digestion", "PROBLEM", 300, 316], ["acidity in the stomach", "PROBLEM", 321, 343], ["fraction", "OBSERVATION_MODIFIER", 4, 12], ["circulation", "OBSERVATION_MODIFIER", 38, 49], ["small", "OBSERVATION_MODIFIER", 188, 193], ["intestine", "ANATOMY", 194, 203], ["acidity", "OBSERVATION", 321, 328], ["stomach", "ANATOMY", 336, 343]]], ["It has been shown that microencapsulation can be an effective method for protecting IgY from gastric inactivation (Chang et al., 2002; Cho et al., 2005; Kovacs-Nolan and Mine, 2005; Li et al., 2007 Li et al., , 2009 ), but this process will undoubtedly add additional costs.", [["gastric", "ANATOMY", 93, 100], ["IgY", "GENE_OR_GENE_PRODUCT", 84, 87], ["gastric", "ORGAN", 93, 100], ["IgY", "PROTEIN", 84, 87], ["microencapsulation", "TREATMENT", 23, 41], ["an effective method", "TREATMENT", 49, 68], ["protecting IgY", "TREATMENT", 73, 87], ["gastric inactivation", "PROBLEM", 93, 113], ["gastric", "ANATOMY", 93, 100]]], ["Additional study will be needed before microencapsulation can be applied under commercial conditions.Limitations of IgY technologyIn vitro studies have demonstrated that IgY is effective against many Gram-negative bacteria.", [["IgY", "GENE_OR_GENE_PRODUCT", 116, 119], ["IgY", "GENE_OR_GENE_PRODUCT", 170, 173], ["Gram", "GENE_OR_GENE_PRODUCT", 200, 204], ["IgY", "PROTEIN", 170, 173], ["Additional study", "TEST", 0, 16], ["microencapsulation", "TREATMENT", 39, 57], ["vitro studies", "TEST", 133, 146], ["many Gram-negative bacteria", "PROBLEM", 195, 222], ["negative bacteria", "OBSERVATION", 205, 222]]], ["In contrast, inhibition activity of IgY on Gram-positive bacteria has only occasionally been reported (Sugita-Konishi et al., 1996; Zhen et al., 2008a Zhen et al., , 2009 Wang et al., 2011) .", [["IgY", "GENE_OR_GENE_PRODUCT", 36, 39], ["Gram", "GENE_OR_GENE_PRODUCT", 43, 47], ["IgY", "PROTEIN", 36, 39], ["Gram", "TEST", 43, 47], ["positive bacteria", "PROBLEM", 48, 65]]], ["This may be due to the fact that Gram-positive bacteria have a more compact cell wall compared with Gram-negative bacteria.", [["cell wall", "ANATOMY", 76, 85], ["Gram-", "GENE_OR_GENE_PRODUCT", 33, 38], ["cell wall", "TISSUE", 76, 85], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 100, 122], ["Gram-positive bacteria", "PROBLEM", 33, 55], ["Gram-negative bacteria", "PROBLEM", 100, 122], ["may be due to", "UNCERTAINTY", 5, 18], ["bacteria", "OBSERVATION", 47, 55], ["more compact", "OBSERVATION_MODIFIER", 63, 75], ["cell", "OBSERVATION", 76, 80], ["wall", "ANATOMY_MODIFIER", 81, 85], ["negative bacteria", "OBSERVATION", 105, 122]]], ["However, this clearly limits the types of diseases that can be treated with IgY technology.Limitations of IgY technologyThe objective to treatment with IgY is not always prevention of a disease but sometimes simply a reduction of infectious agents (Kuroki et al., 1993) .", [["IgY", "GENE_OR_GENE_PRODUCT", 76, 79], ["IgY", "GENE_OR_GENE_PRODUCT", 106, 109], ["IgY", "PROTEIN", 76, 79], ["IgY", "PROTEIN", 152, 155], ["diseases", "PROBLEM", 42, 50], ["IgY technology", "TREATMENT", 76, 90], ["IgY", "TREATMENT", 152, 155], ["a disease", "PROBLEM", 184, 193], ["infectious agents", "TREATMENT", 230, 247], ["diseases", "OBSERVATION", 42, 50], ["disease", "OBSERVATION", 186, 193], ["infectious", "OBSERVATION", 230, 240]]], ["Unlike mammalian IgG, IgY does not bind complement or acts as an opsonin in phagocytosis.", [["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgY", "GENE_OR_GENE_PRODUCT", 22, 25], ["opsonin", "GENE_OR_GENE_PRODUCT", 65, 72], ["mammalian IgG", "PROTEIN", 7, 20], ["IgY", "PROTEIN", 22, 25], ["opsonin", "PROTEIN", 65, 72], ["IgG", "OBSERVATION", 17, 20]]], ["Therefore, IgY are unable to kill bacteria directly.", [["IgY", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgY", "PROTEIN", 11, 14]]], ["It was also shown that IgY antibodies were not able to displace E. coli K88+ MB once bound to the mucosal receptor.", [["mucosal", "ANATOMY", 98, 105], ["IgY antibodies", "GENE_OR_GENE_PRODUCT", 23, 37], ["E. coli", "ORGANISM", 64, 71], ["K88+ MB", "ORGANISM", 72, 79], ["mucosal receptor", "GENE_OR_GENE_PRODUCT", 98, 114], ["IgY antibodies", "PROTEIN", 23, 37], ["mucosal receptor", "PROTEIN", 98, 114], ["E. coli", "SPECIES", 64, 71], ["E. coli", "SPECIES", 64, 71], ["IgY antibodies", "TEST", 23, 37], ["E. coli K88", "TEST", 64, 75], ["mucosal receptor", "ANATOMY", 98, 114]]], ["This indicates that the antibodies have a lower affinity for the receptor than that of K88+ fimbriae.", [["K88+ fimbriae", "GENE_OR_GENE_PRODUCT", 87, 100], ["antibodies", "PROTEIN", 24, 34], ["K88", "PROTEIN", 87, 90], ["fimbriae", "PROTEIN", 92, 100], ["the antibodies", "TEST", 20, 34], ["fimbriae", "PROBLEM", 92, 100]]], ["Since IgY could not remove previously bound E. coli K88+ MB from the mucus, a prophylactic use for IgY is suggested (Jin et al., 1998) .", [["mucus", "ANATOMY", 69, 74], ["IgY", "GENE_OR_GENE_PRODUCT", 6, 9], ["E. coli", "ORGANISM", 44, 51], ["mucus", "ORGANISM_SUBSTANCE", 69, 74], ["IgY", "GENE_OR_GENE_PRODUCT", 99, 102], ["IgY", "PROTEIN", 6, 9], ["IgY", "PROTEIN", 99, 102], ["E. coli", "SPECIES", 44, 51], ["E. coli", "SPECIES", 44, 51], ["previously bound E. coli K88", "PROBLEM", 27, 55], ["MB", "PROBLEM", 57, 59], ["mucus", "ANATOMY", 69, 74]]], ["However, therapeutic effects of IgY in the control of infections have been reported, such as E. coli K88 in piglets Wiedemann et al., 1991) , C. jejuni in chickens (Tsubokura et al., 1997) and Salmonella in mice (Yokoyama et al., 1998) .Limitations of IgY technologyAt present, the production cost of high quality IgY antibodies is higher than the cost of routine antibiotics (Casadevall and Scharff, 1994) .", [["infections", "DISEASE", 54, 64], ["C. jejuni", "DISEASE", 142, 151], ["IgY", "GENE_OR_GENE_PRODUCT", 32, 35], ["E. coli K88", "ORGANISM", 93, 104], ["piglets", "ORGANISM", 108, 115], ["C. jejuni", "ORGANISM", 142, 151], ["chickens", "ORGANISM", 155, 163], ["mice", "ORGANISM", 207, 211], ["IgY", "GENE_OR_GENE_PRODUCT", 252, 255], ["IgY", "PROTEIN", 32, 35], ["IgY antibodies", "PROTEIN", 314, 328], ["E. coli", "SPECIES", 93, 100], ["piglets", "SPECIES", 108, 115], ["C. jejuni", "SPECIES", 142, 151], ["chickens", "SPECIES", 155, 163], ["mice", "SPECIES", 207, 211], ["E. coli", "SPECIES", 93, 100], ["C. jejuni", "SPECIES", 142, 151], ["chickens", "SPECIES", 155, 163], ["mice", "SPECIES", 207, 211], ["IgY", "TREATMENT", 32, 35], ["infections", "PROBLEM", 54, 64], ["E. coli K88", "TREATMENT", 93, 104], ["high quality IgY antibodies", "PROBLEM", 301, 328], ["routine antibiotics", "TREATMENT", 356, 375], ["jejuni", "ANATOMY", 145, 151]]], ["Therefore, the development of methods for large-scale production of IgY with high recovery and purity are needed.", [["IgY", "GENE_OR_GENE_PRODUCT", 68, 71], ["IgY", "PROTEIN", 68, 71], ["methods", "TREATMENT", 30, 37], ["large-scale production of IgY", "TREATMENT", 42, 71], ["large", "OBSERVATION_MODIFIER", 42, 47]]], ["In addition, there is no consensus on the most suitable IgY extraction method for commercial application (Schade et al., 2005) and this requires further study.ConclusionsOral administration of chicken egg yolk immunoglobulin appears to have considerable potential as a means of controlling infectious diseases of bacterial and viral origin and may be the disease treatment of the future.", [["Oral", "ANATOMY", 170, 174], ["egg yolk", "ANATOMY", 201, 209], ["infectious diseases of bacterial and viral origin", "DISEASE", 290, 339], ["Oral", "ORGANISM_SUBDIVISION", 170, 174], ["chicken", "ORGANISM", 193, 200], ["egg yolk immunoglobulin", "GENE_OR_GENE_PRODUCT", 201, 224], ["chicken egg yolk immunoglobulin", "PROTEIN", 193, 224], ["chicken", "SPECIES", 193, 200], ["chicken", "SPECIES", 193, 200], ["further study", "TEST", 145, 158], ["chicken egg yolk immunoglobulin", "TREATMENT", 193, 224], ["controlling infectious diseases", "PROBLEM", 278, 309], ["bacterial and viral origin", "PROBLEM", 313, 339], ["the disease treatment", "TREATMENT", 351, 372], ["no", "UNCERTAINTY", 22, 24], ["bacterial", "OBSERVATION_MODIFIER", 313, 322], ["viral origin", "OBSERVATION", 327, 339]]], ["To date, IgY technology has been used for the treatment of livestock diseases such as mastitis and diarrhea, poultry diseases such as Salmonella, Campylobacteriosis, infectious bursal disease and Newcastle disease, as well as aquatic diseases like shrimp white spot syndrome virus, Y. ruckeri and E. tarda.", [["bursal", "ANATOMY", 177, 183], ["livestock diseases", "DISEASE", 59, 77], ["mastitis", "DISEASE", 86, 94], ["diarrhea", "DISEASE", 99, 107], ["poultry diseases", "DISEASE", 109, 125], ["Campylobacteriosis", "DISEASE", 146, 164], ["infectious bursal disease", "DISEASE", 166, 191], ["Newcastle disease", "DISEASE", 196, 213], ["aquatic diseases", "DISEASE", 226, 242], ["shrimp white spot syndrome", "DISEASE", 248, 274], ["IgY", "GENE_OR_GENE_PRODUCT", 9, 12], ["bursal", "ORGAN", 177, 183], ["shrimp white spot syndrome virus", "ORGANISM", 248, 280], ["Y. ruckeri", "ORGANISM", 282, 292], ["E. tarda", "ORGANISM", 297, 305], ["IgY", "PROTEIN", 9, 12], ["Y. ruckeri", "SPECIES", 282, 292], ["E. tarda", "SPECIES", 297, 305], ["Salmonella", "SPECIES", 134, 144], ["shrimp white spot syndrome virus", "SPECIES", 248, 280], ["Y. ruckeri", "SPECIES", 282, 292], ["E. tarda", "SPECIES", 297, 305], ["livestock diseases", "PROBLEM", 59, 77], ["mastitis", "PROBLEM", 86, 94], ["diarrhea", "PROBLEM", 99, 107], ["poultry diseases", "PROBLEM", 109, 125], ["Salmonella", "PROBLEM", 134, 144], ["Campylobacteriosis", "PROBLEM", 146, 164], ["infectious bursal disease", "PROBLEM", 166, 191], ["Newcastle disease", "PROBLEM", 196, 213], ["aquatic diseases", "PROBLEM", 226, 242], ["shrimp white spot syndrome virus", "PROBLEM", 248, 280], ["mastitis", "OBSERVATION", 86, 94], ["Campylobacteriosis", "OBSERVATION", 146, 164], ["infectious", "OBSERVATION_MODIFIER", 166, 176], ["Newcastle disease", "OBSERVATION", 196, 213], ["shrimp white", "OBSERVATION", 248, 260], ["spot syndrome", "OBSERVATION", 261, 274]]], ["Some advantages of IgY in the control of animal diseases are:Conclusions1.", [["animal diseases", "DISEASE", 41, 56], ["IgY", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgY", "PROTEIN", 19, 22], ["IgY", "TREATMENT", 19, 22]]], ["They are highly effective.", [["highly", "OBSERVATION_MODIFIER", 9, 15], ["effective", "OBSERVATION_MODIFIER", 16, 25]]], ["Collection of eggs is non-invasive.", [["eggs", "ANATOMY", 14, 18], ["eggs", "ORGANISM_SUBSTANCE", 14, 18], ["eggs", "OBSERVATION", 14, 18]]], ["The treatment is safe and live organisms are not used.", [["The treatment", "TREATMENT", 0, 13]]], ["The procedure is environmentally friendly.", [["The procedure", "TREATMENT", 0, 13]]], ["No toxic residues are produced and there is no development of resistance.", [["toxic residues", "PROBLEM", 3, 17], ["resistance", "PROBLEM", 62, 72], ["toxic", "OBSERVATION_MODIFIER", 3, 8], ["residues", "OBSERVATION", 9, 17], ["no development of", "UNCERTAINTY", 44, 61], ["resistance", "OBSERVATION", 62, 72]]], ["The treatment can be used to control many different types of pathogens.", [["The treatment", "TREATMENT", 0, 13], ["pathogens", "PROBLEM", 61, 70], ["pathogens", "OBSERVATION", 61, 70]]]], "327a206d906a71a562dffa0489a0a5d31d96219c": [["In addition to providing the energy and biomass necessary for turning cells into productive 'virus factories', new metabolic contributions to infection have emerged.", [["cells", "ANATOMY", 70, 75], ["infection", "DISEASE", 142, 151], ["cells", "CELL", 70, 75], ["turning cells", "CELL_TYPE", 62, 75], ["the energy and biomass", "TREATMENT", 25, 47], ["turning cells", "PROBLEM", 62, 75], ["productive 'virus factories", "TREATMENT", 81, 108], ["infection", "PROBLEM", 142, 151], ["infection", "OBSERVATION", 142, 151]]], ["These include small molecule enzymatic activities that organize viral maturation compartments, synthesize specialized virion components, or regulate the immunological environment ( Figure 1 ).", [["small molecule enzymatic activities", "PROBLEM", 14, 49], ["viral maturation compartments", "PROBLEM", 64, 93], ["small", "OBSERVATION_MODIFIER", 14, 19], ["molecule enzymatic activities", "OBSERVATION", 20, 49], ["viral maturation", "OBSERVATION", 64, 80]]], ["Collectively, recent findings have made it clear that the landscape for metabolically-targeted therapeutic intervention has expanded.Viral Targeting of Core Metabolic PathwaysA wide variety of viruses activate glycolysis, which drives the production of energy in the form of ATP, NADH, and NADPH ( Figure 2 ).", [["ATP", "CHEMICAL", 275, 278], ["NADH", "CHEMICAL", 280, 284], ["NADPH", "CHEMICAL", 290, 295], ["ATP", "CHEMICAL", 275, 278], ["NADH", "CHEMICAL", 280, 284], ["NADPH", "CHEMICAL", 290, 295], ["ATP", "SIMPLE_CHEMICAL", 275, 278], ["NADH", "SIMPLE_CHEMICAL", 280, 284], ["NADPH", "SIMPLE_CHEMICAL", 290, 295], ["targeted therapeutic intervention", "TREATMENT", 86, 119], ["Core Metabolic PathwaysA", "PROBLEM", 152, 176], ["viruses activate glycolysis", "PROBLEM", 193, 220], ["ATP", "PROBLEM", 275, 278], ["viruses", "OBSERVATION", 193, 200]]], ["Activated glycolysis also supplies the carbon necessary for the synthesis of numerous core biomolecules including nucleotides, lipids, amino acids and carbohydrates ( Figure 2) .", [["amino acids", "CHEMICAL", 135, 146], ["carbon", "CHEMICAL", 39, 45], ["nucleotides", "CHEMICAL", 114, 125], ["amino acids", "CHEMICAL", 135, 146], ["carbohydrates", "CHEMICAL", 151, 164], ["lipids", "SIMPLE_CHEMICAL", 127, 133], ["amino acids", "AMINO_ACID", 135, 146], ["carbohydrates", "SIMPLE_CHEMICAL", 151, 164], ["Activated glycolysis", "TREATMENT", 0, 20], ["the carbon", "TREATMENT", 35, 45], ["the synthesis of numerous core biomolecules", "TREATMENT", 60, 103], ["nucleotides, lipids", "TREATMENT", 114, 133], ["amino acids", "TREATMENT", 135, 146], ["carbohydrates", "TREATMENT", 151, 164]]], ["A number of DNA viruses induce glycolysis, including Kaposi's sarcoma-associated herpesvirus (KSHV) [6] , HCMV [7] , adenovirus [8] , human papillomavirus (HPV) and Epstein-Barr virus (EBV) [9] .", [["Kaposi's sarcoma", "DISEASE", 53, 69], ["human papillomavirus (HPV)", "DISEASE", 134, 160], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 53, 92], ["KSHV", "ORGANISM", 94, 98], ["HCMV [7", "ORGANISM", 106, 113], ["adenovirus [8", "ORGANISM", 117, 130], ["human papillomavirus", "ORGANISM", 134, 154], ["HPV", "ORGANISM", 156, 159], ["Epstein-Barr virus", "ORGANISM", 165, 183], ["EBV", "ORGANISM", 185, 188], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 53, 92], ["human", "SPECIES", 134, 139], ["papillomavirus", "SPECIES", 140, 154], ["Barr virus", "SPECIES", 173, 183], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 53, 92], ["KSHV", "SPECIES", 94, 98], ["HCMV", "SPECIES", 106, 110], ["human papillomavirus", "SPECIES", 134, 154], ["HPV", "SPECIES", 156, 159], ["Epstein-Barr virus", "SPECIES", 165, 183], ["EBV", "SPECIES", 185, 188], ["DNA viruses induce glycolysis", "PROBLEM", 12, 41], ["Kaposi's sarcoma", "PROBLEM", 53, 69], ["associated herpesvirus (KSHV)", "PROBLEM", 70, 99], ["HCMV", "TEST", 106, 110], ["adenovirus", "TEST", 117, 127], ["human papillomavirus (HPV", "TEST", 134, 159], ["Epstein-Barr virus", "PROBLEM", 165, 183], ["DNA viruses", "OBSERVATION", 12, 23], ["Kaposi's sarcoma", "OBSERVATION", 53, 69]]], ["Multiple RNA viruses also activate glycolytic flux, including dengue [10] , hepatitis C (HCV), [11] and influenza A [12] .", [["dengue", "DISEASE", 62, 68], ["hepatitis C (HCV)", "DISEASE", 76, 93], ["dengue [10", "ORGANISM", 62, 72], ["hepatitis C (HCV)", "ORGANISM", 76, 93], ["HCV", "SPECIES", 89, 92], ["Multiple RNA viruses", "PROBLEM", 0, 20], ["glycolytic flux", "TEST", 35, 50], ["dengue", "PROBLEM", 62, 68], ["hepatitis C (HCV)", "PROBLEM", 76, 93], ["influenza A", "PROBLEM", 104, 115], ["RNA viruses", "OBSERVATION", 9, 20], ["glycolytic flux", "OBSERVATION", 35, 50]]], ["Although there are some notable exceptions, such as herpes simplex virus-1 (HSV-1) and vaccinia virus [13, 14] , both the number and evolutionary diversity of viruses that target glycolysis speak to the broad importance of this pathway for viral infection.Viral Targeting of Core Metabolic PathwaysRecently, the specific viral mechanisms targeting glycolysis have begun to be elucidated.", [["herpes simplex virus", "DISEASE", 52, 72], ["viral infection", "DISEASE", 240, 255], ["herpes simplex virus-1", "ORGANISM", 52, 74], ["HSV-1", "ORGANISM", 76, 81], ["vaccinia virus", "ORGANISM", 87, 101], ["herpes simplex virus-1", "SPECIES", 52, 74], ["HSV-1", "SPECIES", 76, 81], ["vaccinia virus", "SPECIES", 87, 101], ["herpes simplex virus-1", "SPECIES", 52, 74], ["HSV-1", "SPECIES", 76, 81], ["vaccinia virus", "SPECIES", 87, 101], ["herpes simplex virus", "TEST", 52, 72], ["HSV", "TEST", 76, 79], ["vaccinia virus", "PROBLEM", 87, 101], ["this pathway", "TREATMENT", 223, 235], ["viral infection", "PROBLEM", 240, 255], ["Core Metabolic PathwaysRecently", "PROBLEM", 275, 306], ["the specific viral mechanisms targeting glycolysis", "PROBLEM", 308, 358], ["notable", "OBSERVATION_MODIFIER", 24, 31], ["infection", "OBSERVATION", 246, 255], ["Metabolic PathwaysRecently", "OBSERVATION", 280, 306]]], ["For instance, the HCV NS5A protein has been shown to bind and activate hexose kinase, a rate controlling glycolytic enzyme [15] .", [["hexose", "CHEMICAL", 71, 77], ["HCV", "ORGANISM", 18, 21], ["hexose kinase", "GENE_OR_GENE_PRODUCT", 71, 84], ["glycolytic enzyme", "GENE_OR_GENE_PRODUCT", 105, 122], ["HCV NS5A protein", "PROTEIN", 18, 34], ["hexose kinase", "PROTEIN", 71, 84], ["glycolytic enzyme", "PROTEIN", 105, 122], ["HCV", "SPECIES", 18, 21], ["the HCV NS5A protein", "TREATMENT", 14, 34], ["hexose kinase", "TEST", 71, 84], ["a rate", "TEST", 86, 92], ["glycolytic enzyme", "TEST", 105, 122]]], ["KSHV employs specific viral microRNAs targeting known regulators of glucose metabolism and mitochondrial biogenesis to induce glycolytic activity [6] .", [["mitochondrial", "ANATOMY", 91, 104], ["glucose", "CHEMICAL", 68, 75], ["glucose", "CHEMICAL", 68, 75], ["KSHV", "ORGANISM", 0, 4], ["glucose", "SIMPLE_CHEMICAL", 68, 75], ["mitochondrial", "CELLULAR_COMPONENT", 91, 104], ["viral microRNAs", "DNA", 22, 37], ["KSHV", "SPECIES", 0, 4], ["glucose metabolism", "PROBLEM", 68, 86], ["mitochondrial biogenesis", "PROBLEM", 91, 115], ["glycolytic activity", "PROBLEM", 126, 145]]], ["HCMV has been shown to induce the activity of the AMP-activated kinase (AMPK) [16] , which regulates numerous glycolytic activities [17] .", [["AMP", "CHEMICAL", 50, 53], ["AMP", "CHEMICAL", 50, 53], ["HCMV", "ORGANISM", 0, 4], ["AMP-activated kinase (AMPK) [16]", "GENE_OR_GENE_PRODUCT", 50, 82], ["AMP-activated kinase", "PROTEIN", 50, 70], ["AMPK", "PROTEIN", 72, 76], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["the AMP", "TEST", 46, 53]]], ["HCMV-mediated activation of AMPK was found to be necessary for glycolytic activation and high titer infection [16] .", [["infection", "DISEASE", 100, 109], ["HCMV", "ORGANISM", 0, 4], ["AMPK", "GENE_OR_GENE_PRODUCT", 28, 32], ["AMPK", "PROTEIN", 28, 32], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["AMPK", "TREATMENT", 28, 32], ["glycolytic activation", "PROBLEM", 63, 84], ["high titer infection", "PROBLEM", 89, 109]]], ["HCMV has also been shown to induce a pro-glycolytic transcriptional program through activation of the host transcription factor, chREBP, which induces the expression of numerous glycolytic enzymes, and is important for virally-mediated activation of glycolysis [18] .Viral Targeting of Core Metabolic PathwaysGlycolytic carbon can enter the tricarboxylic acid (TCA) cycle, the reactions of which provide additional energy as well as metabolic precursors that feed biosynthesis of amino acids and fatty acids ( Figure 2 ).", [["Glycolytic carbon", "CHEMICAL", 309, 326], ["tricarboxylic acid", "CHEMICAL", 341, 359], ["TCA", "CHEMICAL", 361, 364], ["amino acids", "CHEMICAL", 480, 491], ["fatty acids", "CHEMICAL", 496, 507], ["carbon", "CHEMICAL", 320, 326], ["tricarboxylic acid", "CHEMICAL", 341, 359], ["TCA", "CHEMICAL", 361, 364], ["amino acids", "CHEMICAL", 480, 491], ["fatty acids", "CHEMICAL", 496, 507], ["HCMV", "ORGANISM", 0, 4], ["chREBP", "GENE_OR_GENE_PRODUCT", 129, 135], ["glycolytic enzymes", "GENE_OR_GENE_PRODUCT", 178, 196], ["Glycolytic carbon", "SIMPLE_CHEMICAL", 309, 326], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 341, 359], ["TCA", "SIMPLE_CHEMICAL", 361, 364], ["amino acids", "AMINO_ACID", 480, 491], ["fatty acids", "AMINO_ACID", 496, 507], ["transcription factor", "PROTEIN", 107, 127], ["chREBP", "PROTEIN", 129, 135], ["glycolytic enzymes", "PROTEIN", 178, 196], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["a pro-glycolytic transcriptional program", "TREATMENT", 35, 75], ["numerous glycolytic enzymes", "TEST", 169, 196], ["virally-mediated activation of glycolysis", "TREATMENT", 219, 260], ["Glycolytic carbon", "TREATMENT", 309, 326], ["the tricarboxylic acid (TCA) cycle", "TREATMENT", 337, 371], ["metabolic precursors", "TREATMENT", 433, 453], ["amino acids", "TREATMENT", 480, 491], ["fatty acids", "TEST", 496, 507]]], ["Many of the viruses that activate glycolysis also induce increased concentrations of TCA cycle components during infection.", [["infection", "DISEASE", 113, 122], ["TCA", "CHEMICAL", 85, 88], ["TCA", "SIMPLE_CHEMICAL", 85, 88], ["the viruses", "PROBLEM", 8, 19], ["TCA cycle components during infection", "PROBLEM", 85, 122], ["viruses", "OBSERVATION", 12, 19], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["concentrations", "OBSERVATION_MODIFIER", 67, 81], ["infection", "OBSERVATION", 113, 122]]], ["HCMV activates both the TCA cycle and glycolysis simultaneously, using glycolytic carbon to feed the TCA cycle and ultimately produce fatty acids that are important for infection [7] .", [["fatty acids", "CHEMICAL", 134, 145], ["infection", "DISEASE", 169, 178], ["TCA", "CHEMICAL", 24, 27], ["carbon", "CHEMICAL", 82, 88], ["TCA", "CHEMICAL", 101, 104], ["fatty acids", "CHEMICAL", 134, 145], ["HCMV", "ORGANISM", 0, 4], ["TCA", "SIMPLE_CHEMICAL", 24, 27], ["TCA", "SIMPLE_CHEMICAL", 101, 104], ["fatty acids", "SIMPLE_CHEMICAL", 134, 145], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["glycolysis", "TEST", 38, 48], ["glycolytic carbon", "TREATMENT", 71, 88], ["the TCA cycle", "TREATMENT", 97, 110], ["fatty acids", "PROBLEM", 134, 145], ["infection", "PROBLEM", 169, 178]]], ["Similarly to HCMV, vaccinia virus induces increased glutamine catabolism [13] , and both HCMV and vaccinia are dependent on increased glutamine catabolism for high titer infection [13, 19] (Figure 2 ).", [["glutamine", "CHEMICAL", 52, 61], ["glutamine", "CHEMICAL", 134, 143], ["infection", "DISEASE", 170, 179], ["glutamine", "CHEMICAL", 52, 61], ["glutamine", "CHEMICAL", 134, 143], ["HCMV", "ORGANISM", 13, 17], ["vaccinia virus", "ORGANISM", 19, 33], ["glutamine", "AMINO_ACID", 52, 61], ["HCMV", "ORGANISM", 89, 93], ["vaccinia", "ORGANISM", 98, 106], ["glutamine", "AMINO_ACID", 134, 143], ["HCMV", "SPECIES", 13, 17], ["vaccinia virus", "SPECIES", 19, 33], ["HCMV", "SPECIES", 89, 93], ["HCMV", "PROBLEM", 13, 17], ["vaccinia virus", "TREATMENT", 19, 33], ["increased glutamine catabolism", "PROBLEM", 42, 72], ["vaccinia", "TREATMENT", 98, 106], ["increased glutamine catabolism", "TREATMENT", 124, 154], ["high titer infection", "PROBLEM", 159, 179], ["HCMV", "OBSERVATION", 13, 17], ["HCMV", "OBSERVATION", 89, 93]]], ["In contrast, HSV-1 does not substantially impact glycolysis, but induces pyruvate carboxylation to anaplerotically replenish TCA cycle metabolites while diverting other TCA intermediates towards pyrimidine biosynthesis [14] .", [["pyruvate", "CHEMICAL", 73, 81], ["TCA", "CHEMICAL", 125, 128], ["pyrimidine", "CHEMICAL", 195, 205], ["pyruvate", "CHEMICAL", 73, 81], ["TCA", "CHEMICAL", 125, 128], ["TCA", "CHEMICAL", 169, 172], ["pyrimidine", "CHEMICAL", 195, 205], ["HSV-1", "ORGANISM", 13, 18], ["pyruvate", "SIMPLE_CHEMICAL", 73, 81], ["TCA", "SIMPLE_CHEMICAL", 125, 128], ["TCA", "SIMPLE_CHEMICAL", 169, 172], ["pyrimidine", "SIMPLE_CHEMICAL", 195, 205], ["HSV-1", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["substantially impact glycolysis", "PROBLEM", 28, 59], ["pyruvate carboxylation", "TREATMENT", 73, 95], ["TCA cycle metabolites", "TEST", 125, 146], ["diverting other TCA intermediates", "TREATMENT", 153, 186], ["pyrimidine biosynthesis", "TREATMENT", 195, 218]]], ["In comparison to glycolysis, less is known about how various viral infections impact specific TCA cycle metabolic fluxes.Viral Targeting of Core Metabolic PathwaysMeasuring TCA cycle metabolic activity is difficult due to the number of metabolic fluxes that flow into and out of the cycle.", [["viral infections", "DISEASE", 61, 77], ["TCA", "CHEMICAL", 173, 176], ["TCA", "CHEMICAL", 94, 97], ["TCA", "CHEMICAL", 173, 176], ["TCA", "SIMPLE_CHEMICAL", 94, 97], ["TCA", "SIMPLE_CHEMICAL", 173, 176], ["glycolysis", "TEST", 17, 27], ["various viral infections", "PROBLEM", 53, 77], ["metabolic fluxes", "PROBLEM", 236, 252], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infections", "OBSERVATION", 67, 77], ["metabolic fluxes", "OBSERVATION", 104, 120], ["metabolic activity", "OBSERVATION", 183, 201], ["metabolic fluxes", "OBSERVATION", 236, 252]]], ["Additionally, many TCA intermediates are compartmentalized into both cytoplasmic and mitochondrial pools, further complicating metabolic inquiry.Viral Targeting of Core Metabolic PathwaysMitochondrial physiology plays an important role in TCA cycle function, and while not covered in detail here, a number of viruses have been implicated in targeting mitochondrial dynamics (reviewed in [20] ).", [["cytoplasmic", "ANATOMY", 69, 80], ["mitochondrial", "ANATOMY", 85, 98], ["Mitochondrial", "ANATOMY", 187, 200], ["mitochondrial", "ANATOMY", 351, 364], ["TCA", "CHEMICAL", 19, 22], ["TCA", "CHEMICAL", 239, 242], ["TCA", "SIMPLE_CHEMICAL", 19, 22], ["cytoplasmic", "ORGANISM_SUBSTANCE", 69, 80], ["mitochondrial", "CELLULAR_COMPONENT", 85, 98], ["Mitochondrial", "CELLULAR_COMPONENT", 187, 200], ["TCA", "SIMPLE_CHEMICAL", 239, 242], ["mitochondrial", "CELLULAR_COMPONENT", 351, 364], ["many TCA intermediates", "PROBLEM", 14, 36], ["Mitochondrial physiology", "PROBLEM", 187, 211], ["TCA cycle function", "TEST", 239, 257], ["cytoplasmic", "OBSERVATION_MODIFIER", 69, 80], ["mitochondrial pools", "OBSERVATION", 85, 104]]], ["As stated above, KSHV encodes targeted microRNAs that negatively impact mitochondrial biogenesis and activity, potentially through an interaction with heat shock protein HSPA9 [21] .", [["mitochondrial", "ANATOMY", 72, 85], ["KSHV", "ORGANISM", 17, 21], ["mitochondrial", "CELLULAR_COMPONENT", 72, 85], ["heat shock protein HSPA9 [21]", "GENE_OR_GENE_PRODUCT", 151, 180], ["microRNAs", "DNA", 39, 48], ["heat shock protein", "PROTEIN", 151, 169], ["HSPA9", "PROTEIN", 170, 175], ["KSHV", "SPECIES", 17, 21], ["heat shock protein HSPA9", "TREATMENT", 151, 175]]], ["HBV and HCV promote mitochondrial fission and mitophagy through dynamin-related protein 1 (Drp1), which downregulates apoptosis and may enhance viral persistence [22, 23] .", [["mitochondrial", "ANATOMY", 20, 33], ["HBV", "ORGANISM", 0, 3], ["HCV", "ORGANISM", 8, 11], ["mitochondrial", "CELLULAR_COMPONENT", 20, 33], ["dynamin-related protein 1", "GENE_OR_GENE_PRODUCT", 64, 89], ["Drp1", "GENE_OR_GENE_PRODUCT", 91, 95], ["dynamin-related protein 1", "PROTEIN", 64, 89], ["Drp1", "PROTEIN", 91, 95], ["HBV", "SPECIES", 0, 3], ["HCV", "SPECIES", 8, 11], ["HBV", "PROBLEM", 0, 3], ["HCV promote mitochondrial fission", "TREATMENT", 8, 41], ["mitophagy", "TREATMENT", 46, 55], ["protein", "TEST", 80, 87], ["apoptosis", "PROBLEM", 118, 127], ["viral persistence", "PROBLEM", 144, 161], ["HCV", "OBSERVATION", 8, 11], ["mitochondrial fission", "OBSERVATION", 20, 41]]], ["The HCMV U L 37 protein also disrupts the reticular mitochondrial network and blocks mitochondrial apoptotic signaling [24] .", [["reticular mitochondrial network", "ANATOMY", 42, 73], ["mitochondrial", "ANATOMY", 85, 98], ["HCMV", "ORGANISM", 4, 8], ["U L 37", "GENE_OR_GENE_PRODUCT", 9, 15], ["reticular", "CELLULAR_COMPONENT", 42, 51], ["mitochondrial network", "CELLULAR_COMPONENT", 52, 73], ["mitochondrial", "CELLULAR_COMPONENT", 85, 98], ["HCMV U L 37 protein", "PROTEIN", 4, 23], ["HCMV U L 37", "SPECIES", 4, 15], ["The HCMV U L 37 protein", "TEST", 0, 23], ["the reticular mitochondrial network", "PROBLEM", 38, 73], ["blocks mitochondrial apoptotic signaling", "PROBLEM", 78, 118], ["reticular mitochondrial network", "OBSERVATION", 42, 73]]], ["While many of these activities are anti-apoptotic, with clear pro-viral consequences, they would also be predicted to have substantial effects on mitochondrial metabolism including TCA cycle activity and cellular energetics, which are likely also important for viral infection.", [["mitochondrial", "ANATOMY", 146, 159], ["cellular", "ANATOMY", 204, 212], ["viral infection", "DISEASE", 261, 276], ["mitochondrial", "CELLULAR_COMPONENT", 146, 159], ["TCA", "SIMPLE_CHEMICAL", 181, 184], ["cellular", "CELL", 204, 212], ["mitochondrial metabolism", "PROBLEM", 146, 170], ["TCA cycle activity", "TREATMENT", 181, 199], ["cellular energetics", "PROBLEM", 204, 223], ["viral infection", "PROBLEM", 261, 276], ["cellular energetics", "OBSERVATION", 204, 223], ["likely also important", "UNCERTAINTY", 235, 256], ["infection", "OBSERVATION", 267, 276]]], ["However, it is largely unclear how the viral proteins that target mitochondria dynamics impact core mitochondrial metabolic function.Viral Targeting of Core Metabolic PathwaysTCA-cycle-derived citrate is transported out of the mitochondria to supply carbon for fatty acid biosynthesis, which ultimately supports lipid biosynthesis ( Figure 2 ).", [["mitochondria", "ANATOMY", 66, 78], ["mitochondrial", "ANATOMY", 100, 113], ["mitochondria", "ANATOMY", 227, 239], ["citrate", "CHEMICAL", 193, 200], ["fatty acid", "CHEMICAL", 261, 271], ["citrate", "CHEMICAL", 193, 200], ["carbon", "CHEMICAL", 250, 256], ["fatty acid", "CHEMICAL", 261, 271], ["mitochondria", "CELLULAR_COMPONENT", 66, 78], ["mitochondrial", "CELLULAR_COMPONENT", 100, 113], ["citrate", "SIMPLE_CHEMICAL", 193, 200], ["mitochondria", "CELLULAR_COMPONENT", 227, 239], ["carbon", "SIMPLE_CHEMICAL", 250, 256], ["fatty acid", "SIMPLE_CHEMICAL", 261, 271], ["lipid", "SIMPLE_CHEMICAL", 312, 317], ["viral proteins", "PROTEIN", 39, 53], ["the viral proteins", "PROBLEM", 35, 53], ["Core Metabolic PathwaysTCA", "TEST", 152, 178], ["citrate", "TREATMENT", 193, 200], ["fatty acid biosynthesis", "TREATMENT", 261, 284], ["lipid biosynthesis", "TREATMENT", 312, 330], ["metabolic function", "OBSERVATION", 114, 132]]], ["A number of DNA viruses including HCMV and vaccinia induce lipid biosynthesis, which is necessary for their high titer infection [7, 25, 26] .", [["infection", "DISEASE", 119, 128], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["HCMV", "ORGANISM", 34, 38], ["vaccinia", "ORGANISM", 43, 51], ["lipid", "SIMPLE_CHEMICAL", 59, 64], ["HCMV", "SPECIES", 34, 38], ["DNA viruses", "PROBLEM", 12, 23], ["HCMV", "PROBLEM", 34, 38], ["vaccinia", "TREATMENT", 43, 51], ["lipid biosynthesis", "TREATMENT", 59, 77], ["their high titer infection", "PROBLEM", 102, 128], ["DNA viruses", "OBSERVATION", 12, 23]]], ["HCMV activates this pathway in part by inducing the expression and activity of acetyl-CoA carboxylase (ACC1) [25] , a rate controlling enzyme of fatty acid biosynthesis.", [["acetyl-CoA", "CHEMICAL", 79, 89], ["fatty acid", "CHEMICAL", 145, 155], ["acetyl-CoA", "CHEMICAL", 79, 89], ["fatty acid", "CHEMICAL", 145, 155], ["HCMV", "ORGANISM", 0, 4], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 79, 101], ["ACC1", "SIMPLE_CHEMICAL", 103, 107], ["fatty acid", "SIMPLE_CHEMICAL", 145, 155], ["acetyl-CoA carboxylase", "PROTEIN", 79, 101], ["ACC1", "PROTEIN", 103, 107], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["acetyl-CoA carboxylase (ACC1)", "TREATMENT", 79, 108], ["a rate", "TEST", 116, 122], ["fatty acid biosynthesis", "PROBLEM", 145, 168], ["fatty acid", "OBSERVATION", 145, 155]]], ["Inhibition of ACC1 or fatty acid synthase (FASN) attenuates HCMV replication at a late stage of infection without impacting viral protein accumulation [7, 25] .", [["fatty acid", "CHEMICAL", 22, 32], ["infection", "DISEASE", 96, 105], ["fatty acid", "CHEMICAL", 22, 32], ["ACC1", "GENE_OR_GENE_PRODUCT", 14, 18], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 22, 41], ["FASN", "GENE_OR_GENE_PRODUCT", 43, 47], ["HCMV", "ORGANISM", 60, 64], ["ACC1", "PROTEIN", 14, 18], ["fatty acid synthase", "PROTEIN", 22, 41], ["FASN", "PROTEIN", 43, 47], ["viral protein", "PROTEIN", 124, 137], ["HCMV", "SPECIES", 60, 64], ["ACC1 or fatty acid synthase (FASN)", "TREATMENT", 14, 48], ["HCMV replication", "PROBLEM", 60, 76], ["infection", "PROBLEM", 96, 105], ["impacting viral protein accumulation", "PROBLEM", 114, 150], ["late stage", "OBSERVATION_MODIFIER", 82, 92], ["infection", "OBSERVATION", 96, 105], ["viral protein accumulation", "OBSERVATION", 124, 150]]], ["The late timing of this defect is consistent with a role for fatty acid biosynthesis in viral assembly or envelopment.", [["fatty acid", "CHEMICAL", 61, 71], ["fatty acid", "CHEMICAL", 61, 71], ["fatty acid", "SIMPLE_CHEMICAL", 61, 71], ["this defect", "PROBLEM", 19, 30], ["fatty acid biosynthesis", "TREATMENT", 61, 84], ["late", "OBSERVATION_MODIFIER", 4, 8], ["defect", "OBSERVATION", 24, 30], ["consistent with", "UNCERTAINTY", 34, 49]]], ["During HCMV infection, the induction of fatty acid biosynthetic enzymes is mediated by viral activation of the sterol regulatory element binding proteins (SREBPs) 1 and 2 [25, 27] , transcription factors that control the expression of fatty acid metabolic genes.", [["HCMV infection", "DISEASE", 7, 21], ["fatty acid", "CHEMICAL", 40, 50], ["fatty acid", "CHEMICAL", 40, 50], ["sterol", "CHEMICAL", 111, 117], ["fatty acid", "CHEMICAL", 235, 245], ["HCMV", "ORGANISM", 7, 11], ["fatty acid", "SIMPLE_CHEMICAL", 40, 50], ["sterol regulatory element binding proteins (SREBPs) 1", "GENE_OR_GENE_PRODUCT", 111, 164], ["2", "GENE_OR_GENE_PRODUCT", 169, 170], ["fatty acid", "SIMPLE_CHEMICAL", 235, 245], ["fatty acid biosynthetic enzymes", "PROTEIN", 40, 71], ["sterol regulatory element binding proteins (SREBPs) 1 and 2 [25, 27", "PROTEIN", 111, 178], ["transcription factors", "PROTEIN", 182, 203], ["fatty acid metabolic genes", "DNA", 235, 261], ["HCMV", "SPECIES", 7, 11], ["HCMV infection", "PROBLEM", 7, 21], ["fatty acid biosynthetic enzymes", "TEST", 40, 71], ["transcription factors", "TREATMENT", 182, 203], ["fatty acid metabolic genes", "PROBLEM", 235, 261], ["HCMV", "OBSERVATION_MODIFIER", 7, 11], ["infection", "OBSERVATION", 12, 21], ["viral activation", "OBSERVATION", 87, 103], ["fatty acid", "OBSERVATION", 235, 245], ["metabolic genes", "OBSERVATION", 246, 261]]], ["Vaccinia infection is also sensitive to ACC1 or FASN inhibition.", [["Vaccinia infection", "DISEASE", 0, 18], ["Vaccinia", "ORGANISM", 0, 8], ["ACC1", "GENE_OR_GENE_PRODUCT", 40, 44], ["FASN", "GENE_OR_GENE_PRODUCT", 48, 52], ["ACC1", "PROTEIN", 40, 44], ["FASN", "PROTEIN", 48, 52], ["Vaccinia", "SPECIES", 0, 8], ["Vaccinia infection", "PROBLEM", 0, 18], ["FASN inhibition", "TREATMENT", 48, 63], ["infection", "OBSERVATION", 9, 18]]], ["Pharmacological inhibition of either ACC or FASN strongly reduces viral titers and inhibits virion envelopment in a manner that could be partially rescued by the addition of exogenous palmitate, the key product of fatty acid biosynthesis [26] .Viral Targeting of Core Metabolic PathwaysVarious RNA viruses also target fatty acid biosynthesis.", [["palmitate", "CHEMICAL", 184, 193], ["fatty acid", "CHEMICAL", 214, 224], ["fatty acid", "CHEMICAL", 318, 328], ["palmitate", "CHEMICAL", 184, 193], ["fatty acid", "CHEMICAL", 214, 224], ["fatty acid", "CHEMICAL", 318, 328], ["ACC", "SIMPLE_CHEMICAL", 37, 40], ["FASN", "GENE_OR_GENE_PRODUCT", 44, 48], ["palmitate", "SIMPLE_CHEMICAL", 184, 193], ["fatty acid", "SIMPLE_CHEMICAL", 214, 224], ["fatty acid", "SIMPLE_CHEMICAL", 318, 328], ["ACC", "PROTEIN", 37, 40], ["FASN", "PROTEIN", 44, 48], ["Pharmacological inhibition", "TREATMENT", 0, 26], ["viral titers", "PROBLEM", 66, 78], ["exogenous palmitate", "TREATMENT", 174, 193], ["fatty acid biosynthesis", "TREATMENT", 214, 237], ["Core Metabolic PathwaysVarious RNA viruses", "PROBLEM", 263, 305], ["fatty acid biosynthesis", "PROBLEM", 318, 341], ["RNA viruses", "OBSERVATION", 294, 305], ["fatty acid biosynthesis", "OBSERVATION", 318, 341]]], ["Many studies have implicated the importance of lipid metabolism during HCV infection, which are summarized in more detail in the following reviews [28, 29] .", [["HCV infection", "DISEASE", 71, 84], ["lipid", "SIMPLE_CHEMICAL", 47, 52], ["HCV", "SPECIES", 71, 74], ["Many studies", "TEST", 0, 12], ["lipid metabolism", "PROBLEM", 47, 63], ["HCV infection", "PROBLEM", 71, 84], ["infection", "OBSERVATION", 75, 84]]], ["Rotavirus (RV) replication has also been shown to be susceptible to inhibitors targeting various lipid synthetic enzymes, and studies in the context of dengue virus infection show that the viral nonstructural protein 3 preferentially recruits and activates FASN at sites of viral replication [30, 31] .", [["Rotavirus", "DISEASE", 0, 9], ["dengue virus infection", "DISEASE", 152, 174], ["Rotavirus", "ORGANISM", 0, 9], ["dengue virus", "ORGANISM", 152, 164], ["viral nonstructural protein 3", "GENE_OR_GENE_PRODUCT", 189, 218], ["FASN", "GENE_OR_GENE_PRODUCT", 257, 261], ["lipid synthetic enzymes", "PROTEIN", 97, 120], ["viral nonstructural protein 3", "PROTEIN", 189, 218], ["FASN", "PROTEIN", 257, 261], ["dengue virus", "SPECIES", 152, 164], ["RV", "SPECIES", 11, 13], ["dengue virus", "SPECIES", 152, 164], ["Rotavirus (RV) replication", "TREATMENT", 0, 26], ["inhibitors", "TREATMENT", 68, 78], ["various lipid synthetic enzymes", "TEST", 89, 120], ["studies", "TEST", 126, 133], ["dengue virus infection", "PROBLEM", 152, 174], ["the viral nonstructural protein", "PROBLEM", 185, 216], ["viral replication", "TREATMENT", 274, 291], ["RV", "ANATOMY", 11, 13], ["viral replication", "OBSERVATION", 274, 291]]], ["De novo fatty acid biosynthesis and formation of lipid droplets have been found to promote tombusvirus and rhinovirus replication [32] .Viral Targeting of Core Metabolic PathwaysIn addition to targeting fatty acid biosynthesis, viruses have been found to target the reverse catabolic process, fatty acid oxidation.", [["lipid droplets", "ANATOMY", 49, 63], ["fatty acid", "CHEMICAL", 8, 18], ["fatty acid", "CHEMICAL", 203, 213], ["fatty acid", "CHEMICAL", 293, 303], ["fatty acid", "CHEMICAL", 8, 18], ["fatty acid", "CHEMICAL", 203, 213], ["fatty acid", "CHEMICAL", 293, 303], ["fatty acid", "SIMPLE_CHEMICAL", 8, 18], ["lipid droplets", "SIMPLE_CHEMICAL", 49, 63], ["rhinovirus", "ORGANISM", 107, 117], ["fatty acid", "SIMPLE_CHEMICAL", 203, 213], ["fatty acid", "SIMPLE_CHEMICAL", 293, 303], ["De novo fatty acid biosynthesis", "TREATMENT", 0, 31], ["lipid droplets", "TREATMENT", 49, 63], ["rhinovirus replication", "PROBLEM", 107, 129], ["fatty acid biosynthesis", "TREATMENT", 203, 226], ["viruses", "PROBLEM", 228, 235], ["fatty acid oxidation", "TREATMENT", 293, 313], ["fatty acid", "OBSERVATION", 8, 18], ["catabolic process", "OBSERVATION", 274, 291], ["fatty acid oxidation", "OBSERVATION", 293, 313]]], ["HCMV and the Japanese encephalitis virus (JEV) inhibit fatty acid oxidation by targeting the mitochondrial trifunctional protein (MTP) which catalyzes fatty acid oxidation [33, 34] .", [["mitochondrial", "ANATOMY", 93, 106], ["Japanese encephalitis", "DISEASE", 13, 34], ["JEV", "DISEASE", 42, 45], ["fatty acid", "CHEMICAL", 55, 65], ["fatty acid", "CHEMICAL", 151, 161], ["fatty acid", "CHEMICAL", 55, 65], ["fatty acid", "CHEMICAL", 151, 161], ["HCMV", "ORGANISM", 0, 4], ["Japanese encephalitis virus", "ORGANISM", 13, 40], ["JEV", "ORGANISM", 42, 45], ["fatty acid", "SIMPLE_CHEMICAL", 55, 65], ["mitochondrial", "CELLULAR_COMPONENT", 93, 106], ["MTP", "GENE_OR_GENE_PRODUCT", 130, 133], ["fatty acid", "SIMPLE_CHEMICAL", 151, 161], ["mitochondrial trifunctional protein", "PROTEIN", 93, 128], ["MTP", "PROTEIN", 130, 133], ["Japanese encephalitis virus", "SPECIES", 13, 40], ["HCMV", "SPECIES", 0, 4], ["Japanese encephalitis virus", "SPECIES", 13, 40], ["JEV", "SPECIES", 42, 45], ["HCMV", "PROBLEM", 0, 4], ["the Japanese encephalitis virus", "PROBLEM", 9, 40], ["fatty acid oxidation", "PROBLEM", 55, 75], ["the mitochondrial trifunctional protein", "TEST", 89, 128], ["fatty acid oxidation", "TEST", 151, 171]]], ["JEV inhibits MTP through its NS5 protein [33] , while HCMV redirects the cellular viperin protein to inhibit MTP [34] .", [["cellular", "ANATOMY", 73, 81], ["JEV", "ORGANISM", 0, 3], ["MTP", "GENE_OR_GENE_PRODUCT", 13, 16], ["HCMV", "ORGANISM", 54, 58], ["cellular", "CELL", 73, 81], ["MTP", "PROTEIN", 13, 16], ["NS5 protein", "PROTEIN", 29, 40], ["cellular viperin protein", "PROTEIN", 73, 97], ["JEV", "SPECIES", 0, 3], ["HCMV", "SPECIES", 54, 58], ["JEV", "PROBLEM", 0, 3], ["its NS5 protein", "TEST", 25, 40], ["HCMV", "TEST", 54, 58], ["the cellular viperin protein", "TREATMENT", 69, 97]]], ["In contrast to these viruses that inhibit fatty acid oxidation, HCV infection requires fatty acid oxidation for its replication, which again highlights that certain aspects of viral metabolic manipulation are virus specific [35] .", [["fatty acid", "CHEMICAL", 42, 52], ["HCV infection", "DISEASE", 64, 77], ["fatty acid", "CHEMICAL", 87, 97], ["fatty acid", "CHEMICAL", 42, 52], ["fatty acid", "CHEMICAL", 87, 97], ["fatty acid", "SIMPLE_CHEMICAL", 42, 52], ["HCV", "ORGANISM", 64, 67], ["fatty acid", "SIMPLE_CHEMICAL", 87, 97], ["HCV", "SPECIES", 64, 67], ["fatty acid oxidation", "PROBLEM", 42, 62], ["HCV infection", "PROBLEM", 64, 77], ["fatty acid oxidation", "TREATMENT", 87, 107], ["its replication", "PROBLEM", 112, 127], ["viral metabolic manipulation", "TREATMENT", 176, 204], ["viruses", "OBSERVATION", 21, 28], ["fatty acid oxidation", "OBSERVATION", 42, 62], ["HCV", "OBSERVATION_MODIFIER", 64, 67], ["infection", "OBSERVATION", 68, 77]]], ["Combined, the data indicate that virally-mediated manipulation of lipid metabolism is broadly important to viral infection, and further, that viruses have evolved diverse mechanisms to ensure that the host-cell lipid metabolic machinery is co-opted to support viral infection.Small Molecule Enzymatic Activities and Viral Replication, Maturation, and AssemblyAs indicated above, a number of viruses induce and rely on host cell lipid metabolism.", [["cell", "ANATOMY", 206, 210], ["cell", "ANATOMY", 423, 427], ["infection", "DISEASE", 113, 122], ["viral infection", "DISEASE", 260, 275], ["lipid", "SIMPLE_CHEMICAL", 66, 71], ["cell", "CELL", 206, 210], ["host cell", "CELL", 418, 427], ["lipid", "SIMPLE_CHEMICAL", 428, 433], ["lipid metabolism", "PROBLEM", 66, 82], ["viral infection", "PROBLEM", 107, 122], ["viruses", "PROBLEM", 142, 149], ["the host-cell lipid metabolic machinery", "TREATMENT", 197, 236], ["viral infection", "PROBLEM", 260, 275], ["Small Molecule Enzymatic Activities", "PROBLEM", 276, 311], ["Viral Replication", "TREATMENT", 316, 333], ["viruses", "PROBLEM", 391, 398], ["lipid metabolism", "OBSERVATION", 66, 82], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122], ["viral", "OBSERVATION_MODIFIER", 260, 265], ["infection", "OBSERVATION", 266, 275], ["Molecule", "OBSERVATION_MODIFIER", 282, 290], ["Enzymatic Activities", "OBSERVATION", 291, 311], ["Viral Replication", "OBSERVATION", 316, 333], ["viruses", "OBSERVATION", 391, 398], ["host cell", "OBSERVATION", 418, 427], ["lipid metabolism", "OBSERVATION", 428, 444]]], ["In many cases, the exact contributions that specific lipid metabolic enzymes make towards viral infection are unclear however, certain themes are emerging.", [["viral infection", "DISEASE", 90, 105], ["lipid metabolic enzymes", "PROTEIN", 53, 76], ["specific lipid metabolic enzymes", "TEST", 44, 76], ["viral infection", "PROBLEM", 90, 105], ["infection", "OBSERVATION", 96, 105]]], ["Increasingly, it appears that viruses are targeting host-cell lipid modifying enzymes as a means to organize viral assembly and maturation compartments ( Figure 1 ).", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["host-cell lipid modifying enzymes", "PROTEIN", 52, 85], ["viruses", "PROBLEM", 30, 37], ["viruses", "OBSERVATION", 30, 37]]], ["This theme is readily apparent in recent work on the replication complexes formed by plus-strand RNA viruses.", [["replication complexes", "PROTEIN", 53, 74], ["strand RNA viruses", "PROBLEM", 90, 108], ["RNA viruses", "OBSERVATION", 97, 108]]], ["Dengue virus, HCV, and rhinovirus all remodel the endoplasmic reticulum (ER) to generate sites for their replication using mechanisms that rely on host lipid biosynthesis.", [["endoplasmic reticulum", "ANATOMY", 50, 71], ["ER", "ANATOMY", 73, 75], ["sites", "ANATOMY", 89, 94], ["Dengue", "DISEASE", 0, 6], ["Dengue virus", "ORGANISM", 0, 12], ["HCV", "ORGANISM", 14, 17], ["rhinovirus", "ORGANISM", 23, 33], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 50, 71], ["ER", "GENE_OR_GENE_PRODUCT", 73, 75], ["lipid", "SIMPLE_CHEMICAL", 152, 157], ["ER", "PROTEIN", 73, 75], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "SPECIES", 0, 12], ["HCV", "SPECIES", 14, 17], ["Dengue virus", "PROBLEM", 0, 12], ["HCV", "PROBLEM", 14, 17], ["rhinovirus", "PROBLEM", 23, 33], ["host lipid biosynthesis", "TREATMENT", 147, 170], ["HCV", "OBSERVATION", 14, 17], ["rhinovirus", "OBSERVATION", 23, 33], ["endoplasmic reticulum", "OBSERVATION", 50, 71]]], ["The dengue virus NSP3 protein specifically recruits fatty acid synthase to viral replication sites, which is critical for dengue replication [31, 36] .", [["dengue", "DISEASE", 4, 10], ["fatty acid", "CHEMICAL", 52, 62], ["dengue", "DISEASE", 122, 128], ["fatty acid", "CHEMICAL", 52, 62], ["dengue virus", "ORGANISM", 4, 16], ["NSP3", "GENE_OR_GENE_PRODUCT", 17, 21], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 52, 71], ["dengue virus NSP3 protein", "PROTEIN", 4, 29], ["fatty acid synthase", "PROTEIN", 52, 71], ["viral replication sites", "DNA", 75, 98], ["dengue virus", "SPECIES", 4, 16], ["dengue", "SPECIES", 122, 128], ["The dengue virus NSP3 protein", "PROBLEM", 0, 29], ["fatty acid synthase", "TREATMENT", 52, 71], ["viral replication sites", "PROBLEM", 75, 98], ["fatty acid", "OBSERVATION", 52, 62]]], ["For HCV, phosphatidylinositol 4-kinase III alpha (PI4KA) is an important host factor for the formation of replication compartments [37] .", [["phosphatidylinositol", "CHEMICAL", 9, 29], ["phosphatidylinositol 4-kinase III alpha", "GENE_OR_GENE_PRODUCT", 9, 48], ["PI4KA", "GENE_OR_GENE_PRODUCT", 50, 55], ["phosphatidylinositol 4-kinase III alpha", "PROTEIN", 9, 48], ["PI4KA", "PROTEIN", 50, 55], ["HCV", "SPECIES", 4, 7], ["HCV", "PROBLEM", 4, 7], ["phosphatidylinositol", "TEST", 9, 29], ["kinase III alpha (PI4KA)", "TREATMENT", 32, 56]]], ["HCV stimulates PI4KA activity, likely through its interaction with the HCV NS5A, which induces accumulation of phosphatidylinositol 4-phosphate (PI4P) in the ER and allows for productive replication [37] .", [["ER", "ANATOMY", 158, 160], ["phosphatidylinositol 4-phosphate", "CHEMICAL", 111, 143], ["phosphatidylinositol 4-phosphate", "CHEMICAL", 111, 143], ["PI4P", "CHEMICAL", 145, 149], ["HCV", "ORGANISM", 0, 3], ["PI4KA", "GENE_OR_GENE_PRODUCT", 15, 20], ["HCV", "ORGANISM", 71, 74], ["NS5A", "GENE_OR_GENE_PRODUCT", 75, 79], ["phosphatidylinositol 4-phosphate", "GENE_OR_GENE_PRODUCT", 111, 143], ["PI4P", "GENE_OR_GENE_PRODUCT", 145, 149], ["ER", "GENE_OR_GENE_PRODUCT", 158, 160], ["PI4KA", "PROTEIN", 15, 20], ["HCV NS5A", "PROTEIN", 71, 79], ["PI4P", "PROTEIN", 145, 149], ["ER", "PROTEIN", 158, 160], ["HCV", "SPECIES", 0, 3], ["HCV", "SPECIES", 71, 74], ["the HCV NS5A", "TREATMENT", 67, 79], ["phosphatidylinositol", "TREATMENT", 111, 131], ["phosphate (PI4P)", "TREATMENT", 134, 150]]], ["Similarly, rhinovirus replication requires redistribution of PI4P and cholesterol in ER and Golgi membranes [38] .", [["ER", "ANATOMY", 85, 87], ["Golgi membranes", "ANATOMY", 92, 107], ["cholesterol", "CHEMICAL", 70, 81], ["cholesterol", "CHEMICAL", 70, 81], ["rhinovirus", "ORGANISM", 11, 21], ["PI4P", "GENE_OR_GENE_PRODUCT", 61, 65], ["cholesterol", "SIMPLE_CHEMICAL", 70, 81], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["Golgi membranes", "CELLULAR_COMPONENT", 92, 107], ["PI4P", "PROTEIN", 61, 65], ["ER", "PROTEIN", 85, 87], ["rhinovirus replication", "PROBLEM", 11, 33], ["PI4P", "TREATMENT", 61, 65], ["rhinovirus replication", "OBSERVATION", 11, 33], ["redistribution", "OBSERVATION_MODIFIER", 43, 57], ["Golgi membranes", "OBSERVATION", 92, 107]]], ["Despite the similar lipid requirements of these related viruses, their respective ER-derived replication compartments are each unique in both conformation and size [39] .", [["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["ER", "PROTEIN", 82, 84], ["these related viruses", "PROBLEM", 42, 63], ["viruses", "OBSERVATION", 56, 63], ["size", "OBSERVATION_MODIFIER", 159, 163]]], ["Further investigation may reveal virus-specific lipid requirements driving the formation of these structures that may be therapeutically exploitable [40, 41] .Small Molecule Enzymatic Activities and Viral Replication, Maturation, and AssemblyModulation of host-cell lipid metabolic activities also appears to be important for virion assembly.", [["cell", "ANATOMY", 261, 265], ["virion", "ANATOMY", 326, 332], ["cell", "CELL", 261, 265], ["virion", "CELLULAR_COMPONENT", 326, 332], ["Further investigation", "TEST", 0, 21], ["virus", "PROBLEM", 33, 38], ["specific lipid requirements", "PROBLEM", 39, 66], ["Small Molecule Enzymatic Activities", "PROBLEM", 159, 194], ["Viral Replication", "TREATMENT", 199, 216], ["virus", "OBSERVATION", 33, 38], ["may be", "UNCERTAINTY", 114, 120], ["Molecule", "OBSERVATION_MODIFIER", 165, 173], ["Enzymatic Activities", "OBSERVATION", 174, 194], ["Viral Replication", "OBSERVATION", 199, 216], ["cell lipid", "OBSERVATION", 261, 271], ["metabolic activities", "OBSERVATION", 272, 292]]], ["HCV relies on triglyceride (TAG) and cholesterol ester biosynthesis for viral assembly, as pharmaceutical inhibition of these pathways impairs this process and subsequently reduces virus infectivity [42] .", [["triglyceride", "CHEMICAL", 14, 26], ["TAG", "CHEMICAL", 28, 31], ["cholesterol ester", "CHEMICAL", 37, 54], ["triglyceride", "CHEMICAL", 14, 26], ["TAG", "CHEMICAL", 28, 31], ["cholesterol ester", "CHEMICAL", 37, 54], ["HCV", "ORGANISM", 0, 3], ["triglyceride", "SIMPLE_CHEMICAL", 14, 26], ["TAG", "SIMPLE_CHEMICAL", 28, 31], ["cholesterol ester", "SIMPLE_CHEMICAL", 37, 54], ["HCV", "SPECIES", 0, 3], ["HCV relies", "PROBLEM", 0, 10], ["triglyceride (TAG", "TREATMENT", 14, 31], ["cholesterol ester biosynthesis", "TREATMENT", 37, 67], ["viral assembly", "PROBLEM", 72, 86], ["reduces virus infectivity", "PROBLEM", 173, 198]]], ["TAG mediates the interaction of HCV nucleocapsid protein with lipid droplets and plays a critical role in the stability of HCV nucleocapsids [42] .", [["lipid droplets", "ANATOMY", 62, 76], ["TAG", "CHEMICAL", 0, 3], ["TAG", "CHEMICAL", 0, 3], ["TAG", "SIMPLE_CHEMICAL", 0, 3], ["HCV", "ORGANISM", 32, 35], ["lipid droplets", "CELLULAR_COMPONENT", 62, 76], ["HCV", "ORGANISM", 123, 126], ["HCV nucleocapsid protein", "PROTEIN", 32, 56], ["HCV", "SPECIES", 32, 35], ["HCV", "SPECIES", 123, 126], ["HCV nucleocapsid protein", "TREATMENT", 32, 56], ["lipid droplets", "TREATMENT", 62, 76], ["HCV nucleocapsids", "PROBLEM", 123, 140]]], ["Phosphatidylserine, a core phospholipid membrane constituent, has also been implicated as being important for viral infection.", [["membrane", "ANATOMY", 40, 48], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["viral infection", "DISEASE", 110, 125], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["Phosphatidylserine", "SIMPLE_CHEMICAL", 0, 18], ["phospholipid membrane", "CELLULAR_COMPONENT", 27, 48], ["Phosphatidylserine", "TREATMENT", 0, 18], ["a core phospholipid membrane constituent", "TREATMENT", 20, 60], ["viral infection", "PROBLEM", 110, 125], ["infection", "OBSERVATION", 116, 125]]], ["Ebola particles preferentially incorporate phosphatidylserine-rich membranes into their envelope [43] , and during enterovirus infection, specialized phosphatidylserine-rich vesicles facilitate mass transmission of multiple genomes to uninfected cells [44] .", [["membranes", "ANATOMY", 67, 76], ["vesicles", "ANATOMY", 174, 182], ["cells", "ANATOMY", 246, 251], ["Ebola", "DISEASE", 0, 5], ["phosphatidylserine", "CHEMICAL", 43, 61], ["enterovirus infection", "DISEASE", 115, 136], ["phosphatidylserine", "CHEMICAL", 150, 168], ["phosphatidylserine", "CHEMICAL", 43, 61], ["phosphatidylserine", "CHEMICAL", 150, 168], ["Ebola", "ORGANISM", 0, 5], ["phosphatidylserine", "SIMPLE_CHEMICAL", 43, 61], ["rich membranes", "CELLULAR_COMPONENT", 62, 76], ["phosphatidylserine", "SIMPLE_CHEMICAL", 150, 168], ["rich vesicles", "CELLULAR_COMPONENT", 169, 182], ["cells", "CELL", 246, 251], ["uninfected cells", "CELL_TYPE", 235, 251], ["Ebola particles", "PROBLEM", 0, 15], ["enterovirus infection", "PROBLEM", 115, 136], ["specialized phosphatidylserine-rich vesicles", "TREATMENT", 138, 182], ["mass transmission of multiple genomes to uninfected cells", "PROBLEM", 194, 251], ["infection", "OBSERVATION", 127, 136], ["mass", "OBSERVATION", 194, 198]]], ["It is apparent that virallymediated alteration of lipid modifying metabolic activities to shape lipid compartments has emerged as an important component of diverse viral life cycles.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptViral Infection and Specialized Virion ComponentsIt is becoming increasingly evident that in addition to simply elevating the production of molecular precursors to support infection, viruses are targeting specific metabolic activities to individually tailor specialized virion components ( Figure 1 ).", [["lipid compartments", "ANATOMY", 96, 114], ["infection", "DISEASE", 456, 465], ["lipid", "SIMPLE_CHEMICAL", 50, 55], ["diverse viral life cycles", "TREATMENT", 156, 181], ["ManuscriptViral Infection", "PROBLEM", 274, 299], ["Specialized Virion Components", "TREATMENT", 304, 333], ["molecular precursors", "PROBLEM", 424, 444], ["support infection", "PROBLEM", 448, 465], ["viruses", "PROBLEM", 467, 474], ["metabolic activities", "OBSERVATION", 66, 86], ["diverse", "OBSERVATION_MODIFIER", 156, 163], ["viral life cycles", "OBSERVATION", 164, 181], ["Infection", "OBSERVATION", 290, 299], ["infection", "OBSERVATION", 456, 465]]], ["For example, HCMV infection induces the expression of fatty acid elongases, which increase the concentrations of saturated very-long-chain fatty acids (VLCFAs).", [["HCMV infection", "DISEASE", 13, 27], ["fatty acid", "CHEMICAL", 54, 64], ["fatty acids", "CHEMICAL", 139, 150], ["fatty acid", "CHEMICAL", 54, 64], ["saturated very-long-chain fatty acids", "CHEMICAL", 113, 150], ["VLCFAs", "CHEMICAL", 152, 158], ["HCMV", "ORGANISM", 13, 17], ["fatty acid", "SIMPLE_CHEMICAL", 54, 64], ["long-chain fatty acids", "SIMPLE_CHEMICAL", 128, 150], ["VLCFAs", "SIMPLE_CHEMICAL", 152, 158], ["HCMV", "SPECIES", 13, 17], ["HCMV infection", "PROBLEM", 13, 27], ["fatty acid elongases", "PROBLEM", 54, 74], ["HCMV", "OBSERVATION_MODIFIER", 13, 17], ["infection", "OBSERVATION", 18, 27], ["fatty acid", "OBSERVATION", 54, 64]]], ["These VLCFAs are concentrated in the envelope of HCMV virions [45, 46] .", [["VLCFAs", "GENE_OR_GENE_PRODUCT", 6, 12], ["HCMV", "ORGANISM", 49, 53], ["VLCFAs", "PROTEIN", 6, 12], ["HCMV", "SPECIES", 49, 53], ["HCMV virions", "PROBLEM", 49, 61], ["concentrated", "OBSERVATION_MODIFIER", 17, 29], ["envelope", "OBSERVATION_MODIFIER", 37, 45], ["HCMV virions", "OBSERVATION", 49, 61]]], ["Pharmaceutical inhibition or RNAi-mediated knockdown of long-chain acyl-CoA synthetase or fatty acid elongase 7, key enzymes for biosynthesis of VLCFAs, attenuates HCMV replication [45, 46] .", [["fatty acid", "CHEMICAL", 90, 100], ["acyl-CoA", "CHEMICAL", 67, 75], ["fatty acid", "CHEMICAL", 90, 100], ["long-chain acyl-CoA synthetase", "SIMPLE_CHEMICAL", 56, 86], ["fatty acid elongase 7", "GENE_OR_GENE_PRODUCT", 90, 111], ["VLCFAs", "GENE_OR_GENE_PRODUCT", 145, 151], ["HCMV", "ORGANISM", 164, 168], ["long-chain acyl-CoA synthetase", "PROTEIN", 56, 86], ["fatty acid elongase 7", "PROTEIN", 90, 111], ["VLCFAs", "PROTEIN", 145, 151], ["HCMV", "SPECIES", 164, 168], ["Pharmaceutical inhibition", "TREATMENT", 0, 25], ["RNAi", "TEST", 29, 33], ["long-chain acyl-CoA synthetase", "TREATMENT", 56, 86], ["fatty acid elongase", "TEST", 90, 109], ["key enzymes", "TEST", 113, 124], ["biosynthesis of VLCFAs", "TREATMENT", 129, 151], ["attenuates HCMV replication", "TREATMENT", 153, 180]]], ["While the exact contributions that VLFCAs make towards viral replication are unclear, it is likely that specific biophysical properties of VLCFAs contribute to aspects of virion maturation, stability, or transmission.", [["virion", "ANATOMY", 171, 177], ["VLFCAs", "GENE_OR_GENE_PRODUCT", 35, 41], ["VLCFAs", "GENE_OR_GENE_PRODUCT", 139, 145], ["virion", "CELLULAR_COMPONENT", 171, 177], ["VLFCAs", "PROTEIN", 35, 41], ["viral replication", "PROBLEM", 55, 72], ["VLCFAs", "PROBLEM", 139, 145], ["virion maturation", "PROBLEM", 171, 188], ["virion maturation", "OBSERVATION", 171, 188], ["stability", "OBSERVATION_MODIFIER", 190, 199]]], ["Regardless, the findings that viral infection can selectively induce specific host-cell metabolic activities that are important for infection raise the possibility that such activities would make attractive targets for therapeutic intervention.Viral Infection and Specialized Virion ComponentsIn addition to tailoring fatty acid metabolic activities for the viral envelope, viruses target small molecule metabolic activities to post-translationally modify viral proteins.", [["cell", "ANATOMY", 83, 87], ["viral infection", "DISEASE", 30, 45], ["infection", "DISEASE", 132, 141], ["Viral Infection", "DISEASE", 244, 259], ["fatty acid", "CHEMICAL", 318, 328], ["fatty acid", "CHEMICAL", 318, 328], ["cell", "CELL", 83, 87], ["fatty acid", "SIMPLE_CHEMICAL", 318, 328], ["viral proteins", "PROTEIN", 456, 470], ["viral infection", "PROBLEM", 30, 45], ["infection", "PROBLEM", 132, 141], ["therapeutic intervention", "TREATMENT", 219, 243], ["Viral Infection", "PROBLEM", 244, 259], ["Specialized Virion Components", "TREATMENT", 264, 293], ["tailoring fatty acid metabolic activities", "TREATMENT", 308, 349], ["the viral envelope", "PROBLEM", 354, 372], ["viruses target small molecule metabolic activities", "PROBLEM", 374, 424], ["viral proteins", "PROBLEM", 456, 470], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45], ["cell", "OBSERVATION", 83, 87], ["metabolic activities", "OBSERVATION", 88, 108], ["Infection", "OBSERVATION", 250, 259], ["Virion Components", "OBSERVATION", 276, 293]]], ["Such modifications are diverse and include fatty acid-based modifications such as myristoylation and palmitoylation.", [["fatty acid", "CHEMICAL", 43, 53], ["fatty acid", "CHEMICAL", 43, 53], ["fatty acid", "SIMPLE_CHEMICAL", 43, 53], ["fatty acid-based modifications", "TREATMENT", 43, 73], ["myristoylation and palmitoylation", "TREATMENT", 82, 115]]], ["Myristate modification of HIV gag plays a crucial role in gag binding to the plasma membrane, an integral step that allows HIV to enter the cell [47] [48] [49] .Viral Infection and Specialized Virion ComponentsMyristoylation of virion proteins is also important for HCMV infection.", [["plasma membrane", "ANATOMY", 77, 92], ["cell", "ANATOMY", 140, 144], ["Myristate", "CHEMICAL", 0, 9], ["Viral Infection", "DISEASE", 161, 176], ["HCMV infection", "DISEASE", 266, 280], ["Myristate", "CHEMICAL", 0, 9], ["Myristate", "SIMPLE_CHEMICAL", 0, 9], ["HIV", "ORGANISM", 26, 29], ["gag", "GENE_OR_GENE_PRODUCT", 30, 33], ["gag", "GENE_OR_GENE_PRODUCT", 58, 61], ["plasma membrane", "CELLULAR_COMPONENT", 77, 92], ["cell", "CELL", 140, 144], ["HCMV", "ORGANISM", 266, 270], ["HIV gag", "DNA", 26, 33], ["virion proteins", "PROTEIN", 228, 243], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 123, 126], ["HCMV", "SPECIES", 266, 270], ["Myristate modification", "TREATMENT", 0, 22], ["HIV gag", "PROBLEM", 26, 33], ["HIV", "PROBLEM", 123, 126], ["Viral Infection", "PROBLEM", 161, 176], ["Specialized Virion ComponentsMyristoylation of virion proteins", "TREATMENT", 181, 243], ["HCMV infection", "PROBLEM", 266, 280], ["Infection", "OBSERVATION", 167, 176], ["infection", "OBSERVATION", 271, 280]]], ["The addition of a myristoyl group to pp28, a tegument protein required for productive replication, has been shown to be crucial for its proper localization and function [50] [51] [52] .", [["myristoyl", "CHEMICAL", 18, 27], ["pp28", "CHEMICAL", 37, 41], ["myristoyl", "CHEMICAL", 18, 27], ["myristoyl", "SIMPLE_CHEMICAL", 18, 27], ["pp28", "GENE_OR_GENE_PRODUCT", 37, 41], ["pp28", "PROTEIN", 37, 41], ["tegument protein", "PROTEIN", 45, 61], ["a myristoyl group to pp28", "TREATMENT", 16, 41], ["a tegument protein", "TREATMENT", 43, 61], ["productive replication", "TREATMENT", 75, 97]]], ["Another fatty acidbased protein modification, palmitoylation, has been shown to be important for influenza, coronavirus, and HCV replication by participating in processes ranging from protein trafficking to virion assembly [53] [54] [55] [56] .Viral Infection and Specialized Virion ComponentsThe infectivity of many viruses also depends on protein glycosylation.", [["influenza", "DISEASE", 97, 106], ["Viral Infection", "DISEASE", 244, 259], ["coronavirus", "ORGANISM", 108, 119], ["HCV", "ORGANISM", 125, 128], ["virion", "CELLULAR_COMPONENT", 207, 213], ["HCV", "SPECIES", 125, 128], ["Another fatty acidbased protein modification", "TREATMENT", 0, 44], ["influenza", "PROBLEM", 97, 106], ["coronavirus", "PROBLEM", 108, 119], ["HCV replication", "PROBLEM", 125, 140], ["Viral Infection", "PROBLEM", 244, 259], ["Specialized Virion Components", "TREATMENT", 264, 293], ["many viruses", "PROBLEM", 312, 324], ["protein glycosylation", "TREATMENT", 341, 362], ["protein modification", "OBSERVATION", 24, 44], ["Infection", "OBSERVATION", 250, 259], ["Virion Components", "OBSERVATION", 276, 293], ["infectivity", "OBSERVATION_MODIFIER", 297, 308], ["many", "OBSERVATION_MODIFIER", 312, 316], ["viruses", "OBSERVATION", 317, 324]]], ["Glycosylation of dengue viral proteins is important for viral genome replication, and mutations that abolish the glycosylation sites decrease dengue RNA replication and production of infectious virions [57] .", [["dengue", "DISEASE", 17, 23], ["dengue", "DISEASE", 142, 148], ["dengue viral", "ORGANISM", 17, 29], ["dengue viral proteins", "PROTEIN", 17, 38], ["glycosylation sites", "PROTEIN", 113, 132], ["dengue", "SPECIES", 17, 23], ["dengue", "SPECIES", 142, 148], ["Glycosylation", "TREATMENT", 0, 13], ["dengue viral proteins", "TREATMENT", 17, 38], ["viral genome replication", "TREATMENT", 56, 80], ["mutations", "PROBLEM", 86, 95], ["the glycosylation sites", "PROBLEM", 109, 132], ["dengue RNA replication", "TREATMENT", 142, 164], ["infectious virions", "PROBLEM", 183, 201]]], ["HBV infectivity depends on a specific glycosylation of its envelope protein [58] .", [["HBV", "ORGANISM", 0, 3], ["envelope protein", "PROTEIN", 59, 75], ["HBV", "SPECIES", 0, 3], ["HBV infectivity", "PROBLEM", 0, 15]]], ["Further, the infectivity of both HSV and HCMV relies on specific glycosylation of their envelope glycoproteins [59, 60] .", [["HSV", "ORGANISM", 33, 36], ["HCMV", "ORGANISM", 41, 45], ["envelope glycoproteins", "PROTEIN", 88, 110], ["HSV", "SPECIES", 33, 36], ["HCMV", "SPECIES", 41, 45], ["both HSV", "PROBLEM", 28, 36], ["HCMV", "OBSERVATION", 41, 45]]], ["HCMV has recently been found to increase the biosynthesis of various UDP-sugars, the molecular subunits that supply glycosylation reactions, by funneling increased pyrimidine biosynthesis towards UDP-sugar biosynthesis [61] .", [["UDP-sugars", "CHEMICAL", 69, 79], ["pyrimidine", "CHEMICAL", 164, 174], ["UDP-sugar", "CHEMICAL", 196, 205], ["UDP", "CHEMICAL", 69, 72], ["sugars", "CHEMICAL", 73, 79], ["pyrimidine", "CHEMICAL", 164, 174], ["UDP", "CHEMICAL", 196, 199], ["sugar", "CHEMICAL", 200, 205], ["HCMV", "ORGANISM", 0, 4], ["UDP-sugars", "SIMPLE_CHEMICAL", 69, 79], ["pyrimidine", "SIMPLE_CHEMICAL", 164, 174], ["UDP-sugar", "SIMPLE_CHEMICAL", 196, 205], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["glycosylation reactions", "PROBLEM", 116, 139], ["funneling increased pyrimidine biosynthesis", "TREATMENT", 144, 187], ["glycosylation reactions", "OBSERVATION", 116, 139]]], ["Inhibition of de novo pyrimidine biosynthesis attenuates envelope protein glycosylation, depletes UDP-sugar pools in an infection-specific manner and reduces viral titers [61] .", [["pyrimidine", "CHEMICAL", 22, 32], ["UDP-sugar", "CHEMICAL", 98, 107], ["infection", "DISEASE", 120, 129], ["pyrimidine", "CHEMICAL", 22, 32], ["UDP", "CHEMICAL", 98, 101], ["sugar", "CHEMICAL", 102, 107], ["pyrimidine", "SIMPLE_CHEMICAL", 22, 32], ["UDP-sugar", "SIMPLE_CHEMICAL", 98, 107], ["Inhibition of de novo pyrimidine biosynthesis", "TREATMENT", 0, 45], ["envelope protein glycosylation", "TREATMENT", 57, 87], ["UDP", "TEST", 98, 101], ["sugar pools", "TEST", 102, 113], ["an infection", "PROBLEM", 117, 129], ["viral titers", "TEST", 158, 170], ["infection", "OBSERVATION", 120, 129]]], ["Protein glycosylation modifications are varied and complex, so while it is clear that viral protein glycosylation is targeted by and critical for viral infection, numerous questions remain about how specific glycosylation patterns contribute to virus infectivity, and whether specific UDP-glycosyl transferases are recruited for modification of viral proteins.Viral Metabolic Modulation of the Inflammatory EnvironmentA growing body of literature indicates that viral infection modulates small molecule metabolism to modulate inflammation and immune function.", [["viral infection", "DISEASE", 146, 161], ["UDP", "CHEMICAL", 285, 288], ["viral infection", "DISEASE", 462, 477], ["inflammation", "DISEASE", 526, 538], ["UDP", "CHEMICAL", 285, 288], ["glycosyl", "CHEMICAL", 289, 297], ["UDP-glycosyl transferases", "GENE_OR_GENE_PRODUCT", 285, 310], ["UDP-glycosyl transferases", "PROTEIN", 285, 310], ["viral proteins", "PROTEIN", 345, 359], ["Protein glycosylation modifications", "TREATMENT", 0, 35], ["viral protein glycosylation", "TREATMENT", 86, 113], ["viral infection", "PROBLEM", 146, 161], ["virus infectivity", "PROBLEM", 245, 262], ["specific UDP-glycosyl transferases", "TEST", 276, 310], ["viral proteins", "PROBLEM", 345, 359], ["the Inflammatory Environment", "PROBLEM", 390, 418], ["viral infection", "PROBLEM", 462, 477], ["small molecule metabolism", "PROBLEM", 488, 513], ["modulate inflammation", "PROBLEM", 517, 538], ["immune function", "PROBLEM", 543, 558], ["glycosylation modifications", "OBSERVATION", 8, 35], ["viral proteins", "OBSERVATION", 345, 359], ["Metabolic Modulation", "OBSERVATION", 366, 386], ["Inflammatory", "OBSERVATION_MODIFIER", 394, 406], ["viral", "OBSERVATION_MODIFIER", 462, 467], ["infection", "OBSERVATION", 468, 477], ["small", "OBSERVATION_MODIFIER", 488, 493], ["molecule metabolism", "OBSERVATION", 494, 513], ["inflammation", "OBSERVATION", 526, 538], ["immune function", "OBSERVATION", 543, 558]]], ["For example, diverse viruses including HCV, HCMV, and West Nile virus have been observed to target sphingolipid metabolism [62] [63] [64] .", [["sphingolipid", "CHEMICAL", 99, 111], ["HCV", "ORGANISM", 39, 42], ["HCMV", "ORGANISM", 44, 48], ["West Nile virus", "ORGANISM", 54, 69], ["sphingolipid", "SIMPLE_CHEMICAL", 99, 111], ["West Nile virus", "SPECIES", 54, 69], ["HCV", "SPECIES", 39, 42], ["HCMV", "SPECIES", 44, 48], ["West Nile virus", "SPECIES", 54, 69], ["diverse viruses", "PROBLEM", 13, 28], ["HCV", "PROBLEM", 39, 42], ["HCMV", "PROBLEM", 44, 48], ["West Nile virus", "PROBLEM", 54, 69], ["sphingolipid metabolism", "TEST", 99, 122], ["diverse", "OBSERVATION_MODIFIER", 13, 20], ["viruses", "OBSERVATION", 21, 28], ["HCMV", "OBSERVATION", 44, 48]]], ["Sphingolipids are a diverse family of bioactive lipid species that play a role in a variety of immune processes such as lymphocyte migration, mast cell regulation, and apoptotic control (reviewed in [65] ).", [["lymphocyte", "ANATOMY", 120, 130], ["mast cell", "ANATOMY", 142, 151], ["Sphingolipids", "SIMPLE_CHEMICAL", 0, 13], ["lymphocyte", "CELL", 120, 130], ["mast cell", "CELL", 142, 151], ["bioactive lipid species", "TREATMENT", 38, 61], ["immune processes", "TREATMENT", 95, 111], ["lymphocyte migration", "TREATMENT", 120, 140], ["mast cell regulation", "TREATMENT", 142, 162], ["apoptotic control", "TREATMENT", 168, 185], ["bioactive lipid species", "OBSERVATION", 38, 61], ["lymphocyte migration", "OBSERVATION", 120, 140], ["mast cell", "OBSERVATION", 142, 151]]], ["The levels of bioactive sphingolipids, such as sphingosine-1-phosphate (S1P) and ceramide, are induced at early time points during HCMV life cycle and were found to be important for infection [62] .", [["sphingosine-1-phosphate", "CHEMICAL", 47, 70], ["S1P", "CHEMICAL", 72, 75], ["ceramide", "CHEMICAL", 81, 89], ["infection", "DISEASE", 182, 191], ["sphingolipids", "CHEMICAL", 24, 37], ["sphingosine-1-phosphate", "CHEMICAL", 47, 70], ["S1P", "CHEMICAL", 72, 75], ["ceramide", "CHEMICAL", 81, 89], ["sphingolipids", "SIMPLE_CHEMICAL", 24, 37], ["sphingosine-1-phosphate", "GENE_OR_GENE_PRODUCT", 47, 70], ["S1P", "GENE_OR_GENE_PRODUCT", 72, 75], ["ceramide", "SIMPLE_CHEMICAL", 81, 89], ["HCMV", "ORGANISM", 131, 135], ["HCMV", "SPECIES", 131, 135], ["bioactive sphingolipids", "TEST", 14, 37], ["sphingosine", "TEST", 47, 58], ["phosphate (S1P)", "TREATMENT", 61, 76], ["ceramide", "TREATMENT", 81, 89], ["HCMV life cycle", "TREATMENT", 131, 146], ["infection", "PROBLEM", 182, 191], ["bioactive sphingolipids", "OBSERVATION", 14, 37]]], ["HCV infection also induces expression of sphingomyelin synthases and increases sphingolipid synthesis, which if blocked attenuates infection [63] .", [["HCV infection", "DISEASE", 0, 13], ["infection", "DISEASE", 131, 140], ["sphingomyelin", "CHEMICAL", 41, 54], ["sphingolipid", "CHEMICAL", 79, 91], ["HCV", "ORGANISM", 0, 3], ["sphingomyelin synthases", "GENE_OR_GENE_PRODUCT", 41, 64], ["sphingolipid", "SIMPLE_CHEMICAL", 79, 91], ["sphingomyelin synthases", "PROTEIN", 41, 64], ["HCV", "SPECIES", 0, 3], ["HCV infection", "PROBLEM", 0, 13], ["sphingomyelin synthases", "TREATMENT", 41, 64], ["increases sphingolipid synthesis", "PROBLEM", 69, 101], ["blocked attenuates infection", "PROBLEM", 112, 140], ["infection", "OBSERVATION", 4, 13], ["increases", "OBSERVATION_MODIFIER", 69, 78], ["sphingolipid synthesis", "OBSERVATION", 79, 101], ["infection", "OBSERVATION", 131, 140]]], ["Sphingolipids represent a nexus point of cellular immunological processes, with their individual small molecules participating in a variety of context-dependent signaling events.", [["cellular", "ANATOMY", 41, 49], ["Sphingolipids", "GENE_OR_GENE_PRODUCT", 0, 13], ["cellular", "CELL", 41, 49], ["Sphingolipids", "TREATMENT", 0, 13], ["cellular immunological processes", "PROBLEM", 41, 73], ["dependent signaling events", "PROBLEM", 151, 177], ["cellular immunological processes", "OBSERVATION", 41, 73], ["small", "OBSERVATION_MODIFIER", 97, 102], ["molecules", "OBSERVATION", 103, 112]]], ["Induction of sphingolipid pools during viral infection can potentially aid infection in a variety of ways, from enhancing cell proliferation and survival to providing lipid components for replication compartments.Viral Metabolic Modulation of the Inflammatory EnvironmentProstaglandins are another family of bioactive lipids with various immunomodulatory signaling activities.", [["cell", "ANATOMY", 122, 126], ["viral infection", "DISEASE", 39, 54], ["infection", "DISEASE", 75, 84], ["sphingolipid", "CHEMICAL", 13, 25], ["sphingolipid", "SIMPLE_CHEMICAL", 13, 25], ["cell", "CELL", 122, 126], ["sphingolipid pools", "PROBLEM", 13, 31], ["viral infection", "PROBLEM", 39, 54], ["aid infection", "PROBLEM", 71, 84], ["enhancing cell proliferation", "PROBLEM", 112, 140], ["lipid components", "TREATMENT", 167, 183], ["replication compartments", "PROBLEM", 188, 212], ["bioactive lipids", "TREATMENT", 308, 324], ["sphingolipid pools", "OBSERVATION", 13, 31], ["viral infection", "OBSERVATION", 39, 54], ["infection", "OBSERVATION", 75, 84], ["enhancing cell proliferation", "OBSERVATION", 112, 140], ["Metabolic Modulation", "OBSERVATION", 219, 239], ["Inflammatory", "OBSERVATION_MODIFIER", 247, 259]]], ["As a family, prostaglandins are diverse, and their effects on viral infection have been shown to be context dependent, with either pro-or antiviral effects observed depending on the prostaglandin and the specific virus studied.", [["prostaglandins", "CHEMICAL", 13, 27], ["viral infection", "DISEASE", 62, 77], ["prostaglandin", "CHEMICAL", 182, 195], ["prostaglandins", "CHEMICAL", 13, 27], ["prostaglandin", "CHEMICAL", 182, 195], ["prostaglandins", "SIMPLE_CHEMICAL", 13, 27], ["prostaglandin", "SIMPLE_CHEMICAL", 182, 195], ["viral infection", "PROBLEM", 62, 77], ["antiviral effects", "PROBLEM", 138, 155], ["the prostaglandin", "TREATMENT", 178, 195]]], ["Prostaglandins have been shown to inhibit a number of viral families including poxviruses, some herpesviruses, and retroviruses [66, 67] .", [["Prostaglandins", "CHEMICAL", 0, 14], ["Prostaglandins", "GENE_OR_GENE_PRODUCT", 0, 14], ["retroviruses", "ORGANISM", 115, 127], ["Prostaglandins", "TREATMENT", 0, 14], ["poxviruses", "PROBLEM", 79, 89], ["some herpesviruses", "PROBLEM", 91, 109]]], ["However, HCMV induces the expression of the rate-limiting biosynthetic enzyme of prostaglandin biosynthesis, cyclogoxygenase-2 (COX2) [68] .", [["prostaglandin", "CHEMICAL", 81, 94], ["prostaglandin", "CHEMICAL", 81, 94], ["HCMV", "ORGANISM", 9, 13], ["prostaglandin", "SIMPLE_CHEMICAL", 81, 94], ["cyclogoxygenase-2", "GENE_OR_GENE_PRODUCT", 109, 126], ["COX2", "GENE_OR_GENE_PRODUCT", 128, 132], ["COX2", "PROTEIN", 128, 132], ["HCMV", "SPECIES", 9, 13], ["HCMV", "PROBLEM", 9, 13], ["the rate", "TEST", 40, 48], ["prostaglandin biosynthesis", "TREATMENT", 81, 107], ["cyclogoxygenase-", "TEST", 109, 125], ["HCMV", "OBSERVATION", 9, 13]]], ["The induction of COX2 activity increases the levels of prostaglandin E2 (PGE2), which is important for high-titer infection [69] .", [["prostaglandin E2", "CHEMICAL", 55, 71], ["PGE2", "CHEMICAL", 73, 77], ["infection", "DISEASE", 114, 123], ["prostaglandin E2", "CHEMICAL", 55, 71], ["PGE2", "CHEMICAL", 73, 77], ["COX2", "GENE_OR_GENE_PRODUCT", 17, 21], ["prostaglandin E2", "SIMPLE_CHEMICAL", 55, 71], ["PGE2", "SIMPLE_CHEMICAL", 73, 77], ["COX2", "PROTEIN", 17, 21], ["COX2 activity", "PROBLEM", 17, 30], ["prostaglandin E2 (PGE2", "TREATMENT", 55, 77], ["high-titer infection", "PROBLEM", 103, 123], ["COX2 activity", "OBSERVATION", 17, 30]]], ["Further, other primate cytomegaloviruses have acquired COX2 genes from their host, and these virally expressed homologs are important for viral replication in specific contexts [70] .", [["primate", "ORGANISM", 15, 22], ["cytomegaloviruses", "CANCER", 23, 40], ["COX2", "GENE_OR_GENE_PRODUCT", 55, 59], ["COX2 genes", "DNA", 55, 65], ["viral replication", "PROBLEM", 138, 155]]], ["Influenza A virus also upregulates PGE2 during infection, which leads to an inhibition of interferon production and decreases in antigen presentation and T-cell-mediated immunity [71] .", [["T-cell", "ANATOMY", 154, 160], ["PGE2", "CHEMICAL", 35, 39], ["infection", "DISEASE", 47, 56], ["PGE2", "CHEMICAL", 35, 39], ["Influenza A virus", "ORGANISM", 0, 17], ["PGE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["interferon", "GENE_OR_GENE_PRODUCT", 90, 100], ["T-cell", "CELL", 154, 160], ["interferon", "PROTEIN", 90, 100], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "PROBLEM", 0, 17], ["PGE2 during infection", "PROBLEM", 35, 56], ["interferon production", "PROBLEM", 90, 111], ["infection", "OBSERVATION", 47, 56], ["interferon", "OBSERVATION", 90, 100], ["decreases", "OBSERVATION_MODIFIER", 116, 125]]], ["While it is clear that bioactive lipid metabolism and signaling can impact viral infection in diverse ways, their specific contributions to viral infection and host immunity are only just emerging.Metabolic Regulation and Viral TropismA normal cell exhibits a specific metabolic program based on its parent tissue's functional role within an organism.", [["cell", "ANATOMY", 244, 248], ["tissue", "ANATOMY", 307, 313], ["viral infection", "DISEASE", 75, 90], ["viral infection", "DISEASE", 140, 155], ["lipid", "SIMPLE_CHEMICAL", 33, 38], ["cell", "CELL", 244, 248], ["tissue", "TISSUE", 307, 313], ["Viral TropismA normal cell", "CELL_TYPE", 222, 248], ["bioactive lipid metabolism", "PROBLEM", 23, 49], ["viral infection in diverse ways", "PROBLEM", 75, 106], ["viral infection", "PROBLEM", 140, 155], ["Metabolic Regulation", "TEST", 197, 217], ["Viral TropismA", "TEST", 222, 236], ["bioactive lipid metabolism", "OBSERVATION", 23, 49], ["viral", "OBSERVATION_MODIFIER", 75, 80], ["infection", "OBSERVATION", 81, 90], ["viral", "OBSERVATION_MODIFIER", 140, 145], ["infection", "OBSERVATION", 146, 155], ["Viral TropismA", "OBSERVATION", 222, 236], ["cell", "OBSERVATION", 244, 248]]], ["Given the importance of the metabolic network to infection, it follows that viral tropism could be shaped by underlying tissue-specific metabolic differences.", [["tissue", "ANATOMY", 120, 126], ["infection", "DISEASE", 49, 58], ["tissue", "TISSUE", 120, 126], ["infection", "PROBLEM", 49, 58], ["viral tropism", "PROBLEM", 76, 89], ["infection", "OBSERVATION", 49, 58], ["viral tropism", "OBSERVATION", 76, 89], ["specific", "OBSERVATION_MODIFIER", 127, 135], ["metabolic differences", "OBSERVATION", 136, 157]]], ["The tropic differences displayed by retrovirus family members present one such example.", [["retrovirus", "ORGANISM", 36, 46], ["tropic differences", "OBSERVATION", 4, 22], ["retrovirus", "OBSERVATION", 36, 46]]], ["All retroviruses are capable of replicating in dividing cells, whereas only lentiviruses, such as HIV-1 are capable of replicating in non-dividing cells such as macrophages.", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 147, 152], ["macrophages", "ANATOMY", 161, 172], ["retroviruses", "ORGANISM", 4, 16], ["cells", "CELL", 56, 61], ["lentiviruses", "ORGANISM", 76, 88], ["HIV-1", "ORGANISM", 98, 103], ["cells", "CELL", 147, 152], ["macrophages", "CELL", 161, 172], ["dividing cells", "CELL_TYPE", 47, 61], ["non-dividing cells", "CELL_TYPE", 134, 152], ["macrophages", "CELL_TYPE", 161, 172], ["HIV-1", "SPECIES", 98, 103], ["HIV-1", "SPECIES", 98, 103], ["lentiviruses", "PROBLEM", 76, 88], ["HIV", "PROBLEM", 98, 101], ["retroviruses", "OBSERVATION", 4, 16], ["dividing cells", "OBSERVATION", 47, 61], ["lentiviruses", "OBSERVATION", 76, 88], ["non-dividing cells", "OBSERVATION", 134, 152], ["macrophages", "OBSERVATION", 161, 172]]], ["The levels of dNTPs are a major metabolic distinction between quiescent nondividing cells such as macrophages and rapidly dividing cells, with macrophages exhibiting ~100-200 fold reduced concentrations of dNTP precursors relative to CD4 T cells [72] .Metabolic Regulation and Viral TropismComparative biochemical analysis of reverse transcriptases (RT) expressed by HIV-1 versus a variety of retroviruses unable to replicate in macrophages demonstrate that HIV-1 RT has a much higher dNTP binding affinity than non-macrophage-tropic retroviruses [72] .", [["cells", "ANATOMY", 84, 89], ["macrophages", "ANATOMY", 98, 109], ["cells", "ANATOMY", 131, 136], ["macrophages", "ANATOMY", 143, 154], ["CD4 T cells", "ANATOMY", 234, 245], ["macrophages", "ANATOMY", 429, 440], ["dNTPs", "CHEMICAL", 14, 19], ["dNTP", "CHEMICAL", 206, 210], ["dNTP", "CHEMICAL", 485, 489], ["dNTPs", "CHEMICAL", 14, 19], ["dNTP", "CHEMICAL", 206, 210], ["dNTP", "CHEMICAL", 485, 489], ["dNTPs", "SIMPLE_CHEMICAL", 14, 19], ["nondividing cells", "CELL", 72, 89], ["macrophages", "CELL", 98, 109], ["cells", "CELL", 131, 136], ["macrophages", "CELL", 143, 154], ["dNTP", "SIMPLE_CHEMICAL", 206, 210], ["HIV-1", "ORGANISM", 367, 372], ["retroviruses", "ORGANISM", 393, 405], ["macrophages", "CELL", 429, 440], ["HIV-1 RT", "ORGANISM", 458, 466], ["dNTP", "SIMPLE_CHEMICAL", 485, 489], ["retroviruses", "ORGANISM", 534, 546], ["quiescent nondividing cells", "CELL_TYPE", 62, 89], ["macrophages", "CELL_TYPE", 98, 109], ["rapidly dividing cells", "CELL_TYPE", 114, 136], ["macrophages", "CELL_TYPE", 143, 154], ["CD4 T cells", "CELL_TYPE", 234, 245], ["reverse transcriptases", "PROTEIN", 326, 348], ["macrophages", "CELL_TYPE", 429, 440], ["HIV-1", "SPECIES", 367, 372], ["HIV-1", "SPECIES", 458, 463], ["HIV-1", "SPECIES", 367, 372], ["HIV-1", "SPECIES", 458, 463], ["The levels of dNTPs", "PROBLEM", 0, 19], ["quiescent nondividing cells", "PROBLEM", 62, 89], ["macrophages", "PROBLEM", 98, 109], ["rapidly dividing cells", "PROBLEM", 114, 136], ["macrophages", "PROBLEM", 143, 154], ["dNTP precursors", "PROBLEM", 206, 221], ["CD4 T cells", "TEST", 234, 245], ["Metabolic Regulation", "TEST", 252, 272], ["Viral TropismComparative biochemical analysis", "TEST", 277, 322], ["reverse transcriptases", "TREATMENT", 326, 348], ["HIV", "PROBLEM", 367, 370], ["a variety of retroviruses", "PROBLEM", 380, 405], ["HIV", "PROBLEM", 458, 461], ["a much higher dNTP binding affinity", "PROBLEM", 471, 506], ["non-macrophage", "TEST", 512, 526], ["tropic retroviruses", "PROBLEM", 527, 546], ["nondividing cells", "OBSERVATION", 72, 89], ["rapidly", "OBSERVATION_MODIFIER", 114, 121], ["dividing cells", "OBSERVATION", 122, 136], ["macrophages", "OBSERVATION_MODIFIER", 143, 154], ["dNTP precursors", "OBSERVATION", 206, 221], ["retroviruses", "OBSERVATION", 393, 405], ["tropic retroviruses", "OBSERVATION", 527, 546]]], ["This elevated dNTP binding was found to be functionally important for macrophage tropism, as HIV-1 mutants that possessed RT with the reduced retroviral enzymatic kinetics were unable to replicate in macrophages but retained the ability to replicate in dividing CD4 T cells [72] .", [["macrophage", "ANATOMY", 70, 80], ["macrophages", "ANATOMY", 200, 211], ["CD4 T cells", "ANATOMY", 262, 273], ["dNTP", "CHEMICAL", 14, 18], ["dNTP", "CHEMICAL", 14, 18], ["dNTP", "SIMPLE_CHEMICAL", 14, 18], ["macrophage", "CELL", 70, 80], ["HIV-1", "ORGANISM", 93, 98], ["retroviral", "ORGANISM", 142, 152], ["macrophages", "CELL", 200, 211], ["CD4 T cells", "CELL", 262, 273], ["macrophages", "CELL_TYPE", 200, 211], ["CD4 T cells", "CELL_TYPE", 262, 273], ["HIV-1", "SPECIES", 93, 98], ["HIV-1", "SPECIES", 93, 98], ["This elevated dNTP binding", "PROBLEM", 0, 26], ["macrophage tropism", "PROBLEM", 70, 88], ["HIV-1 mutants", "PROBLEM", 93, 106], ["the reduced retroviral enzymatic kinetics", "PROBLEM", 130, 171], ["dNTP binding", "OBSERVATION", 14, 26], ["retroviral enzymatic kinetics", "OBSERVATION", 142, 171]]], ["A more comprehensive review of retroviral tropism and nucleotide pools can be found here [73] .", [["nucleotide", "CHEMICAL", 54, 64], ["nucleotide", "CHEMICAL", 54, 64], ["retroviral", "ORGANISM", 31, 41], ["retroviral tropism", "PROBLEM", 31, 49], ["nucleotide pools", "TEST", 54, 70], ["retroviral tropism", "OBSERVATION", 31, 49]]], ["As we broaden our understanding of how host cell metabolism contributes to viral infection, the impact of tissue-specific metabolic differences on the ability of viruses to grow in different cell types will likely become increasingly apparent.Metabolic Regulation as a Host-Pathogen InteractionWhile viruses target many aspects of host-cell metabolic regulation and activity, it is clear that the host has evolved mechanisms to maintain metabolic control upon infection.", [["cell", "ANATOMY", 44, 48], ["tissue", "ANATOMY", 106, 112], ["cell", "ANATOMY", 191, 195], ["cell", "ANATOMY", 336, 340], ["viral infection", "DISEASE", 75, 90], ["infection", "DISEASE", 460, 469], ["host cell", "CELL", 39, 48], ["tissue", "TISSUE", 106, 112], ["cell", "CELL", 191, 195], ["Pathogen InteractionWhile viruses", "ORGANISM", 274, 307], ["cell", "CELL", 336, 340], ["viral infection", "PROBLEM", 75, 90], ["viruses", "PROBLEM", 162, 169], ["infection", "PROBLEM", 460, 469], ["viral", "OBSERVATION_MODIFIER", 75, 80], ["infection", "OBSERVATION", 81, 90], ["different cell types", "OBSERVATION", 181, 201], ["host-cell", "OBSERVATION", 331, 340], ["metabolic regulation", "OBSERVATION", 341, 361], ["infection", "OBSERVATION", 460, 469]]], ["SAMHD1 is one such restriction factor that limits lentivirus infection in various myeloid and dendritic lineages [74] [75] [76] .", [["myeloid", "ANATOMY", 82, 89], ["dendritic", "ANATOMY", 94, 103], ["infection", "DISEASE", 61, 70], ["SAMHD1", "GENE_OR_GENE_PRODUCT", 0, 6], ["lentivirus", "ORGANISM", 50, 60], ["myeloid", "CELL", 82, 89], ["SAMHD1", "PROTEIN", 0, 6], ["restriction factor", "PROTEIN", 19, 37], ["myeloid and dendritic lineages", "CELL_TYPE", 82, 112], ["lentivirus", "SPECIES", 50, 60], ["SAMHD1", "PROBLEM", 0, 6], ["lentivirus infection", "PROBLEM", 50, 70], ["lentivirus infection", "OBSERVATION", 50, 70], ["myeloid", "ANATOMY", 82, 89]]], ["SAMHD1 is a triphosphohydrolase that controls dNTP pool sizes through its dephosphorylation activity, preventing their utilization by lentiviral reverse transcriptases.", [["dNTP", "CHEMICAL", 46, 50], ["dNTP", "CHEMICAL", 46, 50], ["SAMHD1", "GENE_OR_GENE_PRODUCT", 0, 6], ["dNTP", "SIMPLE_CHEMICAL", 46, 50], ["SAMHD1", "PROTEIN", 0, 6], ["triphosphohydrolase", "PROTEIN", 12, 31], ["lentiviral reverse transcriptases", "PROTEIN", 134, 167], ["SAMHD1", "PROBLEM", 0, 6], ["a triphosphohydrolase", "TREATMENT", 10, 31], ["dNTP pool sizes", "TREATMENT", 46, 61], ["its dephosphorylation activity", "TREATMENT", 70, 100], ["lentiviral reverse transcriptases", "TREATMENT", 134, 167], ["sizes", "OBSERVATION_MODIFIER", 56, 61], ["dephosphorylation activity", "OBSERVATION", 74, 100]]], ["Some lentiviruses have evolved mechanisms to block SAMHD1 activity, such as the Vpx accessory protein encoded by HIV-2 (but not HIV-1).", [["lentiviruses", "ORGANISM", 5, 17], ["SAMHD1", "GENE_OR_GENE_PRODUCT", 51, 57], ["Vpx", "GENE_OR_GENE_PRODUCT", 80, 83], ["HIV-2", "ORGANISM", 113, 118], ["HIV-1", "ORGANISM", 128, 133], ["SAMHD1", "PROTEIN", 51, 57], ["Vpx accessory protein", "PROTEIN", 80, 101], ["HIV-", "SPECIES", 113, 117], ["HIV-1", "SPECIES", 128, 133], ["HIV-2", "SPECIES", 113, 118], ["HIV-1", "SPECIES", 128, 133], ["Some lentiviruses", "PROBLEM", 0, 17], ["block SAMHD1 activity", "PROBLEM", 45, 66], ["the Vpx accessory protein", "PROBLEM", 76, 101], ["HIV", "PROBLEM", 113, 116], ["lentiviruses", "OBSERVATION", 5, 17], ["SAMHD1 activity", "OBSERVATION", 51, 66]]], ["Vpx binds and inhibits SAMHD1, resulting in increased dNTP concentrations and restored viral replication [76] .Metabolic Regulation as a Host-Pathogen InteractionVarious sirtuin family members have also been found to have broad antiviral effects [78] .Metabolic Regulation as a Host-Pathogen InteractionSirtuins are evolutionarily conserved NAD-dependent enzymes whose family members enzymatically regulate a number of protein post-translational modifications including ADPribosylation, acetylation, and acylation (reviewed in [79] ).", [["dNTP", "CHEMICAL", 54, 58], ["NAD", "CHEMICAL", 341, 344], ["dNTP", "CHEMICAL", 54, 58], ["NAD", "CHEMICAL", 341, 344], ["Vpx", "GENE_OR_GENE_PRODUCT", 0, 3], ["SAMHD1", "GENE_OR_GENE_PRODUCT", 23, 29], ["dNTP", "SIMPLE_CHEMICAL", 54, 58], ["sirtuin", "GENE_OR_GENE_PRODUCT", 170, 177], ["NAD", "SIMPLE_CHEMICAL", 341, 344], ["Vpx", "PROTEIN", 0, 3], ["SAMHD1", "PROTEIN", 23, 29], ["Host-Pathogen InteractionVarious sirtuin family members", "PROTEIN", 137, 192], ["NAD-dependent enzymes", "PROTEIN", 341, 362], ["Vpx binds", "PROBLEM", 0, 9], ["SAMHD1", "PROBLEM", 23, 29], ["increased dNTP concentrations", "PROBLEM", 44, 73], ["restored viral replication", "TREATMENT", 78, 104], ["broad antiviral effects", "PROBLEM", 222, 245], ["translational modifications", "TREATMENT", 432, 459], ["ADPribosylation", "TREATMENT", 470, 485], ["acetylation", "TREATMENT", 487, 498], ["acylation", "TREATMENT", 504, 513], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["dNTP concentrations", "OBSERVATION", 54, 73], ["viral replication", "OBSERVATION", 87, 104]]], ["As a class, sirtuins are major metabolic regulators that upon activation typically inhibit metabolic pathways induced by viral infection, including glycolysis [80] and fatty acid biosynthesis [81] .", [["viral infection", "DISEASE", 121, 136], ["fatty acid", "CHEMICAL", 168, 178], ["fatty acid", "CHEMICAL", 168, 178], ["sirtuins", "GENE_OR_GENE_PRODUCT", 12, 20], ["fatty acid", "SIMPLE_CHEMICAL", 168, 178], ["sirtuins", "PROTEIN", 12, 20], ["metabolic pathways", "PROBLEM", 91, 109], ["viral infection", "PROBLEM", 121, 136], ["glycolysis", "TEST", 148, 158], ["fatty acid biosynthesis", "TEST", 168, 191], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["While the specific antiviral effects of various sirtuin family members require further study, the reversion of common virally-induced metabolic phenotypes known to be important for infection likely contributes to the sirtuin family's antiviral effects.Metabolic Regulation as a Host-Pathogen InteractionAs mentioned above, prostaglandins have long been known to have immunomodulatory activities.", [["infection", "DISEASE", 181, 190], ["prostaglandins", "CHEMICAL", 323, 337], ["prostaglandins", "CHEMICAL", 323, 337], ["sirtuin", "GENE_OR_GENE_PRODUCT", 48, 55], ["sirtuin", "GENE_OR_GENE_PRODUCT", 217, 224], ["prostaglandins", "SIMPLE_CHEMICAL", 323, 337], ["sirtuin family members", "PROTEIN", 48, 70], ["sirtuin family", "PROTEIN", 217, 231], ["further study", "TEST", 79, 92], ["common virally-induced metabolic phenotypes", "PROBLEM", 111, 154], ["infection", "PROBLEM", 181, 190], ["prostaglandins", "TREATMENT", 323, 337], ["immunomodulatory activities", "TREATMENT", 367, 394], ["metabolic phenotypes", "OBSERVATION", 134, 154]]], ["New studies continue to identify novel ways in which other small molecule-based signaling contributes to immunity.", [["New studies", "TEST", 0, 11], ["small molecule-based signaling", "PROBLEM", 59, 89], ["small", "OBSERVATION_MODIFIER", 59, 64], ["molecule", "OBSERVATION", 65, 73]]], ["One such example is the discovery of the interferoninduced enzyme, cholesterol-25-hydroxylase (CH25H), which produces oxysterols such as 25-hydroxycholesterol that regulate immune responses [82, 83] .", [["cholesterol", "CHEMICAL", 67, 78], ["25-hydroxycholesterol", "CHEMICAL", 137, 158], ["cholesterol", "CHEMICAL", 67, 78], ["oxysterols", "CHEMICAL", 118, 128], ["25-hydroxycholesterol", "CHEMICAL", 137, 158], ["cholesterol-25-hydroxylase", "GENE_OR_GENE_PRODUCT", 67, 93], ["CH25H", "SIMPLE_CHEMICAL", 95, 100], ["oxysterols", "SIMPLE_CHEMICAL", 118, 128], ["25-hydroxycholesterol", "SIMPLE_CHEMICAL", 137, 158], ["interferoninduced enzyme", "PROTEIN", 41, 65], ["cholesterol-25-hydroxylase", "PROTEIN", 67, 93], ["the interferoninduced enzyme", "TEST", 37, 65], ["cholesterol", "TEST", 67, 78], ["oxysterols", "TREATMENT", 118, 128], ["hydroxycholesterol", "TREATMENT", 140, 158]]], ["Increased CH25H activity disrupts HCV genome replication by interfering with the SREBP lipid biosynthetic transcription factors and attenuating host lipid synthesis [84, 85] .", [["CH25H", "CHEMICAL", 10, 15], ["CH25H", "GENE_OR_GENE_PRODUCT", 10, 15], ["HCV", "ORGANISM", 34, 37], ["SREBP", "GENE_OR_GENE_PRODUCT", 81, 86], ["lipid", "SIMPLE_CHEMICAL", 149, 154], ["CH25H", "PROTEIN", 10, 15], ["SREBP lipid biosynthetic transcription factors", "PROTEIN", 81, 127], ["HCV", "SPECIES", 34, 37], ["Increased CH25H activity", "PROBLEM", 0, 24], ["HCV genome replication", "TREATMENT", 34, 56], ["the SREBP lipid biosynthetic transcription factors", "TREATMENT", 77, 127], ["host lipid synthesis", "TEST", 144, 164]]], ["Other examples of small molecule immunoregulatory activities include recent findings that intracellular metabolites signal to immune cells upon extracellular release, e.g., during apoptosis or necrosis.", [["intracellular", "ANATOMY", 90, 103], ["immune cells", "ANATOMY", 126, 138], ["extracellular", "ANATOMY", 144, 157], ["necrosis", "DISEASE", 193, 201], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["immune cells", "CELL", 126, 138], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 157], ["immune cells", "CELL_TYPE", 126, 138], ["small molecule immunoregulatory activities", "PROBLEM", 18, 60], ["immune cells", "PROBLEM", 126, 138], ["extracellular release", "TEST", 144, 165], ["apoptosis", "PROBLEM", 180, 189], ["necrosis", "PROBLEM", 193, 201], ["small", "OBSERVATION_MODIFIER", 18, 23], ["molecule immunoregulatory activities", "OBSERVATION", 24, 60], ["necrosis", "OBSERVATION", 193, 201]]], ["Release of extracellular nucleotides serves as a 'find-me' signal that recruits monocytes and macrophages [86] .", [["extracellular", "ANATOMY", 11, 24], ["monocytes", "ANATOMY", 80, 89], ["macrophages", "ANATOMY", 94, 105], ["nucleotides", "CHEMICAL", 25, 36], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["monocytes", "CELL", 80, 89], ["macrophages", "CELL", 94, 105], ["monocytes", "CELL_TYPE", 80, 89], ["macrophages", "CELL_TYPE", 94, 105], ["extracellular nucleotides", "TREATMENT", 11, 36], ["extracellular nucleotides", "OBSERVATION", 11, 36]]], ["Examples such as these strongly argue that the intracellular and extracellular small molecule environment can shape immunity.", [["intracellular", "ANATOMY", 47, 60], ["extracellular", "ANATOMY", 65, 78], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["However, the field is still at a very early stage many questions remain about the specific mechanisms involved (see Outstanding Questions).Metabolic Similarities Between Viral Infection and OncogenesisA number of the virally-induced metabolic changes mentioned above mirror metabolic changes that occur during oncogenesis.", [["Viral Infection", "DISEASE", 170, 185], ["Viral Infection", "PROBLEM", 170, 185], ["the virally-induced metabolic changes", "PROBLEM", 213, 250], ["mirror metabolic changes", "PROBLEM", 267, 291], ["Viral", "OBSERVATION_MODIFIER", 170, 175], ["Infection", "OBSERVATION", 176, 185], ["metabolic changes", "OBSERVATION", 233, 250], ["metabolic changes", "OBSERVATION", 274, 291]]], ["Despite arising from diverse tissue types, cancerous cells display relatively similar metabolic programs that include activation of glycolysis, induction of nucleotide biosynthesis, and activation of fatty acid biosynthesis [87] [88] [89] .", [["tissue", "ANATOMY", 29, 35], ["cancerous cells", "ANATOMY", 43, 58], ["nucleotide", "CHEMICAL", 157, 167], ["fatty acid", "CHEMICAL", 200, 210], ["nucleotide", "CHEMICAL", 157, 167], ["fatty acid", "CHEMICAL", 200, 210], ["tissue", "TISSUE", 29, 35], ["cancerous cells", "CELL", 43, 58], ["nucleotide", "SIMPLE_CHEMICAL", 157, 167], ["fatty acid", "SIMPLE_CHEMICAL", 200, 210], ["cancerous cells", "CELL_TYPE", 43, 58], ["cancerous cells", "PROBLEM", 43, 58], ["activation of glycolysis", "TREATMENT", 118, 142], ["nucleotide biosynthesis", "TREATMENT", 157, 180], ["activation of fatty acid biosynthesis", "TEST", 186, 223], ["diverse tissue", "OBSERVATION_MODIFIER", 21, 35], ["cancerous cells", "OBSERVATION", 43, 58], ["metabolic programs", "OBSERVATION", 86, 104]]], ["Many viruses, including HBV [90] , HPV [91] [92] [93] , HCV [11, 15, 94] , and KSHV [6, 95, 96] play direct causal roles in human tumorigenesis induce these various metabolic activities.", [["HBV [90", "ORGANISM", 24, 31], ["HPV [91", "ORGANISM", 35, 42], ["HCV", "ORGANISM", 56, 59], ["KSHV", "ORGANISM", 79, 83], ["human", "ORGANISM", 124, 129], ["human", "SPECIES", 124, 129], ["HBV", "SPECIES", 24, 27], ["HCV", "SPECIES", 56, 59], ["KSHV", "SPECIES", 79, 83], ["human", "SPECIES", 124, 129], ["Many viruses", "PROBLEM", 0, 12], ["HBV", "TEST", 24, 27], ["HPV", "TEST", 35, 38], ["HCV", "TEST", 56, 59], ["KSHV", "TEST", 79, 83], ["human tumorigenesis", "TREATMENT", 124, 143], ["viruses", "OBSERVATION", 5, 12], ["metabolic activities", "OBSERVATION", 165, 185]]], ["The contributions that these metabolic changes make towards oncogenesis, regardless of any infectious etiology, have become a major focus in cancer biology research (reviewed in [97] ).", [["cancer", "ANATOMY", 141, 147], ["cancer", "DISEASE", 141, 147], ["cancer", "CANCER", 141, 147], ["these metabolic changes", "PROBLEM", 23, 46], ["infectious", "OBSERVATION_MODIFIER", 91, 101]]], ["To some extent, the shared metabolic phenotypes associated with oncogenesis and viral infection likely reflect common proliferative goals between cancer cells and viruses, i.e., creation of large amounts of energy and biomass for the production of progeny.", [["cancer cells", "ANATOMY", 146, 158], ["viral infection", "DISEASE", 80, 95], ["cancer", "DISEASE", 146, 152], ["cancer cells", "CELL", 146, 158], ["cancer cells", "CELL_TYPE", 146, 158], ["the shared metabolic phenotypes", "PROBLEM", 16, 47], ["viral infection", "PROBLEM", 80, 95], ["cancer cells", "PROBLEM", 146, 158], ["viruses", "PROBLEM", 163, 170], ["some extent", "OBSERVATION_MODIFIER", 3, 14], ["metabolic phenotypes", "OBSERVATION", 27, 47], ["viral infection", "OBSERVATION", 80, 95], ["common", "OBSERVATION_MODIFIER", 111, 117], ["proliferative", "OBSERVATION_MODIFIER", 118, 131], ["cancer cells", "OBSERVATION", 146, 158], ["large", "OBSERVATION_MODIFIER", 190, 195], ["amounts", "OBSERVATION_MODIFIER", 196, 203]]], ["However, common metabolic phenotypes between infected cells and cancer-derived cell lines also present challenges.", [["cells", "ANATOMY", 54, 59], ["cancer", "ANATOMY", 64, 70], ["cell lines", "ANATOMY", 79, 89], ["cancer", "DISEASE", 64, 70], ["cells", "CELL", 54, 59], ["cancer-derived cell lines", "CELL", 64, 89], ["infected cells", "CELL_TYPE", 45, 59], ["cancer-derived cell lines", "CELL_LINE", 64, 89], ["common metabolic phenotypes", "PROBLEM", 9, 36], ["infected cells", "PROBLEM", 45, 59], ["cancer", "PROBLEM", 64, 70], ["cell lines", "TREATMENT", 79, 89], ["metabolic phenotypes", "OBSERVATION", 16, 36], ["infected cells", "OBSERVATION", 45, 59], ["cancer", "OBSERVATION", 64, 70], ["cell lines", "OBSERVATION", 79, 89]]], ["The study of viral infection occurs predominately in the context of cancer-derived cell lines.", [["cancer", "ANATOMY", 68, 74], ["cell lines", "ANATOMY", 83, 93], ["viral infection", "DISEASE", 13, 28], ["cancer", "DISEASE", 68, 74], ["cancer-derived cell lines", "CELL", 68, 93], ["cancer-derived cell lines", "CELL_LINE", 68, 93], ["The study", "TEST", 0, 9], ["viral infection", "PROBLEM", 13, 28], ["cancer", "PROBLEM", 68, 74], ["cell lines", "TREATMENT", 83, 93], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28], ["cancer", "OBSERVATION", 68, 74], ["cell lines", "OBSERVATION", 83, 93]]], ["Given their metabolic similarities, it is perhaps unsurprising that transformed cell lines produce higher viral titers relative to nontransformed tissue.", [["cell lines", "ANATOMY", 80, 90], ["tissue", "ANATOMY", 146, 152], ["cell lines", "CELL", 80, 90], ["nontransformed tissue", "TISSUE", 131, 152], ["transformed cell lines", "CELL_LINE", 68, 90], ["transformed cell lines", "PROBLEM", 68, 90], ["higher viral titers", "PROBLEM", 99, 118], ["cell lines", "OBSERVATION", 80, 90], ["higher", "OBSERVATION_MODIFIER", 99, 105], ["viral titers", "OBSERVATION", 106, 118], ["nontransformed tissue", "OBSERVATION", 131, 152]]], ["However, in studying viral replication in these cells, viral metabolic phenotypes become difficult to discern from the underlying metabolic contributions associated with oncogenesis.", [["cells", "ANATOMY", 48, 53], ["cells", "CELL", 48, 53], ["viral metabolic phenotypes", "PROBLEM", 55, 81], ["viral replication", "OBSERVATION", 21, 38], ["metabolic phenotypes", "OBSERVATION", 61, 81], ["metabolic contributions", "OBSERVATION", 130, 153]]], ["Further, important contributions of specific viral factors responsible for driving viral metabolic reprogramming would likely be missed when studied in a cancer-cell background which already exhibits these metabolic changes.", [["cancer-cell", "ANATOMY", 154, 165], ["cancer", "DISEASE", 154, 160], ["cancer-cell", "CELL", 154, 165], ["viral factors", "PROTEIN", 45, 58], ["specific viral factors", "PROBLEM", 36, 58], ["driving viral metabolic reprogramming", "PROBLEM", 75, 112], ["these metabolic changes", "PROBLEM", 200, 223], ["metabolic changes", "OBSERVATION", 206, 223]]], ["In more physiologically relevant systems, the contributions made by these factors would be evident, and could be studied with an eye towards therapeutic intervention.", [["eye", "ANATOMY", 129, 132], ["eye", "ORGAN", 129, 132], ["therapeutic intervention", "TREATMENT", 141, 165]]], ["To avoid complications such as these, ideally, analysis of viral metabolic modulation should occur in the most physiologically relevant system possible, thereby moving away from study solely in transformed cells.Concluding Remarks and Future PerspectivesIt is clear that viruses have evolved mechanisms to target host cell metabolism to ensure their persistence.", [["cells", "ANATOMY", 206, 211], ["cell", "ANATOMY", 318, 322], ["cells", "CELL", 206, 211], ["host cell", "CELL", 313, 322], ["transformed cells", "CELL_LINE", 194, 211], ["complications", "PROBLEM", 9, 22], ["viral metabolic modulation", "PROBLEM", 59, 85], ["viruses", "PROBLEM", 271, 278], ["viruses", "OBSERVATION", 271, 278], ["host cell metabolism", "OBSERVATION", 313, 333], ["persistence", "OBSERVATION_MODIFIER", 350, 361]]], ["In doing so, viruses usurp the host's small molecule resources to provide energy and molecular building blocks to support infection.", [["infection", "DISEASE", 122, 131], ["molecular building blocks", "TREATMENT", 85, 110], ["infection", "PROBLEM", 122, 131], ["infection", "OBSERVATION", 122, 131]]], ["Viruses also target small molecule metabolism to organize viral maturation compartments and to modulate immune responses.", [["Viruses", "PROBLEM", 0, 7], ["small molecule metabolism", "PROBLEM", 20, 45], ["viral maturation compartments", "PROBLEM", 58, 87], ["small", "OBSERVATION_MODIFIER", 20, 25], ["molecule metabolism", "OBSERVATION", 26, 45], ["viral maturation", "OBSERVATION", 58, 74]]], ["The host, however, is not a passive bystander with respect to viral metabolic manipulation.", [["viral metabolic manipulation", "TREATMENT", 62, 90], ["viral", "OBSERVATION", 62, 67], ["metabolic manipulation", "OBSERVATION", 68, 90]]], ["Rather, the host responds at various levels, including innate mechanisms to limit viral metabolic modulation in individually infected cells as well as metabolic immunosurveillance by the immune system.", [["cells", "ANATOMY", 134, 139], ["immune system", "ANATOMY", 187, 200], ["cells", "CELL", 134, 139], ["immune system", "ANATOMICAL_SYSTEM", 187, 200], ["individually infected cells", "CELL_TYPE", 112, 139], ["viral metabolic modulation in individually infected cells", "PROBLEM", 82, 139], ["metabolic immunosurveillance", "TREATMENT", 151, 179], ["infected cells", "OBSERVATION", 125, 139]]], ["As such, control of the small molecule network continues to emerge as a core host-pathogen interaction that can determine the outcome of viral infection, making it a worthwhile goal to target viral-host metabolic regulation as a means to limit viral infection.", [["viral infection", "DISEASE", 137, 152], ["viral infection", "DISEASE", 244, 259], ["the small molecule network", "PROBLEM", 20, 46], ["viral infection", "PROBLEM", 137, 152], ["viral infection", "PROBLEM", 244, 259], ["infection", "OBSERVATION", 143, 152], ["infection", "OBSERVATION", 250, 259]]], ["First, continued elucidation of small molecule metabolic activities that are important for viral infection, as well as the mechanisms through which they contribute to infection, will broaden the number of candidate therapeutic targets.", [["viral infection", "DISEASE", 91, 106], ["infection", "DISEASE", 167, 176], ["small molecule metabolic activities", "PROBLEM", 32, 67], ["viral infection", "PROBLEM", 91, 106], ["infection", "PROBLEM", 167, 176], ["therapeutic targets", "TREATMENT", 215, 234], ["small molecule", "OBSERVATION", 32, 46], ["metabolic activities", "OBSERVATION", 47, 67], ["infection", "OBSERVATION", 97, 106], ["infection", "OBSERVATION", 167, 176]]], ["Further, successful therapeutic development requires a sufficiently wide therapeutic window to limit viral replication without inducing toxicity.", [["toxicity", "DISEASE", 136, 144], ["a sufficiently wide therapeutic window", "TREATMENT", 53, 91], ["viral replication", "TREATMENT", 101, 118], ["inducing toxicity", "PROBLEM", 127, 144]]], ["Targeting virally-encoded metabolic activities has been a successful clinical strategy, e.g., various nucleotide analogs.", [["nucleotide", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 102, 112], ["various nucleotide analogs", "PROBLEM", 94, 120], ["metabolic activities", "OBSERVATION", 26, 46]]], ["However, viral enzymes can quickly evolve resistance to these targeted therapeutics, which necessitates cocktail-type therapies increasing concerns about toxicity.", [["toxicity", "DISEASE", 154, 162], ["viral enzymes", "PROTEIN", 9, 22], ["viral enzymes", "TEST", 9, 22], ["these targeted therapeutics", "TREATMENT", 56, 83], ["cocktail-type therapies", "TREATMENT", 104, 127], ["toxicity", "PROBLEM", 154, 162]]], ["Targeting host-cell metabolic activities would largely limit the ability for viruses to evolutionarily acquire resistance, but targeting host enzymes also raises concerns about potential toxicity.", [["cell", "ANATOMY", 15, 19], ["toxicity", "DISEASE", 187, 195], ["cell", "CELL", 15, 19], ["host enzymes", "PROTEIN", 137, 149], ["viruses", "PROBLEM", 77, 84], ["host enzymes", "TEST", 137, 149], ["potential toxicity", "PROBLEM", 177, 195], ["cell", "OBSERVATION", 15, 19], ["metabolic activities", "OBSERVATION", 20, 40]]], ["With these concerns in mind, virallyinduced host lipid metabolic activities appear particularly attractive as candidates for therapeutic targeting, as a number of inhibitors of this type are already FDA approved and widely prescribed, such as the cholesterol-lowering statins.Concluding Remarks and Future PerspectivesIn conclusion, we are at the very initial stages of understanding the mechanisms of virushost metabolic interplay and how they contribute to infectious outcomes.", [["cholesterol", "CHEMICAL", 247, 258], ["statins", "CHEMICAL", 268, 275], ["cholesterol", "CHEMICAL", 247, 258], ["statins", "CHEMICAL", 268, 275], ["cholesterol", "SIMPLE_CHEMICAL", 247, 258], ["virallyinduced host lipid metabolic activities", "PROBLEM", 29, 75], ["inhibitors", "TREATMENT", 163, 173], ["the cholesterol-lowering statins", "TREATMENT", 243, 275], ["infectious", "OBSERVATION", 459, 469]]], ["However, the importance of these mechanisms to both viral infection and immunity continue to emerge, and therefore the area appears increasingly fertile for development of novel therapeutic strategies.Figure 1.", [["viral infection", "DISEASE", 52, 67], ["both viral infection", "PROBLEM", 47, 67], ["novel therapeutic strategies", "TREATMENT", 172, 200], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infection", "OBSERVATION", 58, 67]]], ["Small Molecule Metabolic Contributions to Viral InfectionProduction of infectious virions requires energy and biomolecular building blocks derived from the host cell metabolic network (1) .", [["cell", "ANATOMY", 161, 165], ["cell", "CELL", 161, 165], ["Small Molecule Metabolic", "PROBLEM", 0, 24], ["Viral InfectionProduction of infectious virions", "PROBLEM", 42, 89], ["biomolecular building blocks", "TREATMENT", 110, 138], ["Molecule", "OBSERVATION_MODIFIER", 6, 14], ["Metabolic Contributions", "OBSERVATION", 15, 38], ["Viral InfectionProduction", "OBSERVATION", 42, 67], ["infectious", "OBSERVATION", 71, 81], ["host cell", "OBSERVATION", 156, 165]]], ["A diverse set of host metabolic activities drive the mass production of viral nucleic acids (red), structural proteins (black octagons), nonstructural proteins and phospholipid envelopes (both in black circles), and glycosylated proteins (white circles).", [["nucleic acids", "CHEMICAL", 78, 91], ["viral nucleic acids", "PROTEIN", 72, 91], ["structural proteins", "PROTEIN", 99, 118], ["black octagons", "PROTEIN", 120, 134], ["nonstructural proteins", "PROTEIN", 137, 159], ["glycosylated proteins", "PROTEIN", 216, 237], ["the mass production", "PROBLEM", 49, 68], ["viral nucleic acids", "PROBLEM", 72, 91], ["structural proteins (black octagons)", "PROBLEM", 99, 135], ["nonstructural proteins", "TEST", 137, 159], ["phospholipid envelopes", "TEST", 164, 186], ["glycosylated proteins", "TEST", 216, 237], ["host metabolic activities", "OBSERVATION", 17, 42], ["mass", "OBSERVATION", 53, 57], ["viral nucleic acids", "OBSERVATION", 72, 91], ["nonstructural proteins", "OBSERVATION", 137, 159], ["phospholipid envelopes", "OBSERVATION", 164, 186]]], ["Additionally, organization of viral maturation compartments has increasingly been found to be dependent on lipid modifying enzymes (2) .", [["lipid modifying enzymes", "PROTEIN", 107, 130], ["viral maturation compartments", "PROBLEM", 30, 59], ["lipid modifying enzymes", "TEST", 107, 130], ["viral maturation", "OBSERVATION", 30, 46]]], ["Viral infection has also been found to induce specific metabolic activities to form specialized virion components that are important to infection (3) .", [["Viral infection", "DISEASE", 0, 15], ["infection", "DISEASE", 136, 145], ["Viral", "ORGANISM", 0, 5], ["Viral infection", "PROBLEM", 0, 15], ["specialized virion components", "PROBLEM", 84, 113], ["infection", "OBSERVATION", 6, 15], ["metabolic activities", "OBSERVATION", 55, 75], ["virion components", "OBSERVATION_MODIFIER", 96, 113], ["infection", "OBSERVATION", 136, 145]]], ["Lastly, the evidence supporting the importance of small molecule metabolism for immune regulation is increasing, as are the findings that these processes are targeted by viral infection (4).", [["viral infection", "DISEASE", 170, 185], ["small molecule metabolism", "PROBLEM", 50, 75], ["immune regulation", "PROBLEM", 80, 97], ["viral infection", "PROBLEM", 170, 185], ["small", "OBSERVATION_MODIFIER", 50, 55], ["molecule metabolism", "OBSERVATION", 56, 75], ["increasing", "OBSERVATION_MODIFIER", 101, 111], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["infection", "OBSERVATION", 176, 185]]]]}